
PT J
AU Cheung, KS
   Leung, WK
AF Cheung, Ka-Shing
   Leung, Wai K.
TI Gastrointestinal bleeding in patients on novel oral anticoagulants:
   Risk, prevention and management
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE Warfarin; Endoscopy; Apixaban; Edoxaban; Gastrointestinal bleeding;
   Dabigatran; Rivaroxaban; Novel anticoagulants
ID NONVALVULAR ATRIAL-FIBRILLATION; PROTHROMBIN COMPLEX CONCENTRATE; DIRECT
   THROMBIN INHIBITOR; RE-LY TRIAL; DABIGATRAN ETEXILATE; RANDOMIZED
   EVALUATION; VS. WARFARIN; ROCKET AF; METAANALYSIS; RIVAROXABAN
AB Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation as well as in the prevention and treatment of venous thromboembolism. However, similar to traditional anticoagulants, NOACs have the side effects of bleeding, including gastrointestinal bleeding (GIB). Results from both randomized clinical trials and observations studies suggest that high-dose dabigatran (150 mg b.i.d), rivaroxaban and high-dose edoxaban (60 mg daily) are associated with a higher risk of GIB compared with warfarin. Other risk factors of NOAC-related GIB include concomitant use of ulcerogenic agents, older age, renal impairment, Helicobacter pylori infection and a past history of GIB. Prevention of NOAC-related GIB includes proper patient selection, using a lower dose of certain NOACs and in patients with renal impairment, correction of modifiable risk factors, and prescription of gastroprotective agents. Overt GIB can be managed by withholding NOACs followed by delayed endoscopic treatment. In severe bleeding, additional measures include administration of activated charcoal, use of specific reversal agents such as idarucizumab for dabigatran and andexanent alfa for factor Xa inhibitors, and urgent endoscopic management.
C1 [Cheung, Ka-Shing; Leung, Wai K.] Univ Hong Kong, Queen Mary Hosp, Dept Med, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
RP Leung, WK (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Med, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM waikleung@hku.hk
FU Li Shu Fan Medical Foundation Professorship
FX Supported by the Li Shu Fan Medical Foundation Professorship (to Leung
   WK).
CR Abo-Salem E, 2016, CURR OPIN PHARMACOL, V27, P86, DOI 10.1016/j.coph.2016.02.008
   Abraham NS, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1857
   Abraham NS, 2013, CURR OPIN GASTROEN, V29, P676, DOI 10.1097/MOG.0b013e328365d415
   Barnes GD, 2015, J THROMB HAEMOST, V13, P1154, DOI 10.1111/jth.12969
   Blech S, 2008, DRUG METAB DISPOS, V36, P386, DOI 10.1124/dmd.107.019083
   Caldeira D, 2015, ALIMENT PHARM THER, V42, P1239, DOI 10.1111/apt.13412
   Cannon CP, 2012, J AM COLL CARDIOL, V60, P747, DOI 10.1016/j.jacc.2012.05.012
   Chai-Adisaksopha C, 2014, BLOOD, V124, P2450, DOI 10.1182/blood-2014-07-590323
   Chan EW, 2015, GASTROENTEROLOGY, V149, P586, DOI 10.1053/j.gastro.2015.05.002
   Chan KE, 2015, CIRCULATION, V131, P972, DOI 10.1161/CIRCULATIONAHA.114.014113
   Chang HY, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1585
   Clemens A, 2014, ANN MED, V46, P672, DOI 10.3109/07853890.2014.952327
   Connolly SJ, 2016, NEW ENGL J MED, V375, P1131, DOI 10.1056/NEJMoa1607887
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Dans AL, 2013, CIRCULATION, V127, P634, DOI 10.1161/CIRCULATIONAHA.112.115386
   Desai J, 2013, THROMB HAEMOSTASIS, V110, P205, DOI 10.1160/TH13-02-0150
   Desai J, 2013, GASTROINTEST ENDOSC, V78, P227, DOI 10.1016/j.gie.2013.04.179
   Diener HC, 2017, EUR HEART J, V38, P860, DOI 10.1093/eurheartj/ehw069
   Dusel CH, 2004, BLOOD COAGUL FIBRIN, V15, P405, DOI 10.1097/01.mbc.0000114437.81125.2b
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Falck-Ytter Y, 2012, CHEST, V141, pE278S, DOI 10.1378/chest.11-2404
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Graham DJ, 2016, JAMA INTERN MED, V176, P1662, DOI 10.1001/jamainternmed.2016.5954
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Gregg JP, 1997, AM J MED GENET, V73, P334, DOI 10.1002/(SICI)1096-8628(19971219)73:3<334::AID-AJMG20>3.0.CO;2-J
   Halperin JL, 2014, CIRCULATION, V130, P138, DOI 10.1161/CIRCULATIONAHA.113.005008
   Hankey GJ, 2011, CIRCULATION, V123, P1436, DOI 10.1161/CIRCULATIONAHA.110.004424
   He Y, 2016, BRIT J CLIN PHARMACO, V82, P285, DOI 10.1111/bcp.12911
   Heidbuchel H, 2015, EUROPACE, V17, P1467, DOI 10.1093/europace/euv309
   Holster IL, 2013, GASTROENTEROLOGY, V145, P105, DOI 10.1053/j.gastro.2013.02.041
   Hori M, 2013, STROKE, V44, P1891, DOI 10.1161/STROKEAHA.113.000990
   Htun KT, 2014, ANN HEMATOL, V93, P1785, DOI 10.1007/s00277-014-2039-7
   Husted S, 2014, THROMB HAEMOSTASIS, V111, P781, DOI 10.1160/TH14-03-0228
   Hwang JH, 2012, GASTROINTEST ENDOSC, V75, P1132, DOI 10.1016/j.gie.2012.02.033
   Khadzhynov D, 2013, THROMB HAEMOSTASIS, V109, P596, DOI 10.1160/TH12-08-0573
   Kreutz R, 2012, FUND CLIN PHARMACOL, V26, P27, DOI 10.1111/j.1472-8206.2011.00981.x
   Kubitza D, 2008, CURR MED RES OPIN, V24, P2757, DOI 10.1185/03007990802361499 
   Kujovich JL, 2011, GENET MED, V13, P1, DOI 10.1097/GIM.0b013e3181faa0f2
   Larsen TB, 2013, J AM COLL CARDIOL, V61, P2264, DOI 10.1016/j.jacc.2013.03.020
   Lauffenburger JC, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001798
   Levi M, 2008, BLOOD, V111, P4471, DOI 10.1182/blood-2007-11-123711
   Lim Yun Jeong, 2012, Clin Endosc, V45, P138, DOI 10.5946/ce.2012.45.2.138
   Lip GYH, 2015, J AM COLL CARDIOL, V66, P2282, DOI 10.1016/j.jacc.2015.07.086
   Lip GYH, 2015, INT J CARDIOL, V180, P246, DOI 10.1016/j.ijcard.2014.11.182
   Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024
   Loffredo L, 2015, DIGEST LIVER DIS, V47, P429, DOI 10.1016/j.dld.2015.01.159
   Masotti L, 2015, J THROMB THROMBOLYS, V39, P427, DOI 10.1007/s11239-014-1112-3
   Miller CS, 2012, AM J CARDIOL, V110, P453, DOI 10.1016/j.amjcard.2012.03.049
   Milling TJ, 2016, ACAD EMERG MED, V23, P466, DOI 10.1111/acem.12911
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2014, EUR HEART J, V35, P1873, DOI 10.1093/eurheartj/ehu083
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000
   Raghavan N, 2009, DRUG METAB DISPOS, V37, P74, DOI 10.1124/dmd.108.023143
   Rong F, 2015, THROMB RES, V135, P1117, DOI 10.1016/j.thromres.2015.04.004
   Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0
   Senoo K, 2015, CIRC J, V79, P339, DOI 10.1253/circj.CJ-14-1042
   Southworth MR, 2013, NEW ENGL J MED, V368, P1272, DOI 10.1056/NEJMp1302834
   van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758
   Jones M, 2014, AM J MED, V127, P1179, DOI [10.1016/j.amjmed.2014.07.024, DOI 10.1016/J.AMJMED.2014.07.024]
   Weitz JI, 2015, THROMB HAEMOSTASIS, V114, P1113, DOI 10.1160/TH15-03-0222
   Wong H, 2014, BRIT J HAEMATOL, V166, P152, DOI 10.1111/bjh.12831
   Yavuz B, 2016, J THROMB THROMBOLYS, V42, P399, DOI 10.1007/s11239-016-1361-4
NR 63
TC 0
Z9 0
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAR 21
PY 2017
VL 23
IS 11
BP 1954
EP 1963
DI 10.3748/wjg.v23.i11.1954
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EP8FV
UT WOS:000397612200004
ER


PT J
AU Bonasia, A
   Lazzizera, C
   Elia, A
   Conversa, G
AF Bonasia, Anna
   Lazzizera, Corrado
   Elia, Antonio
   Conversa, Giulia
TI Nutritional, Biophysical and Physiological Characteristics of Wild
   Rocket Genotypes As Affected by Soilless Cultivation System, Salinity
   Level of Nutrient Solution and Growing Period
SO FRONTIERS IN PLANT SCIENCE
LA English
DT Article
DE visual quality; antioxidant capacity; nitrate; glucosinulate; vitamin C
ID ERUCA-SATIVA MILL.; L-ASCORBIC-ACID; ANTIOXIDANT ACTIVITY;
   DIPLOTAXIS-TENUIFOLIA; NACL STRESS; SALT STRESS; VITAMIN-C; BROCCOLI
   CULTIVARS; PHENOLIC-COMPOUNDS; IRRIGATION WATER
AB With the aim of defining the best management of nutrient solution (NS) in a soilless system for obtaining high quality baby-leaf rocket, the present study focuses on two wild rocket genotypes ("Nature" and "Naturelle"), grown in a greenhouse under two Southern Italy growing conditions-autumn-winter (AW) and winter-spring (WS)-using two soilless cultivation systems (SCS)-at two electrical conductivity values (EC) of NS. The SCSs used were the Floating System (FS) and Ebb and Flow System (EFS) and the EC values were 2.5 and 3.5 dS m(-1) (EC2.5; EC3.5) for the AW cycle and 3.5 and 4.5 dS m(-1) (EC3.5; EC4.5) for the WS cycle. The yield, bio-physical, physiological and nutritional characteristics were evaluated. Higher fresh (FY) (2.25 vs. 1.50 kg m(-2)) and dry (DY) (230.6 vs. 106.1 g m(-2)) weight yield, leaf firmness (dry matter, 104.3 vs. 83.2 g kg(-1) FW; specific leaf area, 34.8 vs. 24.2 g cm(-2)) and antioxidant compounds (vitamin C, 239.0 vs. 152.7mg kg(-1) FW; total phenols, 997 vs. 450mg GAE mg kg(-1) FW; total glucosinulates-GLSs, 1,078.8 vs. 405.7mg kg(-1) DW; total antioxidant capacity-TAC, 11,534 vs. 8,637 mu mol eq trolox kg(-1) FW) and lower nitrates (1,470 vs. 3,460mg kg(-1) FW) were obtained under WS conditions. The seasonal differences were evident on the GLS profile: some aliphatic GLSs (gluconapoleiferin, glucobrassicanapin) and indolic 4-OH-glucobrassicin were only expressed in WS conditions, while indolic glucobrassicin was only detected in the AW period. Compared with EFS, FS improved leaf firmness, visual quality, antioxidant content (TAC, +11.6%) and reduced nitrate leaf accumulation (-37%). "Naturelle" performed better than "Nature" in terms of yield, visual quality and nutritional profile, with differences more evident under less favorable climatic conditions and when the cultivars were grown in FS. Compared to EC2.5, the EC3.5 treatment did not affect DY while enhancing firmness, visual quality, and antioxidant compounds (TAC, +8%), and reducing the nitrate content (-47%). The EC4.5 treatment reduced FY and DY and the antioxidant content. Despite seasonal climatic condition variability, FS and the moderate salinity level of NS (3.5 dS m(-1)) can be suggested as optimum.
C1 [Bonasia, Anna; Lazzizera, Corrado; Elia, Antonio; Conversa, Giulia] Univ Foggia, Dept Sci Agr Food & Environm, Foggia, Italy.
RP Elia, A (reprint author), Univ Foggia, Dept Sci Agr Food & Environm, Foggia, Italy.
EM antonio.elia@unifg.it
FU European Union's Seventh Framework Programme for research, technological
   development and demonstration [289719]
FX The research leading to these results has received funding from the
   European Union's Seventh Framework Programme for research, technological
   development and demonstration under grant agreement n 289719 (Project
   QUAFETY).
CR Ahuja I, 2010, TRENDS PLANT SCI, V15, P664, DOI 10.1016/j.tplants.2010.08.002
   Andriolo Jerônimo L., 2005, Hortic. Bras., V23, P931, DOI 10.1590/S0102-05362005000400014
   BARBER MJ, 1989, PLANT PHYSIOL, V90, P70, DOI 10.1104/pp.90.1.70
   Barbieri G, 2011, SCI HORTIC-AMSTERDAM, V128, P393, DOI 10.1016/j.scienta.2011.02.010
   Barillari J, 2005, J AGR FOOD CHEM, V53, P2475, DOI 10.1021/jf047945a
   BARRS HD, 1962, AUST J BIOL SCI, V15, P413
   Bell L, 2015, FOOD CHEM, V172, P852, DOI 10.1016/j.foodchem.2014.09.116
   Bennett RN, 2006, J AGR FOOD CHEM, V54, P4005, DOI 10.1021/jf052756t
   Biehler E, 2010, J FOOD SCI, V75, pC55, DOI 10.1111/j.1750-3841.2009.01417.x
   Bjorkman M, 2011, PHYTOCHEMISTRY, V72, P538, DOI 10.1016/j.phytochem.2011.01.014
   BLOMZANDSTRA M, 1989, ANN APPL BIOL, V115, P553, DOI 10.1111/j.1744-7348.1989.tb06577.x
   Bonasia A, 2013, POSTHARVEST BIOL TEC, V85, P67, DOI 10.1016/j.postharvbio.2013.04.012
   Cavaiuolo M, 2014, NUTRIENTS, V6, P1519, DOI 10.3390/nu6041519
   Conte A, 2008, POSTHARVEST BIOL TEC, V50, P190, DOI 10.1016/j.postharvbio.2008.04.003
   Conversa G, 2016, SCI HORTIC-AMSTERDAM, V213, P76, DOI 10.1016/j.scienta.2016.10.021
   D'Antuono LF, 2009, J SCI FOOD AGR, V89, P713, DOI 10.1002/jsfa.3507
   Davey MW, 2000, J SCI FOOD AGR, V80, P825, DOI 10.1002/(SICI)1097-0010(20000515)80:7<825::AID-JSFA598>3.0.CO;2-6
   De Pascale S, 2001, J HORTIC SCI BIOTECH, V76, P447
   Debouba M, 2007, ANN BOT-LONDON, V99, P1143, DOI 10.1093/aob/mcm050
   Debouba M, 2006, J PLANT PHYSIOL, V163, P1247, DOI 10.1016/j.jplph.2005.09.012
   Dere Sukran, 1998, Turkish Journal of Botany, V22, P13
   Francois L. E., 1994, HDB PLANT CROP STRES, P149
   Gallie DR, 2013, J EXP BOT, V64, P433, DOI 10.1093/jxb/ers330
   Garrido Y, 2014, J SCI FOOD AGR, V94, P1592, DOI 10.1002/jsfa.6462
   Gonnella M, 2003, ACTA HORTIC, P687
   Gruda N, 2009, J APPL BOT FOOD QUAL, V82, P141
   Guo LP, 2014, INT J FOOD SCI NUTR, V65, P476, DOI 10.3109/09637486.2013.860583
   Guo RF, 2013, J ZHEJIANG UNIV-SC B, V14, P124, DOI 10.1631/jzus.B1200096
   Hall M. K. D., 2012, International Journal of Vegetable Science, V18, P393, DOI 10.1080/19315260.2012.660565
   Hall M. K. D., 2012, Vegetable Crops Research Bulletin, V76, P21, DOI 10.2478/v10032-012-0002-5
   Hamilton JM, 2010, HORTSCIENCE, V45, P546
   Jacoby B., 1994, HDB PLANT CROP STRES, P97
   Jahangir M, 2009, COMPR REV FOOD SCI F, V8, P31, DOI [10.1111/j.1541-4337.2008.00065.x, 10.1111/j.1541-4337.2009.00074.x]
   Kim HJ, 2008, J AGR FOOD CHEM, V56, P3772, DOI 10.1021/jf0733719
   Koh E, 2012, J AGR FOOD CHEM, V60, P3144, DOI 10.1021/jf300051f
   Krauss S, 2006, J AGR FOOD CHEM, V54, P441, DOI 10.1021/jf051930a
   Locato V, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00152
   Lopez-Berenguer C, 2006, PLANT SOIL, V279, P13, DOI 10.1007/s11104-005-7010-x
   Lopez-Berenguer C, 2009, J AGR FOOD CHEM, V57, P572, DOI 10.1021/jf802994p
   Lopez-Berenguer C, 2008, PLANT SCI, V174, P321, DOI 10.1016/j.plantsci.2007.11.012
   MAAS E V, 1986, Applied Agricultural Research, V1, P12
   Maas E. V., 1977, Journal of the Irrigation and Drainage Division, American Society of Civil Engineers, V103, P115
   Mahmoudi H, 2010, J AGR FOOD CHEM, V58, P5122, DOI 10.1021/jf904274v
   Morard P, 1996, PLANT SOIL, V184, P243, DOI 10.1007/BF00010453
   MUNNS R, 1986, AUST J PLANT PHYSIOL, V13, P143
   Nicola S, 2003, ACTA HORTIC, P685
   Olympios C.M., 1999, OPTIONS MEDITERRANEE, V31, P307
   Pasini F, 2011, J SCI FOOD AGR, V91, P2858, DOI 10.1002/jsfa.4535
   Pennington JAT, 2009, J FOOD COMPOS ANAL, V22, pS23, DOI 10.1016/j.jfca.2008.11.012
   Petropoulos SA, 2017, FOOD CHEM, V214, P129, DOI 10.1016/j.foodchem.2016.07.080
   Podetta N., 2011, MINERVA BIOTECNOL, V23, P40
   Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3
   Rouphael Y, 2005, EUR J AGRON, V23, P183, DOI 10.1016/j.eja.2004.10.003
   Sambo P., 2001, ITALUS HORTUS, V8, P64
   Sanoubar R, 2016, J SCI FOOD AGR, V96, P319, DOI 10.1002/jsfa.7097
   Santamaria P, 2006, J SCI FOOD AGR, V86, P10, DOI 10.1002/jsfa.2351
   Soengas P., 2011, FUNCT PLANT SCI BIOT, V5, P43
   Taarit Mouna Ben, 2012, J Sci Food Agric, V92, P1614, DOI 10.1002/jsfa.4746
   Vallejo F, 2003, EUR FOOD RES TECHNOL, V216, P395, DOI 10.1007/s00217-003-0664-9
   Velasco P, 2007, J AGR FOOD CHEM, V55, P955, DOI 10.1021/jf0624897
   Villatoro-Pulido M, 2013, J SCI FOOD AGR, V93, P3809, DOI 10.1002/jsfa.6286
   Wei S. Q., 1989, CHINESE J SOIL SCI, V30, P262
   Xu G., 1999, ADV AGRON, V68, P96, DOI [10.1016/S0065-2113(08)60844-5, DOI 10.1016/S0065-2113(08)60844-5]
   Yan B, 1996, PLANT SOIL, V179, P261, DOI 10.1007/BF00009336
   Yin M. J., 1989, SOIL FERT, V1, P3
   Yuan GF, 2010, FOOD CHEM, V121, P1014, DOI 10.1016/j.foodchem.2010.01.040
NR 66
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-462X
J9 FRONT PLANT SCI
JI Front. Plant Sci.
PD MAR 9
PY 2017
VL 8
AR 300
DI 10.3389/fpls.2017.00300
PG 15
WC Plant Sciences
SC Plant Sciences
GA EN0XN
UT WOS:000395734900001
PM 28337211
ER


PT J
AU Raval, AN
   Cigarroa, JE
   Chung, MK
   Diaz-Sandoval, LJ
   Diercks, D
   Piccini, JP
   Jung, HS
   Washam, JB
   Welch, BG
   Zazulia, AR
   Collins, SP
AF Raval, Amish N.
   Cigarroa, Joaquin E.
   Chung, Mina K.
   Diaz-Sandoval, Larry J.
   Diercks, Deborah
   Piccini, Jonathan P.
   Jung, Hee Soo
   Washam, Jeffrey B.
   Welch, Babu G.
   Zazulia, Allyson R.
   Collins, Sean P.
CA Council Clinical Cardiology
   Council Cardiovasc Dis Young
   Council Quality Care Outcomes Res
TI Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants
   in the Acute Care and Periprocedural Setting A Scientific Statement From
   the American Heart Association
SO CIRCULATION
LA English
DT Article
DE AHA Scientific Statements; acute care; anticoagulants; non-vitamin K
   antagonist; periprocedural
ID ACUTE ISCHEMIC-STROKE; NONVALVULAR ATRIAL-FIBRILLATION; PERCUTANEOUS
   CORONARY INTERVENTION; ROCKET AF TRIAL; PROTHROMBIN COMPLEX CONCENTRATE;
   ELEVATION MYOCARDIAL-INFARCTION; ACUTE INTRACEREBRAL HEMORRHAGE; DUAL
   ANTIPLATELET THERAPY; PATIENTS RECEIVING DABIGATRAN; CLINICAL-PRACTICE
   GUIDELINES
AB Non-vitamin K oral anticoagulants (NOACs) are now widely used as alternatives to warfarin for stroke prevention in atrial fibrillation and management of venous thromboembolism. In clinical practice, there is still widespread uncertainty on how to manage patients on NOACs who bleed or who are at risk for bleeding. Clinical trial data related to NOAC reversal for bleeding and perioperative management are sparse, and recommendations are largely derived from expert opinion. Knowledge of time of last ingestion of the NOAC and renal function is critical to managing these patients given that laboratory measurement is challenging because of the lack of commercially available assays in the United States. Idarucizumab is available as an antidote to rapidly reverse the effects of dabigatran. At present, there is no specific antidote available in the United States for the oral factor Xa inhibitors. Prothrombin concentrate may be considered in life-threatening bleeding. Healthcare institutions should adopt a NOAC reversal and perioperative management protocol developed with multidisciplinary input.
FU Johnson Johnson; NIH(National Center for Advancing Translational
   Sciences); National Board of Medical Examiners; NIH NHLBI; Janssen;
   Boehringer Ingelheim; BMS; Pfizer; Bayer; Daiichi Sankyo
FX Deborah Diercks UT Southwestern Emergency Medicine None Johnson &
   Johnson* (Steering Committee member on a study about the treatment of PE
   using NOACS) None None None None None; Hee Soo Jung University of
   Wisconsin NIH(National Center for Advancing Translational Sciences)*;
   National Board of Medical Examiners* None None None None None None;
   Tyler W. Barrett Vanderbilt University NIH NHLBI (PI on a K23 studying A
   Fib that ended in Sept 2015)dagger; Janssen (Site PI for a multicenter
   international ORBITAF II registry)dagger; Boehringer Ingelheim (PI for a
   multicenter retrospective cohort that completed in early 2016)* None
   None None None Boehringer Ingelheim dagger None; John W. Eikelboom
   McMaster University (Canada) BMS dagger; Boehringer Ingelheim dagger;
   Pfizer dagger; Bayer dagger None BMS dagger; Boehringer Ingelheim
   dagger; Pfizer dagger; Bayer dagger; Janssen*; Daiichi Sankyo* None None
   None None; David A. Garcia University of Washington Daiichi Sankyo
   (Local PI and St Committee member for clinical trial involving
   edoxaban)*; Janssen (Local PI for clinical trial)* None None Pfizer*;
   BMS* None Pfizer*; BMS*; Boehringer Ingelheim* None
CR Abouchakra L, 2015, J THORAC CARDIOV SUR, V150, pE19, DOI 10.1016/j.jtcvs.2015.04.054
   Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819
   Alikhan R, 2014, EMERG MED J, V31, P163, DOI 10.1136/emermed-2012-201976
   Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609
   Andreu-Cayuelas JM, 2016, REV ESP CARDIOL, V69, P134, DOI 10.1016/j.rec.2015.06.021
   Ansell JE, 2016, THROMB RES, V146, P113, DOI 10.1016/j.thromres.2016.07.008
   Ansell JE, 2014, NEW ENGL J MED, V371, P2141, DOI 10.1056/NEJMc1411800
   Barnes GD, 2015, J THROMB HAEMOST, V13, P1154, DOI 10.1111/jth.12969
   Bashore TM, 2012, J AM COLL CARDIOL, V59, P2221, DOI 10.1016/j.jacc.2012.02.010
   Berger C, 2001, STROKE, V32, P1330
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Beyer-Westendorf J, 2014, BRIT J CLIN PHARMACO, V78, P908, DOI 10.1111/bcp.12391
   Beyer-Westendorf J, 2014, EUR HEART J, V35, P1888, DOI 10.1093/eurheartj/eht557
   Bhatt DL, 2010, NEW ENGL J MED, V363, P1909, DOI 10.1056/NEJMoa1007964
   Birnie DH, 2014, CIRCULATION, V129, P2062, DOI 10.1161/CIRCULATIONAHA.113.006027
   Birnie DH, 2013, NEW ENGL J MED, V368, P2084, DOI 10.1056/NEJMoa1302946
   Bohm M, 2015, J AM COLL CARDIOL, V65, P2481, DOI 10.1016/j.jacc.2015.03.577
   Bohmann F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040804
   Bouillon K, 2015, LANCET HAEMATOL, V2, pE150, DOI 10.1016/S2352-3026(15)00027-7
   Brodsky SV, 2011, KIDNEY INT, V80, P182, DOI 10.1038/ki.2011.44
   Caldeira D, 2015, PHARMACOEPIDEM DR S, V24, P757, DOI 10.1002/pds.3791
   Caldeira D, 2015, CLIN RES CARDIOL, V104, P582, DOI 10.1007/s00392-015-0821-8
   Caldeira D, 2015, J NEUROL, V262, P516, DOI 10.1007/s00415-014-7462-0
   Caldeira D, 2014, INT J CARDIOL, V177, P117, DOI 10.1016/j.ijcard.2014.09.099
   Calkins H, 2012, EUROPACE, V14, P528, DOI 10.1093/europace/eus027
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501
   Cappato R, 2014, EUR HEART J, V35, P3346, DOI 10.1093/eurheartj/ehu367
   Naranjo IC, 2011, CEREBROVASC DIS, V32, P614, DOI 10.1159/000334578
   Chakraborty S, 2010, BRIT J RADIOL, V83, pE216, DOI 10.1259/bjr/74416385
   Chang DN, 2013, AM J KIDNEY DIS, V61, P487, DOI 10.1053/j.ajkd.2012.08.047
   Chen BC, 2013, AM J KIDNEY DIS, V62, P591, DOI 10.1053/j.ajkd.2013.02.361
   Cheng A, 2011, HEART RHYTHM, V8, P536, DOI 10.1016/j.hrthm.2010.12.016
   Chiew AL, 2014, CLIN TOXICOL, V52, P283, DOI 10.3109/15563650.2014.900179
   Claisse Guillaume, 2015, Clin Kidney J, V8, P199, DOI 10.1093/ckj/sfv001
   Coleman CM, 2015, PACE, V38, P731, DOI 10.1111/pace.12618
   Connolly SJ, 2016, NEW ENGL J MED, V375, P1131, DOI 10.1056/NEJMoa1607887
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Conway SE, 2014, ANN PHARMACOTHER, V48, P354, DOI 10.1177/1060028013513883
   Cotton BA, 2011, NEW ENGL J MED, V365, P2039, DOI 10.1056/NEJMc1111095
   Croft PE, 2013, J EMERG NURS, V39, P302, DOI 10.1016/j.jen.2013.01.016
   Cuker A, 2014, J AM COLL CARDIOL, V64, P1128, DOI 10.1016/j.jacc.2014.05.065
   Dewilde WJM, 2013, LANCET, V381, P1107, DOI 10.1016/S0140-6736(12)62177-1
   Di Biase L, 2014, CIRCULATION, V129, P2638, DOI 10.1161/CIRCULATIONAHA.113.006426
   Di Biase L, 2014, HEART RHYTHM, V11, P791, DOI 10.1016/j.hrthm.2014.03.003
   Di Biase L, 2010, CIRCULATION, V121, P2550, DOI 10.1161/CIRCULATIONAHA.109.921320
   Dias JD, 2015, ARCH PATHOL LAB MED, V139, P665, DOI 10.5858/arpa.2014-0170-OA
   Dibu JR, 2016, NEUROCRIT CARE, V24, P413, DOI 10.1007/s12028-015-0213-y
   Dossett LA, 2011, ARCH SURG-CHICAGO, V146, P565, DOI 10.1001/archsurg.2010.313
   Douketis JD, 2008, CHEST, V133, p299S, DOI 10.1378/chest.08-0675
   Douketis JD, 2015, NEW ENGL J MED, V373, P823, DOI 10.1056/NEJMoa1501035
   Douketis JD, 2015, THROMB HAEMOSTASIS, V113, P625, DOI 10.1160/TH14-04-0305
   Douketis JD, 2012, CHEST, V141, pE326S, DOI 10.1378/chest.11-2298
   Durie R, 2016, J CLIN PHARM THER, V41, P92, DOI 10.1111/jcpt.12339
   Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
   Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
   Fang MC, 2007, AM J MED, V120, P700, DOI 10.1016/j.amjmed.2006.07.034
   Fiorelli M, 1999, STROKE, V30, P2280
   Flaker G, 2014, J AM COLL CARDIOL, V63, P1082, DOI 10.1016/j.jacc.2013.09.062
   Fordyce CB, 2016, CIRCULATION, V134, P37, DOI 10.1161/CIRCULATIONAHA.116.021890
   Fountzilas Christos, 2013, N Z Med J, V126, P110
   Freeman WD, 2012, STROKE, V43, pE48, DOI 10.1161/STROKEAHA.112.652313
   Gallego P, 2012, CIRCULATION, V126, P1573, DOI 10.1161/CIRCULATIONAHA.112.135681
   Gao F, 2015, CONTEMP CLIN TRIALS, V43, P129, DOI 10.1016/j.cct.2015.05.012
   Garcia D, 2014, BLOOD, V124, P3692, DOI 10.1182/blood-2014-08-595496
   Gehrie E, 2015, ARCH PATHOL LAB MED, V139, P687, DOI 10.5858/arpa.2013-0677-RS
   Gibson CM, 2015, AM HEART J, V169, P472, DOI 10.1016/j.ahj.2014.12.006
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Gliem M, 2012, STROKE, V43, P3352, DOI 10.1161/STROKEAHA.112.666818
   Goette A, 2016, LANCET, V388, P1995, DOI 10.1016/S0140-6736(16)31474-X
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Granger CB, 2015, AM HEART J, V169, P25, DOI 10.1016/j.ahj.2014.09.006
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Gupta S, 2015, CATHETER CARDIO INTE, V86, P397, DOI 10.1002/ccd.26124
   Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656
   Healey JS, 2012, CIRCULATION, V126, P343, DOI 10.1161/CIRCULATIONAHA.111.090464
   Heidbuchel H, 2013, EUROPACE, V15, P625, DOI 10.1093/europace/eut083
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Hemphill JC, 2009, NEUROLOGY, V73, P1088, DOI 10.1212/WNL.0b013e3181b8b332
   Hoshi T, J CARDIOL, DOI [10.1016/j.jjcc.2016.06.007, DOI 10.1016/J.JJCC.2016.06.007]
   Huang GS, 2013, AM SURGEON, V79, P113
   Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a
   Javedani PP, 2013, AM J CRIT CARE, V22, P169, DOI 10.4037/ajcc2013125
   Jayathissa S, 2013, INTERN MED J, V43, P826, DOI 10.1111/imj.12182
   Jennings JM, 2013, J CARDIOVASC ELECTR, V24, P1125, DOI 10.1111/jce.12214
   Jolly SS, 2011, LANCET, V377, P1409, DOI 10.1016/S0140-6736(11)60404-2
   Jones WS, 2014, EUR HEART J, V35, P242, DOI 10.1093/eurheartj/eht492
   Joseph B, 2014, AM SURGEON, V80, pE116
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024
   Kimura S, 2014, J STROKE CEREBROVASC, V23, pE427, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.015
   Konduru SV, 2012, J INTERV CARD ELECTR, V35, P277, DOI 10.1007/s10840-012-9719-9
   Kralev S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021778
   Krishna VN, 2015, DRUG SAFETY, V38, P527, DOI 10.1007/s40264-015-0290-z
   Kuwahara T, 2016, J CARDIOVASC ELECTR, V27, P549, DOI 10.1111/jce.12928
   Lansberg MG, 2012, CHEST, V141, pE601S, DOI 10.1378/chest.11-2302
   Lees KR, 2010, LANCET, V375, P1695, DOI 10.1016/S0140-6736(10)60491-6
   Lehmann T, 2014, THROMB HAEMOSTASIS, V112, P834, DOI 10.1160/TH14-02-0138
   Levine GN, 2016, CIRCULATION, V134, pE123, DOI 10.1161/CIR.0000000000000404
   Levine GN, 2011, CIRCULATION, V124, pE574, DOI 10.1161/CIR.0b013e31823ba622
   Levy JH, 2013, ANESTHESIOLOGY, V118, P1466, DOI 10.1097/ALN.0b013e318289bcba
   Linkins L, 2010, J THROMB HAEMOST, V8, P2201, DOI 10.1111/j.1538-7836.2010.04016.x
   Linkins LA, 2014, J THROMB HAEMOST, V12, P1570, DOI 10.1111/jth.12669
   Lip GYH, 2015, EUR HEART J, V36, P3265, DOI 10.1093/eurheartj/ehv415
   Lip GYH, 2015, CLIN CARDIOL, V38, P562, DOI 10.1002/clc.22436
   Lip GYH, 2015, JAMA-J AM MED ASSOC, V314, P949, DOI 10.1001/jama.2015.8995
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Lu DS, 2016, PACE, V39, P54, DOI 10.1111/pace.12771
   Lu DS, 2015, J INTERV CARD ELECTR, V44, P105, DOI 10.1007/s10840-015-0053-x
   Mahaffey KW, 2013, CIRC-CARDIOVASC QUAL, V6, P470, DOI 10.1161/CIRCOUTCOMES.113.000132
   Majeed A, 2013, CIRCULATION, V128, P2325, DOI 10.1161/CIRCULATIONAHA.113.002332
   Mar PL, 2016, INT J CARDIOL, V202, P578, DOI 10.1016/j.ijcard.2015.09.035
   Mega JL, 2013, J AM COLL CARDIOL, V61, P1853, DOI 10.1016/j.jacc.2013.01.066
   Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277
   Mehta Siddhart, 2014, J Vasc Interv Neurol, V7, P5
   Moey AW, 2012, MED J AUSTRALIA, V196, P469, DOI 10.5694/mja11.11617
   Montaruli B, 2015, BLOOD COAGUL FIBRIN, V26, P225, DOI 10.1097/MBC.0000000000000221
   Muller P, 2013, CLIN NEUROL NEUROSUR, V115, P2257, DOI 10.1016/j.clineuro.2013.07.017
   Mumoli N, 2015, J AM GERIATR SOC, V63, P2205, DOI 10.1111/jgs.13684
   Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546
   Nairooz R, 2015, INT J CARDIOL, V187, P345, DOI 10.1016/j.ijcard.2015.03.323
   Narouze S, 2015, REGION ANESTH PAIN M, V40, P182, DOI 10.1097/AAP.0000000000000223
   Nascimento T, 2014, CAN J CARDIOL, V30, P231, DOI 10.1016/j.cjca.2013.11.027
   The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995, NEW ENGL J MED, V333, P1581
   O'Gara PT, 2013, CIRCULATION, V127, pE362, DOI 10.1161/CIR.0b013e3182742cf6
   Obeng-Gyasi S, 2012, J TRAUMA ACUTE CARE, V73, P1064, DOI 10.1097/TA.0b013e31827019c9
   Oldgren J, 2011, EUR HEART J, V32, P2781, DOI 10.1093/eurheartj/ehr113
   Committee on Trauma American College of Surgeons, 2012, ADV TRAUM LIF SUPP S
   Oswald E, 2015, BLOOD COAGUL FIBRIN, V26, P136, DOI 10.1097/MBC.0000000000000203
   Paciaroni M, 2008, STROKE, V39, P2249, DOI 10.1161/STROKEAHA.107.510321
   Paciaroni M, 2007, STROKE, V38, P423, DOI 10.1161/01.STR.00002546000.92975.1f
   Paikin JS, 2015, CHEST, V148, P587, DOI 10.1378/chest.14-2710
   Pallisgaard JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141377
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Perzborn E, 2014, THROMB RES, V133, P671, DOI 10.1016/j.thromres.2014.01.017
   PESSIN MS, 1993, NEUROLOGY, V43, P1298
   Piccini JP, 2016, CIRCULATION, V133, P352, DOI 10.1161/CIRCULATIONAHA.115.018544
   Piccini JP, 2014, EUR HEART J, V35, P1873, DOI 10.1093/eurheartj/ehu083
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Ploen R, 2014, J CEREBR BLOOD F MET, V34, P495, DOI 10.1038/jcbfm.2013.226
   Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000
   Powers WJ, 2015, STROKE, V46, P3020, DOI 10.1161/STR.0000000000000074
   Providencia R, 2014, HEART, V100, P324, DOI 10.1136/heartjnl-2013-304386
   Qureshi AI, 2016, NEW ENGL J MED, V375, P1033, DOI 10.1056/NEJMoa1603460
   Ratanapo S, 2013, AM J MED SCI, V346, P259, DOI [10.1097/MAJ.0b013e318295cc72, 10.1097/MAJ.0b013e3182960987]
   Rodriguez-Luna D, 2013, EUR J NEUROL, V20, P1277, DOI 10.1111/ene.12180
   Rosencher N, 2013, ACTA ANAESTH SCAND, V57, P565, DOI 10.1111/aas.12069
   Rowley CP, 2013, AM J CARDIOL, V111, P1165, DOI 10.1016/j.amjcard.2012.12.046
   Ruff CT, 2015, LANCET, V385, P2288, DOI 10.1016/S0140-6736(14)61943-7
   Ruff CT, 2014, J AM COLL CARDIOL, V64, P576, DOI 10.1016/j.jacc.2014.05.028
   Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0
   Sajkov Dimitar, 2015, Clin Med Insights Case Rep, V8, P57, DOI 10.4137/CCRep.S27992
   Sakamoto Y, 2013, STROKE, V44, P1846, DOI 10.1161/STROKEAHA.113.001212
   Sandercock PAG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000024.pub4
   Santangeli P, 2012, CIRC-ARRHYTHMIA ELEC, V5, P302, DOI 10.1161/CIRCEP.111.964916
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x
   Schulman S, 2015, CIRCULATION, V132, P167, DOI 10.1161/CIRCULATIONAHA.115.015688
   Seiffge DJ, 2015, CIRCULATION, V132, P1261, DOI 10.1161/CIRCULATIONAHA.115.015484
   Sen P, 2016, AM J CARDIOVASC DRUG, V16, P33, DOI 10.1007/s40256-015-0136-1
   Sherwood MW, 2016, JACC-CARDIOVASC INTE, V9, P1694, DOI [10.1016/j.jcin.2016.05.039, 10.1016/j.jcin.2016.05.03]
   Sherwood MW, 2015, J AM COLL CARDIOL, V66, P2271, DOI 10.1016/j.jacc.2015.09.024
   Sherwood MW, 2014, CIRCULATION, V129, P1850, DOI 10.1161/CIRCULATIONAHA.113.005754
   Shurrab M, 2013, CAN J CARDIOL, V29, P1203, DOI 10.1016/j.cjca.2013.07.005
   Siegal DM, 2015, NEW ENGL J MED, V373, P2413, DOI 10.1056/NEJMoa1510991
   Spiller HA, 2016, ANN EMERG MED, V67, P189, DOI 10.1016/j.annemergmed.2015.07.014
   Staerk L, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5876
   Stevenson JW, 2014, AM J EMERG MED, V32, P1077, DOI 10.1016/j.ajem.2014.04.031
   Sun L, 2013, THROMB HAEMOSTASIS, V110, P153, DOI 10.1160/TH12-12-0942
   Terrovitis JV, 2015, HELL J CARDIOL, V56, P20
   Turpie AGG, 2014, THROMB HAEMOSTASIS, V111, P94, DOI 10.1160/TH13-08-0666
   Verheugt FWA, 2015, LANCET, V386, P303, DOI 10.1016/S0140-6736(15)60245-8
   Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3
   Wallace TW, 2010, J CARDIOVASC ELECTR, V21, P849, DOI 10.1111/j.1540-8167.2010.01729.x
   Woo Jason S, 2013, J Med Toxicol, V9, P192, DOI 10.1007/s13181-012-0276-5
   Zahir H, 2015, CIRCULATION, V131, P82, DOI 10.1161/CIRCULATIONAHA.114.013445
NR 178
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD MAR 7
PY 2017
VL 135
IS 10
BP E604
EP E633
DI 10.1161/CIR.0000000000000477
PG 30
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA EN1KP
UT WOS:000395769200003
PM 28167634
ER


PT J
AU Koziolova, NA
   Polyanskaya, EA
   Kolegova, II
AF Koziolova, N. A.
   Polyanskaya, E. A.
   Kolegova, I. I.
TI The Choice of Anticoagulant Therapy in Patients With Non-Valvular Atrial
   Fibrillation and Chronic Kidney Disease
SO KARDIOLOGIYA
LA Russian
DT Article
DE anticoagulation; atrial fibrillation; chronic kidney disease
ID GLOMERULAR-FILTRATION-RATE; SEVERE RENAL IMPAIRMENT; VITAMIN-K; VASCULAR
   CALCIFICATION; HEMODIALYSIS-PATIENTS; ORAL ANTICOAGULANTS; WARFARIN
   TREATMENT; SYSTEMIC EMBOLISM; ANTITHROMBOTIC THERAPY;
   MYOCARDIAL-INFARCTION
AB The review shows the prevalence of atrial fibrillation (AF) in patients with chronic kidney disease (CKD), depending on the severity of the disease. Patients with non-valvular AF and CKD have a significantly increased risk of both bleeding and thromboembolic complications, and death from all causes. Evaluation of the results of randomized clinical trials (RCTs), meta-analyzes of RCTs demonstrated the advantages of the new oral anticoagulants (NOAC), such as dabigatran, rivaroxaban, apixaban, compared with warfarin in reducing the risk of bleeding in patients with AF and CKD in predialysis stage. According to experimental and clinical studies, warfarin can promote renal vascular calcification. With the deterioration of filtration renal function during treatment with anticoagulants in patients with AF on the results of ROCKET AF study found that rivaroxaban is more preferable than warfarin in reducing the risk of stroke and systemic embolism without increasing the risk of bleeding. The absence of RCT data complicates the choice of anticoagulant therapy in patients with CKD on hemodialysis, although the NOAC approved by the Office of Quality Control Food and Drug US drugs (FDA) for the use of patients in this category. According to the instruction drugs rivaroxaban and apixaban are allowed to use in patients with end-stage CKD with creatinine clearance not less than 15 ml/min.
C1 [Koziolova, N. A.; Polyanskaya, E. A.; Kolegova, I. I.] Perm State Med Univ, Hlth Minist Russian Federat, Perm, Russia.
RP Koziolova, NA (reprint author), Perm State Med Univ, Hlth Minist Russian Federat, Propaedeut Internal Dis Dept 2, Perm, Russia.
EM nakoziolova@mail.ru
CR Ahmad Y, 2013, CONTRIB NEPHROL, V179, P81, DOI 10.1159/000346726
   Bai Y, 2016, THROMB RES, V137, P46, DOI 10.1016/j.thromres.2015.11.020
   Bansal N, 2016, CLIN J AM SOC NEPHRO, V11, P1189, DOI 10.2215/CJN.10921015
   Bansal N, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001303
   Bonde AN, 2014, J AM COLL CARDIOL, V64, P2471, DOI 10.1016/j.jacc.2014.09.051
   Brancaccio D, 2016, AM J NEPHROL, V44, P258, DOI 10.1159/000448898
   Carrero JJ, 2014, JAMA-J AM MED ASSOC, V311, P919, DOI 10.1001/jama.2014.1334
   Chan KE, 2016, J AM COLL CARDIOL, V67, P2888, DOI 10.1016/j.jacc.2016.02.082
   Chan KE, 2009, J AM SOC NEPHROL, V20, P2223, DOI 10.1681/ASN.2009030319
   Charytan DM, 2016, CLIN J AM SOC NEPHRO, V11, P721, DOI 10.2215/CJN.09350915
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Dahal K, 2016, CHEST, V149, P951, DOI 10.1378/chest.15-1719
   Danziger J, 2008, CLIN J AM SOC NEPHRO, V3, P1504, DOI 10.2215/CJN.00770208
   De Vriese AS, 2015, AM J KIDNEY DIS, V66, P91, DOI 10.1053/j.ajkd.2015.01.022
   Deal EN, 2014, ANN PHARMACOTHER, V48, P1667, DOI 10.1177/1060028014554446
   El Asmar Margueritta S, 2014, Oman Med J, V29, P172, DOI 10.5001/omj.2014.44
   Elliott MJ, 2007, AM J KIDNEY DIS, V50, P433, DOI 10.1053/j.ajkd.2007.06.017
   Fordyce CB, 2016, CIRCULATION, V134, P37, DOI 10.1161/CIRCULATIONAHA.116.021890
   Fox KAA, 2011, EUR HEART J, V32, P2387, DOI 10.1093/eurheartj/ehr342
   Gill S., 2016, NEPHROL DIAL TRANSPL, DOI [10.1093/ndt/gfw378, DOI 10.1093/NDT/GFW378]
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Han H, 2015, J RENAL NUTR, V25, pE7, DOI 10.1053/j.jrn.2014.10.002
   Hara T, 2015, ATHEROSCLEROSIS, V242, P639, DOI 10.1016/j.atherosclerosis.2015.03.023
   Harel Z, 2014, J AM SOC NEPHROL, V25, P431, DOI 10.1681/ASN.2013040361
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Heidbuchel H, 2015, EUROPACE, V17, P1467, DOI 10.1093/europace/euv309
   Hijazi Z, 2014, CIRCULATION, V129, P961, DOI 10.1161/CIRCULATIONAHA.113.003628
   Hohnloser SH, 2012, EUR HEART J, V33, P2821, DOI 10.1093/eurheartj/ehs274
   Holden RM, 2010, CLIN J AM SOC NEPHRO, V5, P590, DOI 10.2215/CJN.06420909
   January Craig T, 2014, J Am Coll Cardiol, V64, pe1, DOI 10.1016/j.jacc.2014.03.022
   Jonsson KM, 2011, THROMB RES, V128, P341, DOI 10.1016/j.thromres.2011.04.022
   Jun M, 2015, BMJ-BRIT MED J, V350, DOI [10.1136/bmj.h246, 10.1136/BMJ.h246]
   Keskar V, 2016, CLIN J AM SOC NEPHRO, V11, P2085, DOI 10.2215/CJN.03200316
   Kirchhof P, 2016, EUR HEART J
   Kooiman J, 2011, J THROMB HAEMOST, V9, P1652, DOI 10.1111/j.1538-7836.2011.04347.x
   Lee IO, 2012, J PHARMACOL EXP THER, V343, P253, DOI 10.1124/jpet.112.194837
   Lee M, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4249
   Lega JC, 2014, J THROMB HAEMOST, V12, P337, DOI 10.1111/jth.12486
   Liesenfeld KH, 2016, THROMB HAEMOSTASIS, V115, P562, DOI 10.1160/TH15-07-0531
   Marinigh R, 2011, J AM COLL CARDIOL, V57, P1339, DOI 10.1016/j.jacc.2010.12.013
   Ng KP, 2013, AM J KIDNEY DIS, V62, P615, DOI 10.1053/j.ajkd.2013.02.381
   Olesen JB, 2012, NEW ENGL J MED, V367, P625, DOI 10.1056/NEJMoa1105594
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2013, CIRCULATION, V127, P224, DOI 10.1161/CIRCULATIONAHA.112.107128
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Pokorney SD, 2015, AM HEART J, V170, P141, DOI 10.1016/j.ahj.2015.03.017
   Potpara TS, 2015, EUROPACE, V17, P1862, DOI 10.1093/europace/euv416
   Providencia R, 2014, AM J CARDIOL, V114, P646, DOI 10.1016/j.amjcard.2014.05.048
   Raggi P, 2004, ARTERIOSCL THROM VAS, V24, P1272, DOI 10.1161/01.ATV.0000127024.40516.ef
   Ross EA, 2011, AM J NEPHROL, V34, P460, DOI 10.1159/000332221
   Ruiz-Ortiz M, 2015, THROMB HAEMOSTASIS, V114, P695, DOI 10.1160/TH15-02-0169
   Sakaan SA, 2014, PHARMACOTHERAPY, V34, P695, DOI 10.1002/phar.1445
   Saran R, 2016, AM J KIDNEY DIS, V67, pSVII, DOI 10.1053/j.ajkd.2015.12.014
   Sardar P, 2014, CAN J CARDIOL, V30, P888, DOI 10.1016/j.cjca.2014.04.015
   Schurgers LJ, 2008, THROMB HAEMOSTASIS, V100, P593, DOI 10.1160/TH08-02-0087
   Schurgers LJ, 2013, KIDNEY INT, V83, P782, DOI 10.1038/ki.2013.26
   Schurgers LJ, 2010, CLIN J AM SOC NEPHRO, V5, P568, DOI 10.2215/CJN.07081009
   Shah M, 2014, CIRCULATION, V129, P1196, DOI 10.1161/CIRCULATIONAHA.113.004777
   Shang WF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155581
   Shea MK, 2012, ADV NUTR, V3, P158, DOI 10.3945/an.111.001644
   Soliman EZ, 2010, AM HEART J, V159, P1102, DOI 10.1016/j.ahj.2010.03.027
   Tan JW, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0368-6
   Tantisattamo E, 2015, ARTERIOSCL THROM VAS, V35, P237, DOI 10.1161/ATVBAHA.114.304392
   Theuwissen E, 2012, ADV NUTR, V3, P166, DOI 10.3945/an.111.001628
   Toyoda K, 2014, LANCET NEUROL, V13, P823, DOI 10.1016/S1474-4422(14)70026-2
   Verma A, 2014, CAN J CARDIOL, V30, P1114, DOI 10.1016/j.cjca.2014.08.001
   Wang HH, 2014, AM J KIDNEY DIS, V63, P604, DOI 10.1053/j.ajkd.2013.10.013
   Wei FF, 2016, PULSE, V4, P85, DOI 10.1159/000448008
   Winkelmayer WC, 2011, CLIN J AM SOC NEPHRO, V6, P2662, DOI 10.2215/CJN.04550511
   Wizemann V, 2010, KIDNEY INT, V77, P1098, DOI 10.1038/ki.2009.477
   Wong CX, 2016, AM J CARDIOL, V117, P1934, DOI 10.1016/j.amjcard.2016.03.042
   Yang F., 2016, HEART, DOI [10.1136/heartjnl-2016-309266, DOI 10.1136/HEARTJNL-2016-309266]
   Zhang YT, 2014, J CARDIOVASC PHARM, V63, P76, DOI 10.1097/FJC.0000000000000008
   Zimmerman D, 2012, NEPHROL DIAL TRANSPL, V27, P3816, DOI 10.1093/ndt/gfs416
NR 75
TC 0
Z9 0
U1 0
U2 0
PU IZDATELSTVO MEDITSINA
PI MOSCOW
PA PETROVERIGSKII PER 6-8, K-142 MOSCOW, RUSSIA
SN 0022-9040
J9 KARDIOLOGIYA
JI Kardiologiya
PY 2017
VL 57
IS 1
BP 76
EP 85
DI 10.18565/cardio.2017.1.76-85
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EO8WD
UT WOS:000396970300011
ER


PT J
AU Ratliff, C
   Gentry, J
   Kusmierczyk, J
   Hartke, KM
   Acierno, MJ
   Musser, JMB
   Russell, KE
   Heatley, JJ
AF Ratliff, Cameron
   Gentry, Jordan
   Kusmierczyk, James
   Hartke, Kevin M.
   Acierno, Mark J.
   Musser, Jeffrey M. B.
   Russell, Karen E.
   Heatley, J. Jill
TI Venous Blood Gas, Electrolyte, and Hematologic Analytes of the Mottled
   Duck, Anas fulvigula
SO JOURNAL OF WILDLIFE DISEASES
LA English
DT Article
DE Acid-base status; avian; Anseriformes; complete blood count;
   free-living; iSTAT 1; osmolality; Texas Gulf Coast
ID CELL VALUES; PLATYRHYNCHOS; MALLARD; PLASMA; CHEMISTRY; STRESS
AB We collected venous blood samples from 83 apparently healthy Mottled Ducks (Anas fulvigula) July 2012-August 2013 on the Texas, US, Gulf Coast and measured blood gas, electrolyte, biochemical, and hematologic parameters. Age, sex, body condition score, capture year, capture type, and time of day had significant statistical, but not clinically relevant, effects on several analytes. Ducks caught by rocket net had findings consistent with greater stress compared with hand-caught ducks. These analyte data for healthy free-living Mottled Ducks may be useful in the assessment of Mottled Duck population health and in the management and treatment of individual ducks affected by environmental stressors.
C1 [Ratliff, Cameron; Gentry, Jordan; Heatley, J. Jill] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Small Anim Clin Sci, 4474 TAMU, College Stn, TX 77843 USA.
   [Kusmierczyk, James] Cameron Pk Zoo, 1701 N 4th St, Waco, TX 76707 USA.
   [Hartke, Kevin M.] Texas Parks & Wildlife Dept, Wildlife Div, 915 Front St, Richmond, TX 77469 USA.
   [Acierno, Mark J.] Louisiana State Univ, Sch Vet Med, Dept Vet Clin Sci, Skip Bertman Dr, Baton Rouge, LA 70803 USA.
   [Russell, Karen E.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, 4474 TAMU, College Stn, TX 77845 USA.
RP Ratliff, C (reprint author), Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Small Anim Clin Sci, 4474 TAMU, College Stn, TX 77843 USA.
EM cratliff@cvm.tamu.edu
FU Texas General Land Office; Schubot Exotic Bird Health Center; Texas
   Parks & Wildlife Department Central Coast Wetlands Ecosystem Project;
   Wildlife Center of Texas; Texas A&M University, College of Veterinary
   Medicine and Biomedical Sciences
FX We thank the Texas General Land Office, Schubot Exotic Bird Health
   Center, Texas Parks & Wildlife Department Central Coast Wetlands
   Ecosystem Project, the Wildlife Center of Texas, and Texas A&M
   University, College of Veterinary Medicine and Biomedical Sciences, for
   support of this project.
CR Abbott Point of Care Inc, 2012, ISTAT 1 SYST MAN
   Acierno MJ, 2009, AM J VET RES, V70, P1151, DOI 10.2460/ajvr.70.9.1151
   BELL DJ, 1959, BIOCHEM J, V71, P355
   Bielefeld RR, 2010, MOTTLED DUCK ANAS FU
   Carney SM, 1992, SPECIES AGE SEX IDEN, P32
   Clark P, 2009, ATLAS CLIN AVIAN HEM, P27
   DRIVER EA, 1981, J WILDLIFE DIS, V17, P413
   FAIRBROTHER A, 1990, J WILDLIFE DIS, V26, P67
   FAIRBROTHER A, 1990, J WILDLIFE DIS, V26, P78
   Friedrichs KR, 2012, VET CLIN PATH, V41, P441, DOI 10.1111/vcp.12006
   Friend M, 1999, 42 US GEOL SURV, P309
   GROSS WB, 1983, AVIAN DIS, V27, P972, DOI 10.2307/1590198
   Heatley J. J., 2013, Veterinary Medicine: Research and Reports, V4, P21
   HILL EF, 1987, COMP BIOCHEM PHYS B, V87, P933, DOI 10.1016/0305-0491(87)90415-9
   MAXWELL MH, 1993, WORLD POULTRY SCI J, V49, P34, DOI 10.1079/WPS19930004
   Merendino MT, 2005, WILDLIFE SOC B, V33, P1002, DOI 10.2193/0091-7648(2005)33[1002:RDALTI]2.0.CO;2
   MULLEY RC, 1979, J WILDLIFE DIS, V15, P437
   Olayemi Funsho, 2003, Veterinarski Arhiv, V73, P271
   SHAVE H J, 1976, Journal of Wildlife Diseases, V12, P195
   Tully TN, 2000, HDB AVIAN MED
NR 20
TC 0
Z9 0
U1 1
U2 1
PU WILDLIFE DISEASE ASSOC, INC
PI LAWRENCE
PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA
SN 0090-3558
EI 1943-3700
J9 J WILDLIFE DIS
JI J. Wildl. Dis.
PD JAN
PY 2017
VL 53
IS 1
BP 159
EP 164
DI 10.7589/2015-10-288
PG 6
WC Veterinary Sciences
SC Veterinary Sciences
GA EI3HL
UT WOS:000392380700022
PM 27749193
ER


PT J
AU Steinberg, BA
AF Steinberg, Benjamin A.
TI How I use anticoagulation in atrial fibrillation
SO BLOOD
LA English
DT Review
ID PERCUTANEOUS CORONARY INTERVENTION; NET CLINICAL BENEFIT; ROCKET AF
   TRIAL; ORAL ANTICOAGULANTS; STROKE PREVENTION; ANTITHROMBOTIC THERAPY;
   TEMPORAL RELATIONSHIP; ANTIPLATELET THERAPY; CONCOMITANT ASPIRIN;
   INFORMED TREATMENT
AB Atrial fibrillation is the most common cardiac arrhythmia and conveys a significant risk of morbidity and mortality due to related stroke and systemic embolism. Oral anticoagulation (OAC) is the mainstay of thromboembolism prevention, and management of anticoagulation can be challenging. For patients without significant valvular disease, decisions around anticoagulation therapy are first based on the presence of additional stroke risk factors, as measured by the CHA2DS2-VASc (congestive heart failure, hypertension, age >= 75, diabetes, prior stroke or transient ischemic attack, vascular disease, age 65-74, and sex category [female]) score. Patients with increased CHA2DS2-VASc scores (by regional guidelines) should next be evaluated to determine if they are candidates for non-vitamin K antagonist oral anticoagulant (NOAC) therapy. This should focus on assessment of concomitant valve disease and/or impaired renal function. In eligible patients, the cumulative data support a preference for NOACs over warfarin, as NOACs appear safer and more effective as a group. However, there are no direct, randomized comparisons between NOACs, and therefore, selecting among them can be difficult. In addition, important patient groups remain under-represented in major clinical trials, and their management is often left to clinician judgment. Data from emerging clinical trials will help guide physicians; however, patient engagement in decisions regarding OAC management will remain vital to ensuring appropriate balance of risks and optimizing health outcomes.
C1 [Steinberg, Benjamin A.] Univ Utah, Hlth Sci Ctr, Div Cardiovasc Med, Salt Lake City, UT USA.
EM benjamin.steinberg@hsc.utah.edu
CR Ageno W, 2012, CHEST S, V141, DOI DOI 10.1378/CHEST.11-2292
   Alexander JH, 2014, EUR HEART J, V35, P224, DOI 10.1093/eurheartj/eht445
   Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819
   Bhatt DL, 2010, NEW ENGL J MED, V363, P1909, DOI 10.1056/NEJMoa1007964
   Brambatti M, 2014, CIRCULATION, V129, P2094, DOI 10.1161/CIRCULATIONAHA.113.007825
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Cappato R, 2014, EUR HEART J, V35, P3346, DOI 10.1093/eurheartj/ehu367
   Chao TF, 2016, CIRCULATION, V133, P1540, DOI 10.1161/CIRCULATIONAHA.115.019794
   Connolly S, 2006, LANCET, V367, P1903
   Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301
   Connolly SJ, 2011, ANN INTERN MED, V155, P579, DOI 10.7326/0003-4819-155-9-201111010-00004
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Dans AL, 2013, CIRCULATION, V127, P634, DOI 10.1161/CIRCULATIONAHA.112.115386
   Daoud EG, 2011, HEART RHYTHM, V8, P1416, DOI 10.1016/j.hrthm.2011.04.022
   De Caterina R, 2014, EUR HEART J, V35, P3328, DOI 10.1093/eurheartj/ehu352
   Dewilde WJM, 2014, J AM COLL CARDIOL, V64, P1270, DOI 10.1016/j.jacc.2014.06.1193
   Dewilde WJM, 2013, LANCET, V381, P1107, DOI 10.1016/S0140-6736(12)62177-1
   Diener HC, 2017, EUR HEART J, V38, P860, DOI 10.1093/eurheartj/ehw069
   Douketis JD, 2015, NEW ENGL J MED, V373, P823, DOI 10.1056/NEJMoa1501035
   Douketis JD, 2012, CHEST S, V141
   Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
   Fang MC, 2011, J AM COLL CARDIOL, V58, P395, DOI 10.1016/j.jacc.2011.03.031
   Flaker G, 2014, J AM COLL CARDIOL, V63, P1082, DOI 10.1016/j.jacc.2013.09.062
   Friberg L, 2012, CIRCULATION, V125, P2298, DOI 10.1161/CIRCULATIONAHA.111.055079
   Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864
   Gibson CM, 2015, AM HEART J, V169, P472, DOI 10.1016/j.ahj.2014.12.006
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Hart RG, 1999, ANN INTERN MED, V131, P492
   Holmes DR, 2009, LANCET, V374, P534, DOI 10.1016/S0140-6736(09)61343-X
   January CT, 2014, CIRCULATION, V130, pE199, DOI 10.1161/CIR.0000000000000041
   Jones M, 2005, HEART, V91, P472, DOI 10.1136/hrt.2004.042465
   Kamel H, 2016, STROKE, V47, P895, DOI 10.1161/STROKEAHA.115.012004
   Kirchhof P, 2016, EUR HEART J, V2016
   Lip GYH, 2014, EUR HEART J, V35, P3155, DOI 10.1093/eurheartj/ehu298
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277
   Molteni M, 2014, EUROPACE, V16, P1720, DOI 10.1093/europace/euu178
   Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546
   O'Brien EC, 2015, EUR HEART J, V36, P3258, DOI 10.1093/eurheartj/ehv476
   Onundarson PT, 2016, INT J LAB HEMATOL, V38, P78, DOI 10.1111/ijlh.12537
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Perzborn E, 2011, NAT REV DRUG DISCOV, V10, P61, DOI 10.1038/nrd3185
   Piccini JP, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000521
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000
   Rechenmacher SJ, 2015, J AM COLL CARDIOL, V66, P1392, DOI 10.1016/j.jacc.2015.08.002
   Reddy VY, 2013, CIRCULATION, V127, P720, DOI 10.1161/CIRCULATIONAHA.112.114389
   Reddy VY, 2011, CIRCULATION, V123, P417, DOI 10.1161/CIRCULATIONAHA.110.976449
   Ruff CT, 2016, CIRCULATION, V134, P248, DOI 10.1161/CIRCULATIONAHA.116.021831
   Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0
   Savelieva I, 2014, CLIN CARDIOL, V37, P32, DOI 10.1002/clc.22204
   Schotten U, 2011, PHYSIOL REV, V91, P265, DOI 10.1152/physrev.00031.2009
   Sherwood MW, 2015, J AM COLL CARDIOL, V66, P2271, DOI 10.1016/j.jacc.2015.09.024
   Steinberg BA, 2015, CIRCULATION, V131, P488, DOI 10.1161/CIRCULATIONAHA.114.011777
   Steinberg BA, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2116
   Steinberg BA, 2013, CIRCULATION, V128, P721, DOI 10.1161/CIRCULATIONAHA.113.002927
   Wallentin L, 2013, CIRCULATION, V127, P2166, DOI 10.1161/CIRCULATIONAHA.112.142158
   Weitz JI, 2012, HEMATOL-AM SOC HEMAT, P536, DOI 10.1182/asheducation-2012.1.536
   White HD, 2007, ARCH INTERN MED, V167, P239, DOI 10.1001/archinte.167.3.239
   WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561
   WOLF PA, 1978, NEUROLOGY, V28, P973
   Xu HY, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002587
NR 66
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD DEC 22
PY 2016
VL 128
IS 25
BP 2891
EP 2898
DI 10.1182/blood-2016-07-693614
PG 8
WC Hematology
SC Hematology
GA EI7CO
UT WOS:000392655100008
PM 27780804
ER


PT J
AU Hori, T
   Oike, F
   Furuyama, H
   Machimoto, T
   Kadokawa, Y
   Hata, T
   Kato, S
   Yasukawa, D
   Aisu, Y
   Sasaki, M
   Kimura, Y
   Takamatsu, Y
   Naito, M
   Nakauchi, M
   Tanaka, T
   Gunji, D
   Nakamura, K
   Sato, K
   Mizuno, M
   Iida, T
   Yagi, S
   Uemoto, S
   Yoshimura, T
AF Hori, Tomohide
   Oike, Fumitaka
   Furuyama, Hiroaki
   Machimoto, Takafumi
   Kadokawa, Yoshio
   Hata, Toshiyuki
   Kato, Shigeru
   Yasukawa, Daiki
   Aisu, Yuki
   Sasaki, Maho
   Kimura, Yusuke
   Takamatsu, Yuichiro
   Naito, Masato
   Nakauchi, Masaya
   Tanaka, Takahiro
   Gunji, Daigo
   Nakamura, Kiyokuni
   Sato, Kiyoko
   Mizuno, Masahiro
   Iida, Taku
   Yagi, Shintaro
   Uemoto, Shinji
   Yoshimura, Tsunehiro
TI Protocol for laparoscopic cholecystectomy: Is it rocket science?
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE laparoscopic cholecystectomy; gallbladder; critical view of safety;
   biliary injury; protocol
ID BILE-DUCT INJURY; BILIARY INJURY; INTRAOPERATIVE CHOLANGIOGRAPHY;
   FLUORESCENT CHOLANGIOGRAPHY; SURGICAL-MANAGEMENT; RISK-FACTORS;
   EXPERIENCE; EFFICACY; SAFETY; ERA
AB Laparoscopic cholecystectomy (LC) does not require advanced techniques, and its performance has therefore rapidly spread worldwide. However, the rate of biliary injuries has not decreased. The concept of the critical view of safety (CVS) was first documented two decades ago. Unexpected injuries are principally due to misidentification of human factors. The surgeon's assumption is a major cause of misidentification, and a high level of experience alone is not sufficient for successful LC. We herein describe tips and pitfalls of LC in detail and discuss various technical considerations. Finally, based on a review of important papers and our own experience, we summarize the following mandatory protocol for safe LC: (1) consideration that a high level of experience alone is not enough; (2) recognition of the plateau involving the common hepatic duct and hepatic hilum; (3) blunt dissection until CVS exposure; (4) Calot's triangle clearance in the overhead view; (5) Calot's triangle clearance in the view from underneath; (6) dissection of the posterior right side of Calot's triangle; (7) removal of the gallbladder body; and (8) positive CVS exposure. We believe that adherence to this protocol will ensure successful and beneficial LC worldwide, even in patients with inflammatory changes and rare anatomies.
C1 [Hori, Tomohide; Furuyama, Hiroaki; Machimoto, Takafumi; Kadokawa, Yoshio; Hata, Toshiyuki; Kato, Shigeru; Yasukawa, Daiki; Aisu, Yuki; Sasaki, Maho; Kimura, Yusuke; Takamatsu, Yuichiro; Yoshimura, Tsunehiro] Tenriyorodusoudanjyo Hosp, Dept Gastrointestinal & Gen Surg, 200 Mishima Cho, Tenri, Nara 6328552, Japan.
   [Oike, Fumitaka; Naito, Masato; Nakauchi, Masaya; Tanaka, Takahiro; Gunji, Daigo; Nakamura, Kiyokuni] Mitsubishi Kyoto Hosp, Dept Gastrointestinal Surg, Kyoto 6158087, Japan.
   [Sato, Kiyoko] Mitsubishi Kyoto Hosp, Dept Anesthesiol, Kyoto 6158087, Japan.
   [Mizuno, Masahiro] Mitsubishi Kyoto Hosp, Dept Gastroenterol & Hepatol, Kyoto 6158087, Japan.
   [Iida, Taku; Yagi, Shintaro; Uemoto, Shinji] Kyoto Univ Hosp, Dept Hepatobiliary Pancreat Surg, Kyoto 6068507, Japan.
RP Hori, T (reprint author), Tenriyorodusoudanjyo Hosp, Dept Gastrointestinal & Gen Surg, 200 Mishima Cho, Tenri, Nara 6328552, Japan.
EM horitomo@tenriyorozu.jp
CR Amalakuhan B, 2015, INT J CHRONIC OBSTR, V10, P1225, DOI 10.2147/COPD.S71450
   ASBUN HJ, 1993, WORLD J SURG, V17, P547
   Auyang ED, 2009, SURG ENDOSC, V23, P1117, DOI 10.1007/s00464-009-0407-5
   Ballal M, 2009, SURG ENDOSC, V23, P2338, DOI 10.1007/s00464-009-0338-1
   Bismuth H., 1982, THE BILIARY TRACT, P209
   Blrunt LM, 2014, CURRENT SURG THERAPY, P1305
   Breitenstein S, 2008, ANN SURG, V247, P987, DOI 10.1097/SLA.0b013e318172501f
   Callery MP, 2006, SURG ENDOSC, V20, P1654, DOI 10.1007/s00464-006-0488-3
   Dallemagne B, 2009, BRIT J SURG, V96, P1162, DOI 10.1002/bjs.6704
   de Reuver PR, 2007, SURGERY, V142, P1, DOI 10.1016/j.surg.2007.03.004
   Della Flora E, 2008, ANN SURG, V247, P583, DOI 10.1097/SLA.0b013e3181656ce9
   Dolan JP, 2005, SURG ENDOSC, V19, P967, DOI 10.1007/s00464-004-8942-6
   DUBOIS F, 1989, PRESSE MED, V18, P980
   El Nakeeb A, 2010, SURG ENDOSC, V24, P2536, DOI 10.1007/s00464-010-0999-9
   Elsey JK, 2010, J AM COLL SURGEONS, V210, P620, DOI 10.1016/j.jamcollsurg.2009.12.030
   Elsey JK, 2014, CURRENT SURG THERAPY, P387
   Ezer A, 2008, AM J SURG, V196, P456, DOI 10.1016/j.amjsurg.2008.02.006
   Fatima J, 2010, J AM COLL SURGEONS, V211, P495, DOI 10.1016/j.jamcollsurg.2010.06.013
   Ferguson C M, 1992, Surg Laparosc Endosc, V2, P1
   Fletcher DR, 1999, ANN SURG, V229, P449, DOI 10.1097/00000658-199904000-00001
   Flum DR, 2003, JAMA-J AM MED ASSOC, V289, P1639, DOI 10.1001/jama.289.13.1639
   Gentileschi P, 2004, SURG ENDOSC, V18, P232, DOI 10.1007/s00464-003-8815-4
   Georgiades CP, 2008, SURG ENDOSC, V22, P1959, DOI 10.1007/s00464-008-9943-7
   Goto M, 2015, TAIWAN J OBSTET GYNE, V54, P248, DOI 10.1016/j.tjog.2014.09.008
   Gould MK, 2012, CHEST, V141, pE227S, DOI 10.1378/chest.11-2297
   Halawani HM, 2016, SURG ENDOSC, V30, P5395, DOI 10.1007/s00464-016-4896-8
   Hansen N, 2014, JSLS-J SOC LAPAROEND, V18, DOI 10.4293/JSLS.2014.00383
   Hobbs MS, 2006, BRIT J SURG, V93, P844, DOI 10.1002/bjs.5333
   Hogan AM, 2009, ANN SURG, V249, P292, DOI 10.1097/SLA.0b013e318195c50c
   Hori T, 2015, CASE REP SURG, V2015, DOI DOI 10.1155/2015/487639
   Hori Tomohide, 2013, World J Gastrointest Surg, V5, P272, DOI 10.4240/wjgs.v5.i10.272
   Humes DJ, 2010, ARCH SURG-CHICAGO, V145, P96, DOI 10.1001/archsurg.2009.236
   Ingraham AM, 2010, J AM COLL SURGEONS, V211, P176, DOI 10.1016/j.jamcollsurg.2010.04.003
   Jacobsen GR, 2014, SURG ENDOSC, V28, P484, DOI 10.1007/s00464-013-3227-6
   Karvonen J, 2007, SURG ENDOSC, V21, P1069, DOI 10.1007/s00464-007-9316-7
   Kelly K, 2012, BLUMGARTS SURG LIVER, V1, P487
   Keus F, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006231
   Kho ME, 2015, J CRIT CARE, V30, DOI 10.1016/j.jcrc.2015.07.025
   Kitano S, 1994, Surg Technol Int, V3, P181
   Kum CK, 1996, WORLD J SURG, V20, P43
   Kuroda Y, 2010, SURG ENDOSC, V24, P834, DOI 10.1007/s00464-009-0673-2
   Li J, 2008, BRIT J SURG, V95, P460, DOI 10.1002/bjs.6022
   Louizos AA, 2005, SURG ENDOSC, V19, P1503, DOI 10.1007/s00464-005-0108-7
   Maeso S, 2010, ANN SURG, V252, P254, DOI 10.1097/SLA.0b013e3181e6239e
   Maghsoudi H, 2005, AM J SURG, V190, P430, DOI 10.1016/j.amjsurg.2005.04.015
   Mallon P, 2006, SURG ENDOSC, V20, P883, DOI 10.1007/s00464-005-0598-3
   March B, 2016, ANZ J SURG, V86, P874, DOI 10.1111/ans.13676
   Milic DJ, 2007, SURG ENDOSC, V21, P1588, DOI 10.1007/s00464-006-9179-3
   Nagle A, 2012, BLUMGARTS SURG LIVER, V1, P511
   Nooghabi AJ, 2016, SURG LAPARO ENDO PER, V26, P183
   Park JI, 2015, J HEPATO-BIL-PAN SCI, V22, P779, DOI 10.1002/jhbp.288
   PARK YH, 1992, AM SURGEON, V58, P321
   Pesce A, 2015, WORLD J GASTROENTERO, V21, P7877, DOI 10.3748/wjg.v21.i25.7877
   PETERS JH, 1991, ANN SURG, V213, P3, DOI 10.1097/00000658-199101000-00002
   Philipp SR, 2009, J AM COLL SURGEONS, V209, P632, DOI 10.1016/j.jamcollsurg.2009.07.020
   Rauws EAJ, 2004, BEST PRACT RES CL GA, V18, P829, DOI 10.1016/j.bpg.2004.05.003
   Rosemurgy AS, 2010, J AM COLL SURGEONS, V210, P624
   Schmidt SC, 2004, SURGERY, V135, P613, DOI 10.1016/j.surg.2003.11.018
   Schmidt SC, 2005, BRIT J SURG, V92, P76, DOI 10.1002/bjs.4775
   SCHOL FPG, 1994, BRIT J SURG, V81, P1786, DOI 10.1002/bjs.1800811225
   Sicklick JK, 2005, ANN SURG, V241, P786, DOI 10.1097/01.sla.0000161029.27410.71
   SOPER NJ, 1991, CURR PROB SURG, V28, P587, DOI 10.1016/0011-3840(91)90041-M
   STRASBERG SM, 1995, J AM COLL SURGEONS, V180, P101
   Strasberg SM, 2000, J AM COLL SURGEONS, V191, P661, DOI 10.1016/S1072-7515(00)00717-1
   Sun SX, 2016, ANN SURG, V263, P1164, DOI 10.1097/SLA.0000000000001348
   Tantia O, 2008, SURG ENDOSC, V22, P1077, DOI 10.1007/s00464-007-9740-8
   Velimezis G, 2015, AM SURGEON, V81, P1249
   Waage A, 2006, ARCH SURG-CHICAGO, V141, P1207, DOI 10.1001/archsurg.141.12.1207
   WAY LW, 1992, ANN SURG, V215, P195, DOI 10.1097/00000658-199203000-00001
   Way LW, 2003, ANN SURG, V237, P460, DOI 10.1097/00000658-200304000-00004
   Wysocki AP, 2017, WORLD J SURG, V41, P82, DOI 10.1007/s00268-016-3665-0
   Yaghoubian A, 2008, ARCH SURG-CHICAGO, V143, P847, DOI 10.1001/archsurg.143.9.847
   Yamashita Y, 2013, J HEPATO-BIL-PAN SCI, V20, P89, DOI 10.1007/s00534-012-0567-x
   Zroback C, 2016, AM J SURG, V211, P933, DOI 10.1016/j.amjsurg.2016.01.013
   1991, NEW ENGL J MED, V324, P1073, DOI DOI 10.1056/NEJM199104183241601
NR 75
TC 0
Z9 0
U1 4
U2 4
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD DEC 21
PY 2016
VL 22
IS 47
BP 10287
EP 10303
DI 10.3748/wjg.v22.i47.10287
PG 17
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EF2RS
UT WOS:000390172600003
PM 28058010
ER


PT J
AU Ikeda, T
   Atarashi, H
   Inoue, H
   Uchiyama, S
   Kitazono, T
   Yamashita, T
   Shimizu, W
   Kamouchi, M
   Kaikita, K
   Fukuda, K
   Origasa, H
   Sakuma, I
   Saku, K
   Okumura, Y
   Nakamura, Y
   Morimoto, H
   Matsumoto, N
   Tsuchida, A
   Ako, J
   Sugishita, N
   Shimizu, S
   Shimokawa, H
AF Ikeda, Takanori
   Atarashi, Hirotsugu
   Inoue, Hiroshi
   Uchiyama, Shinichiro
   Kitazono, Takanari
   Yamashita, Takeshi
   Shimizu, Wataru
   Kamouchi, Masahiro
   Kaikita, Koichi
   Fukuda, Koji
   Origasa, Hideki
   Sakuma, Ichiro
   Saku, Keijiro
   Okumura, Yasuo
   Nakamura, Yuichiro
   Morimoto, Hideo
   Matsumoto, Naoki
   Tsuchida, Akihito
   Ako, Junya
   Sugishita, Nobuyoshi
   Shimizu, Shogo
   Shimokawa, Hiroaki
TI Study Design and Baseline Characteristics of the EXPAND Study:
   Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for
   the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of
   Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE anticoagulants; atrial fibrillation; Japanese; real world evidence;
   stroke
ID J-RHYTHM REGISTRY; ROCKET AF; WARFARIN; VALIDATION; SCORE; RISK
AB The use of rivaroxaban, a factor Xa inhibitor, has been increasing for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) in Japan. We conducted the nationwide multicenter study, termed as the EXPAND Study, to address its effectiveness and safety in the real-world practice of patients with non-valvular AF in Japan. The EXPAND Study is a prospective, non-interventional, observational cohort study to evaluate the effectiveness and safety of rivaroxaban in non-valvular AF patients in a real-world clinical practice. A total of 7,178 patients with non-valvular AF were enrolled in 684 medical institutes between November 20, 2012 and June 30, 2014. As for the baseline demographic and clinical characteristics of 7,164 patients, the proportion of female patients was 32.2%, and those of patients with creatinine clearance < 50 mL/min and non-paroxysmal (persistent or permanent) AF were 21.8% and 55.1%, respectively. The proportions of patients complicated with hypertension, congestive heart failure, diabetes mellitus, and a history of ischemic stroke were 70.9%, 25.9%, 24.3%, and 20.2%, respectively. The proportions of patients with a CHADS(2) score <= 1 and a CHA(2)DS(2)-VASc score <= 1 were 37.3% and 13.6%, respectively. They were followed up until March 31, 2016 for a mean follow-up period of approximately 2.5 years. The findings of the EXPAND Study will help to establish an appropriate treatment with rivaroxaban for Japanese patients with non-valvular AF.
C1 [Ikeda, Takanori] Toho Univ, Fac Med, Dept Cardiovasc Med, Tokyo, Japan.
   [Atarashi, Hirotsugu] Tama Nagayama Hosp, Nippon Med Sch, Dept Cardiovasc Med, Tokyo, Japan.
   [Inoue, Hiroshi] Saiseikai Toyama Hosp, Toyama, Toyama, Japan.
   [Uchiyama, Shinichiro] Int Univ Hlth & Welf, Clin Res Ctr Med, Tokyo, Japan.
   [Kitazono, Takanari] Kyushu Univ, Grad Sch Med Sci, Dept Med & Clin Sci, Fukuoka, Fukuoka, Japan.
   [Yamashita, Takeshi] Cardiovasc Inst Hosp, Tokyo, Japan.
   [Shimizu, Wataru] Nippon Med Sch, Grad Sch Med, Dept Cardiovasc Med, Tokyo, Japan.
   [Kamouchi, Masahiro] Kyushu Univ, Grad Sch Med Sci, Dept Hlth Care Adm & Management, Fukuoka, Fukuoka, Japan.
   [Kaikita, Koichi] Kumamoto Univ, Dept Cardiovasc Med, Kumamoto, Kumamoto, Japan.
   [Fukuda, Koji; Shimokawa, Hiroaki] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi, Japan.
   [Origasa, Hideki] Toyama Univ, Dept Biostat & Clin Epidemiol, Toyama, Toyama, Japan.
   [Sakuma, Ichiro] Hokko Mem Hosp, Sapporo, Hokkaido, Japan.
   [Saku, Keijiro] Fukuoka Univ, Sch Med, Dept Cardiol, Fukuoka, Fukuoka, Japan.
   [Okumura, Yasuo] Nihon Univ, Sch Med, Div Cardiol, Dept Med, Tokyo, Japan.
   [Nakamura, Yuichiro] Nakamura Cardiovasc Clin, Fukuoka, Japan.
   [Morimoto, Hideo] Fukagawa Municipal Hosp, Dept Med, Fukagawa, Hokkaido, Japan.
   [Matsumoto, Naoki] St Marianna Univ, Sch Med, Dept Pharmacol, Kawasaki, Kanagawa, Japan.
   [Tsuchida, Akihito] JR Sapporo Hosp, Div Cardiol, Sapporo, Hokkaido, Japan.
   [Ako, Junya] Kitasato Univ, Sch Med, Dept Cardiovasc Med, Sagamihara, Kanagawa, Japan.
   [Sugishita, Nobuyoshi] Sugishita Clin, Gujo, Gifu, Japan.
   [Shimizu, Shogo] Mashiko Hosp, Kawaguchi, Saitama, Japan.
RP Ikeda, T (reprint author), Toho Univ, Fac Med, Dept Cardiovasc Med, Ota Ku, 6-11-1 Omorinishi, Tokyo 1438540, Japan.
EM ikety5@gmail.com
FU Nippon Boehringer Ingelheim; Bayer Yakuhin Ltd.; Bristol-Myers Squibb;
   Pfizer; Daiichi Sankyo Co., Ltd.; Bristol-Meyers Squibb; Mitsubishi
   Tanabe Pharma Corporation; Astellas Pharma Inc.; Takeda Pharmaceutical
   Co., Ltd.; Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Merck Sharp
   and Dohme; Sanofi K.K.; Bayer Yakuhin, Ltd.; Ono Pharmaceutical; Toa
   Eiyo; Novartis Pharma; SBI Pharma; MSD Co., Ltd.; Boston Scientific
   Japan Co., Ltd.; Japan Medtronic Co., Ltd.; Japan Lifeline Co., Ltd.;
   Biotronik Japan, Co., Ltd.; St Jude Medical Japan Co., Ltd.; Nihon
   Kohden Co., Ltd., Japan; Bayer Yakuhin, Ltd, (Osaka, Japan)
FX T.I. has received research fund and/or lecture fees from Nippon
   Boehringer Ingelheim, Bayer Yakuhin Ltd., Bristol-Myers Squibb, Pfizer,
   and Daiichi Sankyo Co., Ltd. H.A. has received research fund and/or
   lecture fees from Daiichi Sankyo Co., Ltd. H.I. received lecture fees
   from Daiichi Sankyo Co., Ltd., Bayer Yakuhin Ltd., and Bristol-Meyers
   Squibb. S.U. has received research fund and lecture fees from Bayer
   Yakuhin, Ltd., Nippon Boehringer Ingelheim and Daiichi Sankyo Co., Ltd.
   T.K. has received research fund from Mitsubishi Tanabe Pharma
   Corporation, Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Takeda
   Pharmaceutical Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co.,
   Ltd., Merck Sharp and Dohme, Sanofi K.K., and Bayer Yakuhin, Ltd. and
   lecture fees from Daiichi Sankyo Co., Ltd. and Bayer Yakuhin, Ltd. T.Y.
   has received research fund and/or lecture fees from Bayer Yakuhin, Ltd.,
   Daiichi Sankyo Co., Ltd., Bristol-Myers Squibb, Pfizer, Nippon
   Boehringer Ingelheim, Eisai Co., Ltd., Mitsubishi Tanabe Pharma
   Corporation, Ono Pharmaceutical and Toa Eiyo. W.S. has received research
   fund and/or lecture fees from Bayer, Daiichi Sankyo Co., Ltd.,
   Bristol-Myers Squibb, Pfizer, Nippon Boehringer Ingelheim and Eisai Co.,
   Ltd. M.K. has received lecture fees from Bayer. K.K. has received
   research fund and/or lecture fees from Bayer, Daiichi Sankyo Co., Ltd.,
   Novartis Pharma, and SBI Pharma. K.F. has received no research fund or
   lecture fees from any companies. H.O. has received no research fund or
   lecture fees from any companies. I.S. has received lecture fees from
   Takeda Pharmaceutical Co., Ltd. K.S. has an Endowed Department of
   Molecular Cardiovascular Therapeutics, Fukuoka University, supported by
   MSD Co., Ltd., and an Endowed Department of Advanced Therapeutics for
   Cardiovascular Disease Fukuoka University, which is supported by Boston
   Scientific Japan Co., Ltd., Japan Medtronic Co., Ltd., Japan Lifeline
   Co., Ltd., Biotronik Japan, Co., Ltd., and St Jude Medical Japan Co.,
   Ltd., and an Endowed Department of Future Medicine for Cardiovascular
   Disease, Fukuoka University, which is supported by Nihon Kohden Co.,
   Ltd., Japan. Y.O. has accepted remuneration from Daiichi Sankyo Co.,
   Ltd.. Y.N. has received no research fund or lecture fees from any
   companies. H.M. has received no research fund or lecture fees from any
   companies. N.M. has received research fund and/or lecture fees from
   Bayer Yakuhin Ltd., Daiichi Sankyo Co., Ltd., Pfizer and Bristol-Myers
   Squibb. A.T. has received no research fund or lecture fees from any
   companies. J.A. has received research fund and lecture fees from Bayer
   Yakuhin Ltd. N.S. has received research fund from Bayer Yakuhin Ltd..
   S.S. declare no conflict of interest. H.S. has received lecture fees
   from Bayer Yakuhin, Ltd, (Osaka, Japan) and Daiichi Sankyo Co., Ltd.
CR Akao M, 2013, J CARDIOL, V61, P260, DOI 10.1016/j.jjcc.2012.12.002
   Atarashi H, 2011, CIRC J, V75, P1328, DOI 10.1253/circj.CJ-10-1119
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Carter NJ, 2013, DRUGS, V73, P715, DOI 10.1007/s40265-013-0056-9
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   European H, 2010, EUR HEART J, V31, P2369, DOI DOI 10.1093/EURHEARTJ/EHQ278
   Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Inoue H, 2014, CIRC J, V78, P1997, DOI 10.1253/circj.CJ-66-0092
   Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024
   Ogawa S, 2014, J STROKE CEREBROVASC, V23, P2520, DOI 10.1016/j.jstrokecerebrovasdis.2014.03.006
   Okumura K, 2014, CIRC J, V78, P1593, DOI 10.1253/circj.CJ-14-0144
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Savelieva I, 2014, CLIN CARDIOL, V37, P32, DOI 10.1002/clc.22204
   Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x
   Tanigawa T, 2013, DRUG METAB PHARMACOK, V28, P59, DOI 10.2133/dmpk.DMPK-12-RG-034
   Wolf PA, 1996, AM HEART J, V131, P790, DOI 10.1016/S0002-8703(96)90288-4
   Wong KSL, 2014, STROKE, V45, P1739, DOI 10.1161/STROKEAHA.113.002968
NR 20
TC 0
Z9 0
U1 2
U2 2
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD DEC
PY 2016
VL 240
IS 4
BP 259
EP 268
DI 10.1620/tjem.240.259
PG 10
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA EG9YH
UT WOS:000391417200001
PM 27904005
ER


PT J
AU Plitt, A
   Ruff, CT
   Giugliano, RP
AF Plitt, Anna
   Ruff, Christian T.
   Giugliano, Robert P.
TI Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Atrial fibrillation; NOAC; Dabigatran; Rivaroxaban; Apixaban; Edoxaban
ID FACTOR XA INHIBITOR; DIRECT THROMBIN INHIBITOR; MECHANICAL HEART-VALVES;
   DABIGATRAN ETEXILATE; CLINICAL-PRACTICE; RENAL-FUNCTION; RISK-FACTORS;
   ROCKET AF; WARFARIN; TRIAL
AB For more than 50 years, vitamin K antagonists (VKAs) have been the standard of care for treatment of atrial fibrillation (AF). However, the numerous limitations of VKAs have led to the development of non-VKA oral anticoagulants (NOACs). There are 4 NOACs currently approved for prevention of thromboembolism in patients with nonvalvular AF. This article provides an overview of AF, summarizes basic properties of NOACs, and reviews the landmark trials. Current data on use of NOACs in special populations and specific clinical scenarios are also presented. Lastly, recommendations from experts on controversial topics of bleeding management and reversal are described.
C1 [Plitt, Anna] Mt Sinai Hosp, Dept Internal Med, One Gustave L Levy Pl, New York, NY 10029 USA.
   [Ruff, Christian T.; Giugliano, Robert P.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA.
RP Giugliano, RP (reprint author), Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA.
EM rgiugliano@partners.org
FU American College of Cardiology; Boehringer-Ingelheim; Bristol-Myers
   Squibb; Daiichi Sankyo; Janssen Pharmaceuticals; Merck; Portola; Pfizer;
   Sanofi; Bayer; Boehringer Ingelheim; Astra Zeneca; Eisai; Intarcia
FX A. Plitt reports no conflict of interest. Dr R.P. Giugliano reports
   receiving consulting fees from the American College of Cardiology,
   Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen
   Pharmaceuticals, Merck, Portola, and Pfizer; lecture fees from
   Bristol-Myers Squibb, Daiichi Sankyo, Merck, and Sanofi; and grant
   support through his institution from Daiichi Sankyo and Merck. Dr C.T.
   Ruff reports receiving consulting fees from Bayer, Daiichi Sankyo,
   Portola, and Boehringer Ingelheim and grant support through his
   institution from Daiichi Sankyo, Astra Zeneca, Eisai, and Intarcia.
CR Ansell JE, 2014, NEW ENGL J MED, V371, P2141, DOI 10.1056/NEJMc1411800
   Beasley BN, 2011, NEW ENGL J MED, V364, P1788, DOI 10.1056/NEJMp1103050
   [Anonymous], 2015, PRAD DAB ET PACK INS
   Bristol-Myers Squibb Company and Pfizer Inc, 2015, EL AP PACK INS
   Cappato R, 2014, EUR HEART J, V35, P3346, DOI 10.1093/eurheartj/ehu367
   Connolly SJ, 2008, CIRCULATION, V118, P2029, DOI 10.1161/CIRCULATIONAHA.107.750000
   Connolly SJ, 2013, CIRCULATION, V128, P237, DOI 10.1161/CIRCULATIONAHA.112.001139
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Cuker A, 2014, J AM COLL CARDIOL, V64, P1128, DOI 10.1016/j.jacc.2014.05.065
   De Caterina R, 2014, EUR HEART J, V35, P3328, DOI 10.1093/eurheartj/ehu352
   Dzik WH, 2015, J THROMB HAEMOST, V13, pS187, DOI 10.1111/jth.12949
   Ehrlich JR, 2003, J PHYSIOL-LONDON, V551, P801, DOI 10.1113/jphysiol.2003.046417
   Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
   Enriquez A, 2015, EUROPACE 2015
   Flaker G, 2014, J AM COLL CARDIOL, V63, P1082, DOI 10.1016/j.jacc.2013.09.062
   Furugohri T, 2008, J THROMB HAEMOST, V6, P1542, DOI 10.1111/j.1538-7836.2008.03064.x
   Girgis IG, 2014, J CLIN PHARMACOL, V54, P917, DOI 10.1002/jcph.288
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Gonzalez-Quesada CJ, 2014, AM J CARDIOVASC DRUG, V14, P111, DOI 10.1007/s40256-013-0062-z
   Graham DJ, 2015, CIRCULATION, V131, P157, DOI 10.1161/CIRCULATIONAHA.114.012061
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Heidbuchel H, 2015, EUROPACE, V17, P1467, DOI 10.1093/europace/euv309
   Hijazi Z, 2014, CIRCULATION, V129, P961, DOI 10.1161/CIRCULATIONAHA.113.003628
   Hohnloser SH, 2012, EUR HEART J, V33, P2821, DOI 10.1093/eurheartj/ehs274
   Hylek EM, 2013, NEW ENGL J MED, V369, P1264, DOI 10.1056/NEJMe1310399
   HYLEK EM, 1994, ANN INTERN MED, V120, P897
   Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802
   January Craig T, 2014, J Am Coll Cardiol, V64, pe1, DOI 10.1016/j.jacc.2014.03.022
   [Anonymous], 2015, SAV ED PACK INS
   Kalabalik J, 2015, DRUGS, V75, P979, DOI 10.1007/s40265-015-0405-y
   Kim MH, 2011, CIRC-CARDIOVASC QUAL, V4, P313, DOI 10.1161/CIRCOUTCOMES.110.958165
   Kovacs RJ, 2015, J AM COLL CARDIOL, V65, P1340, DOI 10.1016/j.jacc.2015.01.049
   Majeed A, 2013, BEST PRACT RES CL HA, V26, P191, DOI 10.1016/j.beha.2013.07.001
   McManus DD, 2012, CIRCULATION, V126, pE143, DOI 10.1161/CIRCULATIONAHA.112.129759
   Mega JL, 2015, LANCET, V385, P2280, DOI 10.1016/S0140-6736(14)61994-2
   Nabauer M, 2009, EUROPACE, V11, P423, DOI 10.1093/europace/eun369
   Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546
   Neelankavil J, 2015, J CARDIOTHOR VASC AN, V29, P1328, DOI 10.1053/j.jvca.2015.01.031
   Nerheim P, 2004, CIRCULATION, V110, P247, DOI 10.1161/01.CIR.0000135472.28234.CC
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Pirmohamed M, 2013, NEW ENGL J MED, V369, P2294, DOI 10.1056/NEJMoa1311386
   Plitt A, 2016, CLIN CARDIOL, V39, P345, DOI 10.1002/clc.22537
   Plitt Anna, 2014, Hosp Pract (1995), V42, P48, DOI 10.3810/hp.2014.08.1117
   Rose AJ, 2013, CHEST, V143, P751, DOI 10.1378/chest.12-1119
   Ruff CT, 2014, LANCET, V384, P25, DOI 10.1016/S0140-6736(14)61106-5
   Siegal DM, 2015, NEW ENGL J MED, V373, P2413, DOI 10.1056/NEJMoa1510991
   Siegal DM, 2013, J THROMB THROMBOLYS, V35, P391, DOI 10.1007/s11239-013-0885-0
   Stangier J, 2007, BRIT J CLIN PHARMACO, V64, P292, DOI 10.1111/j.1365-2125.2007.02899.x
   Tucker NR, 2014, CIRC RES, V114, P1469, DOI 10.1161/CIRCRESAHA.114.302225
   van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758
   Watson T, 2009, LANCET, V373, P155, DOI 10.1016/S0140-6736(09)60040-4
   Weinz C, 2009, DRUG METAB DISPOS, V37, P1056, DOI 10.1124/dmd.108.025569
   [Anonymous], 2015, XARALTO RIVAROXABAN
NR 56
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD OCT
PY 2016
VL 30
IS 5
BP 1019
EP +
DI 10.1016/j.hoc.2016.05.002
PG 17
WC Oncology; Hematology
SC Oncology; Hematology
GA DY9QH
UT WOS:000385469700005
PM 27637305
ER


PT J
AU Obamiro, KO
   Chalmers, L
   Bereznicki, LRE
AF Obamiro, Kehinde O.
   Chalmers, Leanne
   Bereznicki, Luke R. E.
TI A Summary of the Literature Evaluating Adherence and Persistence with
   Oral Anticoagulants in Atrial Fibrillation
SO American Journal of Cardiovascular Drugs
LA English
DT Review
ID INTERNATIONAL NORMALIZED RATIO; QUALITY ALLIANCE MEASURE; MEDICATION
   ADHERENCE; PATIENT ADHERENCE; WARFARIN THERAPY; ROCKET AF; RIVAROXABAN;
   DABIGATRAN; STROKE; OUTCOMES
AB Atrial fibrillation (AF) is a growing public health concern and remains an independent risk factor for ischemic stroke. Warfarin, a commonly used oral anticoagulant, is associated with a 60-70 % relative reduction in stroke risk and a reduction in mortality of 26 %. However, warfarin has several limitations, including a narrow therapeutic window, variable dose response, multiple interactions with other drugs and concurrent illnesses, and the need for frequent laboratory monitoring. In recent years, the direct acting oral anticoagulants (DOACs), including dabigatran, rivaroxaban, apixaban and edoxaban, have been developed to overcome the limitations of warfarin therapy. These treatment strategies are either comparable or superior to warfarin in stroke prevention in AF. Despite the documented effectiveness of oral anticoagulants in AF, patients may not derive optimal benefit if they fail to adhere or fail to continue with their medication. This may lead to treatment failure, increased hospitalization and mortality. This review summarizes the literature regarding adherence and persistence (or discontinuation) rates with oral anticoagulants in the management of AF; the impact of non-adherence and non-persistence on treatment outcomes; and the effectiveness of strategies to improve adherence and persistence with oral anticoagulant therapy.
C1 [Obamiro, Kehinde O.; Chalmers, Leanne; Bereznicki, Luke R. E.] Univ Tasmania, Sch Med, Pharm, Hobart, Tas, Australia.
RP Obamiro, KO (reprint author), Univ Tasmania, Sch Med, Pharm, Hobart, Tas, Australia.
EM Kehinde.Obamiro@utas.edu.au
FU Aspen Pharmacare Australia; Boehringer Ingelheim
FX Kehinde Obamiro has no conflicts of interest that might be relevant to
   the content of this manuscript. Leanne Chalmers has received consultancy
   funding from Aspen Pharmacare Australia; Luke Bereznicki was a member of
   the Pradaxa Advisory Board (Boehringer Ingelheim) in Australia in 2015,
   and has received consultancy funding from Boehringer Ingelheim within
   the past 3 years.
CR Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P575, DOI [10.1002/pds.1230, DOI 10.1002/PDS.1230]
   Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P565, DOI 10.1002/pds.1230
   Beyer-Westendorf J, 2015, EUROPACE, V17, P530, DOI 10.1093/europace/euu319
   Beyer-Westendorf J, 2016, EUROPACE
   Burnier M, 2006, AM J HYPERTENS, V19, P1190, DOI 10.1016/j.amjhyper.2006.04.006
   Camm AJ, 2010, EUR HEART J, V31, P2369, DOI 10.1093/eurheartj/ehq278
   Castellucci LA, 2015, THROMB RES, V136, P727, DOI 10.1016/j.thromres.2015.07.007
   Clarkesmith DE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074037
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524-4733.2007.00213.x
   Crivera C, 2015, CURR MED RES OPIN, V31, P1889, DOI 10.1185/03007995.2015.1077213
   Cutler TW, 2014, J MANAGE CARE PHARM, V20, P1028
   Davis NJ, 2005, ANN PHARMACOTHER, V39, P632, DOI 10.1345/aph.1E464
   Diener HC, 2012, CURR OPIN NEUROL, V25, P27, DOI 10.1097/WCO.0b013e32834e604a
   Fang MC, 2010, CIRC-CARDIOVASC QUAL, V3, P624, DOI 10.1161/CIRCOUTCOMES.110.937680
   Friberg J, 2003, EPIDEMIOLOGY, V14, P666, DOI 10.1097/01.ede.0000091649-26364.c0
   Gallagher AM, 2008, J THROMB HAEMOST, V6, P1500, DOI 10.1111/j.1538-7836.2008.03059.x
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Gomes T, 2012, ARCH INTERN MED, V172, P1687, DOI 10.1001/archinternmed.2012.4485
   Gorst-Rasmussen A, 2015, J THROMB HAEMOST, V13, P495, DOI 10.1111/jth.12845
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Hedegaard Ulla, 2014, Cerebrovasc Dis Extra, V4, P221, DOI 10.1159/000369380
   Hixson-Wallace JA, 2001, CLIN APPL THROMB-HEM, V7, P33, DOI 10.1177/107602960100700108
   Ho PM, 2009, CIRCULATION, V119, P3028, DOI 10.1161/CIRCULATIONAHA.108.768986
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Hylek EM, 2007, CIRCULATION, V115, P2689, DOI 10.1161/CIRCULATIONHA.106.653048
   January CT, 2014, CIRCULATION, V130, P2071, DOI 10.1161/CIR.0000000000000040
   Kimmel SE, 2007, ARCH INTERN MED, V167, P229, DOI 10.1001/archinte.167.3.229
   Kimmel SE, 2012, AM HEART J, V164, P268, DOI 10.1016/j.ahj.2012.05.005
   Laliberte F, 2014, CURR MED RES OPIN, V30, P1317, DOI 10.1185/03007995.2014.907140
   Marini C, 2005, STROKE, V36, P1115, DOI 10.1161/01.STR.0000166053.83476.4a
   McHorney CA, 2015, CURR MED RES OPIN, V31, P2167, DOI 10.1185/03007995.2015.1096242
   MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007
   Nau DP, 2012, PROPORTION DAYS COVE
   Nelson WW, 2014, CURR MED RES OPIN, V30, P2461, DOI 10.1185/03007995.2014.933577
   OLIVIERI NF, 1991, ARCH DIS CHILD, V66, P1399
   Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Guiu IMS, 2015, THROMB HAEMOSTASIS, V114, P313, DOI 10.1160/TH14-11-0945
   Schulman S, 2013, J THROMB HAEMOST, V11, P1295, DOI 10.1111/jth.12241
   Shiga Tsuyoshi, 2015, J Arrhythm, V31, P339, DOI 10.1016/j.joa.2015.04.004
   Shore S, 2014, AM HEART J, V167, P810, DOI 10.1016/j.ahj.2014.03.023
   Song X, 2012, AM J CARDIOVASC DRUG, V12, P245, DOI 10.2165/11632540-000000000-00000
   Tsai K, 2013, AM J MANAG CARE, V19
   Waterman AD, 2004, AM J HEALTH-SYST PH, V61, P1258
   White HD, 2007, ARCH INTERN MED, V167, P239, DOI 10.1001/archinte.167.3.239
   WOLF PA, 1991, STROKE, V22, P983
   Yao XX, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003074
   Zalesak M, 2013, CIRC-CARDIOVASC QUAL, V6, P567, DOI 10.1161/CIRCOUTCOMES.113.000192
   Zhou M, 2015, J MANAG CARE SPEC PH, V21, P1054
NR 51
TC 1
Z9 1
U1 7
U2 7
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-3277
EI 1179-187X
J9 AM J CARDIOVASC DRUG
JI Am. J. Cardiovasc. Drugs
PD OCT
PY 2016
VL 16
IS 5
BP 349
EP 363
DI 10.1007/s40256-016-0171-6
PG 15
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA DS3SU
UT WOS:000380703800004
PM 27262433
ER


PT J
AU Miyamoto, K
   Aiba, T
   Arihiro, S
   Watanabe, M
   Kokubo, Y
   Ishibashi, K
   Hirose, S
   Wada, M
   Nakajima, I
   Okamura, H
   Noda, T
   Nagatsuka, K
   Noguchi, T
   Anzai, T
   Yasuda, S
   Ogawa, H
   Kamakura, S
   Shimizu, W
   Miyamoto, Y
   Toyoda, K
   Kusano, K
AF Miyamoto, Koji
   Aiba, Takeshi
   Arihiro, Shoji
   Watanabe, Makoto
   Kokubo, Yoshihiro
   Ishibashi, Kohei
   Hirose, Sayako
   Wada, Mitsuru
   Nakajima, Ikutaro
   Okamura, Hideo
   Noda, Takashi
   Nagatsuka, Kazuyuki
   Noguchi, Teruo
   Anzai, Toshihisa
   Yasuda, Satoshi
   Ogawa, Hisao
   Kamakura, Shiro
   Shimizu, Wataru
   Miyamoto, Yoshihiro
   Toyoda, Kazunori
   Kusano, Kengo
TI Impact of renal function deterioration on adverse events during
   anticoagulation therapy using non-vitamin K antagonist oral
   anticoagulants in patients with atrial fibrillation
SO HEART AND VESSELS
LA English
DT Article
DE Atrial fibrillation; Non-vitamin K antagonist oral anticoagulants; Renal
   function; CHADS(2) score; CHA(2)DS(2)-VASc score
ID CHRONIC KIDNEY-DISEASE; THROMBIN INHIBITOR DABIGATRAN; BLOOD-PRESSURE
   CATEGORY; RE-LY TRIAL; RISK-FACTORS; RANDOMIZED EVALUATION; PREDICTING
   STROKE; ROCKET AF; WARFARIN; RIVAROXABAN
AB Renal function is crucial for patients with non-valvular atrial fibrillation (NVAF) using non-vitamin K antagonist oral anticoagulants (NOAC). The incidence of renal function deterioration during anticoagulation therapy and its impact of adverse events are unknown. In 807 consecutive NVAF patients treated with NOAC and with estimated creatinine clearance (eCCr) a parts per thousand yen 50 ml/min (mean age 68 +/- 11 years, mean CHADS(2) score = 1.8 +/- 1.4, CHA(2)DS(2)-VASc score = 2.8 +/- 1.8, HAS-BLED score = 1.7 +/- 1.1), we analyzed the time course of renal function and clinical outcomes, and compared these with the data of general Japanese inhabitants from the Suita Study (n = 2140). Of the 807 patients, 751 (93 %) maintained eCCr a parts per thousand yen 50 ml/min (group A) whereas the remaining 56 (7 %) fell into the eCCr < 50 ml/min (group B) during the 382 +/- 288 days of follow-up. Multivariate logistic regression analysis revealed that advanced age, lower body weight, and congestive heart failure were independent predictors for renal function deterioration in patients with eCCr a parts per thousand yen 50 ml/min at baseline. Major and/or minor bleedings were more commonly observed in group B than in group A (21 vs. 8 %; P = 0.0004). The CHADS(2), CHA(2)DS(2)-VASc, and HAS-BLED scores were also significant predictors of renal function deterioration (P < 0.0001). The incidences of renal function deterioration were 1.4, 3.4, 10.5 and 11.7 % in patients with CHADS(2) score of 0, 1, 2 and a parts per thousand yen3, respectively. As to CHA(2)DS(2)-VASc score, renal function deterioration occurred in 0, 1.7, 9.8 and 15.0 % with a score of 0, 1-2, 3-4 and a parts per thousand yen5, respectively. In the Suita Study of the general population, on the other hand, 122 of 2140 participants with eCCr a parts per thousand yen 50 ml/min at baseline (5.7 %) fell into the eCCr < 50 ml/min during about 2 years. The incidence of renal function deterioration increased with the CHADS(2) score in the general population as well as in our patients. Renal function deterioration was not uncommon and was associated with more frequent adverse events including major bleeding in NVAF patients with anticoagulation therapy. CHADS(2), CHA(2)DS(2)-VASc, and HAS-BLED scores may be useful as an index of predicting renal function deterioration.
C1 [Miyamoto, Koji; Aiba, Takeshi; Ishibashi, Kohei; Hirose, Sayako; Wada, Mitsuru; Nakajima, Ikutaro; Okamura, Hideo; Noda, Takashi; Noguchi, Teruo; Anzai, Toshihisa; Yasuda, Satoshi; Ogawa, Hisao; Kamakura, Shiro; Shimizu, Wataru; Kusano, Kengo] Natl Cerebral & Cardiovasc Ctr, Div Arrhythmia & Electrophysiol, Dept Cardiovasc Med, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan.
   [Miyamoto, Koji; Okamura, Hideo; Anzai, Toshihisa; Yasuda, Satoshi; Shimizu, Wataru; Kusano, Kengo] Kumamoto Univ, Grad Sch Med Sci, Dept Adv Cardiovasc Med, Kumamoto, Japan.
   [Arihiro, Shoji] Natl Cerebral & Cardiovasc Ctr, Div Stroke Care Unit, Suita, Osaka, Japan.
   [Watanabe, Makoto; Kokubo, Yoshihiro; Miyamoto, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka, Japan.
   [Nagatsuka, Kazuyuki] Natl Cerebral & Cardiovasc Ctr, Dept Neurol, Suita, Osaka, Japan.
   [Ogawa, Hisao] Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Kumamoto, Japan.
   [Shimizu, Wataru] Nippon Med Sch, Dept Cardiovasc Med, Bunkyo, Japan.
   [Toyoda, Kazunori] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Suita, Osaka, Japan.
RP Aiba, T; Kusano, K (reprint author), Natl Cerebral & Cardiovasc Ctr, Div Arrhythmia & Electrophysiol, Dept Cardiovasc Med, 5-7-1 Fujishiro Dai, Suita, Osaka 5658565, Japan.; Kusano, K (reprint author), Kumamoto Univ, Grad Sch Med Sci, Dept Adv Cardiovasc Med, Kumamoto, Japan.
EM aiba@hsp.ncvc.go.jp; kusanokengo@gmail.com
RI Anzai, Toshihisa/J-2179-2015
OI Anzai, Toshihisa/0000-0003-3319-4967
FU Japan Cardiovascular Research Foundation; MEXT of Japan [24591086];
   Intramural Research Fund for Cardiovascular Diseases of National
   Cerebral and Cardiovascular Center [25-4-7]; Health and Labour Sciences
   Research Grants Ministry of Health, Labour and Welfare, Japan [H26
   Iryoukiki Ippan 019];  [25136727]
FX This work was supported by a grant from Japan Cardiovascular Research
   Foundation (Miyamoto); a grant from a Grant-in-Aid for Scientific
   Research on Innovative Areas (25136727, Aiba); a Grant-in-Aid for
   Scientific Research (C) (24591086 Aiba) from MEXT of Japan; Intramural
   Research Fund (25-4-7, Kusano) for Cardiovascular Diseases of National
   Cerebral and Cardiovascular Center; Health and Labour Sciences Research
   Grants (H26 Iryoukiki Ippan 019) Ministry of Health, Labour and Welfare,
   Japan (Kusano).
CR Apostolakis S, 2013, EUR HEART J, V34, P3572, DOI 10.1093/eurheartj/eht328
   Banerjee A, 2013, J AM COLL CARDIOL, V61, P2079, DOI 10.1016/j.jacc.2013.02.035
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Gaede P, 2003, NEW ENGL J MED, V348, P383
   Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Goodman SG, 2014, J AM COLL CARDIOL, V63, P891, DOI 10.1016/j.jacc.2013.11.013
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Guenancia C, 2016, HEART VESSELS, V31, P897, DOI 10.1007/s00380-015-0695-8
   Hijazi Z, 2014, CIRCULATION, V129, P961, DOI 10.1161/CIRCULATIONAHA.113.003628
   Hillege HL, 2006, CIRCULATION, V113, P671, DOI 10.1161/CIRCULATIONAHA.105.580506
   Hohnloser SH, 2012, EUR HEART J, V33, P2821, DOI 10.1093/eurheartj/ehs274
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Japanese Society of Nephrology, 2012, NIHON JINZO GAKKAI S, V54, P1034
   [Anonymous], 2013, KIDNEY INT S, V3, P1
   Kokubo Y, 2009, STROKE, V40, P2674, DOI 10.1161/STROKEAHA.109.550707
   Liesenfeld KH, 2011, J THROMB HAEMOST, V9, P2168, DOI 10.1111/j.1538-7836.2011.04498.x
   Lin TH, 2015, HEART VESSELS, V30, P441, DOI 10.1007/s00380-014-0504-9
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Miyamoto K, 2014, J ARRHYTHMIA, V30, P58
   Muntner P, 2004, ANN INTERN MED, V140, P9
   Ohara T, 2013, STROKE, V44, P3537, DOI 10.1161/STROKEAHA.113.002957
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2013, CIRCULATION, V127, P224, DOI 10.1161/CIRCULATIONAHA.112.107128
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Poggio ED, 2009, KIDNEY INT, V75, P1079, DOI 10.1038/ki.2009.11
   Roldan V, 2013, AM J CARDIOL, V111, P1159, DOI 10.1016/j.amjcard.2012.12.045
   Ronco C, 2012, HEART FAIL REV, V17, P151, DOI 10.1007/s10741-010-9224-0
   Shlipak MG, 2003, CIRCULATION, V107, P87, DOI 10.1161/01.CIR.0000042700.48769.59
   TANAKA H, 1982, STROKE, V13, P62
   WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085
   Yamagata K, 2007, KIDNEY INT, V71, P159, DOI 10.1038/sj.ki.5002017
   Zhou W, 2011, STROKE, V42, P3594, DOI 10.1161/STROKEAHA.111.624650
NR 35
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0910-8327
EI 1615-2573
J9 HEART VESSELS
JI Heart Vessels
PD AUG
PY 2016
VL 31
IS 8
BP 1327
EP 1336
DI 10.1007/s00380-015-0725-6
PG 10
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA DS3HB
UT WOS:000380672600015
PM 26276272
ER


PT J
AU Liang, DL
   Liu, JZ
   Zhou, JH
   Wang, Y
   Yang, YX
AF Liang, Daolun
   Liu, Jianzhong
   Zhou, Junhu
   Wang, Yang
   Yang, Yuxin
TI Combustion Characteristics and Propulsive Performance of Boron/Ammonium
   Perchlorate Mixtures in Microtubes
SO JOURNAL OF ENERGETIC MATERIALS
LA English
DT Article
DE ammonium perchlorate; amorphous boron; component; differential scanning
   calorimetry; microtube; performance; propellant
ID SOLID-PROPELLANT MICROTHRUSTERS; ROCKET ARRAY THRUSTER; MEMS; BORON;
   IGNITION; TEMPERATURE; FABRICATION; PRODUCTS; DESIGN
AB A microthruster is used for the operation tracking and posture control of microsatellites. In this work, the combustion characteristics and propulsive performance of a boron/ammonium perchlorate (B/AP) propellant mixture for a microthruster were investigated. Amorphous B and AP were used in different mass ratios to prepare the propellant samples. A laser-ignition solid micropropulsion test system was set up, and a differential scanning calorimeter was used. The solid combustion products of the samples with good performance were collected. Microstructural and component analyses of the combustion products were performed. Various performance parameters, including the combustion temperature, combustion velocity, spectral intensity, ignition delay time, thrust, specific impulse, density specific impulse, and heat flow, changed with the fuel-oxidant ratio. The optimal fuel-oxidant mass ratio of the propellant samples was 40%, with a density specific impulse of 0.474kg/m(2)center dot s and a maximum heat flow of 4.4913mW/mg. Analysis of the combustion products revealed that the clearance between particles significantly diminished after combustion. During combustion, the AP completely decomposed, and a large amount of H3BO3, B2O3, and HBO2 was generated.
C1 [Liang, Daolun; Liu, Jianzhong; Zhou, Junhu] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Zhejiang, Peoples R China.
   [Wang, Yang] Zhejiang Univ, Ind Technol Inst, A503 Zhiquan Bldg,38 Zheda Rd, Hangzhou 310027, Zhejiang, Peoples R China.
   [Yang, Yuxin] Fourth Acad CASC, Inst 41st, Xian, Peoples R China.
RP Wang, Y (reprint author), Zhejiang Univ, Ind Technol Inst, A503 Zhiquan Bldg,38 Zheda Rd, Hangzhou 310027, Zhejiang, Peoples R China.
EM wy_coal@sina.com
FU National Natural Science Foundation of China [51336010]; Aerospace
   Science Technology Foundation of China [YF-2014-0106-wx]
FX This work was funded by the National Natural Science Foundation of China
   (No. 51336010) and the Aerospace Science Technology Foundation of China
   (No. YF-2014-0106-wx).
CR Ao W, 2014, PROPELL EXPLOS PYROT, V39, P185, DOI 10.1002/prep.201300079
   Bechtold T, 2005, J MICROMECH MICROENG, V15, P430, DOI 10.1088/0960-1317/15/3/002
   Chaalane A, 2007, SENSOR ACTUAT A-PHYS, V138, P161, DOI 10.1016/j.sna.2007.04.029
   de Koninck DA, 2011, J MICROELECTROMECH S, V20, P1259, DOI 10.1109/JMEMS.2011.2167667
   Foelsche RO, 1999, COMBUST FLAME, V117, P32, DOI 10.1016/S0010-2180(98)00080-7
   Kondo K., 2004, IEICE ELECTRON EXPR, V1, P222, DOI [10.1587/elex.1.222, DOI 10.1587/ELEX.1.222]
   Laixing L., 2010, SPACECRAFT ENG, V19, P13
   Lee J, 2010, SENSOR ACTUAT A-PHYS, V157, P126, DOI 10.1016/j.sna.2009.11.010
   Li H., 2014, J ZHEJIANG U ENG SCI, V48, P917, DOI 10.3785/j.issn.1008-973X.2014.05.024
   Li YC, 2010, J ENERG MATER, V28, P77, DOI 10.1080/07370650903193299
   Liang DL, 2015, J THERM ANAL CALORIM, V122, P497, DOI 10.1007/s10973-015-4750-6
   Liang DL, 2015, ACTA ASTRONAUT, V112, P182, DOI 10.1016/j.actaastro.2015.03.019
   Liu J., 2010, STUDY MICROSCALE COM
   [刘林林 Liu Linlin], 2013, [火炸药学报, Chinese Journal of Explosives & Propellants], V36, P46
   Mao C., 2001, J PROPULSION TECHNOL, V22, P6
   Mueller J., 1997, 30581997 AIAA
   Rossi C, 2006, SENSOR ACTUAT A-PHYS, V126, P241, DOI 10.1016/j.sna.2005.08.024
   Rossi C, 2005, SENSOR ACTUAT A-PHYS, V121, P508, DOI 10.1016/j.sna.2005.03.017
   Rossi C., 2003, POWERMEMS 2003, V1, P57
   Rossi C, 2007, J MICROELECTROMECH S, V16, P919, DOI 10.1109/JMEMS.2007.893519
   Rossi C, 2006, J MICROELECTROMECH S, V15, P1805, DOI 10.1109/JMEMS.2006.880232
   Spalding M. J., 1997, 97 AIAA
   Tanaka S, 2003, T JPN SOC AERONAUT S, V46, P47, DOI 10.2322/tjsass.46.47
   Tanaka S, 2008, SENSOR ACTUAT A-PHYS, V144, P361, DOI 10.1016/j.sna.2008.02.015
   Voelkl H. R., 1970, THERMAL DECOMPOSITIO
   Xi JF, 2014, J PROPUL POWER, V30, P47, DOI 10.2514/1.B35037
   Xi X., 2003, J ENERG MATER, V21, P63, DOI [10.1080/07370650305582, DOI 10.1080/07370650305582]
   Yeh CL, 1996, PROG ENERG COMBUST, V22, P511, DOI 10.1016/S0360-1285(96)00012-3
   Zhang KL, 2005, SENSOR ACTUAT A-PHYS, V122, P113, DOI 10.1016/j.sna.2005.04.021
   Zhang KL, 2005, J MICROMECH MICROENG, V15, P944, DOI 10.1088/0960-1317/15/5/007
NR 30
TC 1
Z9 1
U1 9
U2 57
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0737-0652
EI 1545-8822
J9 J ENERG MATER
JI J. Energ. Mater.
PD JUL 2
PY 2016
VL 34
IS 3
BP 297
EP 317
DI 10.1080/07370652.2015.1066464
PG 21
WC Chemistry, Applied; Chemistry, Physical; Engineering, Chemical;
   Materials Science, Multidisciplinary
SC Chemistry; Engineering; Materials Science
GA DC8TK
UT WOS:000369492400006
ER


PT J
AU Curto, G
   Dallavalle, E
   Matteo, R
   Lazzeri, L
AF Curto, G.
   Dallavalle, E.
   Matteo, R.
   Lazzeri, L.
TI Biofumigant effect of new defatted seed meals against the southern
   root-knot nematode, Meloidogyne incognita
SO ANNALS OF APPLIED BIOLOGY
LA English
DT Article
DE Allelopathic effect; biofumigation; biostimulation; Brassicaceae;
   defatted seed meals; root-knot nematode
ID WHITE CHITW.; BRASSICACEAE; HYDROLYSIS; MANAGEMENT; FIELD
AB In recent years, Brassica carinata defatted seed meals (DSMs) have been successfully applied as an amendment in the control of pests and soil pathogens in several countries with clear advantages for the environment and soil fertility. The effectiveness of this product is clearly linked to the release of bioactive compounds by the well-known glucosinolate (GL)-myrosinase (MYR) system. Until now, this commercial know-how has been limited to allyl-isothiocyanate, the breakdown product of hydrolysis catalysed by MYR of the GL sinigrin. Brassicaceae germplasm is an extremely wide-ranging family, considering that more than 3500 species have been classified in this family in nature, which contains around 200 different GLs. Therefore, there is a great potential for the availability of new still unexplored bioactive compounds. This study evaluated, in controlled glasshouse conditions, the effect of biofumigation on the nematode Meloidogyne incognita and that of biostimulation on tomato plants of 13 DSMs obtained from different Brassicaceae species at different levels of soil inoculation. Among the tested DSMs, the best results for all inoculations were achieved by Eruca sativa (rocket), Barbarea verna (land cress) and Brassica nigra (black mustard), whereas the other species gave either alternate results or results not different from untreated or sunflower DSM controls. All the DSMs, including sunflower, determined a clear positive effect on plant vigour. These first results open new perspectives for the application of biofumigation in plant protection and management.
C1 [Curto, G.; Dallavalle, E.] Plant Protect Serv Emilia Romagna Reg, Bologna, Italy.
   [Matteo, R.; Lazzeri, L.] Council Agr Res & Econ, Res Ctr Ind Crops, Via Corticella 133, I-40128 Bologna, Italy.
RP Matteo, R (reprint author), Council Agr Res & Econ, Res Ctr Ind Crops, Via Corticella 133, I-40128 Bologna, Italy.
EM roberto.matteo@crea.gov.it
CR Agerbirk N, 2012, PHYTOCHEMISTRY, V77, P16, DOI 10.1016/j.phytochem.2012.02.005
   Barker K.R., 1985, ADV TREATISE MELOIDO, P19
   Burow M, 2007, PLANT MOL BIOL, V63, P49, DOI 10.1007/s11103-006-9071-5
   Clarke DB, 2010, ANAL METHODS-UK, V2, P310, DOI 10.1039/b9ay00280d
   Curto G, 2005, NEMATOLOGY, V7, P203, DOI 10.1163/1568541054879494
   Curto G., 2006, LINFORMATORE AGRARIO, V48, P52
   Curto G, 2012, NEMATOLOGY, V14, P759, DOI 10.1163/156854112X627291
   Curto Giovanna, 2008, Redia, V91, P81
   Ente nazionale italiano di unificazione, 1992, 226041992 UNI ENT NA
   Furlan L, 2010, IND CROP PROD, V31, P245, DOI 10.1016/j.indcrop.2009.10.012
   HUSSEY RS, 1973, PLANT DIS REP, V57, P1025
   International Standards Organization (ISO), 1992, 91671 ISO, P1
   Jepson S.B., 1987, IDENTIFICATION ROOT, P265
   Kirkegaard JA, 2000, AUST J AGR RES, V51, P445, DOI 10.1071/AR99106
   Lamberti F., 1979, P341
   Lamberti F., 1971, TABACCO, V733, P8
   Larkin RP, 2007, CROP PROT, V26, P1067, DOI 10.1016/j.cropro.2006.10.004
   Lazzeri L, 2004, J AGR FOOD CHEM, V52, P6703, DOI 10.1021/jf030776u
   Lazzeri L, 2013, ACTA HORTIC, V1005, P331
   Lazzeri L, 2009, J SUSTAIN AGR, V33, P349, DOI 10.1080/10440040902773202
   Lazzeri L, 2011, 19 EU BC E C P 2011, P1080
   Manici Luisa M., 1999, Pesticide Science, V55, P486, DOI 10.1002/(SICI)1096-9063(199904)55:4<486::AID-PS941>3.3.CO;2-T
   Meyer SLF, 2011, J NEMATOL, V43, P7
   Moens M, 2010, ROOT-KNOT NEMATODES, P1
   Oliveira RDL, 2011, PLANT SOIL, V341, P155, DOI 10.1007/s11104-010-0631-8
   Sanchi S, 2005, ACTA HORTIC, P287
   Tacconi R., 1995, Nematodi da quarantena., P175
   Yu Q, 2007, J FOOD AGRIC ENVIRON, V5, P374
   Zasada IA, 2009, J NEMATOL, V41, P221
   Lazzeri L, 2010, US Patent, Patent No. [7, 749, 549, 7749549, US 7749549]
NR 30
TC 0
Z9 0
U1 11
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4746
EI 1744-7348
J9 ANN APPL BIOL
JI Ann. Appl. Biol.
PD JUL
PY 2016
VL 169
IS 1
BP 17
EP 26
DI 10.1111/aab.12275
PG 10
WC Agriculture, Multidisciplinary
SC Agriculture
GA DW0YV
UT WOS:000383370600002
ER


PT J
AU Gilardi, G
   Demarchi, S
   Gullino, ML
   Garibaldi, A
AF Gilardi, Giovanna
   Demarchi, Stefano
   Gullino, Maria Lodovica
   Garibaldi, Angelo
TI Evaluation of the short term effect of nursery treatments with
   phosphite-based products, acibenzolar-S-methyl, pelleted Brassica
   carinata and biocontrol agents, against lettuce and cultivated rocket
   fusarium wilt under artificial inoculation and greenhouse conditions
SO CROP PROTECTION
LA English
DT Article
DE Lactuca sativa; Eruca vesicaria; Fusarium oxysporum f. sp lactucae;
   Fusarium oxysporum f. sp raphani; Integrated control
ID SYSTEMIC ACQUIRED-RESISTANCE; F-SP LACTUCAE; DISEASE MANAGEMENT;
   OXYSPORUM; EFFICACY; SUPPRESSION; PATHOGENS; PLANTS; AZOXYSTROBIN;
   STROBILURINS
AB Experimental trials have been carried out in order to evaluate the efficacy of preventative treatments based on plant defense activator products, biocontrol agents, a microbial complex with arbuscular mycorrhizal fungi, and Brassica carinata pellets against Fusarium oxysporum f. sp. lactucae race 1 on lettuce and Fusarium oxysporum f. sp. raphani on cultivated rocket under greenhouse conditions. These products were compared with fungicides known for their ability to induce host resistance (phosethyl-Al and acibenzolar-S-methyl), and with azoxystrobin. Three and four applications of the tested products were carried out on lettuce and rocket seedlings grown in nursery conditions. Treated and untreated plants were transplanted into soil infested with Fusarium wilt agents to obtain an average disease severity (DS) of 65.6-69.2 and of 56.9-62.1 on the untreated lettuce and rocket plants, respectively. The best Fusarium wilt biocontrol was obtained after four applications of Bacillus subtilis Qst713 and with the Glomas microbial complex (42 and 46.7%, efficacy, respectively). B. carinata pellets provided a consistent control when applied 14 days before the rocket and lettuce were transplanted into the infested soil. Acibenzolar-S-methyl, applied at 0.025 g/Liter, showed a DS reduction in F. oxysporum f. sp. lactucae from 36 to 61% and of F. oxysporum f. sp. raphani from 54 to 73%, thus showing statistically similar results to those of azoxystrobin, which was used as a reference (DS reduction from 59 to 65%). Although the Fusarium wilt control provided by such products was not complete in the present experimental conditions, these products can be considered interesting components for an integrated pest management of the Fusarium wilt of leafy vegetables, starting from nursey applications. Moreover, the tested BCAs could become potentially useful, especially for plant monocultures. This study has been produced new information on the effects of potassium phosphite, applied at the nursery level, on reducing lettuce and rocket fusarium wilt. An average efficacy of 69.5% was observed for lettuce, while an average efficacy of 65.2% was observed for cultivated rocket. The good fungicidal activity of the phosphite-based product, coupled with the positive effect on plant biomass, is of special interest. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Gilardi, Giovanna; Demarchi, Stefano; Gullino, Maria Lodovica; Garibaldi, Angelo] Univ Turin, AGROINNOVA, Ctr Innovat Agroenvironm Sect, Largo P Braccini 2, I-10095 Grugliasco, TO, Italy.
   [Gilardi, Giovanna; Gullino, Maria Lodovica] Univ Turin, Dept Agr Forest & Food Sci DISAFA, Largo P Braccini 2, I-10095 Grugliasco, TO, Italy.
RP Gullino, ML (reprint author), Univ Turin, AGROINNOVA, Ctr Innovat Agroenvironm Sect, Largo P Braccini 2, I-10095 Grugliasco, TO, Italy.
EM marialodovica.gullino@unito.it
FU European Union's Horizon research and innovation programme EUCLID
   EU-CHINA Lever for IPM Demonstration [633999]
FX The present study has received funding from the European Union's Horizon
   2020 research and innovation programme EUCLID EU-CHINA Lever for IPM
   Demonstration. Grant agreement no 633999. The authors kindly thank
   Marguerite Jones for the language revision.
CR Barriere V, 2014, AGRON SUSTAIN DEV, V34, P175, DOI 10.1007/s13593-013-0158-5
   Bonanomi G, 2010, SOIL BIOL BIOCHEM, V42, P136, DOI 10.1016/j.soilbio.2009.10.012
   BOSLAND PW, 1988, PLANT DIS, V72, P777, DOI 10.1094/PD-72-0777
   Bubici G, 2006, CROP PROT, V25, P814, DOI 10.1016/j.cropro.2005.06.008
   Colla P, 2012, PHYTOPARASITICA, V40, P515, DOI 10.1007/s12600-012-0252-2
   Eikemo H, 2003, PLANT DIS, V87, P345, DOI 10.1094/PDIS.2003.87.4.345
   Elmer WH, 2006, CAN J PLANT PATHOL, V28, P609
   Elmer WH, 2006, CROP PROT, V25, P671, DOI 10.1016/j.cropo.2005.09.010
   Fujinaga Masashi, 2005, Journal of General Plant Pathology, V71, P457, DOI 10.1007/s10327-005-0224-1
   Garibaldi A, 2004, CROP PROT, V23, P845, DOI 10.1016/j.cropro.2004.01.005
   Garibaldi A, 2014, ACTA HORTIC, V1044, P43
   Garibaldi A, 2010, ACTA HORTIC, V883, P37
   Garibaldi A, 2002, PLANT DIS, V86, P1052, DOI 10.1094/PDIS.2002.86.9.1052B
   Garibaldi A, 2006, PHYTOPARASITICA, V34, P115, DOI 10.1007/BF02981311
   Garibaldi A., 2011, ACTA HORTIC, V883, P295
   Gilardi G, 2014, Commun Agric Appl Biol Sci, V79, P21
   Gilardi G., 2007, J PLANT PATHOL, V89, P127
   Gilardi G., 2014, PHYTOPATHOL MEDITERR, V53, P313
   Gilardi G, 2013, PHYTOPARASITICA, V41, P59, DOI 10.1007/s12600-012-0264-y
   Gordon TR, 2015, CROP PROT, V73, P45, DOI 10.1016/j.cropro.2015.01.011
   Gullino ML, 2002, CROP PROT, V21, P57, DOI 10.1016/S0261-2194(01)00066-7
   Gullino M.L., 2014, GLOBAL PERSPECTIVES, P47
   Hyeon M.N., 2009, J MICROBIOL BIOTECHN, V19, P520
   Kapoor R., 2008, J BIOL SCI, V8, P49
   Katan J., 2012, FUSARIUM WILTS GREEN, P61
   Kloepper JW, 2004, PHYTOPATHOLOGY, V94, P1259, DOI 10.1094/PHYTO.2004.94.11.1259
   Levey N.O., 2015, PLANT PATHOL, V64, P365
   LOCKE T, 1974, Phytopathologische Zeitschrift, V79, P77
   Lopez-Reyes G.G., 2014, J PLANT PATHOL, V96, P535
   Martinez-Medina A, 2010, PHYTOPATHOLOGY, V100, P682, DOI 10.1094/PHYTO-100-7-0682
   Matheron M., 2012, FUSARIUM WILT GREENH
   Matheron ME, 2005, PLANT DIS, V89, P565, DOI 10.1094/PD-89-0565
   Matheron M.E., 2012, PLANT DIS, V94, P1323
   Mazzola M, 2007, PHYTOPATHOLOGY, V97, P454, DOI 10.1094/PHYTO-97-4-0454
   Oostendorp M, 2001, EUR J PLANT PATHOL, V107, P19, DOI 10.1023/A:1008760518772
   Pozo MJ, 2007, CURR OPIN PLANT BIOL, V10, P393, DOI 10.1016/j.pbi.2007.05.004
   Scott JC, 2014, PLANT PATHOL, V63, P548, DOI 10.1111/ppa.12135
   Scott JC, 2010, PLANT PATHOL, V59, P139, DOI 10.1111/j.1365-3059.2009.02179.x
   Scott JC, 2010, PLANT DIS, V94, P13, DOI 10.1094/PDIS-94-1-0013
   Shoresh M, 2005, PHYTOPATHOLOGY, V95, P76, DOI 10.1094/PHYTO-95-0076
   Srinivasan K, 2012, PHYTOPARASITICA, V40, P157, DOI 10.1007/s12600-011-0207-z
   Sticher L, 1997, ANNU REV PHYTOPATHOL, V35, P235, DOI 10.1146/annurev.phyto.35.1.235
   Termorshuizen AJ, 2014, ACTA HORTIC, V1044, P75
   Thao B.T.H., 2009, J PLANT NUTR SOIL SC, V172, P378
   Vallad GE, 2004, CROP SCI, V44, P1920
   Vinale F, 2008, SOIL BIOL BIOCHEM, V40, P1, DOI 10.1016/j.soilbio.2007.07.002
   Walters D.R., 2012, FUSARIUM WILT GREENH
   Whipps JM, 2004, CAN J BOT, V82, P1198, DOI [10.1139/B04-082, 10.1139/b04-082]
NR 48
TC 1
Z9 1
U1 11
U2 29
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0261-2194
EI 1873-6904
J9 CROP PROT
JI Crop Prot.
PD JUL
PY 2016
VL 85
BP 23
EP 32
DI 10.1016/j.cropro.2016.03.011
PG 10
WC Agronomy
SC Agriculture
GA DL7GP
UT WOS:000375809300004
ER


PT J
AU Bennett, T
   Stevenson, D
   Hogan, E
   Schaub, H
AF Bennett, Trevor
   Stevenson, Daan
   Hogan, Erik
   Schaub, Hanspeter
TI Prospects and challenges of touchless electrostatic detumbling of small
   bodies
SO ADVANCES IN SPACE RESEARCH
LA English
DT Article
DE Remote electrostatic despin; GEO debris servicing; Asteroid retrieval
ID MULTI-SPHERE METHOD; SPACE DEBRIS
AB The prospects of touchlessly detumbling a small, multiple meters in size, space object using electrostatic forces are intriguing. Physically capturing an object with a large rotation rate poses significant momentum transfer and collision risks. If the spin rate is reduced to less than 1 deg/s, relative motion sensing and control associated with mechanical docking becomes manageable. In particular, this paper surveys the prospects and challenges of detumbling large debris objects near Geostationary Earth Orbit for active debris remediation, and investigates if sUch electrostatic tractors are suitable for small asteroids being considered for asteroid retrieval missions. Active charge transfer is used to impart arresting electrostatic torques on such objects, given that they are sufficiently non-spherical. The concept of touchless electrostatic detumbling of space debris is outlined through analysis and experiments and is shown to hold great promise to arrest the rotation within days to weeks. However, even conservatively optimistic simulations of small asteroid detumbling scenarios indicate that such a method could take over a year to arrest the asteroid rotation. The numerical debris detumbling simulation includes a charge transfer model in a space environment, and illustrates how a conducting rocket body could be despun without physical contact. (C) 2015 COSPAR. Published by Elsevier Ltd. All rights reserved.
C1 [Bennett, Trevor; Stevenson, Daan; Hogan, Erik; Schaub, Hanspeter] Univ Colorado, Aerosp Engn Sci, Boulder, CO 80309 USA.
RP Bennett, T (reprint author), Univ Colorado, Aerosp Engn Sci, 431 UCB,ECNT 320, Boulder, CO 80309 USA.
EM trevor.bennett@colorado.edu; daan.stevenson@colorado.edu;
   erik.hogan@colorado.edu; hanspeter.schaub@colorado.edu
CR Bennett T., 2014, AAS AIAA SPAC MECH M
   Bombardelli C., 2011, INT S SPAC FLIGHT DY
   Bombardelli C, 2011, J GUID CONTROL DYNAM, V34, P916, DOI 10.2514/1.51832
   Brophy J., 2012, AER C 2012, P1
   Couzin P., 2013, 6 EUR C SPAC DEBR DA
   Couzin P., 2012, 2 EUR WORKSH ACT DEB
   Denton M.H., 2005, J GEOPHYS RES, V110
   Gibson W. C., 2007, METHOD MOMENTS ELECT
   Ortiz Gomez N., 2014, 40 COSPAR SCI ASS HE
   Hogan E., 2014, AAS AIAA SPAC MECH M
   Hogan E.A., 2014, 13 SPAC CHARG TECHN
   Hogan E.A., 2014, INT HIGH POW LAS ABL
   Hogan EA, 2013, J GUID CONTROL DYNAM, V36, P240, DOI 10.2514/1.56118
   Jasper L.E.Z., 2012, ADVENTURES INTERFACE, P267
   Karavaev Y.S., 2004, ADV ASTRONAUT SCI, P1457
   Kitamura S., 2012, 63 INT ASTR C NAPL I
   Murdoch N., 2008, 58 INT ASTR C
   Ogilvie A., 2008, P 9 INT S ART INT RO, P25
   Papushev P, 2009, ADV SPACE RES, V43, P1416, DOI 10.1016/j.asr.2009.02.007
   Sadiku M. N., 2009, MONTE CARLO METHODS
   Schaub H., 2010, AAS KT ALFR ASTR S M
   Schaub H., 2013, 6 EUR C SPAC DEBR
   Schaub H., 2012, JN JUANG ASTR S COLL
   Seubert C.R., 2009, AIAA J GUID CONTROL, V33, P1856
   Seubert C.R., 2010, 61 INT ASTR C
   Smith ES, 2013, J SPACECRAFT ROCKETS, V50, P1268, DOI 10.2514/1.A32439
   Stevenson D., 2013, 5 INT C SPAC FORM FL
   Stevenson D, 2013, IEEE T PLASMA SCI, V41, P3526, DOI 10.1109/TPS.2013.2283716
   Stevenson D, 2013, ADV SPACE RES, V51, P10, DOI 10.1016/j.asr.2012.08.014
   Stiles L.A., 2012, AAS SPAC MECH M CHAR
   Stiles LA, 2013, ACTA ASTRONAUT, V84, P109, DOI 10.1016/j.actaastro.2012.11.007
   Sugai F, 2013, IEEE INT C INT ROBOT, P783, DOI 10.1109/IROS.2013.6696440
   Vatrisano M., 2015, IEEE AER C BIG SKY M
   Vetrisano M., 2013, 64 INT ASTR C BEIJ C
   Xu WF, 2011, ADV SPACE RES, V48, P95, DOI 10.1016/j.asr.2011.02.012
   Moorer D.F., 2011, US Patent, Patent No. [0036951-A1, 17, 0036951]
   Moorer D.F., 2011, US Patent, Patent No. [8,205,838 B2, 17, 8205838]
NR 37
TC 2
Z9 2
U1 1
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0273-1177
EI 1879-1948
J9 ADV SPACE RES
JI Adv. Space Res.
PD AUG 1
PY 2015
VL 56
IS 3
BP 557
EP 568
DI 10.1016/j.asr.2015.03.037
PG 12
WC Astronomy & Astrophysics; Geosciences, Multidisciplinary; Meteorology &
   Atmospheric Sciences
SC Astronomy & Astrophysics; Geology; Meteorology & Atmospheric Sciences
GA CM7VS
UT WOS:000357905200017
ER


PT J
AU Dolado-Perez, JC
   Pardini, C
   Anselmo, L
AF Dolado-Perez, J. C.
   Pardini, Carmen
   Anselmo, Luciano
TI Review of uncertainty sources affecting the long-term predictions of
   space debris evolutionary models
SO ACTA ASTRONAUTICA
LA English
DT Review
DE Space debris; Long-term evolution; Uncertainty sources; Space
   environment
ID DELTA MODEL; ENVIRONMENT; BREAKUP; IMPACT
AB Since the launch of Sputnik-I in 1957, the amount of space debris in Earth's orbit has increased continuously. Historically, besides abandoned intact objects (spacecraft and orbital stages), the primary sources of space debris in Earth's orbit were (i) accidental and intentional break-ups which produced long-lasting debris and (ii) debris released intentionally during the operation of launch vehicle orbital stages and spacecraft. In the future, fragments generated by collisions are expected to become a significant source as well.
   In this context, and from a purely mathematical point of view, the orbital debris population in Low Earth Orbit (LEO) should be intrinsically unstable, due to the physics of mutual collisions and the relative ineffectiveness of natural sink mechanisms above-700 km. Therefore, the real question should not be "if", but "when" the exponential growth of the space debris population is supposed to start. From a practical point of view, and in order to answer the previous question, since the end of the 1980's several sophisticated long-term debris evolutionary models have been developed.
   Unfortunately, the predictions performed with such models, in particular beyond a few decades, are affected by considerable uncertainty. Such uncertainty comes from a relative important number of variables that being either under the partial control or completely out of the control of modellers, introduce a variability on the long-term simulation of the space debris population which cannot be captured with standard Monte Carlo statistics.
   The objective of this paper is to present and discuss many of the uncertainty sources affecting the long-term predictions done with evolutionary models, in order to serve as a roadmap for the uncertainty and the statistical robustness analysis of the long-term evolution of the space debris population. (C) 2015 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [Dolado-Perez, J. C.] CNES French Space Agcy, Toulouse Space Ctr, Toulouse, France.
   [Pardini, Carmen; Anselmo, Luciano] Natl Res Council CNR, ISTI, Space Flight Dynam Lab, Pisa, Italy.
RP Dolado-Perez, JC (reprint author), CNES French Space Agcy, Toulouse Space Ctr, Toulouse, France.
EM juan-carlos.doladoperez@cnes.fr; carmen.pardini@isti.cnr.it;
   luciano.anselmo@isti.cnr.it
RI Pardini, Carmen/C-7170-2015; 
OI Pardini, Carmen/0000-0001-6060-2335; Anselmo,
   Luciano/0000-0001-5875-2975
CR Alfano S., 2009, AAS AIAA SPAC FLIGHT
   Anselmo L, 1999, ADV SPACE RES, V23, P201, DOI 10.1016/S0273-1177(99)00005-8
   FAA Commercial Space Transportation (AST) and the Commercial Space Transportation Advisory Committee (COMSTAC), 2013, 2013 SPAC TRANSP FOR
   Dolado J.C., 2011, P AAS AIAA ASTR SPEC
   Dolado-Perez J.C., P 65 INT ASTR C 29 S
   Dolado-Perez J.C., 2013, EUROPEAN SPACE AGENC
   Dolado-Perez J.C., P 7 INT SPAC SAF C 2
   EICHLER P, 1993, ADV SPACE RES, V13, P225, DOI 10.1016/0273-1177(93)90595-3
   Fraysse H., 2012, P 5 INT C ASTR TOOLS
   Inter- Agency Space Debris Coordination Committee, IADC1208
   Inter-Agency Space Debris Coordination Committee, 2007, IADC0201
   Johnson NL, 2001, ADV SPACE RES, V28, P1377, DOI 10.1016/S0273-1177(01)00423-9
   Kato B., 2013, EUROPEAN SPACE AGENC, V723
   KESSLER DJ, 1978, J GEOPHYS RES-SPACE, V83, P2637, DOI 10.1029/JA083iA06p02637
   Kilinkrad H., 1997, ESA, P217
   Krag H., 2014, P 13 INT C SPAC OP 5
   Krisko P.H., P 65 INT ASTR C 29 S
   Lamy A., 2011, P 22 INT S SPAC FLIG
   Le Fevre C, 2014, ACTA ASTRONAUT, V94, P234, DOI 10.1016/j.actaastro.2013.07.038
   Lewis B., 2014, P 65 INT ASTR C 29 S
   Lewis HG, 2005, ESA SP PUBL, V587, P243
   Liou JC, 2008, ACTA ASTRONAUT, V62, P264, DOI 10.1016/j.actaastro.2006.12.030
   Liou JC, 2011, ADV SPACE RES, V47, P1865, DOI 10.1016/j.asr.2011.02.003
   Liou JC, 2004, ADV SPACE RES, V34, P981, DOI 10.1016/j.asr.2003.02.027
   LIOU JC, 2006, ADV SPACE RES SERIES, V38, P2102
   Liou J.C., 2013, P 64 INT ASTR C 23 2
   Martin C, 2004, ADV SPACE RES, V34, P969, DOI 10.1016/j.asr.2003.02.028
   Martin C., 2005, P 23 IADC M 21 22 AP
   McKnight D, 1995, INT J IMPACT ENG, V17, P547, DOI 10.1016/0734-743X(95)99879-V
   Morand V., 2012, P AIAA GUID NAV CONT
   Morand V., 2014, P 7 INT SPAC SAF C 2
   Pardini C., P 3 EUR WORKSH SPAC
   Pardini C., 2007, P 20 INT S SPAC FLIG
   Pardini C, 2014, ACTA ASTRONAUT, V100, P30, DOI 10.1016/j.actaastro.2014.03.013
   Patera R.P., 2001, J GUID CONTROL DYN, V24
   RISHBETH H, 1992, PLANET SPACE SCI, V40, P1011, DOI 10.1016/0032-0633(92)90141-A
   Rivero M., 2014, P 65 INT ASTR C 29 S
   Rossi A, 1998, PLANET SPACE SCI, V46, P1583, DOI 10.1016/S0032-0633(98)00070-1
   Rossi A., 2009, ESA
   Space Debris Program Office, 2011, ORBITAL DEBRIS Q NEW, V15
   Su SY, 1997, ADV SPACE RES-SERIES, V19, P351, DOI 10.1016/S0273-1177(97)00024-0
   Su Shin-Yi, 1986, ADV SPACE RES, V6, P109, DOI 10.1016/0273-1177(86)90219-X
   Vallado D. A., P ASTR SPEC C 21 24
   Walker R, 2001, ADV SPACE RES, V28, P1437, DOI 10.1016/S0273-1177(01)00445-8
   Weeden W., 2013, P WORKSH ACT DEBR RE
   White A.E., 2012, P 16 INT SPAC U ANN
   [Anonymous], 2008, AAC105890 SCI TECHN
NR 47
TC 5
Z9 5
U1 2
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
EI 1879-2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD AUG-SEP
PY 2015
VL 113
BP 51
EP 65
DI 10.1016/j.actaastro.2015.03.033
PG 15
WC Engineering, Aerospace
SC Engineering
GA CL8RA
UT WOS:000357240600006
ER


PT J
AU Verheugt, FWA
   Granger, CB
AF Verheugt, Freek W. A.
   Granger, Christopher B.
TI Oral anticoagulants for stroke prevention in atrial fibrillation:
   current status, special situations, and unmet needs
SO LANCET
LA English
DT Article
ID ACUTE CORONARY SYNDROME; ROCKET AF TRIAL; RE-LY TRIAL; ARISTOTLE TRIAL;
   ANTITHROMBOTIC THERAPY; PERCUTANEOUS CORONARY; RANDOMIZED EVALUATION;
   PROSPECTIVE REGISTRY; CATHETER ABLATION; CLINICAL EVENTS
AB In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, including causing serious bleeding such as intracranial haemorrhage and the need for anticoagulation monitoring. In part related to these limitations, they are used in only about half of patients who should be treated according to guideline recommendations. In the past decade, oral agents have been developed that directly block the activity of thrombin (factor IIa), as well as drugs that directly inhibit activated factor X (Xa), which is the first protein in the final common pathway to the activation of thrombin. These novel non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to be at least as good as warfarin for stroke prevention in atrial fibrillation and they have proved to have better safety profiles. Their net advantage is underscored by significantly lower all-cause mortality compared with warfarin in large clinical trials. Because of these features and their ease of use, they are recommended for stroke prevention in atrial fibrillation. They have also a fast onset and off set of action, but they currently lack specific antidotes. This paper addresses the role of anticoagulation for stroke prevention in atrial fibrillation in the era of NOACs, with a focus on special situations including management in the event of bleeding and around the time of procedures including cardioversion, catheter ablation, and device implantation. Also their use in patients with concomitant coronary artery disease, with advanced age, with chronic kidney disease, or with valvular heart disease will be discussed as well as the interaction of NOACs with other cardiac medication, and switching between anticoagulants.
C1 [Verheugt, Freek W. A.] Onze Lieve Vrouw Hosp, Amsterdam, Netherlands.
   [Granger, Christopher B.] Duke Univ, Durham, NC USA.
RP Verheugt, FWA (reprint author), PC Hooftstr 188, NL-1071 CH Amsterdam, Netherlands.
EM f.w.a.verheugt@olvg.nl
RI Verheugt, F.W.A./H-8105-2014
FU Bayer Healthcare; Janssen; BMS/Pfizer; Daiichi-Sankyo; Armetheon;
   Boehringer Ingelheim
FX FWAV has received educational and research grants from Bayer Healthcare,
   as well as honoraria for consultancies or presentations from Bayer
   Healthcare, BMS/Pfizer, Daiichi-Sankyo, and Boehringer Ingelheim. CBG
   has received research grants and consulting fees from Bayer Healthcare,
   Janssen, BMS/Pfizer, Daiichi-Sankyo, Armetheon, and Boehringer
   Ingelheim.
CR Alexander JH, 2014, EUR HEART J, V35, P224, DOI 10.1093/eurheartj/eht445
   Ansell JE, 2014, NEW ENGL J MED, V371, P2141, DOI 10.1056/NEJMc1411800
   Beyer-Westendorf J, 2014, EUR HEART J, V35, P1888, DOI 10.1093/eurheartj/eht557
   Breithardt G, 2014, EUR HEART J, V35, P3377, DOI 10.1093/eurheartj/ehu305
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Cappato R, 2014, EUR HEART J, V35, P3346, DOI 10.1093/eurheartj/ehu367
   Chatterjee S, 2014, MAYO CLIN PROC, V89, P896, DOI 10.1016/j.mayocp.2014.01.030
   Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301
   Connolly SJ, 2013, CIRCULATION, V128, P237, DOI 10.1161/CIRCULATIONAHA.112.001139
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Cuker A, 2014, J AM COLL CARDIOL, V64, P1128, DOI 10.1016/j.jacc.2014.05.065
   Dans AL, 2013, CIRCULATION, V127, P634, DOI 10.1161/CIRCULATIONAHA.112.115386
   Dewilde WJM, 2013, LANCET, V381, P1107, DOI 10.1016/S0140-6736(12)62177-1
   Di Biase L, 2014, CIRCULATION, V129, P2638, DOI 10.1161/CIRCULATIONAHA.113.006426
   Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
   Eikelboom JW, 2014, J AM COLL CARDIOL, V64, P585, DOI 10.1016/j.jacc.2014.06.008
   Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Flaker G, 2014, J AM COLL CARDIOL, V64, P1541, DOI 10.1016/j.jacc.2014.07.967
   Flaker G, 2014, J AM COLL CARDIOL, V63, P1082, DOI 10.1016/j.jacc.2013.09.062
   Gallego P, 2014, AM J MED, V127, P1083, DOI 10.1016/j.amjmed.2014.05.023
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Gorst-Rasmussen A, 2015, J THROMB HAEMOST, V13, P495, DOI 10.1111/jth.12845
   Graham DJ, 2015, CIRCULATION, V131, P157, DOI 10.1161/CIRCULATIONAHA.114.012061
   Granger CB, 2015, AM HEART J, V169, P25, DOI 10.1016/j.ahj.2014.09.006
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Halperin JL, 2014, CIRCULATION, V130, P138, DOI 10.1161/CIRCULATIONAHA.113.005008
   Halvorsen S, 2014, EUR HEART J, V35, P1864, DOI 10.1093/eurheartj/ehu046
   Hansen ML, 2010, ARCH INTERN MED, V170, P1433, DOI 10.1001/archinternmed.2010.271
   Heidbuchel H, 2013, EUROPACE, V15, P625, DOI 10.1093/europace/eut083
   January CT, 2014, CIRCULATION, V130, P2071, DOI 10.1161/CIR.0000000000000040
   Kasmeridis C, 2013, PHARMACOECONOMICS, V31, P971, DOI 10.1007/s40273-013-0090-1
   Kim JS, 2013, HEART RHYTHM, V10, P483, DOI 10.1016/j.hrthm.2012.12.011
   LaHaye SA, 2012, EUR HEART J, V33, P2163, DOI 10.1093/eurheartj/ehs167
   Lakkireddy D, 2012, J AM COLL CARDIOL, V59, P1168, DOI 10.1016/j.jacc.2011.12.014
   Lip GYH, 2014, EUR HEART J, V35, P3155, DOI 10.1093/eurheartj/ehu298
   Lu GM, 2013, NAT MED, V19, P446, DOI 10.1038/nm.3102
   Matchar DB, 2002, AM J MED, V113, P42, DOI 10.1016/S0002-9343(02)01131-2
   Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546
   Oldgren J, 2014, CIRCULATION, V129, P1568, DOI 10.1161/CIRCULATIONAHA.113.005451
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Reilly PA, 2014, J AM COLL CARDIOL, V63, P321, DOI 10.1016/j.jacc.2013.07.104
   Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0
   Sardar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077694
   Savelieva I, 2014, CLIN CARDIOL, V37, P32, DOI 10.1002/clc.22204
   Schiele F, 2013, BLOOD, V121, P3554, DOI 10.1182/blood-2012-11-468207
   Shore S, 2014, AM HEART J, V167, P810, DOI 10.1016/j.ahj.2014.03.023
   Verheugt FWA, 2013, EUR HEART J, V34, P1618, DOI 10.1093/eurheartj/eht075
   Windecker S, 2014, EUR HEART J, V35, P2541, DOI 10.1093/eurheartj/ehu278
NR 51
TC 28
Z9 28
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD JUL 18
PY 2015
VL 386
IS 9990
BP 303
EP 310
DI 10.1016/S0140-6736(15)60245-8
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA CN1XI
UT WOS:000358213700035
PM 25777666
ER


PT J
AU Taddeo, L
   Gascoin, N
   Fedioun, I
   Chetehouna, K
   Lamoot, L
   Fau, G
AF Taddeo, L.
   Gascoin, N.
   Fedioun, I.
   Chetehouna, K.
   Lamoot, L.
   Fau, G.
TI Dimensioning of automated regenerative cooling: Setting of high-end
   experiment
SO AEROSPACE SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Regenerative cooling; Hydrocarbon fuel pyrolysis; Ramjet engine cooling
   efficiency; Energy saving strategies; Lab scale testing
ID REAL-TIME METHOD; N-DODECANE; HYDROCARBON PYROLYSIS;
   THERMAL-DECOMPOSITION; NUMERICAL-SIMULATION; HEAT-TRANSFER; VALIDATION;
   FUEL; QUANTIFICATION; IDENTIFICATION
AB Regenerative cooling is widely used in high-pressure and high-thrust fuel-cooled rocket engines, also suitable for hypersonic structures. The propellant duality in terms of functions (fuel and coolant) makes the thermal and combustion management quite challenging. Dynamics of the system must be studied to develop regulation and control strategies which should be performed with a response time lower than the lowest characteristic time found in supersonic combustion ramjets, i.e. about 1 ms. The present work aims at setting experiments at lab scale by simplifying the additional difficulty of supersonic flow, to determine appropriate regulation dynamics for latter model and control developments. A combustion chamber was dimensioned with similitude rules in terms of heat flux density, conversion rate, chemical compositions, dynamics. Computational Fluid Dynamics and analytical calculations were developed to dimension the experimental bench. It was found that a pyrolysis rate up to 100% can be obtained using ethylene as fuel at 50 bar and 1200 K and with a residence time of about 100 s. Combustion with air (adiabatic flame temperature up to 2400 K) will provide the required heat flux density. The operating range in terms of fuel pressure (10-50 bar), of fuel mass flow rates (50-100 mg s(-1)) and of equivalence ratio (0.8 to 1.0) have been certified. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Taddeo, L.; Gascoin, N.; Chetehouna, K.; Lamoot, L.; Fau, G.] INSA Ctr Vol Loire, PRISME, F-18000 Bourges, France.
   [Fedioun, I.] CNRS ICARE, F-45100 Orleans, France.
RP Taddeo, L (reprint author), INSA Ctr Vol Loire, PRISME, 88 Blvd Lahitolle, F-18000 Bourges, France.
EM lucio.taddeo@insa-cvl.fr; nicolas.gascoin@insa-cvl.fr
RI Gascoin, Nicolas/K-6151-2013; Fedioun, Ivan/C-8987-2016
OI Gascoin, Nicolas/0000-0002-6434-5716; 
CR Abraham G, 2011, J ANAL APPL PYROL, V91, P368, DOI 10.1016/j.jaap.2011.03.014
   Back M.H., 1972, NATL BUREAU STANDARD, V357, P17
   Bao W, 2010, INT J HYDROGEN ENERG, V35, P7002, DOI 10.1016/j.ijhydene.2010.04.033
   Bao W., 2010, INT J HYDROGEN ENERG, V35, P10589
   Bear J., 1991, MODELING APPL TRANSP
   Bear J., 1988, DYNAMICS FLUIDS PORO, P119
   Bhata D.R., 1963, 278 MARQ CORP, V2
   Bouchez M., 2003, 12 AIAA INT SPAC PLA
   Curran ET, 2001, J PROPUL POWER, V17, P1138, DOI 10.2514/2.5875
   Dahm KD, 2004, J ANAL APPL PYROL, V71, P865, DOI 10.1016/j.jaap.2003.11.005
   Djokic MR, 2014, COMBUST FLAME, V161, P2739, DOI 10.1016/j.combustflame.2014.04.013
   Fau G, 2012, J ANAL APPL PYROL, V95, P180, DOI 10.1016/j.jaap.2012.02.005
   Fry R.S., 2004, J PROPULS POWER, V20
   Gascoin N, 2012, COMBUST SCI TECHNOL, V184, P2136, DOI 10.1080/00102202.2012.703729
   Gascoin N, 2007, J THERMOPHYS HEAT TR, V21, P86, DOI 10.2514/1.26022
   Gascoin N, 2011, J ANAL APPL PYROL, V91, P377, DOI 10.1016/j.jaap.2011.04.005
   Gascoin N, 2008, FUEL PROCESS TECHNOL, V89, P1416, DOI 10.1016/j.fuproc.2008.07.004
   Herbinet O, 2007, J ANAL APPL PYROL, V78, P419, DOI 10.1016/j.jaap.2006.10.010
   Hou LY, 2013, FUEL, V103, P1132, DOI 10.1016/j.fuel.2012.09.021
   Huang H., 2002, 20023871 AIAA
   Kima S.K., 2014, INT J HEAT MASS TRAN, V70, P1066
   Liu GZ, 2013, J ANAL APPL PYROL, V104, P384, DOI 10.1016/j.jaap.2013.06.007
   Liu ZH, 2013, APPL THERM ENG, V51, P1047, DOI 10.1016/j.applthermaleng.2012.10.029
   MacDonald ME, 2013, FUEL, V103, P1060, DOI 10.1016/j.fuel.2012.09.068
   Malewicki T, 2013, P COMBUST INST, V34, P361, DOI 10.1016/j.proci.2012.06.156
   Norinaga K., 2007, DETAILED CHEM KINETI
   Norinaga K, 2007, IND ENG CHEM RES, V46, P3547, DOI 10.1021/ie061207p
   SCHOENMAN L, 1986, ACTA ASTRONAUT, V14, P423, DOI 10.1016/0094-5765(86)90143-8
   SCHOETTLE UM, 1989, ACTA ASTRONAUT, V20, P117, DOI 10.1016/0094-5765(89)90061-1
   Teng H, 2000, CHEM ENG SCI, V55, P2727, DOI 10.1016/S0009-2509(99)00546-1
   Timnat Y.M., 1990, PROGR AEROSPACE SCI, V27, P201, DOI 10.1016/0376-0421(90)90007-7
   Ulas A, 2013, AEROSP SCI TECHNOL, V24, P187, DOI 10.1016/j.ast.2011.11.006
   Vasu SS, 2009, P COMBUST INST, V32, P173, DOI 10.1016/j.proci.2008.05.006
   Wang H, 2014, FUEL, V136, P25, DOI 10.1016/j.fuel.2014.07.028
   Wang XQ, 2014, J CONSTR STEEL RES, V99, P129, DOI 10.1016/j.jcsr.2014.04.020
   Yang W, 2013, APPL THERM ENG, V54, P460, DOI 10.1016/j.applthermaleng.2013.02.021
   Yu G, 2001, J PROPUL POWER, V17, P1263, DOI 10.2514/2.5874
NR 37
TC 1
Z9 1
U1 4
U2 15
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 1270-9638
EI 1626-3219
J9 AEROSP SCI TECHNOL
JI Aerosp. Sci. Technol.
PD JUN
PY 2015
VL 43
BP 350
EP 359
DI 10.1016/j.ast.2015.03.015
PG 10
WC Engineering, Aerospace
SC Engineering
GA CL2DR
UT WOS:000356754300032
ER


PT J
AU Song, W
   Feng, SQ
   Shi, J
   Xu, R
   Wang, GC
   Liu, Y
   Li, S
   Cao, R
   Cai, HX
   Zhang, XH
   Tan, Y
AF Song Wei
   Feng Shi-qi
   Shi Jing
   Xu Rong
   Wang Gong-chang
   Liu Yu
   Li Shuang
   Cao Rui
   Cai Hong-xing
   Zhang Xi-he
   Tan Yong
TI Research of Identify Spatial Object Using Spectrum Analysis Technique
SO SPECTROSCOPY AND SPECTRAL ANALYSIS
LA Chinese
DT Article
DE Space fragment; Scattering spectroscopy; Discrete rate; Lapsed
   satellites; Docket debris
AB The high precision scattering spectrum of spatial fragment with the minimum brightness of 4.2 and the resolution of 0.5 nm has been observed using spectrum detection technology on the ground. The obvious differences for different types of objects are obtained by the normalizing and discrete rate analysis of the spectral data. Each of normalized multi-frame scattering spectral line shape for rocket debris is identical. However, that is different for lapsed satellites. The discrete rate of the single frame spectrum of normalized space debris for rocket debris ranges from 0.978% to 3.067%, and the difference of oscillation and average value is small. The discrete rate for lapsed satellites ranges from 3.118 4% to 19.472 7%, and the difference of oscillation and average value relatively large. The reason is that the composition of rocket debris is single, while that of the lapsed satellites is complex. Therefore, the spectrum detection technology on the ground can be used to the classification of the spatial fragment.
C1 [Song Wei; Feng Shi-qi; Shi Jing; Liu Yu; Li Shuang; Cao Rui; Cai Hong-xing; Zhang Xi-he; Tan Yong] Changchun Univ Sci & Technol, Sch Sci, Changchun 130000, Peoples R China.
   [Xu Rong; Wang Gong-chang] Xian Satellite Control Ctr, Xian 710000, Peoples R China.
RP Tan, Y (reprint author), Changchun Univ Sci & Technol, Sch Sci, Changchun 130000, Peoples R China.
EM song_wei_32111@126.com; laser95111@126.com
CR ZHAO Bin, 2009, ACTA OPT SINICA, V29, P3395
   Yu-ge HAN, 2005, INFRARED LASER ENG, V34, P34
   Hasegawa K, 2010, REMOTE SENS ENVIRON, V114, P514, DOI 10.1016/j.rse.2009.10.005
   [黄涛 Huang Tao], 2010, [激光与红外, Laser and Infrared], V40, P685
   [李雅男 Li Yanan], 2009, [光学学报, Acta Optica Sinica], V29, P67
   Liu Wenqing, 2000, Chinese Journal of Lasers, VA27
   Marschner SR, 2000, APPL OPTICS, V39, P2592, DOI 10.1364/AO.39.002592
   MEN Tao, 2013, HIGH POWER LASER PAR, V25, P587, DOI 10.3788/HPLPB20132503.0587
   NGAN A., 2005, EUR S REND, P117
   Nicodemus F E, 1977, NATL BUREAU STANDARD
   Otremba Z, 2004, OPT EXPRESS, V12, P1671, DOI 10.1364/OPEX.12.001671
   WANG Fu-gang, 2012, ACTA OPT SINICA, V32, P1004002
NR 12
TC 1
Z9 1
U1 1
U2 2
PU OFFICE SPECTROSCOPY & SPECTRAL ANALYSIS
PI BEIJING
PA NO 76 COLLAGE SOUTH RD BEIJING, BEIJING 100081, PEOPLES R CHINA
SN 1000-0593
J9 SPECTROSC SPECT ANAL
JI Spectrosc. Spectr. Anal.
PD JUN
PY 2015
VL 35
IS 6
BP 1464
EP 1468
DI 10.3964/j.issn.1000-0593(2015)06-1464-05
PG 5
WC Spectroscopy
SC Spectroscopy
GA CK0GJ
UT WOS:000355883400002
ER


PT J
AU Gilardi, G
   Demarchi, S
   Gullino, ML
   Garibaldi, A
AF Gilardi, Giovanna
   Demarchi, Stefano
   Gullino, Maria Lodovica
   Garibaldi, Angelo
TI Management of leaf spot of wild rocket using fungicides, resistance
   inducers and a biocontrol agent, under greenhouse conditions
SO CROP PROTECTION
LA English
DT Article
DE Diplotaxis tenuifolia; Plectosphaerella cucumerina; Phosphite;
   Acibenzolar-S-methyl; Streptomyces griseoviridis; Disease control
ID PLECTOSPHAERELLA-CUCUMERINA; FUSARIUM-TABACINUM; 1ST REPORT;
   PLECTOSPORIUM-TABACINUM; DIPLOTAXIS-TENUIFOLIA; BRASSICA-NAPUS;
   PHOSPHITE; DISEASE; CITRUS; FIELD
AB A new leaf spot of wild rocket (Diplotaxis tenuifolia), caused by the seed transmitted pathogen Plectosphaerella cucumerina, is causing severe losses on this crop. Disease management is complicated, as few chemicals are registered for use on rocket. Four experimental trials using fungicides, resistance inducers, and a biocontrol agent against P. cucumerina were carried out on two cultivars of wild rocket, under greenhouse conditions, in order to evaluate the efficacy of the different treatments. In the presence of a disease severity ranging from 5.8 to 26.6 in the control plots of wild rocket (cvs Grazia and Rucola selvatica), one foliar application of azoxystrobin, boscalid alone or combined with pyraclostrobin provided a significant reduction in disease severity, compared with the untteated control, at values ranging between 48.5% and 84.8%. The phosphites-based products and acibenzolar-S-methyl provided the most constant results when applied in three treatments, with a disease severity reduction ranging between 34%-82% and 45%-70.3%, respectively. The highest disease reduction in disease severity was observed by using two sprays of mandipropamid at 18.7 mL/100 L with an efficacy ranging between 64% and 92%. Among the copper-based products, the most effective treatments compared with the untreated control plants were the copper hydroxide and terpenic alcohols. Thiram provided a significant reduction in disease severity compared with the untreated control plants at values ranging from 53% to 78%; however, the plants generally did not improve in biomass compared with the untreated control. The most effective treatment in terms of disease severity reduction did not always provide a better response in plant biomass. Streptomyces griseoviridis provided only a partial, but consistent, reduction of leaf spot on wild rocket when applied in three treatments at seven day-intervals, with results statistically different from those observed in the untreated control plants. Considering the difficulty in reaching a complete disease management level against P. cucumerina, an integrated approach should be considered. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Gilardi, Giovanna; Demarchi, Stefano; Gullino, Maria Lodovica; Garibaldi, Angelo] Univ Torino, AGROINNOVA, Ctr Innovat Agroenvironm Sect, I-10095 Grugliasco, TO, Italy.
   [Gullino, Maria Lodovica] Univ Torino, Dept Agr Forest & Food Sci DISAFA, I-10095 Grugliasco, TO, Italy.
RP Gullino, ML (reprint author), Univ Torino, AGROINNOVA, Ctr Innovat Agroenvironm Sect, Largo Braccini 2, I-10095 Grugliasco, TO, Italy.
EM marialodovica.gullino@unito.it
FU European Union [261752]
FX The results reported have received funding from the European Union's
   Seventh Framework Programme (FP7/2007-2013) under grant agreement no
   261752, "PlantFoodSec - Plant and Food Biosecurity, Network of
   Excellence". The authors kindly thank Kathryn Webb for language
   revision.
CR Agostini JP, 2003, PLANT DIS, V87, P69, DOI 10.1094/PDIS.2003.87.1.69
   Barlett D.W., 2002, PEST MANAG SCI, V58, P649
   Bianco V. V., 2009, Italus Hortus, V16, P1
   Bock CH, 2012, CROP PROT, V36, P58, DOI 10.1016/j.cropro.2012.01.009
   Carlucci A, 2012, PERSOONIA, V28, P34, DOI 10.3767/003158512X638251
   Cerioni L, 2013, PLANT DIS, V97, P201, DOI 10.1094/PDIS-03-12-0299-RE
   Egel D, 2010, PLANT DIS, V94, P484, DOI 10.1094/PDIS-94-4-0484B
   Garibaldi A, 2013, PLANT DIS, V97, P848, DOI 10.1094/PDIS-12-12-1168-PDN
   Garibaldi A, 2012, PLANT DIS, V96, P1825, DOI 10.1094/PDIS-06-12-0583-PDN
   Gilardi G, 2013, ACTA HORTIC, V1005, P569
   Gilardi G, 2013, PHYTOPARASITICA, V41, P411, DOI 10.1007/s12600-013-0302-4
   Huggenberger F., 2005, P BCPC INT C GLASG U, P87
   HUMPHERSONJONES FM, 1982, ANN APPL BIOL, V100, P99, DOI 10.1111/j.1744-7348.1982.tb07196.x
   Kahn A.B., 2005, HORTSCIENCE, V40, P1324
   Kanakala S., 2013, Archives of Phytopathology and Plant Protection, V46, P2016, DOI 10.1080/03235408.2013.782674
   Liu SY, 2006, PLANT PATHOL, V55, P401, DOI 10.1111/j.1365-3059.2006.01354.x
   MATHUR S.B., 2003, COMMON LAB SEED HLTH
   MATTA A, 1978, RIV PATOL VEG, V14, P119
   McDonald AE, 2001, J PLANT NUTR, V24, P1505, DOI 10.1081/PLN-100106017
   Miles AK, 2004, AUSTRALAS PLANT PATH, V33, P371, DOI 10.1071/AP04025
   Oostendorp M, 2001, EUR J PLANT PATHOL, V107, P19, DOI 10.1023/A:1008760518772
   Oxley SJP, 2012, CROP PROT, V40, P59, DOI 10.1016/j.cropro.2012.04.028
   PALM ME, 1995, MYCOLOGIA, V87, P397, DOI 10.2307/3760837
   Pignone D, 1997, ROCKET MEDITERRANEAN, P2
   SAAD AT, 1981, PHYTOPATHOLOGY, V71, P902
   Segarra G, 2013, ACTA HORTIC, V1013, P515
   SMILLIE R, 1989, PHYTOPATHOLOGY, V79, P921, DOI 10.1094/Phyto-79-921
   Vallance J, 2011, AGRON SUSTAIN DEV, V31, P191, DOI 10.1051/agro/2010018
   Walters DR, 2013, J EXP BOT, V64, P1263, DOI 10.1093/jxb/ert026
   WICKS TJ, 1991, PLANT DIS, V75, P40
   Youssef YA, 2001, J PHYTOPATHOL, V149, P29, DOI 10.1046/j.1439-0434.2001.00565.x
   ZAZZERINI A, 1987, PLANT DIS, V71, P1043, DOI 10.1094/PD-71-1043
   [Anonymous], 2012, FRESH PLAZA GLOBAL F
NR 33
TC 2
Z9 2
U1 3
U2 33
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0261-2194
EI 1873-6904
J9 CROP PROT
JI Crop Prot.
PD MAY
PY 2015
VL 71
BP 39
EP 44
DI 10.1016/j.cropro.2015.01.021
PG 6
WC Agronomy
SC Agriculture
GA CE4OR
UT WOS:000351810400005
ER


PT J
AU Maan, A
   Heist, EK
   Ruskin, JN
   Mansour, M
AF Maan, Abhishek
   Heist, E. Kevin
   Ruskin, Jeremy N.
   Mansour, Moussa
TI Practical issues in the management of novel oral
   anticoagulants-cardioversion and ablation
SO JOURNAL OF THORACIC DISEASE
LA English
DT Review
DE Novel oral anticoagulants (NOACs); atrial fibrillation (AF);
   cardioversion; catheter ablation
ID NONVALVULAR ATRIAL-FIBRILLATION; ASSAYS LABORATORY RECOMMENDATIONS;
   THROMBIN INHIBITOR DABIGATRAN; ROCKET AF TRIAL; CATHETER ABLATION;
   COAGULATION ASSAYS; RADIOFREQUENCY ABLATION; STROKE PREVENTION;
   COST-EFFECTIVENESS; RENAL IMPAIRMENT
AB Recent research and publication of various landmark trials have led to the approval and subsequent use of novel oral anticoagulants (NOACs) in clinical practice. The use of these newer agents for anticoagulation offers several benefits such as greater specificity, relatively rapid onset and offset of action and a predictable pharmacological profile as compared to warfarin. With the increasing use of these agents, several key issues ranging from appropriate selection to management of complications and considerations for concurrent procedures (cardioversion and catheter ablation) have also emerged. The timing of interruption of anticoagulants prior to catheter ablation and re-initiation after the procedure to minimize the peri-procedural thromboembolism risk without increasing the bleeding risk is of key relevance in electrophysiology practice. The use of NOACs in patients undergoing catheter ablation and cardioversion also requires special considerations based on the pharmacological properties of the individual agent and the presence of comorbidities such as renal and or hepatic impairment. In this review we aim to discuss the practical considerations with the use of NOACs in the setting of cardioversion and catheter ablation based on the currently available data.
C1 [Maan, Abhishek; Heist, E. Kevin; Ruskin, Jeremy N.; Mansour, Moussa] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Div Electrophysiol, Boston, MA 02114 USA.
RP Mansour, M (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
EM mmansour@mgh.harvard.edu
FU E. Kevin Heist: Biotronik; Boston Scientific
FX E. Kevin Heist: Biotronik (research grant, honoraria), Boston Scientific
   (research grant, consultant, honoraria), Medtronic (honoraria), Sanofi
   (consultant), Sorin (consultant, honoraria), St. Jude Medical (research
   grant, consultant, honoraria); Jeremy N. Ruskin: Astellas/
   Cardiome-Consultant (significant); Biosense Webster-Consultant (modest)
   & Fellowship Support (significant); Boston Scientific-Fellowship Support
   (significant); CardioFocus-Clinical Oversight Committee (no
   compensation); CardioInsight-Scientific Advisory Board (modest);
   CryoCath-Scientific Steering Committee (no compensation);
   Medtronic-Consultant (modest) & Fellowship Support (significant);
   Med-IQ-Honoraria (modest); Pfizer-Consultant and Scientific Steering
   Committee (modest); Portola-Consultant & equity (modest);
   Sanofi-Consultant (modest), St. Jude Medical-Fellowship Support
   (significant); Third Rock Ventures-consultant (significant); Moussa
   Mansour: Biosense-Webster (consultant, research grant), Boston
   Scientific (research grant), St. Jude (consultant), Cardiofocus
   (research grant), Endosense (research grant), MC10 (research grant), St.
   Jude Medical (consultant, research grant), Voyage Medical (research
   grant).
CR Airaksinen KEJ, 2013, J AM COLL CARDIOL, V62, P1187, DOI 10.1016/j.jacc.2013.04.089
   Anderson JL, 2013, J AM COLL CARDIOL, V61, P1935, DOI 10.1016/j.jacc.2013.02.001
   Asmis LM, 2012, THROMB RES, V129, P492, DOI 10.1016/j.thromres.2011.06.031
   Atay JK, 2012, CLIN APPL THROMB-HEM, V18, P181, DOI 10.1177/1076029611416642
   Barrett YC, 2013, CLIN APPL THROMB-HEM, V19, P522, DOI 10.1177/1076029612441859
   Camm AJ, 2012, EUROPACE, V14, P1385, DOI 10.1093/europace/eus305
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Colilla S, 2013, AM J CARDIOL, V112, P1142, DOI 10.1016/j.amjcard.2013.05.063
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Cui Yimin, 2013, Clin Pharmacol, V5, P177, DOI 10.2147/CPAA.S51981
   Di Biase L, 2010, CIRCULATION, V121, P2550, DOI 10.1161/CIRCULATIONAHA.109.921320
   Dorbala S, 1998, J CARDIOVASC ELECTR, V9, P1152, DOI 10.1111/j.1540-8167.1998.tb00086.x
   Douxfils J, 2013, THROMB HAEMOSTASIS, V110, P283, DOI 10.1160/TH12-12-0898
   Douxfils J, 2012, THROMB RES, V130, P956, DOI 10.1016/j.thromres.2012.09.004
   Douxfils J, 2012, THROMB HAEMOSTASIS, V107, P985, DOI 10.1160/TH11-11-0804
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Eitel C, 2013, EUROPACE, V15, P1587, DOI 10.1093/europace/eut128
   European H, 2010, EUR HEART J, V31, P2369, DOI DOI 10.1093/EURHEARTJ/EHQ278
   Ferrandis R, 2013, THROMB HAEMOSTASIS, V110, P515, DOI 10.1160/TH12-11-0868
   Flaker G, 2014, J AM COLL CARDIOL, V63, P1082, DOI 10.1016/j.jacc.2013.09.062
   Fox KAA, 2011, EUR HEART J, V32, P2387, DOI 10.1093/eurheartj/ehr342
   Freeman JV, 2011, ANN INTERN MED, V154, P1, DOI 10.7326/0003-4819-154-1-201101040-00289
   Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238
   Goodman SG, 2014, J AM COLL CARDIOL, V63, P891, DOI 10.1016/j.jacc.2013.11.013
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Haines DE, 2013, J INTERV CARD ELECTR, V37, P233, DOI 10.1007/s10840-013-9800-z
   Hawes EM, 2013, J THROMB HAEMOST, V11, P1493, DOI 10.1111/jth.12308
   Healey JS, 2012, CIRCULATION, V126, P343, DOI 10.1161/CIRCULATIONAHA.111.090464
   Huisman MV, 2012, THROMB HAEMOSTASIS, V107, P838, DOI 10.1160/TH11-10-0718
   Imamura K, 2013, J INTERV CARD ELECTR, V37, P223, DOI 10.1007/s10840-013-9801-y
   Kaiser DW, 2013, J INTERV CARD ELECTR, V37, P241, DOI 10.1007/s10840-013-9793-7
   Kim JS, 2013, HEART RHYTHM, V10, P483, DOI 10.1016/j.hrthm.2012.12.011
   Klein AL, 2001, NEW ENGL J MED, V344, P1411, DOI 10.1056/NEJM200105103441901
   Konduru SV, 2012, J INTERV CARD ELECTR, V35, P277, DOI 10.1007/s10840-012-9719-9
   Kubitza D, 2010, BRIT J CLIN PHARMACO, V70, P703, DOI 10.1111/j.1365-2125.2010.03753.x
   Lakkireddy D, 2014, J AM COLL CARDIOL, V63, P982, DOI 10.1016/j.jacc.2013.11.039
   Lakkireddy D, 2012, J AM COLL CARDIOL, V59, P1168, DOI 10.1016/j.jacc.2011.12.014
   Lindahl TL, 2011, THROMB HAEMOSTASIS, V105, P371, DOI 10.1160/TH10-06-0342
   Lip GYH, 2014, CLIN THER, V36, P192, DOI 10.1016/j.clinthera.2013.12.011
   Maan Abhishek, 2011, Crit Pathw Cardiol, V10, P76, DOI 10.1097/HPC.0b013e318224b7bd
   Maddox W, 2013, J CARDIOVASC ELECTR, V24, P861, DOI 10.1111/jce.12143
   Marlu R, 2012, THROMB HAEMOSTASIS, V108, P217, DOI 10.1160/TH12-03-0179
   McGrath ER, 2013, NEUROLOGY, V81, P825, DOI 10.1212/WNL.0b013e3182a2cc15
   Mueck W, 2013, BRIT J CLIN PHARMACO, V76, P455, DOI 10.1111/bcp.12075
   Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Providencia R, 2014, EUROPACE, V16, P1137, DOI 10.1093/europace/euu007
   Rognoni C, 2014, CLIN DRUG INVEST, V34, P9, DOI 10.1007/s40261-013-0144-3
   Saeed M, 2006, INT J CARDIOL, V113, P401, DOI 10.1016/j.ijcard.2006.03.036
   Samama MM, 2012, THROMB HAEMOSTASIS, V107, P379, DOI 10.1160/TH11-06-0391
   Sartori MT, 2009, CLIN APPL THROMB-HEM, V15, P628, DOI 10.1177/1076029609335909
   Snipelisky D, 2012, J INTERV CARD ELECTR, V35, P29, DOI 10.1007/s10840-012-9708-z
   Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001
   Stangier J, 2010, CLIN PHARMACOKINET, V49, P259, DOI 10.2165/11318170-000000000-00000
   van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758
   Viles-Gonzalez Juan F, 2011, Curr Cardiol Rep, V13, P38, DOI 10.1007/s11886-010-0153-2
   Winkle RA, 2012, J CARDIOVASC ELECTR, V23, P264, DOI 10.1111/j.1540-8167.2011.02175.x
   WOLF PA, 1991, STROKE, V22, P983
   You JJ, 2012, CHEST, V141, pE531S, DOI 10.1378/chest.11-2304
NR 62
TC 6
Z9 6
U1 1
U2 4
PU PIONEER BIOSCIENCE PUBL CO
PI HONG KONG
PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG,
   00000, PEOPLES R CHINA
SN 2072-1439
EI 2077-6624
J9 J THORAC DIS
JI J. Thorac. Dis.
PD FEB
PY 2015
VL 7
IS 2
BP 115
EP 131
DI 10.3978/j.issn.2072-1439.2014.11.35
PG 17
WC Respiratory System
SC Respiratory System
GA CD0AP
UT WOS:000350732600001
PM 25713727
ER


PT J
AU Poustini, MJ
   Esmaelzadeh, R
   Adami, A
AF Poustini, Mohammad Javad
   Esmaelzadeh, Reza
   Adami, Amirhossein
TI A new approach to trajectory optimization based on direct transcription
   and differential flatness
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Trajectory optimization; Differential flatness; Reentry vehicle
   trajectory optimization
AB The objective of the present paper is to introduce a reliable method to produce an optimal trajectory in the presence of all limitations and constraints. Direct transcription, has been employed to convert the trajectory optimization problem into nonlinear programming problem via discretizing the profile of state and control parameters and solving for a constrained problem. Differential flatness as a complementary theory leads to model the optimization problem in a lowered dimensional space through defining flat variables. Several curvilinear functions have been used to approximate flat variables and have their own benefits and disadvantages. Accuracy, complexity and number of needed points are examples of related issues. A new approach is developed based on an indirect approximation of flat variables, which leads to decrease the optimization variables and computational costs while preserving the needed accuracy. The proposed method deals with a 3rd order approximation of flat variables via integrating linear function of the acceleration profile. The new method is implemented on the terminal area energy management phase of a reusable launch vehicle. Test results show that the suggested method, as compared with other conventional methods, requires lower computational efforts in cases of the number of iterations and function evaluations, while providing a more accurate optimal solution. (C) 2014 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [Poustini, Mohammad Javad; Esmaelzadeh, Reza] Space Res Inst, Tehran 3159916111, Iran.
   [Adami, Amirhossein] Amirkabir Univ Technol, Tehran 158754413, Iran.
RP Poustini, MJ (reprint author), Space Res Inst, Tehran 3159916111, Iran.
EM javadpoostini@yahoo.com; rsmael@gmail.com; Aha.aerospace@autac.ir
OI Adami, Amirhossein/0000-0003-3972-7541
CR Betts JT, 2010, ADV DES CONTROL, P1, DOI 10.1137/1.9780898718577
   Betts JT, 2000, J COMPUT APPL MATH, V120, P27, DOI 10.1016/S0377-0427(00)00301-0
   Christopher L. Darby, 2011, J SPACECR ROCKETS, V48
   Desiderio D, 2013, IEEE T CONTR SYST T, V21, P1280, DOI 10.1109/TCST.2012.2202664
   Dickmanns E.D., 1975, APPROXIMATE SOLUTION
   Esmaelzadeh R., 2014, INT J COMPUT APPL, V89
   Fliess M., 1995, INT J CONTROL
   Geng LN, 2009, CCDC 2009: 21ST CHINESE CONTROL AND DECISION CONFERENCE, VOLS 1-6, PROCEEDINGS, P1913, DOI 10.1109/CCDC.2009.5192065
   HARGRAVES CR, 1987, J GUID CONTROL DYNAM, V10, P338, DOI 10.2514/3.20223
   Jamilnia R., 2013, J AEROSP ENG, V26
   Mono Vincent, 2009, CONTROL ENG PRACT, V17, P588
   Neckel Tobias, 2003, P 5 INT C LAUNCH TEC
   Petropoulos A.E., 2002, NASA JET PROPOLSION
   Poustini M.J., 2014, THESIS SPACE RES I A
   Ross IM, 2006, MATH COMPUT MODEL, V43, P1172, DOI 10.1016/j.mcm.2005.05.021
   Ross M., 2010, 04010 NAV POSTGR SCH
   Siouris G. M., 2003, MISSILE GUIDANCE CON
   Guo Xiao, 2013, CHIN J AERONAUT, V26
   Qingzhen Zhang, 2008, P 2 IEEE INT S SYST
   Zhao J, 2013, CHINESE J AERONAUT, V26, P1544, DOI 10.1016/j.cja.2013.10.009
   Zimmerman Curtis, 2003, J GUID CONTROL DYN, V26
NR 21
TC 0
Z9 0
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
EI 1879-2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD FEB-MAR
PY 2015
VL 107
BP 1
EP 13
DI 10.1016/j.actaastro.2014.10.018
PG 13
WC Engineering, Aerospace
SC Engineering
GA CA6XQ
UT WOS:000349061200001
ER


PT J
AU Morra, L
   Bilotto, M
   Baiano, S
   Saviello, G
   Cerrato, D
AF Morra, Luigi
   Bilotto, Maurizio
   Baiano, Salvatore
   Saviello, Giovanni
   Cerrato, Domenico
TI Annual effects of different organic fertilisers in a baby leaf crops
   system under tunnel in Southern Italy
SO ITALIAN JOURNAL OF AGRONOMY
LA English
DT Article
DE Biowaste compost; buffalo manure; olive pomace compost; soil organic
   carbon balance; rocket; leaf nitrate content
ID QUALITY; MANAGEMENT; NITROGEN; DYNAMICS
AB In a farm devoted to the production of fresh cut leafy vegetables located in Eboli (Salerno), it was carried out a trial to compare the effects on crops and soil organic carbon (SOC) of biowaste compost. olive pomace compost, buffalo manure applied to soil in two doses (15 and 30 t ha(-1) fresh weight). The amendments were tested in order to start in defining a feasible strategy for the recovery/maintenance of soils in degradation due to the organic matter depletion triggered by the intensive soil tillage and the lack of organic matter returned to soil. In the year following the soil amendment, it was studied the crop sequence: rocket-basil-rocket. Analysis of nitrates concentration in leaves of rocket was carried out on samples of all the treatments picked up in the two cycles of rocket. Along the year, we observed that the higher yields promoted in the first six months (May September) from the dose 15 t ha(-1), were obtained with the dose 30 t ha(-1) in the successive six months (November May). This was due, probably, to the larger stock of total N supplied with dose 30 and its release in time. Buffalo manure amendment showed a higher quickness than composts in the supplying mineral nitrogen to the first crops. On the other hand nitrates in leaves of rocket exceeded, more frequently, the limits fixed in EU Regulation n. 1258/2011 in the plots amended with buffalo manure. Instead, the treatments with olive pomace compost showed to exceed rarely the EU limits. Under tunnel, the intensive management based on 4-5 crop cycles per year and as much soil tillage, appeared the first cause to explain the lack of significant variation in SOC of plots treated with organic improvers after one year from their distribution. This result let us to suppose the need to study some modifications of the standard farm management in order to reduce the number of soil tillage in a year and, as a consequence, the main stress causing the high carbon mineralisation rate in soil under tunnel.
C1 [Morra, Luigi; Bilotto, Maurizio; Baiano, Salvatore; Saviello, Giovanni; Cerrato, Domenico] Consiglio Ric Agr & Anal Econ Agr, Unita Ric Frutticoltura, I-81100 Caserta, Italy.
RP Morra, L (reprint author), Consiglio Ric Agr & Anal Econ Agr, Unita Ric Frutticoltura, Via Torrino 3, I-81100 Caserta, Italy.
EM luigi.morra@entecra.it
FU Campania Region, Assessorato Agricoltura - Project Centro Orticolo
   Campion
FX research was funded by Campania Region, Assessorato Agricoltura -
   Project Centro Orticolo Campion.
CR Balesdent J, 2000, SOIL TILL RES, V53, P215, DOI 10.1016/S0167-1987(99)00107-5
   Bonanomi G, 2011, APPL SOIL ECOL, V47, P184, DOI 10.1016/j.apsoil.2010.12.007
   Bronick CJ, 2005, GEODERMA, V124, P3, DOI 10.1016/j.geoderma.2004.03.005
   Buckwell A., 2014, SUSTAINABLE INTENSIF
   Cavaiuolo M, 2014, NUTRIENTS, V6, P1519, DOI 10.3390/nu6041519
   European Commission, 2006, OFFICIAL J L, V364, P25
   Fontana E., 2010, Italus Hortus, V17, P28
   Franceschini A, 2014, INF AGRARIO, V19, P33
   Garcia-Ruiz R, 2012, AGRON SUSTAIN DEV, V32, P803, DOI 10.1007/s13593-011-0080-7
   Hartz TK, 2000, HORTSCIENCE, V35, P209
   Martinetti L, 1996, RIV AGRON, V1, P92
   Morra L, 2013, ITAL J AGRON, V8, P206
   Nicola S, 2007, ACTA HORTIC, P273
   Official Journal of the European Union, 2011, OFFICIAL J L
   Paradiso R, 2001, ITALUS HORTUS, V4, P14
   Parente A, 2002, COLTURE PROTETTE, V12, P28
   Penati M, 2009, ASPORTAZIONI ELEMENT, V107
   Pimpini F., 2005, ORTAGGI FOGLIA TAGLI
   Santamaria P, 2002, J PLANT NUTR, V25, P245, DOI 10.1081/PLN-100108833
   Santamaria P, 2006, J SCI FOOD AGR, V86, P10, DOI 10.1002/jsfa.2351
   Scotti R, 2012, ITALUS HORTUS, V5, P65
   Selma MV, 2010, J AGR FOOD CHEM, V58, P8331, DOI 10.1021/jf1016187
   Suslow TV, 2003, COMPREHENSIVE REV FO, V2S, P38, DOI DOI 10.1111/J.1541-4337.2003.TB00030.X
NR 23
TC 0
Z9 0
U1 3
U2 6
PU PAGEPRESS PUBL
PI PAVIA
PA MEDITGROUP, VIA G BELLI, 4, PAVIA, 27100, ITALY
SN 1125-4718
EI 2039-6805
J9 ITAL J AGRON
JI Ital. J. Agron.
PY 2015
VL 10
IS 3
BP 144
EP 150
DI 10.4081/ija.2015.642
PG 7
WC Agronomy
SC Agriculture
GA CY2BX
UT WOS:000366214900005
ER


PT J
AU Kochhauser, S
   Khaykin, Y
   Beardsall, J
   Juta, R
   Hache, P
   Trought, K
   Lenton-Brym, T
   Tsang, B
   Pantano, A
   Beardsall, M
   Wulffhart, Z
   Verma, A
AF Kochhaeuser, Simon
   Khaykin, Yaariv
   Beardsall, Jessica
   Juta, Rasna
   Hache, Philip
   Trought, Kathleen
   Lenton-Brym, Talia
   Tsang, Bernice
   Pantano, Alfredo
   Beardsall, Marianne
   Wulffhart, Zaev
   Verma, Atul
TI Comparison of Outcomes After Cardioversion or Atrial Fibrillation
   Ablation in Patients With Differing Periprocedural Anticoagulation
   Regimens
SO CANADIAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID CATHETER ABLATION; RADIOFREQUENCY ABLATION; ROCKET AF; SAFETY;
   RIVAROXABAN; DABIGATRAN; WARFARIN; FLUTTER; STROKE; PREVENTION
AB Background: There is a paucity of data that compare traditional vitamin K antagonist (VKA) with novel oral anticoagulant regimens in periprocedural management of cardioversion or ablation of atrial fibrillation (AF). We sought to compare outcomes of use of VKA, dabigatran (DABI), and rivaroxaban (RIVA) anticoagulation around the time of intervention.
   Methods: We studied consecutive patients undergoing cardioversion or ablation of AF at our centre from October 2010 to October 2013. There were 3 different anticoagulation groups: warfarin (VKA), DABI, and RIVA. Safety was assessed according to number of strokes, transient ischemic attacks (TIAs), and clinically important and not important bleeding events.
   Results: Baseline characteristics were well balanced between the groups. Average follow-up was 6 months (+/- 4 months). A total of 901 patients who underwent cardioversion were studied (VKA [n = 471], DABI [n = 288] and RIVA [n = 141]). In these patients there were no strokes seen during follow-up and 2 TIAs in the DABI group. Bleeding rates were low, with no significant difference between the 3 groups. A total of 680 patients who underwent ablation were studied (VKA [n = 319], DABI [n = 220] and RIVA [n = 171]). There were no strokes reported during follow-up and 3 TIAs: 2 in the VKA group and 1 in the DABI group not resulting in a significant difference between the groups. Bleeding rates were low, with no significant difference between the groups.
   Conclusions: Overall, there was a low incidence of adverse events for all anticoagulation regimens. Warfarin, DABI, and RIVA use around the time of the procedure are safe and reasonable options for patients who undergo cardioversion or AF ablation.
C1 [Kochhaeuser, Simon; Khaykin, Yaariv; Beardsall, Jessica; Juta, Rasna; Hache, Philip; Trought, Kathleen; Lenton-Brym, Talia; Tsang, Bernice; Pantano, Alfredo; Beardsall, Marianne; Wulffhart, Zaev; Verma, Atul] Southlake Reg Hlth Ctr, Newmarket, ON L3Y 2P6, Canada.
RP Verma, A (reprint author), Southlake Reg Hlth Ctr, 602-581 Davis Dr, Newmarket, ON L3Y 2P6, Canada.
EM atul.verma@utoronto.ca
FU German Cardiac Society; Bayer Inc.
FX Simon Kochhauser is supported by a research grant of the German Cardiac
   Society. Funding for some of the research students was provided by an
   unrestricted grant from Bayer Inc.
CR Bin Abdulhak AA, 2013, EUROPACE, V15, P1412, DOI 10.1093/europace/eut239
   Cairns JA, 2011, CAN J CARDIOL, V27, P74, DOI 10.1016/j.cjca.2010.11.007
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Di Biase L, 2014, CIRCULATION, V129, P2638, DOI 10.1161/CIRCULATIONAHA.113.006426
   Gautam S, 2011, J CARDIOVASC ELECTR, V22, P248, DOI 10.1111/j.1540-8167.2010.01894.x
   Gopinath D, 2011, J CARDIOVASC ELECTR, V22, P236, DOI 10.1111/j.1540-8167.2010.01940.x
   Hakalahti A, 2011, EUROPACE, V13, P640, DOI 10.1093/europace/eur038
   Healey JS, 2011, CAN J CARDIOL, V27, P31, DOI 10.1016/j.cjca.2010.11.015
   Lakkireddy D, 2014, J AM COLL CARDIOL, V63, P982, DOI 10.1016/j.jacc.2013.11.039
   Lakkireddy D, 2012, J AM COLL CARDIOL, V59, P1168, DOI 10.1016/j.jacc.2011.12.014
   Mardigyan V, 2013, CAN J CARDIOL, V29, P219, DOI 10.1016/j.cjca.2012.04.013
   Naccarelli GV, 2010, CLIN CARDIOL, V33, P270, DOI 10.1002/clc.20759
   Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546
   Page SP, 2011, J CARDIOVASC ELECTR, V22, P265, DOI 10.1111/j.1540-8167.2010.01910.x
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Providencia R, 2014, EUROPACE, V16, P1137, DOI 10.1093/europace/euu007
   Santangeli P, 2011, CARDIOL RES PRACT, V2011
   Shurrab M, 2013, CAN J CARDIOL, V29, P1203, DOI 10.1016/j.cjca.2013.07.005
   Skanes AC, 2012, CAN J CARDIOL, V28, P125, DOI 10.1016/j.cjca.2012.01.021
   Stepanyan G, 2014, J INTERV CARD ELECTR, V40, P33, DOI 10.1007/s10840-014-9888-9
   Verma A, 2011, CAN J CARDIOL, V27, P60, DOI 10.1016/j.cjca.2010.11.011
   Yadlapati A, 2014, AM J CARDIOL, V113, P1362, DOI 10.1016/j.amjcard.2013.12.044
   [Anonymous], 2010, AM HEART J, V159, P340
NR 23
TC 3
Z9 3
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0828-282X
EI 1916-7075
J9 CAN J CARDIOL
JI Can. J. Cardiol.
PD DEC
PY 2014
VL 30
IS 12
BP 1541
EP 1546
DI 10.1016/j.cjca.2014.09.018
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AU4ME
UT WOS:000345584400018
PM 25475459
ER


PT J
AU Okata, T
   Toyoda, K
   Okamoto, A
   Miyata, T
   Nagatsuka, K
   Minematsu, K
AF Okata, Takuya
   Toyoda, Kazunori
   Okamoto, Akira
   Miyata, Toshiyuki
   Nagatsuka, Kazuyuki
   Minematsu, Kazuo
TI Anticoagulation Intensity of Rivaroxaban for Stroke Patients at a
   Special Low Dosage in Japan
SO PLOS ONE
LA English
DT Article
ID NONVALVULAR ATRIAL-FIBRILLATION; FACTOR-XA INHIBITOR; WARFARIN
AB Objectives: In Japan, low-dose rivaroxaban [15 mg QD/10 mg QD for creatinine clearance of 30-49 mL/min] was approved for clinical use in NVAF patients partly because of its unique pharmacokinetics in Japanese subjects. The aim of the study was to determine the anticoagulation intensity of rivaroxaban and its determinant factors in Japanese stroke patients.
   Methods: Consecutive stroke patients with NVAF admitted between July 2012 and December 2013 were studied. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and estimated plasma concentration of rivaroxaban (C-riv) based on an anti-factor Xa chromogenic assay were measured just before and 4 and 9 h after administration at the steady state level of rivaroxaban. Determinant factors for C-riv were explored using a linear mixed-model approach.
   Results: Of 110 patients (37 women, 75+/-9 years old), 59 took 15 mg QD of rivaroxaban and 51 took 10 mg QD. C-riv at 4 h was 186 ng/mL for patients taking 15 mg QD and 147 ng/mL for those taking 10 mg QD. Both PT and aPTT were positively correlated with C-riv. C-riv was 72% lower at 4 h in 15 patients receiving crushed tablets than in the other patients, and tablet crushing was significantly associated with lower C-riv (adjusted estimate -0.43, 95% CI -0.60 to -0.26) after multivariate-adjustment.
   Conclusion: The anticoagulation effects of rivaroxaban in the acute stroke setting for Japanese NVAF patients were relatively low as compared with those in the ROCKET-AF and J-ROCKET AF trials. Tablet crushing, common in dysphagic patients, decreased C-riv.
C1 [Okata, Takuya; Toyoda, Kazunori; Minematsu, Kazuo] Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Osaka, Japan.
   [Okamoto, Akira] Natl Cerebral & Cardiovasc Ctr, Dept Clin Chem, Osaka, Japan.
   [Miyata, Toshiyuki] Natl Cerebral & Cardiovasc Ctr, Dept Mol Pathogenesis, Osaka, Japan.
   [Nagatsuka, Kazuyuki] Natl Cerebral & Cardiovasc Ctr, Dept Neurol, Osaka, Japan.
RP Toyoda, K (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Cerebrovasc Med, Osaka, Japan.
EM toyoda@ncvc.go.jp
RI Toyoda, Kazunori/J-3828-2015
OI Toyoda, Kazunori/0000-0002-8346-9845
FU National Cerebral and Cardiovascular Center [23-4-3, 25-6-4]
FX The present study was supported by Intramural Research Funds (23-4-3,
   25-6-4) for Cardiovascular Diseases of the National Cerebral and
   Cardiovascular Center. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 2013, XAR PACK INS
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Dyke CK, 2002, CIRCULATION, V105, P2385, DOI 10.1161/01.CIR.0000016351.12759.52
   Fuster V, 2006, EUR HEART J, V27, P1979, DOI 10.1093/eurheartj/ehl176
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Kaneko M, 2013, DRUG METAB PHARMACOK, V28, P321, DOI 10.2133/dmpk.DMPK-12-RG-109
   LANGE N, 1989, J AM STAT ASSOC, V84, P241, DOI 10.2307/2289869
   Moore KT, 2012, ACCP ANN M
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Perzborn E, 2005, J THROMB HAEMOST, V3, P514, DOI 10.1111/j.1538-7836.2005.01166.x
   Samama MM, 2012, THROMB HAEMOSTASIS, V107, P379, DOI 10.1160/TH11-06-0391
   Samama MM, 2010, THROMB HAEMOSTASIS, V103, P815, DOI 10.1160/TH09-03-0176
   Samama MM, 2002, PATHOPHYSIOL HAEMO T, V32, P218, DOI 10.1159/000073570
   Tanigawa T, 2013, DRUG METAB PHARMACOK, V28, P59, DOI 10.2133/dmpk.DMPK-12-RG-034
   Toyoda K, 2013, CONTRIB NEPHROL, V179, P1, DOI 10.1159/000346944
   Toyoda K, 2012, NEUROLOGY, V78, P1898, DOI 10.1212/WNL.0b013e318259e29f
NR 19
TC 3
Z9 3
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 26
PY 2014
VL 9
IS 11
AR e113641
DI 10.1371/journal.pone.0113641
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CA8CZ
UT WOS:000349145400071
PM 25479967
ER


PT J
AU Radchenko, AV
   Radchenko, PA
AF Radchenko, A. V.
   Radchenko, P. A.
TI Modeling of space debris interaction with an element of a
   solid-propellant rocket engine
SO MECHANICS OF SOLIDS
LA English
DT Article
DE anisotropy; strength; fracture; elasticity; plasticity; compression
   wave; unloading wave; detonation
AB The interaction of a steel cylindrical indenter with an element of a solid-propellant rocket engine (SPRE) is modeled numerically. The SPRE shell material is an orthotropic organic plastic rigidly fixed to the solid propellant. The influence of the indenter geometric and kinetic parameters and of the orientation of elastic and strength properties of the shell on the parameters of the compression wave incident on the solid propellant is investigated. The range of interaction velocities from 400 to 1000 m/s is considered. The problem is solved numerically by the finite-element method in three dimensions. The indenter material behavior is described by an elastoplastic model, the behavior of the shell anisotropic material is described in the framework of an elastobrittle model, and the propellant is modeled by an elastic medium.
C1 [Radchenko, A. V.; Radchenko, P. A.] Tomsk State Univ Architecture & Civil Engn, Tomsk 634003, Russia.
RP Radchenko, AV (reprint author), Tomsk State Univ Architecture & Civil Engn, Solyanaya Pl 2, Tomsk 634003, Russia.
EM andrey-radchenko@live.ru; radchenko@live.ru
CR Johnson G. R., 1977, APPL MECH, V44, P95
   KANEL GI, 1980, COMBUST EXPLO SHOCK+, V16, P439, DOI 10.1007/BF00742994
   Kanel' G. I., 1996, SHOCK WAVE PHENOMENA
   Krivoshein M. N., 2003, VESTNIK TOMSK GOS AR, P194
   Radchenko AV, 1999, INT J IMPACT ENG, V23, P745, DOI 10.1016/S0734-743X(99)00119-0
   Radchenko A. V., 2011, 2011615952
   Radchenko A. V., 2003, VESTNIK TOMSK GOS AR, P179
   Vlasov M. N., 1999, ECOLOGICAL RISKS COS
   Wilkins M. L., 1967, COMPUTATIONAL METHOD, P212
   Wu E. M., 1985, COMPOSITE MAT, V2, P401
NR 10
TC 0
Z9 0
U1 0
U2 5
PU ALLERTON PRESS INC
PI NEW YORK
PA 18 WEST 27TH ST, NEW YORK, NY 10001 USA
SN 0025-6544
EI 1934-7936
J9 MECH SOLIDS+
JI Mech. Sol.
PD NOV
PY 2014
VL 49
IS 6
BP 683
EP 689
DI 10.3103/S0025654414060107
PG 7
WC Mechanics
SC Mechanics
GA AY4NK
UT WOS:000347555300010
ER


PT J
AU Reddy, P
   Giugliano, RP
AF Reddy, Prabashni
   Giugliano, Robert P.
TI The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary
   Syndromes
SO JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Review
DE rivaroxaban; anticoagulant; atrial fibrillation; acute coronary syndrome
ID FACTOR-XA INHIBITOR; TOTAL KNEE ARTHROPLASTY; COST-EFFECTIVENESS; STROKE
   PREVENTION; ORAL ANTICOAGULANTS; VENOUS THROMBOEMBOLISM; ANTITHROMBOTIC
   AGENTS; PULMONARY-EMBOLISM; HIP-ARTHROPLASTY; DOUBLE-BLIND
AB Rivaroxaban, a direct factor Xa inhibitor, is a novel oral anticoagulant approved for stroke prevention in patients with nonvalvular atrial fibrillation and also approved in Europe (but not in the United States) to prevent recurrent ischemic events in patients with recent acute coronary syndromes. Advantages of rivaroxaban over oral anticoagulants such as warfarin are the lack of need for ongoing monitoring, a fixed-dose regimen, and fewer drug and food interactions. Drawbacks include a lack of an antidote and the absence of a widely available method to reliably monitor the anticoagulant effect. In patients at risk of stroke due to atrial fibrillation, rivaroxaban was noninferior compared to warfarin in preventing stroke/systemic embolism in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) trial and was associated with a similar risk of major bleeding; the incidence of intracranial hemorrhage was 33% lower with rivaroxaban. Concerns raised about the trial were the adequacy of warfarin management and the increase in event rate at the end of the trial. The drug acquisition cost of rivaroxaban is higher than that of warfarin although decision-analytic models suggest that it is cost effective in atrial fibrillation. In patients with recent acute coronary syndrome, low-dose rivaroxaban reduced mortality and the composite end point of death from cardiovascular causes, myocardial infarction and stroke, but this was accompanied by an increased risk of intracranial hemorrhage and major bleeding in the Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction (ATLAS ACS 2-TIMI) 5 I trial. Thus, rivaroxaban appears to be a valuable addition to the therapeutic armamentarium in atrial fibrillation although caution should be exercised, given the limited experience in combination with novel oral antiplatelet agents. The role of rivaroxaban as part of a modern regimen in acute coronary syndrome continues to be evaluated.
C1 [Reddy, Prabashni] Partners Healthcare, Ctr Drug Policy, Needham, MA USA.
   [Giugliano, Robert P.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Giugliano, RP (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA.
EM rgiugliano@partners.org
FU AstraZeneca; Daiichi Sankyo; Johnson Johnson; Merck; Sanofi
FX The author(s) declared the following potential conflicts of interest
   with respect to the research, authorship, and/or publication of this
   article. Prabashni Reddy has no conflicts of interest to declare. Robert
   P. Giugliano is a member of the TIMI Study Group, which has received
   research grant support from AstraZeneca, Daiichi Sankyo, Johnson &
   Johnson, Merck, and Sanofi to conduct clinical trials with
   antithrombotic drugs. Dr. Giugliano has received honoraria for CME
   lectures and/or consulting from Bristol-Myers Squibb, Pfizer Daiichi
   Sankyo, Jansssen, Merck, and Sanofi.
CR Bauer KA, 2012, AM J HEMATOL, V87, pS119, DOI 10.1002/ajh.23165
   Bauersachs R, 2010, NEW ENGL J MED, V363, P2499, DOI 10.1056/NEJMoa1007903
   Buller HR, 2012, NEW ENGL J MED, V366, P1287, DOI 10.1056/NEJMoa1113572
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Coyle D, 2013, VALUE HEALTH, V16, P498, DOI 10.1016/j.jval.2013.01.009
   Cutts BA, 2013, AM J OBSTET GYNECOL, V208, P102, DOI 10.1016/j.ajog.2012.06.035
   Deitelzweig Steve, 2012, J Med Econ, V15, P776, DOI 10.3111/13696998.2012.680555
   Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
   Eriksson BI, 2008, NEW ENGL J MED, V358, P2765, DOI 10.1056/NEJMoa0800374
   Favaloro EJ, 2011, PATHOLOGY, V43, P682, DOI 10.1097/PAT.0b013e32834bf5f4
   Food and Drug Administration, 2012, SUMM MIN CARD VASC R
   Furie KL, 2012, STROKE, V43, P3442, DOI 10.1161/STR.0b013e318266722a
   Harrington AR, 2013, STROKE, V44, P1676, DOI 10.1161/STROKEAHA.111.000402
   Kaatz S, 2012, AM J HEMATOL, V87, pS141, DOI 10.1002/ajh.23202
   Kakkar AK, 2008, LANCET, V372, P31, DOI 10.1016/S0140-6736(08)60880-6
   Kansal AR, 2012, THROMB HAEMOSTASIS, V108, P672, DOI 10.1160/TH12-06-0388
   Kubitza D, 2005, CLIN PHARMACOL THER, V78, P412, DOI 10.1016/j.clpt.2005.06.011
   Kubitza D, 2010, BRIT J CLIN PHARMACO, V70, P703, DOI 10.1111/j.1365-2125.2010.03753.x
   Lassen MR, 2008, NEW ENGL J MED, V358, P2776, DOI 10.1056/NEJMoa076016
   Lee S, 2012, AM J CARDIOL, V110, P845, DOI 10.1016/j.amjcard.2012.05.011
   Mega J L, 2009, Lancet, V374, P29, DOI 10.1016/S0140-6736(09)60738-8
   Mega JL, 2011, NEW ENGL J MED, V366, P9
   Mueck W, 2011, CLIN PHARMACOKINET, V50, P675, DOI 10.2165/11595320-000000000-00000
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Perzborn E, 2005, J THROMB HAEMOST, V3, P514, DOI 10.1111/j.1538-7836.2005.01166.x
   Portola Pharmaceuticals, PORT ANN POS PHAS 2
   Rose AJ, 2011, CIRC-CARDIOVASC QUAL, V4, P22, DOI 10.1161/CIRCOUTCOMES.110.957738
   Scaglione F, 2013, CLIN PHARMACOKINET, V52, P69, DOI 10.1007/s40262-012-0030-9
   Skanes AC, 2012, CAN J CARDIOL, V28, P125, DOI 10.1016/j.cjca.2012.01.021
   Turpie AGG, 2009, LANCET, V373, P1673, DOI 10.1016/S0140-6736(09)60734-0
   Vandvik PO, 2012, CHEST, V141, pe637S, DOI DOI 10.1378/CHEST.11-2306
   Weinz C, 2009, DRUG METAB DISPOS, V37, P1056, DOI 10.1124/dmd.108.025569
   Wieloch M, 2011, EUR HEART J, V32, P2282, DOI 10.1093/eurheartj/ehr134
   Winkelmayer WC, 2002, MED DECIS MAKING, V22, P417, DOI 10.1177/027298902236927
   You JJ, 2012, CHEST, V141, DOI DOI 10.1378/CHEST.II-2304
   [Anonymous], 2012, COPAYMENT COINSURANC
   [Anonymous], 2012, NICE TECHNOLOGY APPR
   [Anonymous], 2010, AM HEART J, V159, P340
NR 40
TC 1
Z9 1
U1 0
U2 8
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1074-2484
EI 1940-4034
J9 J CARDIOVASC PHARM T
JI J. Cardiovasc. Pharmacol. Ther.
PD NOV
PY 2014
VL 19
IS 6
BP 526
EP 532
DI 10.1177/1074248414525505
PG 7
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA AR5HC
UT WOS:000343614600003
PM 24659084
ER


PT J
AU Gilardi, G
   Demarchi, S
   Gullino, ML
   Garibaldi, A
AF Gilardi, Giovanna
   Demarchi, Stefano
   Gullino, Maria Lodovica
   Garibaldi, Angelo
TI Effect of Simulated Soil Solarization and Organic Amendments on Fusarium
   Wilt of Rocket and Basil Under Controlled Conditions
SO JOURNAL OF PHYTOPATHOLOGY
LA English
DT Article
DE biofumigation; compost; Fusarium oxysporum f.sp basilici; Fusarium
   oxysporum f.sp conglutinans; integrated disease management; thermal
   treatment
ID RHIZOCTONIA ROOT-ROT; SOILBORNE DISEASES; PLANT-PATHOGENS; SUPPRESSION;
   DISINFESTATION; BIOFUMIGATION; MANAGEMENT; COMPOSTS; GROWTH
AB Pot trials were carried out under controlled conditions to evaluate the effectiveness against Fusarium wilt of rocket (Fusarium oxysporum f.sp. conglutinans) and basil (F. oxysporum f.sp. basilici) of soil amendments based on a patented formulation of Brassica carinata defatted seed meal and compost, combined or not with a simulation of soil solarization. The soil solarization treatment was carried out in a growth chamber by heating the soil for 7 and 14 days at optimal (55-52 degrees C for 6 h, 50-48 degrees C for 8 h and 47-45 degrees C for 10 h/day) and sub-optimal (50-48 degrees C for 6 h, 45-43 degrees C for 8 h and 40-38 degrees C for 10 h/day) temperatures similar to those observed in summer in solarized soil in greenhouses in Northern Italy. Two subsequent cycles of plant cultivation were carried out in the same soil. Even at sub-optimal temperature regimes, 7 days of thermal treatment provided very valuable results in terms of disease control on both rocket and basil. In general, the thermal treatment was more effective against F. oxysporum f.sp. basilici than against F. oxysporum f.sp. conglutinans. Control of Fusarium wilt of rocket is improved with 14 days of thermal treatment. The combination of organic amendments with a short period of soil solarization (7 or 14 days), although not providing any improvement to the level of disease management, did significantly increase biomass and positively affected yield.
C1 [Gilardi, Giovanna; Demarchi, Stefano; Gullino, Maria Lodovica; Garibaldi, Angelo] Univ Turin, AGROINNOVA, Ctr Innovat Agroenvironm Sect, I-10095 Grugliasco, TO, Italy.
   [Gullino, Maria Lodovica] Univ Turin, DISAFA, I-10095 Grugliasco, TO, Italy.
RP Gullino, ML (reprint author), Univ Turin, AGROINNOVA, Ctr Innovat Agroenvironm Sect, Via Leonardo da Vinci 44, I-10095 Grugliasco, TO, Italy.
EM marialodovica.gullino@unito.it
FU EU [LIFE08 ENV/IT/000432]; Italian Ministry for the Environment, Land
   and Sea
FX This work was carried out within the EU Project 'Sustainable Use of
   Chemical Fumigants for the control of soil-borne pathogens in the
   horticultural sector' (Contract No LIFE08 ENV/IT/000432), with
   co-funding by the Italian Ministry for the Environment, Land and Sea.
   The authors thank Mr. Marco Moizio for the technical support. Authors
   are also grateful to Ms. Kathryn Webb for her kind help in language
   editing.
CR BOLLEN G J, 1969, Netherlands Journal of Plant Pathology, V75, P157, DOI 10.1007/BF02137211
   Bonanomi G, 2007, J PLANT PATHOL, V89, P311
   Bonanomi G, 2010, SOIL BIOL BIOCHEM, V42, P136, DOI 10.1016/j.soilbio.2009.10.012
   Cohen MF, 2005, SOIL BIOL BIOCHEM, V37, P1215, DOI 10.1016/j.soilbio.2004.11.027
   Deadman M, 2006, J PLANT PATHOL, V88, P335
   Gamliel A, 2000, CROP PROT, V19, P847, DOI 10.1016/S0261-2194(00)00112-5
   Gamliel A., 2012, SOIL SOLARIZATION TH, P99
   Gamliel A, 1997, PHYTOPARASITICA S, VS25, P31
   Gamliel A., 2012, FUSARIUM WILTS GREEN, P121
   Gamliel A., 2012, SOIL SOLARIZATION TH, P109
   Garibaldi A, 2010, ACTA HORTIC, V883, P37
   Garibaldi A., 1991, Soil solarization., P227
   Garibaldi A, 2006, PHYTOPARASITICA, V34, P115, DOI 10.1007/BF02981311
   Granados MR, 2010, ACTA HORTIC, V927, P747
   Grasso S., 1975, Informatore Fitopatologico, V25, P5
   Gullino ML, 2003, PLANT DIS, V87, P1012, DOI 10.1094/PDIS.2003.87.9.1012
   Gullino ML, 1998, CROP PROT, V17, P497, DOI 10.1016/S0261-2194(98)00047-7
   Gullino ML, 2012, SOIL SOLARIZATION TH, P187
   Gullino M. L., 2012, FUSARIUM WILTS GREEN, P185
   Hadar Y, 2012, ANNU REV PHYTOPATHOL, V50, P133, DOI 10.1146/annurev-phyto-081211-172914
   Hoitink HAJ, 1999, ANNU REV PHYTOPATHOL, V37, P427, DOI 10.1146/annurev.phyto.37.1.427
   Katan J, 2000, ACTA HORTIC, P29
   Katan J., 2012, FUSARIUM WILTS GREEN, P61
   Katan J., 2012, SOIL SOLARIZATION TH, P91
   Katan J, 2012, SOIL SOLARIZATION TH, P45
   Katan J., 2010, J PLANT PATHOL, V92
   Katan J., 1991, SOIL SOLARIZATION
   Klein E, 2007, PHYTOPATHOLOGY, V97, P1476, DOI 10.1094/PHYTO-97-11-1476
   Klein E, 2011, PLANT DIS, V95, P1116, DOI 10.1094/PDIS-01-11-0065
   Klein E, 2011, CROP PROT, V30, P368, DOI 10.1016/j.cropro.2010.12.005
   Larkin RP, 2007, CROP PROT, V26, P1067, DOI 10.1016/j.cropro.2006.10.004
   Lazzeri L, 2004, IND CROP PROD, V20, P59, DOI 10.1016/j.indcrop.2003.12.018
   Locke T, 1974, J PHYTOPATHOL, V79, P77, DOI 10.1111/j.1439-0434.1974.tb02691.x
   LODHA S, 1995, CROP PROT, V14, P215, DOI 10.1016/0261-2194(95)00014-D
   Lu PX, 2010, PHYTOPARASITICA, V38, P175, DOI 10.1007/s12600-010-0086-8
   Mazzola M, 2007, PHYTOPATHOLOGY, V97, P454, DOI 10.1094/PHYTO-97-4-0454
   Minuto A, 2006, CROP PROT, V25, P468, DOI 10.1016/j.cropro.2005.08.001
   Minuto A., 2000, Journal of Plant Pathology, V82, P179
   Motisi N, 2009, FIELD CROP RES, V113, P238, DOI 10.1016/j.fcr.2009.05.011
   Noble R, 2005, BIOCONTROL SCI TECHN, V15, P3, DOI 10.1080/09583150400015904
   Pane C, 2011, BIOL CONTROL, V56, P115, DOI 10.1016/j.biocontrol.2010.10.002
   STAPLETON JJ, 1984, PHYTOPATHOLOGY, V74, P255, DOI 10.1094/Phyto-74-255
   Stapleton JJ, 2000, CROP PROT, V19, P837, DOI 10.1016/S0261-2194(00)00111-3
   Tamietti G, 1987, P GROUP M INT PEST M, P193
   Termorshuizen AJ, 2008, FUNGAL ECOL, V1, P108, DOI 10.1016/j.funeco.2008.10.006
   Tjamos EC, 2000, CROP PROT, V19, P843, DOI 10.1016/S0261-2194(00)00132-0
   Weller DM, 2002, ANNU REV PHYTOPATHOL, V40, P309, DOI 10.1146/annurev.phyto.40.030402.110010
NR 47
TC 5
Z9 6
U1 2
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0931-1785
EI 1439-0434
J9 J PHYTOPATHOL
JI J. Phytopathol.
PD SEP
PY 2014
VL 162
IS 9
BP 557
EP 566
DI 10.1111/jph.12223
PG 10
WC Plant Sciences
SC Plant Sciences
GA AQ4IY
UT WOS:000342760400001
ER


PT J
AU Chai, PR
   Wilhite, AW
AF Chai, Patrick R.
   Wilhite, Alan W.
TI Cryogenic thermal system analysis for orbital propellant depot
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Commercial launch; Cryogenic thermal management; Exploration
   architecture; Propellant depot; Space system analysis; Thermal system
AB In any manned mission architecture, upwards of seventy percent of all payload delivered to orbit is propellant, and propellant mass fraction dominates almost all transportation segments of any mission requiring a heavy lift launch system like the Saturn V. To mitigate this, the use of an orbital propellant depot has been extensively studied. In this paper, a thermal model of an orbital propellant depot is used to examine the effects of passive and active thermal management strategies. Results show that an all passive thermal management strategy results in significant boil-off for both hydrogen and oxygen. At current launch vehicle prices, these boil-offs equate to millions of dollars lost per month. Zero boil-off of propellant is achievable with the use of active cryocoolers; however, the cooling power required to produce zero-boil-off is an order of magnitude higher than current state-of-the-art cryocoolers. This study shows a zero-boil-off cryocooler minimum power requirement of 80-100 W at 80 K for liquid oxygen, and 100-120 W at 20 K for liquid hydrogen for a representative Near-Earth Object mission. Research and development effort is required to improve the state-of-the-arts in-space cryogenic thermal management. (C) 2014 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [Chai, Patrick R.; Wilhite, Alan W.] Georgia Inst Technol, Sch Aerosp Engn, Atlanta, GA 30332 USA.
   [Chai, Patrick R.; Wilhite, Alan W.] Natl Inst Aerosp, Hampton, VA 23666 USA.
RP Chai, PR (reprint author), Natl Inst Aerosp, 100 Exploration Way, Hampton, VA 23666 USA.
EM patrick.chai@gatech.edu; wilhite@nianet.org
CR Aceves S.M., 2010, TECHNICAL REPORT
   Arney D, 2010, J SPACECRAFT ROCKETS, V47, P353, DOI 10.2514/1.44532
   Augustine N., 2009, SEEKING HUMAN SPACEL
   Axdhal E., 2009, 2009 AIAA SPACE C EX
   Bate R. R., 1971, FUNDAMENTALS ASTRODY
   Braun R.D., 2010, INVESTMENT OUR FUTUR
   Cadu E., 1990, 19903713 AIAA
   Chai P.R., 2010, THESIS GEORGIA I TEC
   Chai P.R., 2012, GLOB SPAC EXPL C INT
   Chai P.R., 2010, 2010 AIAA SPACE C EX
   Chandler F., 2007, AIM SPACE 2007 C EXP
   Connolly J.F., 2006, CONSTELLATION PROGRA
   Crenwelge D., 2010, 38 COSPAR SCI ASS, V38, P489
   Davis T., 2005, CRYOCOOLERS, V13, P599
   Dew M., 2008, AIAA SPACE 2008 C EX
   Dipprey N., 2003, AIAA ASME SAE ASEE J
   Donabedian M., 2003, SPACECRAFT THERMAL C, VII
   Feller J., 2008, CRYOCOOLERS, V16, P601
   Gilmore DG, 1994, SATELLITE THERMAL CO
   Glaister D., 2002, CRYOCOOLERS, V10, P1
   Griffin M.D., 2011, SPACENEWS
   Gully W., 2007, CRYOCOOLERS, V14, P49
   Hastings L., 2004, 200421375 NAT AER SP
   Howell J.T., 2005, 56 INT ASTR C INT AS
   Keller C., 1974, 134477 NAT AER SPAC
   Kittel P., 2006, P 14 INT CRY C ANN M, V14, P563
   Ladner D., 2011, CRYOCOOLERS, V16, P633
   Larson W.J., 2004, SPACE TECHNOLOGY
   LeBar J.F., 2006, 2006 AIAA SPACE C EX
   McLean C., 2008, 44 AIAA ASME SAE ASE
   [Anonymous], 1962, NASATMX66764
   [Anonymous], 1962, NASATMX74752
   Nast T., 2011, AIAA2011806
   Obama B., 2010, NATL SPACE POLICY US
   Olson J., 2010, HUMAN EXPLORATION FR
   Petach M, 2007, CRYOCOOLERS, V14, P89
   Plachta DW, 2006, CRYOGENICS, V46, P89, DOI 10.1016/j.cryogenics.2005.11.012
   Radebaugh R., 2009, J PHYS CONDENS MATTE, V21
   Smith J., 1984, 5490 NAV RES LAB
   Stronbridge T., 1974, 655 NAT BUR STAND
   Tanner C., 2006, INT ASTR C VAL SPAIN
   ter Brake HJM, 2002, CRYOGENICS, V42, P705, DOI 10.1016/S0011-2275(02)00143-1
   Tramel T., 2008, 20087622 AIAA
   Trollier T., 2007, CRYOCOOLERS, V14, P75
   United Launch Alliance, 2007, DELT 4 PAYLOAD PLANN
   Wilson K., 2007, CRYOCOOLERS, V14, P123
   Young J., 2006, 2006 AIAA SPACE C EX
   Zegler F., 2010, AIAA SPACE 2010 C EX
NR 48
TC 4
Z9 4
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
EI 1879-2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD SEP-OCT
PY 2014
VL 102
BP 35
EP 46
DI 10.1016/j.actaastro.2014.05.013
PG 12
WC Engineering, Aerospace
SC Engineering
GA AN6HB
UT WOS:000340694500004
ER


PT J
AU Piccini, JP
   Garg, J
   Patel, MR
   Lokhnygina, Y
   Goodman, SG
   Becker, RC
   Berkowitz, SD
   Breithardt, G
   Hacke, W
   Halperin, JL
   Hankey, GJ
   Nessel, CC
   Mahaffey, KW
   Singer, DE
   Califf, RM
   Fox, KAA
AF Piccini, Jonathan P.
   Garg, Jyotsna
   Patel, Manesh R.
   Lokhnygina, Yuliya
   Goodman, Shaun G.
   Becker, Richard C.
   Berkowitz, Scott D.
   Breithardt, Guenter
   Hacke, Werner
   Halperin, Jonathan L.
   Hankey, Graeme J.
   Nessel, Christopher C.
   Mahaffey, Kenneth W.
   Singer, Daniel E.
   Califf, Robert M.
   Fox, Keith A. A.
CA ROCKET AF Investigators
TI Management of major bleeding events in patients treated with rivaroxaban
   vs. warfarin: results from the ROCKET AF trial
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Factor Xa inhibitor; Bleeding; Atrial fibrillation
ID COAGULOPATHY; CONCENTRATE; DABIGATRAN; REVERSAL; PLACEBO
AB Aims There are no data regarding management and outcomes of major bleeding events in patients treated with oral factor Xa inhibitors.
   Methods and results Using data from ROCKET AF, we analysed the management and outcomes of major bleeding overall and according to the randomized treatment. During a median follow-up of 1.9 years, 779 (5.5%) patients experienced major bleeding at a rate of 3.52 events/100 patient-years with a similar event rate in each arm (n = 395 rivaroxaban vs. n = 384 warfarin). The median number of transfused packed red blood cells (PRBC) per episode was similar in both arms [2 (25th, 75th: 2, 4) units]. Overall, few transfusions of whole blood (n = 14), platelets (n = 10), or cryoprecipitate (n = 2) were used. Transfusion of fresh frozen plasma (FFP) was significantly less in the rivaroxaban arm (n = 45 vs. n = 81 units) after adjustment for covariates [odds ratio (OR) 0.43 (95% CI 0.29-0.66); P < 0.0001]. Prothrombin complex concentrates (PCC) were administered less in the rivaroxaban arm (n = 4 vs. n = 9). Outcomes after major bleeding, including stroke or non-central nervous system embolism (4.7% rivaroxaban vs. 5.4% warfarin; HR 0.89; 95% CI 0.42-1.88) and all-cause death (20.4% rivaroxaban vs. 26.1% warfarin; HR 0.69, 95% CI 0.46-1.04) were similar in patients treated with rivaroxaban and warfarin (interaction P = 0.51 and 0.11).
   Conclusion Among high-risk patients with atrial fibrillation who experienced major bleeding in ROCKET AF, the use of FFP and PCC was less among those allocated rivaroxaban compared with warfarin. However, use of PRBCs and outcomes after bleeding were similar among patients randomized to rivaroxaban or to warfarin.
C1 [Piccini, Jonathan P.; Garg, Jyotsna; Patel, Manesh R.; Lokhnygina, Yuliya] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27710 USA.
   [Goodman, Shaun G.] Univ Toronto, St Michaels Hosp, Canadian Heart Res Ctr, Toronto, ON, Canada.
   [Goodman, Shaun G.] Univ Toronto, St Michaels Hosp, Div Cardiol, Terrence Donnelly Heart Ctr, Toronto, ON, Canada.
   [Becker, Richard C.] Univ Cincinnati, Div Cardiovasc Hlth & Dis, Cincinnati, OH USA.
   [Berkowitz, Scott D.] Bayer HealthCare Pharmaceut, Montville, NJ USA.
   [Breithardt, Guenter] Hosp Univ Munster, Munster, Germany.
   [Hacke, Werner] Heidelberg Univ, Heidelberg, Germany.
   [Halperin, Jonathan L.] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA.
   [Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA 6009, Australia.
   [Nessel, Christopher C.] Janssen Res & Dev, Raritan, NJ USA.
   [Mahaffey, Kenneth W.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
   [Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
   [Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC 27710 USA.
   [Fox, Keith A. A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
   [Fox, Keith A. A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
RP Piccini, JP (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, POB 17969, Durham, NC 27710 USA.
EM jonathan.piccini@duke.edu
RI Hankey, Graeme /H-4968-2014
OI Hankey, Graeme /0000-0002-6044-7328
FU Johnson Johnson; Bayer HealthCare
FX This work was supported by Johnson & Johnson and Bayer HealthCare.
CR Crowther MA, 2009, ANN INTERN MED, V150, P293
   Dentali F, 2006, J THROMB HAEMOST, V4, P1853, DOI 10.1111/j.1538-7836.2006.01986.x
   Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
   Lee SB, 2006, NEUROLOGY, V67, P1272, DOI 10.1212/01.wnl.0000238104.75563.2f
   Majeed A, 2013, CIRCULATION, V128, P2325, DOI 10.1161/CIRCULATIONAHA.113.002332
   Makris M, 1997, THROMB HAEMOSTASIS, V77, P477
   Patel M., 2010, AM HEART J, V2159, P2340
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x
   Schulman S, 2003, NEW ENGL J MED, V349, P675, DOI 10.1056/NEJMcp025373
   Siegal DM, 2013, EUR HEART J, V34, P489, DOI 10.1093/eurheartj/ehs408
NR 11
TC 39
Z9 40
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD JUL
PY 2014
VL 35
IS 28
BP 1873
EP 1880
DI 10.1093/eurheartj/ehu083
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AM7SI
UT WOS:000340068200012
PM 24658769
ER


PT J
AU Mohanty, BD
   Looser, PM
   Gokanapudy, LR
   Handa, R
   Mohanty, S
   Choi, SS
   Goldman, ME
   Fuster, V
   Halperin, JL
AF Mohanty, Bibhu D.
   Looser, Patrick M.
   Gokanapudy, Lakshmi R.
   Handa, Rishi
   Mohanty, Sudipta
   Choi, Sharon S.
   Goldman, Martin E.
   Fuster, Valentin
   Halperin, Jonathan L.
TI Controversies regarding the new oral anticoagulants for stroke
   prevention in patients with atrial fibrillation
SO VASCULAR MEDICINE
LA English
DT Review
DE atrial fibrillation; oral anticoagulants; stroke prevention
ID ACUTE CORONARY SYNDROME; FACTOR XA INHIBITOR; RE-LY TRIAL; DIRECT
   THROMBIN INHIBITOR; NORMALIZED RATIO CONTROL; TOTAL HIP-REPLACEMENT;
   ROCKET AF TRIAL; PHASE-II TRIAL; DABIGATRAN ETEXILATE;
   COST-EFFECTIVENESS
AB Increasing use of the new oral anticoagulants (NOACs) - dabigatran, rivaroxaban, and apixaban - has prompted considerable discussion in the medical community even as warfarin remains the mainstay of therapy. This article raises 10 controversial issues regarding the use of NOACs for stroke prevention in patients with atrial fibrillation, and offers a review of the latest available evidence. We provide a brief overview of the mechanism and dosing of these drugs, as well as a summary of the key clinical trials that have brought them into the spotlight. Comparative considerations relative to warfarin such as NOAC safety, efficacy, bleeding risk, reversibility, drug-transitioning and use in patients well controlled on warfarin are addressed. Use in select populations such as the elderly, those with coronary disease, renal impairment, or on multiple anti-platelet drugs is also discussed. Finally, we consider such specific issues as comparative efficacy, off-label use, cost, rebound and management during events. Ultimately, the rise of the NOACs to mainstream use will depend on further data and clinical experience amongst the medical community.
C1 [Mohanty, Bibhu D.; Goldman, Martin E.; Fuster, Valentin; Halperin, Jonathan L.] Mt Sinai Heart Hosp, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA.
   [Looser, Patrick M.; Choi, Sharon S.] Mt Sinai Sch Med, Dept Med, New York, NY USA.
   [Gokanapudy, Lakshmi R.] St Georges Univ, Sch Med, St Georges, Grenada.
   [Handa, Rishi] Morristown Med Ctr, Dept Med, Morristown, NJ USA.
   [Mohanty, Sudipta] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Looser, PM (reprint author), Dept Internal Med, Attn Internal Med Residency Program, 1 Gustave Levy Pl, New York, NY 10029 USA.
EM patrick.looser@mountsinai.org
RI Fuster, Valentin/H-4319-2015
OI Fuster, Valentin/0000-0002-9043-9986
FU Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer
FX Dr Halperin receives honoraria from Johnson & Johnson and Bayer, and
   advisory fees from Boehringer Ingelheim, Bristol-Myers Squibb, and
   Pfizer. None of the other authors have any disclosures or conflicts of
   interests to declare.
CR Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819
   Alexander JH, 2009, CIRCULATION, V119, P2877, DOI 10.1161/CIRCULATIONAHA.108.832139
   Bassiouny M, 2013, CIRC-ARRHYTHMIA ELEC, V6, P460, DOI 10.1161/CIRCEP.113.000320
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   De Caterina R, 2012, J AM COLL CARDIOL, V59, P1413, DOI 10.1016/j.jacc.2012.02.008
   Deitelzweig Steve, 2012, J Med Econ, V15, P776, DOI 10.3111/13696998.2012.680555
   Dentali F, 2012, CIRCULATION, V126, P2381, DOI 10.1161/CIRCULATIONAHA.112.115410
   Dewilde WJM, 2013, LANCET, V381, P1107, DOI 10.1016/S0140-6736(12)62177-1
   Dzik W, 2012, TRANSFUSION, V52, p45S, DOI 10.1111/j.1537-2995.2012.03690.x
   Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
   Eikelboom JW, 2010, CIRCULATION, V121, P1523, DOI 10.1161/CIRCULATIONAHA.109.853119
   Eisert WG, 2010, ARTERIOSCL THROM VAS, V30, P1885, DOI 10.1161/ATVBAHA.110.203604
   Eriksson BI, 2009, CLIN PHARMACOKINET, V48, P1, DOI 10.2165/0003088-200948010-00001
   Eriksson BI, 2004, J THROMB HAEMOST, V2, P1573, DOI 10.1111/j.1538-7836.2004.00890.x
   Ezekowitz MD, 2009, AM HEART J, V157, P805, DOI 10.1016/j.ahj.2009.02.005
   Freeman JV, 2011, ANN INTERN MED, V154, P1, DOI 10.7326/0003-4819-154-1-201101040-00289
   Friedman RJ, 2009, ORTHOPEDICS, V32, P79, DOI 10.3928/01477447-20091103-53
   Frost C, 2013, BRIT J CLIN PHARMACO, V75, P476, DOI 10.1111/j.1365-2125.2012.04369.x
   Furugohri T, 2008, J THROMB HAEMOST, V6, P1542
   Gangireddy SR, SCI SESSIONS 2013 AM
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Goldenberg NA, 2011, BLOOD, V117, P2089, DOI 10.1182/blood-2010-09-308858
   Gomes T, 2012, ARCH INTERN MED, V172, P1687, DOI 10.1001/archinternmed.2012.4485
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Hart RG, 2012, STROKE, V43, P1511, DOI 10.1161/STROKEAHA.112.650614
   Healey JS, 2012, CIRCULATION, V126, P343, DOI 10.1161/CIRCULATIONAHA.111.090464
   Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825
   Heidbuchel H, 2013, EUROPACE, V15, P625, DOI 10.1093/europace/eut083
   Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5
   Hohnloser SH, 2012, EUR HEART J, V33, P2821, DOI 10.1093/eurheartj/ehs274
   Hohnloser SH, 2012, CIRCULATION, V125, P669, DOI 10.1161/CIRCULATIONAHA.111.055970
   Holbrook A, 2012, CHEST S, V141, DOI DOI 10.1378/CHEST.11-2295
   Huang C, 2013, J EVAL CLIN PRACT, V19, P938, DOI 10.1111/j.1365-2753.2012.01886.x
   Jiang J, 2010, THROMB HAEMOSTASIS, V103, P234, DOI 10.1160/TH09-03-0196
   Kansal AR, 2012, HEART, V98, P573, DOI 10.1136/heartjnl-2011-300646
   Kim JS, 2013, HEART RHYTHM, V10, P483, DOI 10.1016/j.hrthm.2012.12.011
   Kim MH, 2009, ADV THER, V26, P847, DOI 10.1007/s12325-009-0066-x
   Kirley K, 2012, CIRC-CARDIOVASC QUAL, V5, P615, DOI 10.1161/CIRCOUTCOMES.112.967299
   Komocsi A, 2012, ARCH INTERN MED, V172, P1537, DOI 10.1001/archinternmed.2012.4026
   Lakkireddy D, 2012, J AM COLL CARDIOL, V59, P1168, DOI 10.1016/j.jacc.2011.12.014
   Lamberts M, 2013, J AM COLL CARDIOL, V62, P981, DOI 10.1016/j.jacc.2013.05.029
   Larsen TB, 2013, J AM COLL CARDIOL, V61, P2264, DOI 10.1016/j.jacc.2013.03.020
   Lopes RD, 2013, LANCET, V380, P1749
   Lopes RD, 2010, AM HEART J, V159, P331, DOI 10.1016/j.ahj.2009.07.035
   Mack DR, 2012, ANN PHARMACOTHER, V46, P1105, DOI 10.1345/aph.1R057
   Mahaffey KW, 2013, CIRC-CARDIOVASC QUAL, V6, P470, DOI 10.1161/CIRCOUTCOMES.113.000132
   Majeed A, 2013, CIRCULATION, V128, P2325, DOI 10.1161/CIRCULATIONAHA.113.002332
   McCullagh L, 2012, Ir Med J, V105, P134
   McKeage K, 2012, PHARMACOECONOMICS, V30, P841, DOI 10.2165/11209130-000000000-00000
   Mega J L, 2009, Lancet, V374, P29, DOI 10.1016/S0140-6736(09)60738-8
   Mega JL, 2013, J AM COLL CARDIOL, V61, P1853, DOI 10.1016/j.jacc.2013.01.066
   Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277
   Mendell J, 2013, AM J CARDIOVASC DRUG, V13, P331, DOI 10.1007/s40256-013-0029-0
   Mydin MI, 2012, INTERACT CARDIOV TH, V15, P109, DOI 10.1093/icvts/ivs102
   Nessel C, 2012, CHEST, V142, p84A
   Oldgren J, 2011, EUR HEART J, V32, P2781, DOI 10.1093/eurheartj/ehr113
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Peacock WF, 2012, CLIN CARDIOL, V35, P730, DOI 10.1002/clc.22037
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Price J, 2012, J AM COLL CARDIOL, V60, P1710, DOI 10.1016/j.jacc.2012.06.039
   Providencia R, 2014, HEART, V100, P324, DOI 10.1136/heartjnl-2013-304386
   ROCKET AF Investigators, 2010, AM HEART J, V159
   Rose AJ, 2008, J THROMB HAEMOST, V6, P1647, DOI 10.1111/j.1538-7836.2008.03075.x
   Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0
   Sarode R, 2013, CIRCULATION, V128, P1234, DOI 10.1161/CIRCULATIONAHA.113.002283
   Schiele F, 2013, BLOOD, V121, P3554, DOI 10.1182/blood-2012-11-468207
   Shah SV, 2011, CIRCULATION, V123, P2562, DOI 10.1161/CIRCULATIONAHA.110.985655
   Siegal DM, 2013, J THROMB THROMBOLYS, V35, P391, DOI 10.1007/s11239-013-0885-0
   Sorensen R, 2013, BMJ OPEN, P3
   Sorensen SV, 2011, THROMB HAEMOSTASIS, V105, P908, DOI 10.1160/TH11-02-0089
   Southworth MR, 2013, NEW ENGL J MED, V368, P1272, DOI 10.1056/NEJMp1302834
   Spinler SA, 2012, CIRCULATION, V126, P133, DOI 10.1161/CIRCULATIONAHA.112.099283
   Spyropoulos AC, 2012, J THROMB HAEMOST, V10, P2621, DOI 10.1111/jth.12005
   Stangier J, 2005, J CLIN PHARMACOL, V45, P555, DOI 10.1177/0091270005274550
   Wallentin L, 2013, CIRCULATION, V127, P2166, DOI 10.1161/CIRCULATIONAHA.112.142158
   Wallentin L, 2010, LANCET, V376, P975, DOI 10.1016/S0140-6736(10)61194-4
   Wiedermann CJ, 2008, THROMB RES, V122, pS13, DOI 10.1016/S0049-3848(08)70004-5
   [Anonymous], 2013, MED LETT DRUGS THER, V55, P53
NR 82
TC 2
Z9 2
U1 0
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1358-863X
EI 1477-0377
J9 VASC MED
JI Vasc. Med.
PD JUN
PY 2014
VL 19
IS 3
BP 190
EP 204
DI 10.1177/1358863X14532869
PG 15
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AJ3PS
UT WOS:000337579800006
PM 24879715
ER


PT J
AU Wong, KSL
   Hu, DY
   Oomman, A
   Tan, RS
   Patel, MR
   Singer, DE
   Breithardt, G
   Mahaffey, KW
   Becker, RC
   Califf, R
   Fox, KAA
   Berkowitz, SD
   Hacke, W
   Hankey, GJ
AF Wong, Ka Sing Lawrence
   Hu, Dai Yi
   Oomman, Abraham
   Tan, Ru-San
   Patel, Manesh R.
   Singer, Daniel E.
   Breithardt, Guenter
   Mahaffey, Kenneth W.
   Becker, Richard C.
   Califf, Robert
   Fox, Keith A. A.
   Berkowitz, Scott D.
   Hacke, Werner
   Hankey, Graeme J.
CA Executive Steering Comm
   ROCKET AF Study Investigators
TI Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET
   AF Trial
SO STROKE
LA English
DT Article
DE atrial fibrillation; Far East; rivaroxaban; stroke
ID ATRIAL-FIBRILLATION; JAPANESE PATIENTS; WARFARIN; ANTICOAGULATION;
   THERAPY; CHINA; PHARMACODYNAMICS; PHARMACOKINETICS; INTENSITY; SUBTYPES
AB Background and Purpose-In Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, rivaroxaban was noninferior to dose-adjusted warfarin in preventing stroke or systemic embolism among patients with nonvalvular atrial fibrillation at moderate to high stroke risk. Because of differences in patient demographics, epidemiology, and stroke risk management in East Asia, outcomes and relative effects of rivaroxaban versus warfarin were assessed to determine consistency among East Asians versus other ROCKET AF participants.
   Methods-Baseline demographics and interaction of treatment effects of rivaroxaban and warfarin among patients within East Asia and outside were assessed.
   Results-A total of 932 (6.5%) ROCKET AF participants resided in East Asia. At baseline, East Asians had lower weight, creatinine clearance, and prior vitamin K antagonist use; higher prevalence of prior stroke; and less congestive heart failure and prior myocardial infarction than other participants. Despite higher absolute event rates for efficacy and safety outcomes in East Asians, the relative efficacy of rivaroxaban (20 mg once daily; 15 mg once daily for creatinine clearance of 30-49 mL/min) versus warfarin with respect to the primary efficacy end point (stroke/systemic embolism) was consistent among East Asians and non-East Asians (interaction P=0.666). Relative event rates for the major or nonmajor clinically relevant bleeding in patients treated with rivaroxaban and warfarin were consistent among East Asians and non-East Asians (interaction P=0.867).
   Conclusions-Observed relative efficacy and safety of rivaroxaban versus warfarin were similar among patients within and outside East Asia. Rivaroxaban, 20 mg once daily, is an alternative to warfarin for stroke prevention in East Asians with nonvalvular atrial fibrillation.
C1 [Wong, Ka Sing Lawrence] Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Hu, Dai Yi] Peking Univ, Peoples Hosp, Ctr Heart, Beijing 100871, Peoples R China.
   [Oomman, Abraham] Apollo Hosp, Dept Cardiol, Madras, Tamil Nadu, India.
   [Tan, Ru-San] Natl Heart Ctr, Singapore, Singapore.
   [Patel, Manesh R.; Mahaffey, Kenneth W.; Becker, Richard C.] Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Clin Res Inst, Durham, NC 27710 USA.
   [Califf, Robert] Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Translat Med Inst, Durham, NC 27710 USA.
   [Singer, Daniel E.] Massachusetts Gen Hosp, Dept Epidemiol, Boston, MA 02114 USA.
   [Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
   [Breithardt, Guenter] Univ Hosp Munster, Dept Cardiovasc Med, Munster, Germany.
   [Fox, Keith A. A.] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland.
   [Fox, Keith A. A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
   [Berkowitz, Scott D.] Bayer HealthCare Pharmaceut, Montville, NJ USA.
   [Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany.
   [Hankey, Graeme J.] Univ Western Australia, Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6009, Australia.
RP Wong, KSL (reprint author), Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.
EM ks-wong@cuhk.edu.hk
RI Hankey, Graeme /H-4968-2014; Wong, Ka Sing Lawrence/N-3434-2015
OI Hankey, Graeme /0000-0002-6044-7328; Wong, Ka Sing
   Lawrence/0000-0002-2031-9866
FU Janssen Research and Development, LLC; Bayer HealthCare Pharmaceuticals
FX The ROCKET study was funded by Janssen Research and Development, LLC,
   and Bayer HealthCare Pharmaceuticals.
CR Atarashi H, 2011, CIRC J, V75, P1328, DOI 10.1253/circj.CJ-10-1119
   Camm AJ, 2010, EUR HEART J, V31, P2369, DOI 10.1093/eurheartj/ehq278
   Chang Yeu-Jhy, 2008, Acta Neurol Taiwan, V17, P275
   Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0
   Gao QC, 2013, INT J STROKE, V8, P150, DOI 10.1111/j.1747-4949.2011.00716.x
   Garcia DA, 2010, THROMB HAEMOSTASIS, V104, P1099, DOI 10.1160/TH10-07-0491
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Hankey GJ, 2012, LANCET NEUROL, V11, P315, DOI 10.1016/S1474-4422(12)70042-X
   Hori M, 2013, STROKE, V44, P1891, DOI 10.1161/STROKEAHA.113.000990
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Huang CX, 2010, CHIN J CARDIAC ARRHY, V14, P328
   Kim AS, 2011, CIRCULATION, V124, P314, DOI 10.1161/CIRCULATIONAHA.111.018820
   Korean Clinical Research Center for Stroke, 2010, CLIN PRACT GUID STRO
   Kubitza D, 2007, J CLIN PHARMACOL, V47, P218, DOI 10.1177/0091270006296058
   Mueck W, 2008, CLIN PHARMACOKINET, V47, P203
   Ng WK, 1998, NEUROL J SE ASIA, V3, P19
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   ROCKET AF Study Investigators, 2010, AM HEART J, V159, P340
   ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236
   Shen AYJ, 2008, CNS DRUGS, V22, P815, DOI 10.2165/00023210-200822100-00003
   Shen AYJ, 2007, J AM COLL CARDIOL, V50, P309, DOI 10.1016/j.jacc.2007.01.098
   Thrift AG, 2001, STROKE, V32, P1732
   Wang D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019835
   Wen-Hang QI, 2005, INT J CARDIOL, V105, P283, DOI 10.1016/j.ijcard.2004.12.042
   You JHS, 2005, BRIT J CLIN PHARMACO, V59, P582, DOI 10.1111/j.1365-2125.2005.02361.x
   You JJ, 2012, CHEST, V141, pE531S, DOI 10.1378/chest.11-2304
   Yuen E, 2010, J PHARMACOKINET PHAR, V37, P3, DOI 10.1007/s10928-009-9138-4
   Zhang LF, 2003, STROKE, V34, P2091, DOI 10.1161/01.STR.0000087149.42294.8C
   Zhao F, 2004, CLIN PHARMACOL THER, V76, P210, DOI 10.1016/j.clpt.2004.05.005
NR 29
TC 37
Z9 37
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2014
VL 45
IS 6
BP 1739
EP +
DI 10.1161/STROKEAHA.113.002968
PG 20
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA AI7QR
UT WOS:000337090700034
PM 24763930
ER


PT J
AU David, T
   Mendler, D
   Mosyak, A
   Bar-Cohen, A
   Hetsroni, G
AF David, T.
   Mendler, D.
   Mosyak, A.
   Bar-Cohen, A.
   Hetsroni, G.
TI Thermal Management of Time-Varying High Heat Flux Electronic Devices
SO JOURNAL OF ELECTRONIC PACKAGING
LA English
DT Article
DE pin-fin microchannel; varying high heat flux; chip cooling; infrared
ID PARALLEL MICRO-CHANNELS; SILICON MICROCHANNELS; BOILING INSTABILITY;
   PRESSURE-DROP; VAPOR QUALITY; 2-PHASE FLOW; SINKS; VISUALIZATION
AB The thermal characteristics of a laboratory pin-fin microchannel heat sink were empirically obtained for heat flux, q '', in the range of 30-170 W/cm(2), mass flux, m, in the range of 230-380 kg/m(2) s, and an exit vapor quality, x(out), from 0.2 to 0.75. Refrigerant R 134a (HFC-134a) was chosen as the working fluid. The heat sink was a pin-fin microchannel module installed in open flow loop. Deviation from the measured average temperatures was 1.5 degrees C at q = 30 W/cm(2), and 2.0 degrees C at q = 170 W/cm(2). These results indicate that use of pin-fin microchannel heat sink enables keeping an electronic device near uniform temperature under steady state and transient conditions. The heat transfer coefficient varied significantly with refrigerant quality and showed a peak at an exit vapor quality of 0.55 in all the experiments. At relatively low heat fluxes and vapor qualities, the heat transfer coefficient increased with vapor quality. At high heat fluxes and vapor qualities, the heat transfer coefficient decreased with vapor quality. A noteworthy feature of the present data is the larger magnitude of the transient heat transfer coefficients compared to values obtained under steady state conditions. The results of transient boiling were compared with those for steady state conditions. In contrast to the more common techniques, the low cost technique, based on open flow loop was developed to promote cooling using micropin fin sinks. Results of this experimental study may be used for designing the cooling high power laser and rocket-born electronic devices.
C1 [David, T.; Mendler, D.; Mosyak, A.; Hetsroni, G.] Technion Israel Inst Technol, Dept Mech Engn, IL-32000 Haifa, Israel.
   [Bar-Cohen, A.] Univ Maryland, Dept Mech Engn, College Pk, MD 20742 USA.
RP Hetsroni, G (reprint author), Technion Israel Inst Technol, Dept Mech Engn, IL-32000 Haifa, Israel.
EM hetsroni@techunix.technion.ac.il
FU United States-Israel Binational Science Foundation (BSF), Jerusalem
   [2009-504]; Department of Mechanical Engineering at the Technion
FX This research was supported by a grant from the United States-Israel
   Binational Science Foundation (BSF), Jerusalem, No. 2009-504. Thanks to
   Mr. M. Komisar who engineered the experimental facility. The financial
   support of the Department of Mechanical Engineering at the Technion is
   acknowledged.
CR Agostini B, 2008, INT J HEAT MASS TRAN, V51, P5400, DOI 10.1016/j.ijheatmasstransfer.2008.03.006
   Bergles AE, 2005, J HEAT TRANS-T ASME, V127, P101, DOI 10.1115/1.1839587
   Bertsch SS, 2008, INT J HEAT MASS TRAN, V51, P4775, DOI 10.1016/j.ijheatmasstransfer.2008.01.026
   Bogojevic D, 2009, INT J HEAT FLUID FL, V30, P854, DOI 10.1016/j.ijheatfluidflow.2009.03.013
   Bohr MT, 1995, INTERNATIONAL ELECTRON DEVICES MEETING, 1995 - IEDM TECHNICAL DIGEST, P241, DOI 10.1109/IEDM.1995.499187
   Brutin D, 2003, INT J HEAT MASS TRAN, V46, P2957, DOI 10.1016/S0017-9310(03)00093-0
   Diaz C. M., 2007, INT J HEAT FLUID FL, V28, P95
   [Anonymous], 2004, THERM PROP HFC 134A
   Hetsrom G., 2000, ASME INT MECH ENG C
   Hetsroni G, 2006, INT J MULTIPHAS FLOW, V32, P1141, DOI 10.1016/j.ijmultiphaseflow.2006.06.005
   Hetsroni G, 2005, INT J MULTIPHAS FLOW, V31, P371, DOI 10.1016/j.ijmultiphaseflow.2005.01.003
   Hetsroni G, 2003, INT J MULTIPHAS FLOW, V29, P341, DOI 10.1016/S0301-9322(03)00002-8
   Hetsroni G, 2002, INT J HEAT MASS TRAN, V45, P3275, DOI 10.1016/S0017-9310(02)00048-0
   Hetsroni G, 2001, IEEE T COMPON PACK T, V24, P16, DOI 10.1109/6144.910797
   [Anonymous], 1995, GUID EXPR UNC MEAS
   Kandlikar SG, 2006, J HEAT TRANS-T ASME, V128, P389, DOI 10.1115/1.2165208
   Kandlikar S. G., 2004, ASME C P, P539, DOI 10.1115/ICMM2004-2379
   Khan W. A., 2007, ASME 2007 INTERPACK, P653, DOI 10.1115/IPACK2007-33983
   Khan WA, 2008, IEEE T COMPON PACK T, V31, P536, DOI 10.1109/TCAPT.2008.2002554
   Kosar A, 2006, J HEAT TRANS-T ASME, V128, P251, DOI 10.1115/1.2150837
   Kosar A, 2006, J HEAT TRANS-T ASME, V128, P121, DOI 10.1115/1.2137760
   Kosar A, 2006, INT J HEAT MASS TRAN, V49, P3142, DOI 10.1016/j.ijheatmasstransfer.2006.02.013
   Koz M., 2010, ASME INT MECH ENG C, P387
   Koz M., 2010, ASME 8 C NAN MICR MI, P531, DOI 10.1115/FEDSM-ICNMM2010-30473
   Krebs D., 2010, EXP THERM FLUID SCI, V34, P435
   Kuo CJ, 2009, INT J HEAT MASS TRAN, V52, P271, DOI 10.1016/j.ijheatmasstransfer.2008.06.015
   Lee J, 2005, INT J HEAT MASS TRAN, V48, P941, DOI 10.1016/j.ijheatmasstransfer.2004.09.019
   Lee J, 2008, INT J HEAT MASS TRAN, V51, P4315, DOI 10.1016/j.ijheatmasstransfer.2008.02.012
   Park J.E., 2009, 25 ANN IEEE SEM THER
   Qu WL, 2008, J HEAT TRANS-T ASME, V130, DOI 10.1115/1.2970080
   Qu WL, 2003, INT J HEAT MASS TRAN, V46, P2755, DOI 10.1016/S0017-9310(03)00041-3
   Qu WL, 2003, INT J HEAT MASS TRAN, V46, P2737, DOI 10.1016/S0017-9310(03)00044-9
   Wang GD, 2008, INT J HEAT MASS TRAN, V51, P2267, DOI 10.1016/j.ijheatmasstransfer.2007.08.027
   Wang G, 2007, INT J HEAT MASS TRAN, V50, P4297, DOI 10.1016/j.ijheatmasstransfer.2007.01.033
   Workman GO, 1998, IEEE T ELECTRON DEV, V45, P125, DOI 10.1109/16.658822
   Wu HY, 2004, INT J HEAT MASS TRAN, V47, P3631, DOI 10.1016/j.ijheatmasstransfer.2004.04.012
   Wu HY, 2003, INT J HEAT MASS TRAN, V46, P2603, DOI 10.1016/S0017-9310(03)00039-5
   Wu HY, 2003, INT COMMUN HEAT MASS, V30, P295, DOI 10.1016/S0735-1933(03)00048-4
   Xu JL, 2009, INT J MULTIPHAS FLOW, V35, P773, DOI 10.1016/j.ijmultiphaseflow.2009.03.008
   Xu JL, 2005, J MICROMECH MICROENG, V15, P1344, DOI 10.1088/0960-1317/15/6/028
   Zhang LA, 2005, INT J HEAT MASS TRAN, V48, P1572, DOI 10.1016/j.ijheatmasstransfer.2004.09.048
NR 41
TC 6
Z9 6
U1 1
U2 30
PU ASME
PI NEW YORK
PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA
SN 1043-7398
EI 1528-9044
J9 J ELECTRON PACKAGING
JI J. Electron. Packag.
PD JUN
PY 2014
VL 136
IS 2
SI SI
AR 021003
DI 10.1115/1.4027325
PG 10
WC Engineering, Electrical & Electronic; Engineering, Mechanical
SC Engineering
GA AH2AF
UT WOS:000335922400004
ER


PT J
AU Uchiyama, S
   Hori, M
   Matsumoto, M
   Tanahashi, N
   Momomura, S
   Goto, S
   Izumi, T
   Koretsune, Y
   Kajikawa, M
   Kato, M
   Ueda, H
   Iekushi, K
   Yamanaka, S
   Tajiri, M
AF Uchiyama, Shinichiro
   Hori, Masatsugu
   Matsumoto, Masayasu
   Tanahashi, Norio
   Momomura, Shin-ichi
   Goto, Shinya
   Izumi, Tohru
   Koretsune, Yukihiro
   Kajikawa, Mariko
   Kato, Masaharu
   Ueda, Hitoshi
   Iekushi, Kazuma
   Yamanaka, Satoshi
   Tajiri, Masahiro
CA J-ROCKET AF Study Investigators
TI Net Clinical Benefit of Rivaroxaban versus Warfarin in Japanese Patients
   with Nonvalvular Atrial Fibrillation: A Subgroup Analysis of J-ROCKET AF
SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
LA English
DT Article
DE Atrial fibrillation; oral anticoagulation; stroke prevention; net
   clinical benefit
ID FACTOR-XA INHIBITOR; ORAL ANTICOAGULATION; STROKE PREVENTION; PREDICTING
   STROKE; RISK FACTOR; PHARMACODYNAMICS; PHARMACOKINETICS; BAY-59-7939;
   COHORT
AB Background: The risk factors that have been identified for bleeding events with rivaroxaban are predominantly the same as those predicting thromboembolic ones in patients with atrial fibrillation (AF). Our aim was to determine the net clinical benefit (NCB) from the results of the J- ROCKET AF trial, in which rivaroxaban was compared with warfarin in Japanese patients with AF. Methods: Two strategies were adopted to quantify the NCB. First, the NCB was calculated as the number of ischemic strokes avoided with anticoagulation minus the number of excess intracranial hemorrhage (ICH) with a weight of 1.5. Second, the composite end point of major bleeding events and secondary efficacy end points (stroke, noncentral nervous system systemic embolism, myocardial infarction and death) to ascertain the NCB were established. Subgroup analysis by CHADS(2) score or creatinine clearance was also performed. Results: The adjusted NCB, which was given a weight of 1.5 for ICH, was nominally significant in favor of rivaroxaban therapy (difference in incidence rate -2.13; 95% confidence interval [CI]: -.26 to -3.99). Furthermore, the event rate of the composite end point tended to be lower in patients treated with rivaroxaban than in those treated with warfarin (rivaroxaban: 4.97% per year, warfarin: 6.11% per year; difference in incidence rate: -1.14; 95% CI: -3.40 to 1.12). The event rate of the composite end point tended to be consistently low in patients treated with rivaroxaban in the subanalysis by CHADS(2) score and renal function. Conclusion: Analysis of the NCB supports that rivaroxaban therapy provides clinical benefit for Japanese patients with AF.
C1 [Uchiyama, Shinichiro] Tokyo Womens Med Univ, Dept Neurol, Tokyo 1628666, Japan.
   [Hori, Masatsugu] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka, Japan.
   [Matsumoto, Masayasu] Hiroshima Univ, Dept Clin Neurosci & Therapeut, Hiroshima, Japan.
   [Tanahashi, Norio] Saitama Med Univ, Int Med Ctr, Dept Neurol, Saitama, Japan.
   [Momomura, Shin-ichi] Jichi Med Univ, Saitama Med Ctr, Div Cardiovasc Med, Saitama, Japan.
   [Goto, Shinya] Tokai Univ, Sch Med, Dept Med Cardiol, Tokyo 151, Japan.
   [Izumi, Tohru] Kitasato Univ, Sch Med, Dept Cardioangiol, Sagamihara, Kanagawa 228, Japan.
   [Koretsune, Yukihiro] Osaka Natl Hosp, Inst Clin Res, Osaka, Japan.
   [Kajikawa, Mariko; Kato, Masaharu; Ueda, Hitoshi; Iekushi, Kazuma; Yamanaka, Satoshi; Tajiri, Masahiro] Bayer Yakuhin Ltd, Osaka, Japan.
RP Uchiyama, S (reprint author), Tokyo Womens Med Univ, Dept Neurol, Sch Med, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.
EM suchiyam@nij.twmu.ac.jp
FU Janssen Pharmaceuticals, Inc. (Raritan, NJ); Bayer HealthCare
   Pharmaceuticals AG (Leverkusen, Germany); Bayer Healthcare
   Pharmaceuticals AG's Japanese subsidiary, Bayer Yakuhin Ltd.
FX The rivaroxaban clinical development program is cosponsored by Janssen
   Pharmaceuticals, Inc. (Raritan, NJ) and Bayer HealthCare Pharmaceuticals
   AG (Leverkusen, Germany). The trial was funded by Bayer Healthcare
   Pharmaceuticals AG's Japanese subsidiary, Bayer Yakuhin Ltd.
CR Banerjee A, 2012, THROMB HAEMOSTASIS, V107, P584, DOI 10.1160/TH11-11-0784
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Camm A.J., 2010, EUR HEART J, V31, P2369
   Fang MC, 2007, AM J MED, V120, P700, DOI 10.1016/j.amjmed.2006.07.034
   Friberg L, 2012, CIRCULATION, V125, P2298, DOI 10.1161/CIRCULATIONAHA.111.055079
   Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864
   Garcia DA, 2012, THROMB RES, V129, P9, DOI 10.1016/j.thromres.2011.09.023
   GLASZIOU PP, 1995, BRIT MED J, V311, P1356
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913
   Kubitza D, 2005, EUR J CLIN PHARMACOL, V61, P873, DOI 10.1007/s00228-005-0043-5
   Kubitza D, 2008, CURR MED RES OPIN, V24, P2757, DOI 10.1185/03007990802361499 
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Olesen JB, 2012, NEW ENGL J MED, V367, P625, DOI 10.1056/NEJMoa1105594
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Perzborn E, 2005, J THROMB HAEMOST, V3, P514, DOI 10.1111/j.1538-7836.2005.01166.x
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Singer DE, 2009, ANN INTERN MED, V151, P297
   Skanes AC, 2012, CAN J CARDIOL, V28, P125, DOI 10.1016/j.cjca.2012.01.021
   Tanigawa T, 2013, DRUG METAB PHARMACOK, V28, P59, DOI 10.2133/dmpk.DMPK-12-RG-034
   WOLF PA, 1991, STROKE, V22, P983
   [Anonymous], 2011, J STROKE CEREBROVASC, V20, pS197
NR 22
TC 1
Z9 1
U1 1
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1052-3057
EI 1532-8511
J9 J STROKE CEREBROVASC
JI J. Stroke Cerebrovasc. Dis.
PD MAY-JUN
PY 2014
VL 23
IS 5
BP 1142
EP 1147
DI 10.1016/j.jstrokecerebrovasdis.2013.10.001
PG 6
WC Neurosciences; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA AH9SI
UT WOS:000336482000065
PM 24189454
ER


PT J
AU McCall, PD
   Naudeau, ML
   Adjouadi, M
AF McCall, Paul D.
   Naudeau, Madeleine L.
   Adjouadi, Malek
TI Debris characterization techniques via unresolved long-wave infrared
   imaging from a space-based platform
SO JOURNAL OF APPLIED REMOTE SENSING
LA English
DT Article
DE space debris; space situational awareness; long-wave infrared imaging;
   wavelet decomposition; local area awareness; debris characterization
ID RATIO HAMR OBJECTS; SPECTROPHOTOMETRIC OBSERVATIONS; HIGH AREA; GEO
AB Every space launch increases the overall amount of space debris, especially when circumstances result in the orbital objects being stranded in orbit with no deorbiting capabilities. Studies contributing to the understanding of space debris aid spacecraft operators in mitigating risk associated with Earth-orbiting debris objects. Accurately characterizing the debris threat to a spacecraft is of vital importance in maximizing the lifespan and mission capabilities of the spacecraft. This investigation aims to develop long-wave infrared radiometric-based techniques for detection and characterization of typical debris objects via signal analysis of unresolved imagery. Tumble rate, absorptivity-to-emissivity ratio, and cross-sectional area are analyzed and estimates made regarding their values. Fusion of astrometric and radiometric data allows for a more accurate, and less ambiguous, hypothesis to be reached concerning the cross-sectional area of debris objects. (C) 2014 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [McCall, Paul D.; Adjouadi, Malek] Florida Int Univ, Miami, FL 33174 USA.
   [Naudeau, Madeleine L.] Kirtland Air Force Base, Air Force Res Lab, Space Vehicles Directorate, Albuquerque, NM 87116 USA.
RP McCall, PD (reprint author), Florida Int Univ, 10555 West Flagler St,EC 2220, Miami, FL 33174 USA.
EM pmcca001@fiu.edu
FU National Science Foundation [CNS-0959985, CNS-1042341, HRD-0833093,
   IIP-1338922, IIP-1230661]; Department of Defense (DoD) through the
   National Defense Science & Engineering Graduate Fellowship (NDSEG)
   Program; Department of Defense (DoD) through the Air Force Research
   Laboratory Summer Scholars Program; Florida International University
FX This work was supported by the National Science Foundation under grants
   CNS-0959985, CNS-1042341, HRD-0833093 and IIP-1338922 and IIP-1230661.
   The author of this dissertation was partially supported by the
   Department of Defense (DoD) through the National Defense Science &
   Engineering Graduate Fellowship (NDSEG) Program, and through
   participation in the Air Force Research Laboratory Summer Scholars
   Program. The author is supported through the Betty G. Reader Graduate
   Scholarship from Florida International University.
CR [Anonymous], 2013, SYST TOOL KIT
   [Anonymous], 2013, 101 STK
   Black S, 2010, B ATOM SCI, V66, P1, DOI 10.2968/066002001
   Dawson J. A., 2010, P ADV MAUI OPT SPAC, pE40
   Debnath L., 2001, WAVELET TRANSFORMS T
   Gaposchkin E. M., 1995, P MIT LINC LAB SPAC
   Gillmore D. G., 1994, SATELLITE THERMAL CO
   Goswami J. C., 1999, FUNDAMENTALS WAVELET
   Griffiths M., 2010, SPACE DEBRIS, V355, P1
   Hall D., 2012, P ADV MAUI OPT SPAC
   Harms A., 2011, P ADV MAUI OPT SPAC, pE14
   Kervin PW, 2005, ADV SPACE RES, V35, P1214, DOI 10.1016/j.asr.2004.11.038
   Lambert J. V., 1993, P SOC PHOTO-OPT INS, V1951, P32
   Mainzer A. K., 2005, P SOC PHOTO-OPT INS, V5899, P262
   McCall PD, 2013, PROC SPIE, V8706, DOI 10.1117/12.2017890
   Pozer D. M., 2005, MICROWAVE ENG
   Price SD, 2001, ADV SPACE RES-SERIES, V28, P1117, DOI 10.1016/S0273-1177(01)00493-8
   Seniw W. P., 1993, P SPAC SURV WORKSH 1, P21
   Skinner MA, 2012, ACTA ASTRONAUT, V80, P154, DOI 10.1016/j.actaastro.2012.04.044
   Skinner MA, 2011, ACTA ASTRONAUT, V69, P1007, DOI 10.1016/j.actaastro.2011.06.018
   West J., 2010, SPACE SECURITY
   Wyatt C. L., 1991, ELECTROOPTICAL SYSTE
NR 22
TC 0
Z9 0
U1 1
U2 9
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1931-3195
J9 J APPL REMOTE SENS
JI J. Appl. Remote Sens.
PD MAY 1
PY 2014
VL 8
AR 084989
DI 10.1117/1.JRS.8.084989
PG 13
WC Environmental Sciences; Remote Sensing; Imaging Science & Photographic
   Technology
SC Environmental Sciences & Ecology; Remote Sensing; Imaging Science &
   Photographic Technology
GA AG8CP
UT WOS:000335646700001
ER


PT J
AU Sabir, I
   Khavandi, K
   Brownrigg, J
   Camm, AJ
AF Sabir, Ian
   Khavandi, Kaivan
   Brownrigg, Jack
   Camm, A. John
TI Oral anticoagulants for Asian patients with atrial fibrillation
SO NATURE REVIEWS CARDIOLOGY
LA English
DT Review
ID FACTOR-XA INHIBITOR; DIRECT THROMBIN INHIBITOR; RANDOMIZED
   CONTROLLED-TRIAL; CARDIOVASCULAR EVENT RATES; CHRONIC KIDNEY-DISEASE;
   J-ROCKET AF; STROKE PREVENTION; RISK-FACTORS; JAPANESE PATIENTS;
   CEREBRAL MICROBLEEDS
AB Anticoagulation is the most-important intervention to prevent stroke in patients with atrial fibrillation (AF). Despite a lower point prevalence of AF in Asian communities and Asian countries than in other populations, individuals of Asian ethnicity are at a disproportionately high risk of stroke and have greater consequent mortality. Warfarin and other vitamin K antagonists are conventionally used for anticoagulation, and demonstrably reduce the risk of stroke and all-cause mortality in patients with AF. The use of warfarin in Asian countries is suboptimal, primarily owing to the universal challenge of achieving controlled anticoagulation with an unpredictable drug as well as concerns about the particularly high-risk of haemorrhage in Asian patients. Instead, antiplatelet therapy has been favoured in Asian communities, this strategy is neither safe nor effective for stroke prevention in these individuals. The non-vitamin K antagonist, oral anticoagulant drugs offer a solution to this challenge. The direct thrombin inhibitor dabigatran, and the direct factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, have demonstrated noninferiority to warfarin in the prevention of stroke and systemic embolism in international, randomized, controlled trials. Importantly, some of these drugs are also associated with a significantly lower incidence of major haemorrhage, and all result in lower rates of intracranial haemorrhage and haemorrhagic stroke than warfarin. In this article, we review the use of the non-vitamin K antagonist anticoagulants in the management of AF in Asian populations.
C1 [Sabir, Ian; Khavandi, Kaivan] St Thomas Hosp, Rayne Inst, London SE1 7EH, England.
   [Brownrigg, Jack] St Georges Univ London, St Georges Vasc Inst, Div Cardiovasc Sci, London SW17 0RE, England.
   [Camm, A. John] St Georges Univ London, Cardiovasc Sci Res Ctr, London SW17 0RE, England.
RP Sabir, I (reprint author), St Thomas Hosp, Rayne Inst, London SE1 7EH, England.
EM ins20@cam.ac.uk
CR Ahrens I, 2012, DISCOV MED, V13, P445
   Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2
   Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
   Albers GW, 2003, LANCET, V362, P1691
   Albertsen IE, 2013, STROKE, V44, P1329, DOI 10.1161/STROKEAHA.113.000883
   Alonso A, 2011, CIRCULATION, V123, P2946, DOI 10.1161/CIRCULATIONAHA.111.020982
   Ansell J, 2013, NAT MED, V19, P402, DOI 10.1038/nm.3157
   Benjamin EJ, 1998, CIRCULATION, V98, P946
   BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840
   Blech S, 2008, DRUG METAB DISPOS, V36, P386, DOI 10.1124/dmd.107.019083
   BODE W, 1989, EMBO J, V8, P3467
   Bokura H, 2011, STROKE, V42, P1867, DOI 10.1161/STROKEAHA.110.601922
   Bruins Slot K. M., 2013, COCHRANE DB SYST REV
   Buller HR, 2003, NEW ENGL J MED, V349, P1695
   Capodanno D, 2013, INT J CARDIOL, V167, P1237, DOI 10.1016/j.ijcard.2012.03.148
   Chien KL, 2010, INT J CARDIOL, V139, P173, DOI 10.1016/j.ijcard.2008.10.045
   Chugh SS, 2001, J AM COLL CARDIOL, V37, P371, DOI 10.1016/S0735-1097(00)01107-4
   Chung N, 2011, THROMB HAEMOSTASIS, V105, P535, DOI 10.1160/TH10-07-0451
   Connolly SJ, 2013, EUR HEART J, V34, P1498, DOI 10.1093/eurheartj/eht039
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   D'Andrea G, 2005, BLOOD, V105, P645, DOI 10.1182/blood-2004-06-2111
   Deinum J, 2009, THROMB HAEMOSTASIS, V101, P1051, DOI 10.1160/TH08-09-0586
   Dentali F, 2012, CIRCULATION, V126, P2381, DOI 10.1161/CIRCULATIONAHA.112.115410
   Department of Health Western Australia, 2011, QUICK REF GUID ATR F
   Depasse F, 2005, J THROMB HAEMOST S1, V3, pP1104
   Di Nisio M, 2005, NEW ENGL J MED, V353, P1028, DOI 10.1056/NEJMra044440
   Ducrocq G., PREV CARDIOL
   Easton JD, 2012, LANCET NEUROL, V11, P503, DOI 10.1016/S1474-4422(12)70092-3
   Ezekowitz MD, 2007, AM J CARDIOL, V100, P1419, DOI 10.1016/j.amjcard.2007.06.034
   Food and Drug Administration, 2011, FDA DRAFT BRIEF DOC
   FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469
   Fox CS, 2004, JAMA-J AM MED ASSOC, V291, P2851, DOI 10.1001/jama.291.23.2851
   Frosi C, 2008, J CLIN PHARMACOL, V48, P1132
   Frost C, 2013, BRIT J CLIN PHARMACO, V75, P476, DOI 10.1111/j.1365-2125.2012.04369.x
   Fujii Y, 2007, DRUG METAB PHARMACOK, V22, P26, DOI 10.2133/dmpk.22.26
   Furugohri T, 2008, J THROMB HAEMOST, V6, P1542, DOI 10.1111/j.1538-7836.2008.03064.x
   Gami AS, 2004, CIRCULATION, V110, P364, DOI 10.1161/01.CIR.0000136587.68725.8E
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Goto S, 2013, EUR HEART J, V34, P1039
   Goto S, 2013, EUR HEART J, V34, P790
   Goto S, 2011, CIRC J, V75, P2598, DOI 10.1253/circj.CJ-11-0378
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4
   Group J. J, 2010, CIRC J, V74, P2479
   Gunarathne A, 2009, STROKE, V40, pE415, DOI 10.1161/STROKEAHA.108.535724
   Guo YT, 2013, INT J CARDIOL, V168, P515, DOI 10.1016/j.ijcard.2012.09.187
   Hartter S, 2012, THROMB HAEMOSTASIS, V107, P260, DOI 10.1160/TH11-08-0551
   HARA T, 1994, THROMB HAEMOSTASIS, V71, P314
   Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825
   Ho Shir-Jing, 2006, Vasc Health Risk Manag, V2, P49, DOI 10.2147/vhrm.2006.2.1.49
   Holbrook AM, 2005, ARCH INTERN MED, V165, P1095, DOI 10.1001/archinte.165.10.1095
   Hori M, 2013, STROKE, V44, P1891, DOI 10.1161/STROKEAHA.113.000990
   Hori M, 2013, CIRC J, V77, P632, DOI 10.1253/circj.CJ-12-0899
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Hori M, 2011, CIRC J, V75, P800, DOI 10.1253/circj.CJ-11-0191
   Hyun KK, 2013, INT J STROKE, V8, P606, DOI 10.1111/ijs.12166
   Inoue H, 2009, INT J CARDIOL, V137, P102, DOI 10.1016/j.ijcard.2008.06.029
   Investigators AF, 1994, ARCH INTERN MED, V154, P1449
   Iwasaki YK, 2011, CIRCULATION, V124, P2264, DOI 10.1161/CIRCULATIONAHA.111.019893
   Jiang J, 2010, THROMB HAEMOSTASIS, V103, P234, DOI 10.1160/TH09-03-0196
   Jiang XS, 2009, THROMB HAEMOSTASIS, V101, P780, DOI 10.1160/TH08-07-0486
   Kakkar AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063479
   Kamal A. K., COCHRANE DATABASE SY
   Khan NA, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-74
   Kim AS, 2011, CIRCULATION, V124, P314, DOI 10.1161/CIRCULATIONAHA.111.018820
   Kim MH, 2011, CIRC-CARDIOVASC QUAL, V4, P313, DOI 10.1161/CIRCOUTCOMES.110.958165
   Kimmel SE, 2013, NEW ENGL J MED, V369, P2283, DOI 10.1056/NEJMoa1310669
   Koennecke HC, 2006, NEUROLOGY, V66, P165, DOI 10.1212/01.wnl.0000194266.55694.1e
   KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9
   Kubitza D, 2005, CLIN PHARMACOL THER, V78, P412, DOI 10.1016/j.clpt.2005.06.011
   Kubitza D, 2005, EUR J CLIN PHARMACOL, V61, P873, DOI 10.1007/s00228-005-0043-5
   Kubo M, 2006, NEUROLOGY, V66, P1539, DOI 10.1212/01.wnl.0000216132.95207.b4
   Lassen MR, 2003, BLOOD, V102, p15A
   Lau CP, 2013, J CARDIOVASC ELECTR, V24, P381, DOI 10.1111/jce.12066
   Lee CJ, 2011, BRIT J CLIN PHARMACO, V72, P581, DOI 10.1111/j.1365-2125.2011.03916.x
   Lee M, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4249
   Lee SH, 2009, NEUROLOGY, V72, P171, DOI 10.1212/01.wnl.0000339060.11702.dd
   Li SY, 2012, CNS NEUROSCI THER, V18, P988, DOI 10.1111/cns.12021
   Lip GYH, 2012, CHEST, V142, P1489, DOI 10.1378/chest.11-2888
   Lip GYH, 2012, J AM COLL CARDIOL, V60, P738, DOI 10.1016/j.jacc.2012.03.019
   Lip GYH, 2011, THROMB RES, V127, P91, DOI 10.1016/j.thromres.2010.11.012
   Lip GYH, 2009, EUR HEART J, V30, P2897, DOI 10.1093/eurheartj/ehp318
   Lip GYH, 2002, STROKE, V33, P238, DOI 10.1161/hs0102.101817
   Lip GYH, 1998, INT J CARDIOL, V65, P187, DOI 10.1016/S0167-5273(98)00125-9
   Lloyd-Jones DM, 2004, CIRCULATION, V110, P1042, DOI 10.1161/01.CIR.0000140263.20897.42
   Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667
   Lopes RD, 2012, LANCET, V380, P1749, DOI 10.1016/S0140-6736(12)60986-6
   Lu GM, 2013, NAT MED, V19, P446, DOI 10.1038/nm.3102
   Lubitz SA, 2010, CIRC-ARRHYTHMIA ELEC, V3, P291, DOI 10.1161/CIRCEP.110.942441
   Mathur R, 2013, HEART, V99, P1087, DOI 10.1136/heartjnl-2013-303767
   Matsushima N, 2013, CLIN PHARM DRUG DEV, V2, P358, DOI 10.1002/cpdd.53
   Mendell J, 2011, J CLIN PHARMACOL, V51, P687, DOI 10.1177/0091270010370974
   Miller CS, 2012, AM J CARDIOL, V110, P453, DOI 10.1016/j.amjcard.2012.03.049
   Ogawa S, 2013, J ARRHYTHMIA, V29, P190
   Ogawa S, 2011, CIRC J, V75, P1852, DOI 10.1253/circj.CJ-10-1183
   Olesen JB, 2012, NEW ENGL J MED, V367, P625, DOI 10.1056/NEJMoa1105594
   Olsson SB, 2010, THROMB HAEMOSTASIS, V103, P604, DOI 10.1160/TH09-07-0509
   PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441
   Palladino M, 2013, EXPERT OPIN INV DRUG, V22, P1465, DOI 10.1517/13543784.2013.825605
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Perzborn E, 2005, J THROMB HAEMOST, V3, P514, DOI 10.1111/j.1538-7836.2005.01166.x
   Perzborn E, 2011, NAT REV DRUG DISCOV, V10, P61, DOI 10.1038/nrd3185
   Pirmohamed M, 2013, NEW ENGL J MED, V369, P2294, DOI 10.1056/NEJMoa1311386
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Rasmussen LH, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7097
   Rose AJ, 2009, CIRC-CARDIOVASC QUAL, V2, P591, DOI 10.1161/CIRCOUTCOMES.109.862763
   ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236
   Santangeli P, 2012, HEART RHYTHM, V9, P1761, DOI 10.1016/j.hrthm.2012.07.026
   Sardar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077694
   Sato H, 2006, STROKE, V37, P447, DOI 10.1161/01.STR.0000198839.61112.ee
   Savelieva I, 2014, CLIN CARDIOL, V37, P32, DOI 10.1002/clc.22204
   Sen S, 2013, INT J NEUROSCI, V123, P568, DOI 10.3109/00207454.2013.783030
   Shinohara Y, 2010, LANCET NEUROL, V9, P959, DOI 10.1016/S1474-4422(10)70198-8
   Stampfuss J, 2013, INT J CLIN PHARM TH, V51, P549, DOI 10.5414/CP201812
   Steg PG, 2007, JAMA-J AM MED ASSOC, V297, P1197, DOI 10.1001/jama.297.11.1197
   Stewart S, 2002, AM J MED, V113, P359, DOI 10.1016/S0002-9343(02)01236-6
   Suzuki S, 2007, CIRC J, V71, P761, DOI 10.1253/circj.71.761
   Tanizaki Y, 2000, STROKE, V31, P2616
   Toda E, 2012, J AM COLL CARDIOL, V59, pE674
   Tsai CF, 2013, NEUROLOGY, V81, P264, DOI 10.1212/WNL.0b013e31829bfde3
   Vakkalagadda B, 2009, J CLIN PHARMACOL, V49, P1124
   van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441
   Veenstra DL, 2005, PHARMACOGENET GENOM, V15, P687, DOI 10.1097/01.fpc.0000174789.77614.68
   Verhoef TI, 2013, NEW ENGL J MED, V369, P2304, DOI 10.1056/NEJMoa1311388
   Wallentin L, 2010, LANCET, V376, P975, DOI 10.1016/S0140-6736(10)61194-4
   Wan Y, 2008, CIRC-CARDIOVASC QUAL, V1, P84, DOI 10.1161/CIRCOUTCOMES.108.796185
   Wang TJ, 2003, CIRCULATION, V107, P2920, DOI 10.1161/01.CIR.0000072767.89944.6E
   Watanabe H, 2008, CIRCULATION, V117, P1255, DOI 10.1161/CIRCULATIONAHA.107.744466
   WOLF PA, 1991, STROKE, V22, P983
   Wong PC, 2008, J THROMB HAEMOST, V6, P820, DOI 10.1111/j.1538-7836.2008.02939.x
   Wong PC, 2007, J THROMB THROMBOLYS, V24, P43, DOI 10.1007/s11239-007-0017-9
   Yamashita T, 2012, CIRC J, V76, P1840, DOI 10.1253/circj.CJ-11-1140
   Yap KB, 2008, J ELECTROCARDIOL, V41, P94, DOI 10.1016/j.electrocard.2007.03.012
   Yeh CH, 2012, CIRC RES, V111, P1069, DOI 10.1161/CIRCRESAHA.112.276741
   You J. H., J GEN INTERN MED
   Yusuf S, 2006, NEW ENGL J MED, V354, P1464
   Zafar MU, 2007, THROMB HAEMOSTASIS, V98, P883, DOI 10.1160/TH07-04-0312
   Zhao D, 2008, STROKE, V39, P1668, DOI 10.1161/STROKEAHA.107.502807
   Zhao X, 2009, BRIT J CLIN PHARMACO, V68, P77, DOI 10.1111/j.1365-2125.2009.03390.x
   Zhou ZQ, 2008, J EPIDEMIOL, V18, P209, DOI 10.2188/jea.JE2008021
NR 142
TC 7
Z9 7
U1 2
U2 24
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5002
EI 1759-5010
J9 NAT REV CARDIOL
JI Nat. Rev. Cardiol.
PD MAY
PY 2014
VL 11
IS 5
BP 290
EP 303
DI 10.1038/nrcardio.2014.22
PG 14
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AF8WX
UT WOS:000334997400006
PM 24614113
ER


PT J
AU Steinberg, BA
   Piccini, JP
AF Steinberg, Benjamin A.
   Piccini, Jonathan P.
TI Anticoagulation in atrial fibrillation
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Review
ID NORMALIZED RATIO CONTROL; VITAMIN-K ANTAGONISM; CLINICAL CLASSIFICATION
   SCHEMES; RISK STRATIFICATION SCHEMES; RANDOMIZED CONTROLLED-TRIAL;
   COAGULATION-FACTOR XA; ORAL DIRECT THROMBIN; RE-LY TRIAL; STROKE
   PREVENTION; ROCKET AF
AB Atrial fibrillation increases the risk of stroke, which is a leading cause of death and disability worldwide. The use of oral anticoagulation in patients with atrial fibrillation at moderate or high risk of stroke, estimated by established criteria, improves outcomes. However, to ensure that the benefits exceed the risks of bleeding, appropriate patient selection is essential. Vitamin K antagonism has been the mainstay of treatment; however, newer drugs with novel mechanisms are also available. These novel oral anticoagulants (direct thrombin inhibitors and factor Xa inhibitors) obviate many of warfarin's shortcomings, and they have demonstrated safety and efficacy in large randomized trials of patients with non-valvular atrial fibrillation. However, the management of patients taking warfarin or novel agents remains a clinical challenge. There are several important considerations when selecting anticoagulant therapy for patients with atrial fibrillation. This review will discuss the rationale for anticoagulation in patients with atrial fibrillation; risk stratification for treatment; available agents; the appropriate implementation of these agents; and additional, specific clinical considerations for treatment.
C1 [Steinberg, Benjamin A.; Piccini, Jonathan P.] Duke Univ, Electrophysiol Sect, Duke Clin Res Inst, Med Ctr, Durham, NC 27715 USA.
   [Steinberg, Benjamin A.; Piccini, Jonathan P.] Duke Clin Res Inst, Durham, NC USA.
RP Steinberg, BA (reprint author), Duke Univ, Electrophysiol Sect, Duke Clin Res Inst, Med Ctr, Durham, NC 27715 USA.
EM benjamin.steinberg@duke.edu
FU Janssen Scientific; GE Healthcare; ARCA pharmaceuticals; ResMed; NIH [5
   T32 HL 7101-38]
FX We have read and understood the BMJ Group policy on declaration of
   interests and declare the following interests: JPP discloses
   institutional research grant support from Janssen Scientific, GE
   Healthcare, ARCA pharmaceuticals, and ResMed; and consulting
   relationships with Johnson & Johnson, Pfizer/BMS, Medtronic, and
   Spectranetics. BAS was funded by NIH T-32 training grant #5 T32 HL
   7101-38.
CR Al-Khatib SM, 2013, EUR HEART J, V34, P2464, DOI 10.1093/eurheartj/eht135
   Anderson DC, 2002, STROKE, V33, P1963, DOI 10.1161/01.STR.0000023445.A8
   Bartus K, 2013, J AM COLL CARDIOL, V62, P108, DOI 10.1016/j.jacc.2012.06.046
   Bartus K, 2011, HEART RHYTHM, V8, P188, DOI 10.1016/j.hrthm.2010.10.040
   Bauer KA, 2012, AM J HEMATOL, V87, pS119, DOI 10.1002/ajh.23165
   Beasley BN, 2011, NEW ENGL J MED, V364, P1788, DOI 10.1056/NEJMp1103050
   Benjamin EJ, 1998, CIRCULATION, V98, P946
   Boehringer-Ingelheim, DAB PRESCR INF SEC D
   Boehringer-Ingelheim, 2013, DAB PRESCR INF STROK
   BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Camm AJ, 2010, EUR HEART J, V31, P2369, DOI 10.1093/eurheartj/ehq278
   Chugh SS, 2014, CIRCULATION, V129, P837, DOI 10.1161/CIRCULATIONAHA.113.005119
   Conen D, 2011, JAMA-J AM MED ASSOC, V305, P2080, DOI 10.1001/jama.2011.659
   Connolly S, 2006, LANCET, V367, P1903
   Connolly SJ, 2008, CIRCULATION, V118, P2029, DOI 10.1161/CIRCULATIONAHA.107.750000
   Connolly SJ, 2013, CIRCULATION, V128, P237, DOI 10.1161/CIRCULATIONAHA.112.001139
   Connolly SJ, 2013, EUR HEART J, V34, P1498, DOI 10.1093/eurheartj/eht039
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Dewland TA, 2013, CIRCULATION, V128, P2470, DOI 10.1161/CIRCULATIONAHA.113.002449
   Dogliotti A, 2013, HEART
   Douketis JD, 2012, CHEST, V141, pE326S, DOI 10.1378/chest.11-2298
   Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
   Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
   Eriksson BI, 2009, CLIN PHARMACOKINET, V48, P1, DOI 10.2165/0003088-200948010-00001
   EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002
   Ezekowitz MD, 1999, JAMA-J AM MED ASSOC, V281, P1830, DOI 10.1001/jama.281.19.1830
   Fang MC, 2012, STROKE, V43, P1795, DOI 10.1161/STROKEAHA.111.630731
   Fang MC, 2011, J AM COLL CARDIOL, V58, P395, DOI 10.1016/j.jacc.2011.03.031
   Food and Drug Administration, 2011, FDA BRIEF D IN PRESS
   Fox KAA, 2011, EUR HEART J, V32, P2387, DOI 10.1093/eurheartj/ehr342
   Friberg L, 2012, EUR HEART J, V33, P1500, DOI 10.1093/eurheartj/ehr488
   Friberg L, 2012, CIRCULATION, V125, P2298, DOI 10.1161/CIRCULATIONAHA.111.055079
   Fuster V, 2011, CIRCULATION, V123, pE269, DOI 10.1161/CIR.0b013e318214876d
   Gage BF, 2006, AM HEART J, V151, P713, DOI 10.1016/j.ahj.2005.04.017
   Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864
   Garcia DA, 2008, ARCH INTERN MED, V168, P63, DOI 10.1001/archinternmed.2007.23
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685
   Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Guyatt Gordon H, 2012, Chest, V141, p7S, DOI 10.1378/chest.1412S3
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Hart RG, 2012, STROKE, V43, P1511, DOI 10.1161/STROKEAHA.112.650614
   Hashimoto T, 2013, XENOBIOTICA, V43, P534, DOI 10.3109/00498254.2012.738045
   Healey JS, 2012, CIRCULATION, V126, P343, DOI 10.1161/CIRCULATIONAHA.111.090464
   Heidbuchel H, 2013, EUROPACE, V15, P625, DOI 10.1093/europace/eut083
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Investigators SPAF, 1990, STROKE, V21, P538
   Johansson S, 2011, INT J CLIN PHARM TH, V49, P258, DOI 10.5414/CP201465
   Keogh C, 2011, THROMB HAEMOSTASIS, V106, P528, DOI 10.1160/TH11-02-0061
   Landmesser U, 2012, EUR HEART J, V33, P698, DOI 10.1093/eurheartj/ehr393
   Larsen TB, 2013, J AM COLL CARDIOL, V61, P2264, DOI 10.1016/j.jacc.2013.03.020
   Limone BL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062183
   Lin HJ, 1996, STROKE, V27, P1760
   Lip GYH, 2012, J AM COLL CARDIOL, V60, P738, DOI 10.1016/j.jacc.2012.03.019
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Lloyd-Jones DM, 2004, CIRCULATION, V110, P1042, DOI 10.1161/01.CIR.0000140263.20897.42
   Lopes RD, 2013, EUR HEART J S1, V34, DOI 10.1093/eurheartj/eht307.P535
   Lopes RD, 2012, LANCET, V380, P1749, DOI 10.1016/S0140-6736(12)60986-6
   Lu GM, 2013, NAT MED, V19, P446, DOI 10.1038/nm.3102
   Mahaffey KW, 2013, CIRC-CARDIOVASC QUAL, V6, P470, DOI 10.1161/CIRCOUTCOMES.113.000132
   Majeed A, 2013, CIRCULATION, V128, P2325, DOI 10.1161/CIRCULATIONAHA.113.002332
   Marlu R, 2012, THROMB HAEMOSTASIS, V108, P217, DOI 10.1160/TH12-03-0179
   McGrath ER, 2013, NEUROLOGY, V81, P825, DOI 10.1212/WNL.0b013e3182a2cc15
   Mitusch R, 1996, THROMB HAEMOSTASIS, V75, P219
   Morgan CL, 2009, THROMB RES, V124, P37, DOI 10.1016/j.thromres.2008.09.016
   Olesen JB, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d124
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Patel MR, 2010, AM HEART J, V159, P340, DOI 10.1016/j.ahj.2009.11.025
   Perzborn E, 2011, NAT REV DRUG DISCOV, V10, P61, DOI 10.1038/nrd3185
   PETERSEN P, 1989, LANCET, V1, P175
   [Anonymous], 2011, RIV PRESCR INF SEC R
   Piccini JP, 2013, CIRCULATION, V127, P224, DOI 10.1161/CIRCULATIONAHA.112.107128
   Piccini JP, 2012, CIRC-CARDIOVASC QUAL, V5, P85, DOI 10.1161/CIRCOUTCOMES.111.962688
   Pinto DJP, 2007, J MED CHEM, V50, P5339, DOI 10.1021/jm070245n
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Reddy VY, 2013, CIRCULATION, V127, P720, DOI 10.1161/CIRCULATIONAHA.112.114389
   Reddy VY, 2011, CIRCULATION, V123, P417, DOI 10.1161/CIRCULATIONAHA.110.976449
   ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236
   Ruff C.T., 2013, LANCET
   Sherwood MW, 2014, CIRCULATION
   Singer DE, 2008, CHEST, V133, p546S, DOI 10.1378/chest.08-0678
   Sorensen R, 2013, BMJ OPEN, V3, P2758
   Southworth MR, 2013, NEW ENGL J MED, V368, P1272, DOI 10.1056/NEJMp1302834
   B-M Squibb, APIXABAN PRESCRIBING
   Stewart S, 2001, HEART, V86, P516, DOI 10.1136/heart.86.5.516
   Tu HTH, 2010, CEREBROVASC DIS, V30, P389, DOI 10.1159/000316886
   Uchino K, 2012, ARCH INTERN MED, V172, P397, DOI 10.1001/archinternmed.2011.1666
   UNO M, 1988, JPN CIRC J, V52, P9
   Wallentin L, 2013, CIRCULATION, V127, P2166, DOI 10.1161/CIRCULATIONAHA.112.142158
   Wallentin L, 2010, LANCET, V376, P975, DOI 10.1016/S0140-6736(10)61194-4
   WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561
   WOLF PA, 1991, STROKE, V22, P983
   WOLF PA, 1978, NEUROLOGY, V28, P973
   Wysokinski WE, 2008, MAYO CLIN PROC, V83, P639, DOI 10.4065/83.6.639
   [Anonymous], 1998, ANN INTERN MED, V128, P639
   [Anonymous], 1994, LANCET, V343, P687
NR 100
TC 13
Z9 13
U1 0
U2 8
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD APR 14
PY 2014
VL 348
AR g2116
DI 10.1136/bmj.g2116
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA AF5GH
UT WOS:000334741500016
PM 24733535
ER


PT J
AU Noll, G
   Noll, S
   Hurlimann, D
AF Noll, Georg
   Noll, Sarah
   Huerlimann, David
TI Direct Oral Anticoagulants in Atrial Fibrillation
SO SEMINARS IN HEMATOLOGY
LA English
DT Article
ID VITAMIN-K ANTAGONISM; ROCKET AF TRIAL; HEART-FAILURE;
   MYOCARDIAL-INFARCTION; RANDOMIZED EVALUATION; RISK STRATIFICATION;
   SECONDARY ANALYSIS; COST-EFFECTIVENESS; STROKE PREVENTION; CATHETER
   ABLATION
AB Atrial fibrillation (AF), the most frequent sustained arrhythmia, is associated with an increased risk of thromboembolic events. The risk of stroke depends on risk factors such as age, hypertension, heart failure, and vascular disease. Thus, antithrombotic therapy is a cornerstone in the management of AF. Warfarin is successfully used to reduce thromboembolic events. More recently, direct thrombin (dabigatran) and factor Xa (apixaban, edoxaban, rivaroxaban) inhibitors have been compared to warfarin in large randomized trials. All new substances have been shown to be non-inferior to warfarin concerning thromboembolic events. Severe bleeding, such as fatal and intracranial bleeding, was less frequent with direct oral anticoagulants. Results of the studies and subgroup analyses are discussed. Further trials using direct oral anticoagulants in special populations such as very old and patients with kidney disease are needed. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Noll, Georg; Huerlimann, David] Heart Clin Hirslanden Zurich, Zurich, Switzerland.
   [Noll, Sarah] Univ Zurich, Zurich, Switzerland.
RP Noll, G (reprint author), Herzklin Hirslanden, Witellikerstr 40, CH-8032 Zurich, Switzerland.
EM georg.noll@hirslanden.ch
FU Bayer; Boeluinger; Pfizer
FX GN received speaker fees from Bayer, Boeluinger, and Pfizer.
CR Amin A, 2014, J THROMB THROMBOLYS, V38, P150, DOI 10.1007/s11239-013-1048-z
   Badheka AO, 2011, AM J CARDIOL, V108, P1283, DOI 10.1016/j.amjcard.2011.06.045
   Banerjee A, 2012, EUR J HEART FAIL, V14, P295, DOI 10.1093/eurjhf/hfs005
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Canestaro WJ, 2013, CIRC-CARDIOVASC QUAL, V6, P724, DOI 10.1161/CIRCOUTCOMES.113.000661
   Conen D, 2011, JAMA-J AM MED ASSOC, V305, P2080, DOI 10.1001/jama.2011.659
   Connolly SJ, 2013, CIRCULATION, V128, P237, DOI 10.1161/CIRCULATIONAHA.112.001139
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Deitelzweig Steve, 2013, J Med Econ, V16, P1163, DOI 10.3111/13696998.2013.826664
   Dentali F, 2012, CIRCULATION, V126, P2381, DOI 10.1161/CIRCULATIONAHA.112.115410
   DeWilde S, 2006, HEART, V92, P1064, DOI 10.1136/hrt.2005.069492
   Dogliotti A, 2014, HEART, V100, P396, DOI 10.1136/heartjnl-2013-304347
   Ferreira J, 2013, EUR J HEART FAIL, V15, P1053, DOI 10.1093/eurjhf/hft111
   Flaker G, 2014, J AM COLL CARDIOL, V63, P1082, DOI 10.1016/j.jacc.2013.09.062
   Flaker GC, 2012, STROKE, V43, P3291, DOI 10.1161/STROKEAHA.112.664144
   Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864
   Garcia DA, 2013, AM HEART J, V166, P549, DOI 10.1016/j.ahj.2013.05.016
   Gattellari M, 2011, CEREBROVASC DIS, V32, P370, DOI 10.1159/000330637
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Gomez-Outes A, 2013, THROMBOSIS
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Hankey GJ, 2012, LANCET NEUROL, V11, P512, DOI 10.1016/S1474-4422(12)70091-1
   Harel Z, 2014, J AM SOC NEPHROL, V25, P431, DOI 10.1681/ASN.2013040361
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825
   Hijazi Z, 2014, J AM COLL CARDIOL, V63, P52, DOI 10.1016/j.jacc.2013.07.093
   Hijazi Z, 2013, J AM COLL CARDIOL, V61, P2274, DOI 10.1016/j.jacc.2012.11.082
   Hohnloser SH, 2013, EUR HEART J, V34, P2752, DOI 10.1093/eurheartj/eht292
   Hohnloser SH, 2012, CIRCULATION, V125, P669, DOI 10.1161/CIRCULATIONAHA.111.055970
   Holmes DR, 2009, LANCET, V374, P534, DOI 10.1016/S0140-6736(09)61343-X
   Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496
   Huxley RR, 2011, CIRCULATION, V123, P1501, DOI 10.1161/CIRCULATIONAHA.110.009035
   Ichiki H, 2013, PACE, V36, P1328, DOI 10.1111/pace.12195
   Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a
   Krejczy M, 2014, J THROMB THROMBOLYS, V37, P507, DOI 10.1007/s11239-013-0989-6
   Larsen TB, 2014, AM J MED, V127, P650, DOI 10.1016/j.amjmed.2014.01.031
   Limone BL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062183
   Lip GYH, 2013, CIRC-ARRHYTHMIA ELEC, V6, P31, DOI 10.1161/CIRCEP.112.975847
   Lip GYH, 2012, CHEST, V142, P1489, DOI 10.1378/chest.11-2888
   Lip GY, 2012, COCHRANE DB SYST REV, V6
   Lloyd-Jones DM, 2004, CIRCULATION, V110, P1042, DOI 10.1161/01.CIR.0000140263.20897.42
   Lopes RD, 2012, LANCET, V380, P1749, DOI 10.1016/S0140-6736(12)60986-6
   Mahaffey KW, 2013, CIRC-CARDIOVASC QUAL, V6, P470, DOI 10.1161/CIRCOUTCOMES.113.000132
   Mahaffey KW, 2013, ANN INTERN MED, V158, P861, DOI 10.7326/0003-4819-158-12-201306180-00003
   Mak KH, 2012, BMJ OPEN, P2
   Marijon E, 2013, CIRCULATION, V128, P2192, DOI 10.1161/CIRCULATIONAHA.112.000491
   McMurray JJV, 2013, CIRC-HEART FAIL, V6, P451, DOI 10.1161/CIRCHEARTFAILURE.112.000143
   Miller VT, 1996, NEUROLOGY, V46, P238
   Miyasaka Y, 2007, J AM COLL CARDIOL, V49, P986, DOI 10.1016/j.jacc.2006.10.062
   Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140
   Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546
   Olesen JB, 2012, NEW ENGL J MED, V367, P625, DOI 10.1056/NEJMoa1105594
   Olesen JB, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d124
   Park JW, 2011, CATHETER CARDIO INTE, V77, P700, DOI 10.1002/ccd.22764
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Piccini JP, 2013, CIRCULATION, V127, P224, DOI 10.1161/CIRCULATIONAHA.112.107128
   Providencia R, 2014, HEART, V100, P324, DOI 10.1136/heartjnl-2013-304386
   Reddy VY, 2011, CIRCULATION, V123, P417, DOI 10.1161/CIRCULATIONAHA.110.976449
   Sardar P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077694
   Sato H, 2006, STROKE, V37, P447, DOI 10.1161/01.STR.0000198839.61112.ee
   Schnabel RB, 2009, LANCET, V373, P739, DOI 10.1016/S0140-6736(09)60443-8
   Schneeweiss S, 2012, CIRC-CARDIOVASC QUAL, V5, P480, DOI 10.1161/CIRCOUTCOMES.112.965988
   Shurrab M, 2013, CAN J CARDIOL, V29, P1203, DOI 10.1016/j.cjca.2013.07.005
   Bruins Slot KM, 2013, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD008980.PUB2
   SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302
   Steinberg BA, 2013, J INTERV CARD ELECTR, V37, P213, DOI 10.1007/s10840-013-9813-7
   The ACTIVE Investigators, 2009, N ENGL J MED, V360, P2066
   Uchino K, 2012, ARCH INTERN MED, V172, P397, DOI 10.1001/archinternmed.2011.1666
   van Diepen S, 2013, CIRC-HEART FAIL, V6, P740, DOI 10.1161/CIRCHEARTFAILURE.113.000212
   Verheugt FWA, 2006, LANCET, V367, P1877, DOI 10.1016/S0140-6736(06)68819-3
   Wallentin L, 2013, CIRCULATION, V127, P2166, DOI 10.1161/CIRCULATIONAHA.112.142158
   Wann LS, 2011, HEART RHYTHM, V8, P157, DOI 10.1016/j.hrthm.2010.11.047
   WOLF PA, 1991, STROKE, V22, P312
   Yadlapati A, 2014, AM J CARDIOL, V113, P1362, DOI 10.1016/j.amjcard.2013.12.044
   [Anonymous], 1980, LANCET, V2, P989
NR 78
TC 0
Z9 0
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0037-1963
EI 1532-8686
J9 SEMIN HEMATOL
JI Semin. Hematol.
PD APR
PY 2014
VL 51
IS 2
BP 139
EP 146
DI 10.1053/j.seminhematol.2014.04.001
PG 8
WC Hematology
SC Hematology
GA AI6RS
UT WOS:000337005200008
PM 24861798
ER


PT J
AU Miszczak, M
   Swiderski, W
AF Miszczak, M.
   Swiderski, W.
TI Optical detection of combustion zone movement in solid high-energy
   materials
SO COMBUSTION EXPLOSION AND SHOCK WAVES
LA English
DT Article
DE combustion zone movement; IR detection; VIS detection; solid high-energy
   materials; pyrolytic graphite (pyrographite); thermochromic substances
AB Optical methods in infrared (IR) and visible (VIS) ranges for detection of combustion zone propagation in solid high-energy materials, such as pyrotechnic compositions inserted into pyrolytic graphite (pyrographite) tubes and ignited at one end by a CO2 laser beam are presented. The pyrographite tube is used as a thermal management transducer enabling detection of combustion zone movement because of unique thermal conductivity anisotropy of pyrographite resulting in low thermal conductivity of the tube along its axis and high thermal conductivity along the tube radius. In the first method, an IR thermal camera is applied for detection of heat zone movement induced on the external side surface of the pyrographite tube by the combustion zone travelling inside the tube. According to the second method, a VIS camera and a thermochromic layer covering the external side surface of the pyrographite tube are used for visualization of heat zone movement registered as the color change boundary traveling along the thermochromic layer. The change in color of this layer is caused by its thermochromic substance response to heat delivered by the heat zone. As thermochromic substances, leuko dyes or chiral-nematic liquid crystals are used. These methods seem to be particularly promising for continuous measurements of burning rates of solid high-energy materials, such as solid rocket propellants and pyrotechnic compositions.
C1 [Miszczak, M.; Swiderski, W.] Mil Inst Armament Technol, PL-05220 Zielonka, Poland.
RP Miszczak, M (reprint author), Mil Inst Armament Technol, PL-05220 Zielonka, Poland.
EM waldemar.swiderski@wp.pl
CR Arkhipov VA, 2010, COMBUST EXPLO SHOCK+, V46, P570, DOI 10.1007/s10573-010-0075-8
   Arkhipov VA, 2010, COMBUST EXPLO SHOCK+, V46, P564, DOI 10.1007/s10573-010-0074-9
   Eisenreich N., 1987, PROPELL EXPLOS PYROT, V12, P78, DOI 10.1002/prep.19870120304
   Miszczak Maciej, 2009, Pomiary Automatyka Kontrola, V55, P950
   Rozhdestvenskii Yu. V., 1975, ROCKET PROPELLANTS, P171
   Shelukhin G. G., 1969, FIZ GOREN VZRYVA, V5, P42
   Swiderski W, 2011, QIRT J, V8, P111
NR 7
TC 1
Z9 1
U1 1
U2 7
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0010-5082
EI 1573-8345
J9 COMBUST EXPLO SHOCK+
JI Combust. Explos.
PD MAR
PY 2014
VL 50
IS 2
BP 178
EP 182
DI 10.1134/S0010508214020087
PG 5
WC Thermodynamics; Energy & Fuels; Engineering, Multidisciplinary;
   Engineering, Chemical; Materials Science, Multidisciplinary
SC Thermodynamics; Energy & Fuels; Engineering; Materials Science
GA AF0YP
UT WOS:000334441400008
ER


PT J
AU Kitamura, S
   Hayakawa, Y
   Kawamoto, S
AF Kitamura, Shoji
   Hayakawa, Yukio
   Kawamoto, Satomi
TI A reorbiter for large GEO debris objects using ion beam irradiation
SO ACTA ASTRONAUTICA
LA English
DT Article; Proceedings Paper
CT 63rd International Astronautical Congress (IAC)
CY OCT 01-05, 2012
CL Naples, ITALY
SP Int Astronaut Federat
DE Reorbiter; GEO debris; Ion beam; Irradiation; Ion engine
AB In recent years, space debris problems have become very serious. The worst case occurs in the low Earth orbit (LEO) region, where debris-to-debris collisions generate new debris. The situation in the geostationary orbit (GEO) region is not as bad as that in the LEO. The debris problem in the GEO region, however, should not be left as it is because the GEO is unique and has few debris-cleansing modes. Thus, we proposed a concept for a reorbiter to reorbit large GEO debris objects such as satellites and rocket upper stages left in orbit after the ends of their missions. This concept is based on the idea of thrusting a debris object by irradiating it with an ion beam. The reorbiter, equipped with two ion engines, approaches a debris object, and the ion beam exhausted from one of the ion engines irradiates and thrusts it to change its orbit. The other engine on the opposite side is operated so that the reorbiter follows the debris object. Their orbits are raised in a spiral to a disposal orbit approximately 300 km higher. After that, the reorbiter returns to GEO to approach another debris object. This system can operate without catching debris objects; thus, it can be applied to a wide range of debris objects without regard to their shapes or rotations. A mission scenario was made to conduct efficient maneuvers. In the GEO region, a number of debris objects are distributed on orbit planes close to each other, and they can be reorbited one after another using a single reorbiter. For a typical model mission, the mission time and the total impulse of the ion engines were calculated. The results show that six debris objects can be reorbited in 170 days. The reorbiter has a targeted launch mass of 2500 kg and 6.9 kW of total power. The ion beam convergence, the effects of ion beam irradiation, and non-cooperative rendezvous were recognized as the critical issues of this system. A highly converged beam is required to make efficient debris irradiation. Numerical calculations and basic experiments gave a feasibility of the required irradiation efficiency of over 25%. The irradiation of debris objects may cause sputtering of their surfaces and depositions of the back-sputtered materials on the reorbiter surface. The data were obtained experimentally to evaluate the effects of the depositions, especially on solar cells. The results indicated no serious contamination problems. Preliminary studies were conducted on the approach to an uncollaborative object and the maintenance of the separation distance. (C) 2013 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [Kitamura, Shoji] Hosei Univ, Tokyo, Japan.
   [Hayakawa, Yukio; Kawamoto, Satomi] Japan Aerosp Explorat Agcy, Tokyo, Japan.
RP Kitamura, S (reprint author), Hosei Univ, Tokyo, Japan.
EM shoji.kitamura.zf@hosei.ac.jp; hayakawa.yukio@jaxa.jp;
   kawamoto.satomi@jaxa.jp
CR Bombardelli C., 2011, 104611 EUR SPAC AG A
   Bombardelli C., 2011, 62 INT ASTR C OCT
   Flohrer T., 2012, GENDBLOG00086OPSGR
   HAYAKAWA Y, 1992, J PROPUL POWER, V8, P110, DOI 10.2514/3.23450
   Kawamoto S., 2009, 27 INT S SPAC TECHN
   Kitamura S., 2011, 32 INT EL PROP C SEP
   Kitamura S., 2010, 61 INT ASTR C SEPT
   Kronman J.D., 2000, ION GPS 2000 SEPT
   McKnight D., 2011, 62 INT ASTR C OCT
   Ruiz J.L, 2005, ION GNSS 18 INT TECH
   Schaub H., 2009, NASA DARPA INT C ORB
   Starke J., 2009, NASA DARPA INT C ORB
NR 12
TC 6
Z9 6
U1 1
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
EI 1879-2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD FEB
PY 2014
VL 94
IS 2
BP 725
EP 735
DI 10.1016/j.actaastro.2013.07.037
PG 11
WC Engineering, Aerospace
SC Engineering
GA 275GE
UT WOS:000328663500020
ER


PT J
AU Jiang, W
   Yang, ZH
AF Jiang, Wen
   Yang, Zhaohua
TI Guidance Law Design for Terminal Area Energy Management of Reusable
   Launch Vehicle by Energy-to-Range Ratio
SO MATHEMATICAL PROBLEMS IN ENGINEERING
LA English
DT Article
ID SUSPENSION SYSTEMS
AB A new guidance scheme that utilizes a trajectory planning algorithm by energy-to-range ratio has been developed under the circumstance of surplus energy for the terminal area energy management phase of a reusable launch vehicle. The trajectory planning scheme estimates the reference flight profile by piecing together several flight phases that are defined by a set of geometric parameters. Guidance commands are readily available once the best reference trajectory is determined. The trajectory planning algorithm based on energy-to-range ratio is able to quickly generate new reference profiles for testing cases with large variations in initial vehicle condition and energy. The designed flight track has only one turn heading, which simplifies the trajectory planning algorithm. The effectiveness of the trajectory planning algorithm is demonstrated by simulations, which shows that the guided vehicle is able to successfully dissipate energy and reach the desired approach and landing glideslope target with small tracking errors.
C1 [Jiang, Wen; Yang, Zhaohua] Beihang Univ, Sch Instrumentat Sci & Optoelect Engn, Beijing 100191, Peoples R China.
RP Jiang, W (reprint author), Beihang Univ, Sch Instrumentat Sci & Optoelect Engn, Beijing 100191, Peoples R China.
EM jiangwen-1937@163.com
FU Fundamental Scientific Research Project of Beihang University
   [YWF-14-YQGD-007]
FX The research work presented in this paper was supported by the
   Fundamental Scientific Research Project of Beihang University under
   Grant no. YWF-14-YQGD-007.
CR Abbasi D, 2013, MATH PROBL ENG, DOI 10.1155/2013/419409
   Burchett BT, 2004, J SPACECRAFT ROCKETS, V41, P444, DOI 10.2514/1.10938
   Filipe N. R. S., 2009, 20095768 AIAA
   Grantham K., 2003, 20030305 AIAA
   Hall CE, 2006, J GUID CONTROL DYNAM, V29, P1315, DOI 10.2514/1.20151
   Hanson JM, 2004, J GUID CONTROL DYNAM, V27, P960, DOI 10.2514/1.10886
   Hanson JM, 2003, AEROSPACE AM, V41, P36
   Hanson J. M., 2002, 024557 AIAA
   Harpold J. C., 1979, N7974791 NASA
   Horneman K.R., 2004, 20045183 AIAA
   Kluever CA, 2007, J GUID CONTROL DYNAM, V30, P162, DOI 10.2514/1.24864
   Kluever C.A., 2009, 20095766 AIAA
   Li HY, 2014, IEEE T CYBERNETICS, V44, P1111, DOI 10.1109/TCYB.2013.2279534
   Li HY, 2014, IEEE T IND ELECTRON, V61, P436, DOI 10.1109/TIE.2013.2242418
   Li HY, 2013, IEEE T IND ELECTRON, V60, P3328, DOI 10.1109/TIE.2012.2202354
   Moore T.E., 1991, 104744 NASA
   Saldia JP, 2009, MATH PROBL ENG, DOI 10.1155/2009/859678
   Shen ZJ, 2003, J GUID CONTROL DYNAM, V26, P111, DOI 10.2514/2.5021
   Tang Y, 2013, IEEE ACM T COMPUT BI, V10, P708, DOI 10.1109/TCBB.2013.72
   Tang Y, 2012, IEEE T IND INFORM, V8, P828, DOI 10.1109/TII.2012.2187911
NR 20
TC 0
Z9 0
U1 1
U2 17
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA
SN 1024-123X
EI 1563-5147
J9 MATH PROBL ENG
JI Math. Probl. Eng.
PY 2014
AR 929731
DI 10.1155/2014/929731
PG 8
WC Engineering, Multidisciplinary; Mathematics, Interdisciplinary
   Applications
SC Engineering; Mathematics
GA AH7OR
UT WOS:000336323400001
ER


PT J
AU Halbe, O
   Raja, RG
   Padhi, R
AF Halbe, Omkar
   Raja, Ramsingh G.
   Padhi, Radhakant
TI Robust Reentry Guidance of a Reusable Launch Vehicle Using Model
   Predictive Static Programming
SO JOURNAL OF GUIDANCE CONTROL AND DYNAMICS
LA English
DT Article
ID CONTROL DESIGN
AB A robust suboptimal reentry guidance scheme is presented for a reusable launch vehicle using the recently developed, computationally efficient model predictive static programming. The formulation uses the nonlinear vehicle dynamics with a spherical and rotating Earth, hard constraints for desired terminal conditions, and an innovative cost function having several components with associated weighting factors that can account for path and control constraints in a soft constraint manner, thereby leading to smooth solutions of the guidance parameters. The proposed guidance essentially shapes the trajectory of the vehicle by computing the necessary angle of attack and bank angle that the vehicle should execute. The path constraints are the structural load constraint, thermal load constraint, bounds on the angle of attack, and bounds on the bank angle. In addition, the terminal constraints include the three-dimensional position and velocity vector components at the end of the reentry. Whereas the angle-of-attack command is generated directly, the bank angle command is generated by first generating the required heading angle history and then using it in a dynamic inversion loop considering the heading angle dynamics. Such a two-loop synthesis of bank angle leads to better management of the vehicle trajectory and avoids mathematical complexity as well. Moreover, all bank angle maneuvers have been confined to the middle of the trajectory and the vehicle ends the reentry segment with near-zero bank angle, which is quite desirable. It has also been demonstrated that the proposed guidance has sufficient robustness for state perturbations as well as parametric uncertainties in the model.
C1 [Halbe, Omkar; Raja, Ramsingh G.; Padhi, Radhakant] Indian Inst Sci, Dept Aerosp Engn, Bangalore 560012, Karnataka, India.
EM padhi@aero.iisc.ernet.in
CR Ananthasayanam M. R., 1987, ADV SPACE RES, V7, P117, DOI 10.1016/0273-1177(87)90084-6
   Bryson A. E., 1975, APPL OPTIMAL CONTROL, P1
   Cavallo A, 1996, J GUID CONTROL DYNAM, V19, P47, DOI 10.2514/3.21578
   Chawla C, 2010, AEROSP SCI TECHNOL, V14, P377, DOI 10.1016/j.ast.2010.04.001
   Donnay J. D. H., 1945, SPHERICAL TRIGONOMET, P28
   Dwivedi PN, 2011, J GUID CONTROL DYNAM, V34, P860, DOI 10.2514/1.50821
   ENNS D, 1994, INT J CONTROL, V59, P71, DOI 10.1080/00207179408923070
   Gallais P., 2007, ATMOSPHERIC REENTRY, P31, DOI 10.1007/978-3-540-73647-9_4
   Gong Q, 2008, J GUID CONTROL DYNAM, V31, P460, DOI 10.2514/1.32908
   Harpold J. C., 1979, N7974791 NASA
   Kirk D.E., 1970, OPTIMAL CONTROL THEO, P329
   McHenry R. L., 1979, J ASTRONAUT SCI, V27, P1
   MEASE KD, 1994, J GUID CONTROL DYNAM, V17, P1350, DOI 10.2514/3.21355
   Padhi R, 2009, INT J INNOV COMPUT I, V5, P399
   Rossiter J. A., 2003, MODEL BASED PREDICTI, P40
   Shen ZJ, 2004, J GUID CONTROL DYNAM, V27, P949, DOI 10.2514/1.8008
   Shen ZJ, 2003, J GUID CONTROL DYNAM, V26, P111, DOI 10.2514/2.5021
   Vinh N.X., 1980, HYPERSONIC PLANETARY, P19
   Werbos P. J., 1992, HDB INTELLIGENT CONT, P65
   Young J., 1961, TND954 NASA
NR 20
TC 9
Z9 11
U1 0
U2 10
PU AMER INST AERONAUTICS  ASTRONAUTICS
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 0731-5090
EI 1533-3884
J9 J GUID CONTROL DYNAM
JI J. Guid. Control Dyn.
PD JAN-FEB
PY 2014
VL 37
IS 1
BP 134
EP 148
DI 10.2514/1.61615
PG 15
WC Engineering, Aerospace; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA AD9UG
UT WOS:000333609400016
ER


PT J
AU Turpie, AGG
AF Turpie, Alexander G. G.
TI Rivaroxaban as an oral anticoagulant for stroke prevention in atrial
   fibrillation
SO THERAPEUTICS AND CLINICAL RISK MANAGEMENT
LA English
DT Review
DE atrial fibrillation; stroke; rivaroxaban; anticoagulation
ID FACTOR-XA INHIBITOR; DEEP-VEIN THROMBOSIS; PROTHROMBIN COMPLEX
   CONCENTRATE; POPULATION PHARMACOKINETICS; VENOUS THROMBOEMBOLISM;
   COAGULATION ASSAYS; PHARMACODYNAMICS; REVERSAL; WARFARIN; RISK
AB Atrial fibrillation (AF) is the most common cardiac arrhythmia in the developed world and is associated with a fivefold increase in the risk of stroke, accounting for up to 15% of strokes in the general population. The European Society of Cardiology now recommends direct oral anticoagulants, such as rivaroxaban, apixaban, and dabigatran, in preference to vitamin K antagonist therapy for the prevention of stroke in patients with AF. This review focuses on the direct Factor Xa inhibitor rivaroxaban, summarizing the properties that make rivaroxaban appropriate for anticoagulant therapy in this indication (including its predictable pharmacokinetic and pharmacodynamic profile and once-daily dosing regimen) and describing data from the Phase III ROCKET AF trial, which showed once-daily rivaroxaban to be noninferior to warfarin for the prevention of stroke in patients with nonvalvular AF. In this trial, similar rates of major and nonmajor clinically relevant bleeding were observed; however, when compared with warfarin, rivaroxaban was associated with clinically significant reductions in intracranial and fatal bleeding. On the basis of these results, rivaroxaban was approved in both the United States and the European Union for the prevention of stroke and systemic embolism in patients with nonvalvular AF. Subanalyses of ROCKET AF data showed rivaroxaban to have consistent efficacy and safety across a wide range of patients, and studies to confirm these results in real-world settings are underway. This review also describes practical considerations for treatment with rivaroxaban in clinical practice (including dose reductions in specific high-risk patients, eg, those with renal impairment), recommendations for the transition from vitamin K antagonists to rivaroxaban, the management of bleeding events, and the measurement of rivaroxaban exposure.
C1 [Turpie, Alexander G. G.] McMaster Univ, Dept Med, Hamilton, ON L8L 2X2, Canada.
RP Turpie, AGG (reprint author), McMaster Univ, Dept Med, Hamilton Hlth Sci, Hamilton Gen Hosp, 237 Barton St East, Hamilton, ON L8L 2X2, Canada.
EM turpiea@mcmaster.ca
FU Bayer HealthCare Pharmaceuticals; Janssen Research and Development, LLC.
FX The author would like to acknowledge Isabel Ruthven and Claudia
   Wiedemann, who provided editorial support with funding from Bayer
   HealthCare Pharmaceuticals and Janssen Research and Development, LLC.
CR Ageno W, 2012, CHEST, V141, pe44S
   Agnelli G, 2007, CIRCULATION, V116, P180, DOI 10.1161/CIRCULATIONAHA.106.668020
   Asmis LM, 2012, THROMB RES, V129, P492, DOI 10.1016/j.thromres.2011.06.031
   Barco S, 2013, BEST PRACT RES CL HA, V26, P215, DOI 10.1016/j.beha.2013.07.011
   Bayer, XAR PREV STROK PAT A
   Bayer Pharma AG, 2013, XAR RIV SUMM PROD CH
   Boehringer Ingelheim International GmbH, 2013, PRAD DAB ET SUMM PRO
   Boehringer Ingelheim Pharmaceuticals Inc, 2013, PRAD DAB ET PRESCR I
   Bristol-Myers Squibb Company, 2012, EL AP PRESCR INF
   Bristol-Myers Squibb Pfizer EEIG, 2013, EL AP SUMM PROD CHAR
   Buller HR, 2008, BLOOD, V112, P2242, DOI 10.1182/blood-2008-05-160143
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
   Fox KAA, 2011, EUR HEART J, V32, P2387, DOI 10.1093/eurheartj/ehr342
   Freyburger G, 2011, THROMB RES, V127, P457, DOI 10.1016/j.thromres.2011.01.001
   Gerotziafas GT, 2012, THROMB RES, V129, P101, DOI 10.1016/j.thromres.2011.09.004
   Gladstone DJ, 2009, STROKE, V40, P235, DOI 10.1161/STROKEAHA.108.516344
   Godier A, 2012, ANESTHESIOLOGY, V116, P94, DOI 10.1097/ALN.0b013e318238c036
   Halperin JL, 2012, STROKE, V43, pA148
   Hankey GJ, 2012, LANCET NEUROL, V11, P315, DOI 10.1016/S1474-4422(12)70042-X
   Harenberg J, 2012, SEMIN THROMB HEMOST, V38, P178, DOI 10.1055/s-0032-1301415
   Hillarp A, 2011, J THROMB HAEMOST, V9, P133, DOI 10.1111/j.1538-7836.2010.04098.x
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Janssen Pharmaceuticals Inc, 2011, XAR RIV FULL PRESCR
   Johann Wolfgang Goethe University Hospitals, REV AG US PAT TREAT
   Kaatz S, 2012, AM J HEMATOL, V87, pS141, DOI 10.1002/ajh.23202
   Kakkar AK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063479
   Kreutz R, 2012, FUND CLIN PHARMACOL, V26, P27, DOI 10.1111/j.1472-8206.2011.00981.x
   Kubitza D, 2005, CLIN PHARMACOL THER, V78, P412, DOI 10.1016/j.clpt.2005.06.011
   Kubitza D, 2005, EUR J CLIN PHARMACOL, V61, P873, DOI 10.1007/s00228-005-0043-5
   Kubitza D, 2008, CURR MED RES OPIN, V24, P2757, DOI 10.1185/03007990802361499 
   Lloyd-Jones DM, 2004, CIRCULATION, V110, P1042, DOI 10.1161/01.CIR.0000140263.20897.42
   Lu GM, 2013, NAT MED, V19, P446, DOI 10.1038/nm.3102
   Mahaffey KW, 2013, ANN INTERN MED, V158, P861, DOI 10.7326/0003-4819-158-12-201306180-00003
   Mahaffey KW, 2011, CIRCULATION S, V124
   Mahlmann A, 2013, J THROMB THROMBOLYS, V36, P533, DOI 10.1007/s11239-013-0891-2
   Makaryus JN, 2013, NAT REV CARDIOL, V10, P397, DOI 10.1038/nrcardio.2013.73
   Mani H, 2012, THROMB HAEMOSTASIS, V108, P191, DOI 10.1160/TH11-12-0832
   Mani H, 2011, THROMB HAEMOSTASIS, V106, P156, DOI 10.1160/TH10-10-0667
   Marini C, 2005, STROKE, V36, P1115, DOI 10.1161/01.STR.0000166053.83476.4a
   Mercury Pharmaceuticals Ltd, 2013, WARF 0 5 MG TABL SUM
   Mueck W, 2008, THROMB HAEMOSTASIS, V100, P453, DOI 10.1160/07-12-0714
   Mueck W, 2008, CLIN PHARMACOKINET, V47, P203
   Mueck W, 2011, CLIN PHARMACOKINET, V50, P675, DOI 10.2165/11595320-000000000-00000
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Perzborn E, 2013, THROMB HAEMOSTASIS, V110, P162, DOI 10.1160/TH12-12-0907
   Perzborn E, 2011, NAT REV DRUG DISCOV, V10, P61, DOI 10.1038/nrd3185
   Portola Pharmaceuticals, PHAS 2 HLTH VOL STUD
   Samama MM, 2012, CLIN APPL THROMB-HEM, V18, P150, DOI 10.1177/1076029611426282
   Samama MM, 2010, THROMB HAEMOSTASIS, V103, P815, DOI 10.1160/TH09-03-0176
   Steger C, 2004, EUR HEART J, V25, P1734, DOI 10.1016/j.ehj.2004.06.030
   Turpie AGG, 2012, THROMB HAEMOSTASIS, V108, P876, DOI 10.1160/TH12-03-0209
   van Diepen S, 2013, CIRC-HEART FAIL, V6, P740, DOI 10.1161/CIRCHEARTFAILURE.113.000212
   WOLF PA, 1991, STROKE, V22, P983
   You JJ, 2012, CHEST, V141, pE531S, DOI 10.1378/chest.11-2304
NR 55
TC 5
Z9 5
U1 0
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176-6336
EI 1178-203X
J9 THER CLIN RISK MANAG
JI Therap. Clin. Risk Manag.
PY 2014
VL 10
BP 197
EP 205
DI 10.2147/TCRM.S30159
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AD3YQ
UT WOS:000333182800001
PM 24711702
ER


PT J
AU Scursoni, JA
   Gigon, R
   Martin, AN
   Vigna, M
   Leguizamon, ES
   Istilart, C
   Lopez, R
AF Scursoni, Julio A.
   Gigon, Ramon
   Martin, Andres N.
   Vigna, Mario
   Leguizamon, Eduardo S.
   Istilart, Carolina
   Lopez, Ricardo
TI Changes in Weed Communities of Spring Wheat Crops of Buenos Aires
   Province of Argentina
SO WEED SCIENCE
LA English
DT Article
DE Floristic composition; tillage systems weed shifts; weed survey
ID VERTICAL-DISTRIBUTION; SEEDLING RECRUITMENT; TILLAGE SYSTEMS; ASSEMBLY
   THEORY; ARABLE FIELDS; SOIL; MANAGEMENT; DIVERSITY; ROTATION; FLORA
AB During 2004 to 2008, weed surveys were conducted in 373 wheat fields of two different cropped areas (southwest [SW] and southeast [SE]) of the southern region of Buenos Aires Province of Argentina where different weed communities were expected because of changes in cropping practices over time, including tillage, crop sequence, fertilizers, and herbicides applied. Weed communities differed between regions, with greater numbers of native species for the SW. Weed community diversity was also greater for the SW region, probably due to the more diverse land use that resulted in greater landscape heterogeneity. Rush skeletonweed, sand rocket, yellow starthistle and turnipseed occurred at higher constancy (proportion of fields in which a given species is present) in the SW region, whereas common chickweed, false bishop's weed, corn speedwell, and common lambsquarters were present more frequently in the SE region. Compared with the 1982 survey, constancy of weeds increased, but those species with high constancy in 1982 were also with high constancy in the recent surveys. Diversity (species richness) was greater in conventional than in a no-tillage system. The constancy of Italian ryegrass, sand rocket, and yellow starthistle was lower under no-till than conventional tillage. Surveys allow identification of changes in weed community related to different agricultural systems. Rotation of crops and livestock avoid the homogenization of the environment at the landscape level. Management strategies will be necessary to prevent the increase of weeds populations' size, preserving plant diversity and the properties of the agroecosystem.
C1 [Scursoni, Julio A.; Martin, Andres N.] Univ Buenos Aires, Fac Agron, Dept Prod Vegetal, RA-1417 Buenos Aires, DF, Argentina.
   [Gigon, Ramon; Vigna, Mario; Lopez, Ricardo] Inst Nacl Tecnol Agr, Estn Expt Agr Bordenave, RA-8187 Buenos Aires, DF, Argentina.
   [Leguizamon, Eduardo S.] Univ Nacl Rosario, Fac Ciencias Agr, Catedra Malezas, RA-2125 Santa Fe, NM, Argentina.
   [Istilart, Carolina] INTA, Estac Expt Agropecuaria Barrow, RA-7500 Buenos Aires, DF, Argentina.
RP Scursoni, JA (reprint author), Univ Buenos Aires, Fac Agron, Dept Prod Vegetal, Av San Martin 4453, RA-1417 Buenos Aires, DF, Argentina.
EM scursoni@agro.uba.ar
FU Proyecto UBACyT [G019, 00440]
FX This work was supported by Proyecto UBACyT (G019 Prog. Cientifica
   2008-011 and 00440 Prog. Cientifica 2011-014) (University of Buenos
   Aires). We thank D. Desmery, J. Doeyo, R. Grosse, J. Ustarroz, Coop.
   Agrop. Gral. Necochea, Agro El Carretero S. A., and Syngenta Agro S. A.
   for providing logistical and assistance support for the surveys. We also
   thank Frank Forcella and Claudio Ghersa for reading and making
   suggestions on the manuscript.
CR Altieri MA, 1999, AGR ECOSYST ENVIRON, V74, P19, DOI 10.1016/S0167-8809(99)00028-6
   Andreasen C, 1996, J APPL ECOL, V33, P619, DOI 10.2307/2404990
   Booth BD, 2002, WEED SCI, V50, P2, DOI 10.1614/0043-1745(2002)050[0002:AIATAT]2.0.CO;2
   Catullo JC, 1983, P 9 REUN ARG MAL CON, P204
   Chaneton EJ, 2006, CIENCIA HOY, V16, P18
   Chauhan BS, 2006, WEED SCI, V54, P658, DOI 10.1614/WS-05-135R.1
   Chauhan BS, 2006, WEED SCI, V54, P669, DOI 10.1614/WS-05-184R.1
   Cobb AH, 2000, HERBICIDES THEIR MEC, P1
   Cruzate G, 2008, SUELOS AMBIENTES BUE
   de la Fuente EB, 2006, AGR ECOSYST ENVIRON, V115, P229, DOI 10.1016/j.agee.2006.01.009
   Doucet C, 1999, WEED SCI, V47, P729
   [EPPO] Plant Protection Thesaurus, 2011, PLANT PROT THES
   [FAO] Organizacion de las Naciones Unidas para la Agricultura y la Alimentacion Roma, 2004, ORG NAC UN AGR AL RO
   Gabriel D, 2005, PERSPECT PLANT ECOL, V7, P85, DOI 10.1016/j.ppees.2005.04.001
   Ghersa Claudio M., 1999, V16, P487
   Ghersa CM, 2000, FIELD CROP RES, V67, P141, DOI 10.1016/S0378-4290(00)00089-7
   Ghersa C.M., 1998, HACIA AGR PRODUCTIVA, P38
   Hanf M, 1983, ARABLE WEEDS EUROPE
   Heap I, 2012, INT SURVEY HERBICIDE
   Hierro JL, 2006, AM NAT, V168, P144, DOI 10.1086/505767
   Leemis LM, 1996, AM STAT, V50, P63, DOI 10.2307/2685046
   Legere A, 2004, WEED SCI, V52, P881, DOI 10.1614/WS-04-011R
   Legere A, 2008, WEED TECHNOL, V22, P309, DOI 10.1614/WT-07-124.1
   Martinez-Ghersa MA, 2000, FIELD CROP RES, V67, P181, DOI 10.1016/S0378-4290(00)00092-7
   Mas MT, 2010, WEED RES, V50, P320, DOI 10.1111/j.1365-3180.2010.00785.x
   McCune B, 1999, PC ORD MULTIVARIATE
   [MDA] Ministerio de Agricultura Ganaderia y Pesca de la Republica Argentina, 2011, SIST INT INF AGR
   Mohler CL, 1997, WEED RES, V37, P147, DOI 10.1046/j.1365-3180.1997.d01-21.x
   SCOPEL AL, 1994, NEW PHYTOL, V126, P145, DOI 10.1111/j.1469-8137.1994.tb07540.x
   SCOPEL AL, 1991, PLANT CELL ENVIRON, V14, P501, DOI 10.1111/j.1365-3040.1991.tb01520.x
   Scursoni J., 1995, Revista de la Facultad de Agronomia (La Plata), V71, P235
   Scursoni J. A., 2007, Revista de la Facultad de Agronomia (Universidad de Buenos Aires), V27, P251
   SORIANO A., 1965, Ciencia e investigacion, V21, P259
   Sosnoskie LM, 2006, WEED SCI, V54, P263
   Spafford JH, 2006, WEED SCI, V54, P148
   Stevenson FC, 1997, WEED SCI, V45, P798
   Storkey J, 2006, WEED RES, V46, P513, DOI 10.1111/j.1365-3180.2006.00528.x
   Storkey J, 2010, WEED SCI, V58, P39, DOI 10.1614/WS-09-096.1
   Suarez SA, 2000, 3 INT WEED SCI C FOZ
   Tuesca D, 2001, WEED RES, V41, P369, DOI 10.1046/j.1365-3180.2001.00245.x
   Van Acker RC, 2000, CAN J PLANT SCI, V80, P963
   Vitta JI, 2004, AGR ECOSYST ENVIRON, V103, P621, DOI 10.1016/j.agee.2003.10.016
   WAPSHERE AJ, 1976, J APPL ECOL, V13, P545, DOI 10.2307/2401802
   Webster TM, 2001, WEED TECHNOL, V15, P771, DOI 10.1614/0890-037X(2001)015[0771:ASOWIV]2.0.CO;2
   Westerman PR, 2009, WEED RES, V49, P142, DOI 10.1111/j.1365-3180.2008.00684.x
   YENISH JP, 1992, WEED SCI, V40, P429
   ZADOKS JC, 1974, WEED RES, V14, P415, DOI 10.1111/j.1365-3180.1974.tb01084.x
   ZIMMERMAN GM, 1985, ECOLOGY, V66, P606, DOI 10.2307/1940409
NR 48
TC 2
Z9 2
U1 1
U2 5
PU WEED SCI SOC AMER
PI LAWRENCE
PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA
SN 0043-1745
EI 1550-2759
J9 WEED SCI
JI Weed Sci.
PD JAN-MAR
PY 2014
VL 62
IS 1
BP 51
EP 62
DI 10.1614/WS-D-12-00141.1
PG 12
WC Agronomy; Plant Sciences
SC Agriculture; Plant Sciences
GA 294HO
UT WOS:000330036100008
ER


PT J
AU Savelieva, I
   Camm, AJ
AF Savelieva, Irene
   Camm, A. John
TI Practical Considerations for Using Novel Oral Anticoagulants in Patients
   With Atrial Fibrillation
SO CLINICAL CARDIOLOGY
LA English
DT Review
ID RE-LY TRIAL; HEART RHYTHM ASSOCIATION; ACUTE CORONARY SYNDROME;
   TRANSIENT ISCHEMIC ATTACK; DIRECT THROMBIN INHIBITOR; CARDIOLOGY WORKING
   GROUP; ROCKET AF TRIAL; STROKE PREVENTION; DABIGATRAN ETEXILATE;
   RANDOMIZED EVALUATION
AB Novel oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, represent new options for preventing stroke in patients with atrial fibrillation, as shown by the results from large, randomized phase III trials. Because of their greater specificity, rapid onset of action, and predictable pharmacokinetics, the novel oral anticoagulants (dabigatran, rivaroxaban, and apixaban) address several limitations of warfarin or other vitamin K antagonists in day-to-day clinical practice. However, a range of practical questions relating to the novel oral anticoagulants has emerged, including topics such as patient selection, treatment of patients with renal impairment, risk of myocardial infarction, drug interactions, switching between anticoagulants, and management of bleeding, in addition to use of these agents in patients requiring antiplatelet drug treatment or undergoing cardioversion or percutaneous interventions (eg, ablation). In this review, practical aspects of the use of novel oral anticoagulants in patients with atrial fibrillation are discussed, with reference to available data and guidance from prescribing information.
C1 [Savelieva, Irene; Camm, A. John] St Georges Univ London, Div Cardiac & Vasc Sci, London SW17 0RE, England.
RP Camm, AJ (reprint author), St Georges Univ London, Div Clin Sci, Cranmer Terrace, London SW17 0RE, England.
EM jcamm@sgul.ac.uk
FU Bayer HealthCare Pharmaceuticals; Janssen Janssen Scientific Affairs,
   LLC.
FX The authors acknowledge Jeremy Gardner and Geraint Owens, who provided
   medical writing services with funding from Bayer HealthCare
   Pharmaceuticals and Janssen Janssen Scientific Affairs, LLC.
CR Alexander JH, 2012, J AM COLL CARDIOL, V59, pE1697
   Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819
   Ansell J, 2010, HEMATOL-AM SOC HEMAT, P221, DOI 10.1182/asheducation-2010.1.221
   ARNOLD AZ, 1992, J AM COLL CARDIOL, V19, P851
   Baker WL, 2012, CIRC-CARDIOVASC QUAL, V5, P711, DOI 10.1161/CIRCOUTCOMES.112.966572
   Barrett YC, 2010, THROMB HAEMOSTASIS, V104, P1263, DOI 10.1160/TH10-05-0328
   Beasley BN, 2011, NEW ENGL J MED, V364, P1788, DOI 10.1056/NEJMp1103050
   Bin Abdulhak AA, 2013, EUROPACE, V15, P1412, DOI 10.1093/europace/eut239
   Boehringer Ingelheim International GmbH, 2013, PRAD DAB ET SUMM PRO
   Boehringer Ingelheim Pharmaceuticals Inc, 2012, PRAD DAB PRESCR INF
   Bristol-Myers Squibb, 2013, PFIZ EEIG EL AP SUMM
   Bristol-Myers Squibb Company, 2012, EL AP PRESCR INF
   Camm AJ, 2012, EUROPACE, V14, P1385, DOI 10.1093/europace/eus305
   Camm AJ, 2010, EUROPACE, V12, P1360, DOI 10.1093/europace/euq350
   Coleman CI, 2012, J MANAGE CARE PHARM, V18, P527
   Coleman CI, 2012, CURR MED RES OPIN, V28, P669, DOI 10.1185/03007995.2012.677419
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Cotton BA, 2011, NEW ENGL J MED, V365, P2039, DOI 10.1056/NEJMc1111095
   Diener HC, 2010, LANCET NEUROL, V9, P1157, DOI 10.1016/S1474-4422(10)70274-X
   Easton JD, 2012, LANCET NEUROL, V11, P503, DOI 10.1016/S1474-4422(12)70092-3
   Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Eikelboom JW, 2010, AM HEART J, V159, P348, DOI 10.1016/j.ahj.2009.08.026
   Eriksson BI, 2011, ANNU REV MED, V62, P41, DOI 10.1146/annurev-med-062209-095159
   Ezekowitz MD, 2010, CIRCULATION, V122, P2246, DOI 10.1161/CIRCULATIONAHA.110.973735
   Ezekowitz MD, 2009, AM HEART J, V157, P805, DOI 10.1016/j.ahj.2009.02.005
   Flaker G, 2012, EUR HEART J, V33, P686
   Fox KAA, 2011, EUR HEART J, V32, P2387, DOI 10.1093/eurheartj/ehr342
   Furie KL, 2012, STROKE, V43, P3442, DOI 10.1161/STR.0b013e318266722a
   Fuster V, 2011, CIRCULATION, V123, pE269, DOI 10.1161/CIR.0b013e318214876d
   Garcia DA, 2012, CIRCULATION S, V126
   Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Halperin JL, 2012, STROKE, V43, pA148
   Hankey GJ, 2012, LANCET NEUROL, V11, P315, DOI 10.1016/S1474-4422(12)70042-X
   Harder S, 2012, J CLIN PHARMACOL, V52, P964, DOI 10.1177/0091270011409231
   Hariharan S, 2012, J CLIN PHARMACOL, V52, p119S, DOI 10.1177/0091270011415527
   Harper P, 2012, NEW ENGL J MED, V366, P864, DOI 10.1056/NEJMc1112874
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Hart RG, 2012, STROKE, V43, P1511, DOI 10.1161/STROKEAHA.112.650614
   Haynes RB, 2008, COCHRANE DB SYST REV, V2, P2, DOI DOI 10.1002/14651858.CD000011.PUB3
   Healey JS, 2012, CIRCULATION, V126, P343, DOI 10.1161/CIRCULATIONAHA.111.090464
   Heeringa J, 2006, EUR HEART J, V27, P949, DOI 10.1093/eurheartj/ehi825
   Heidbuchel H, 2013, EUROPACE, V15, P625, DOI 10.1093/europace/eut083
   Hohnloser SH, 2013, EUROPACE, V15, P1407, DOI 10.1093/europace/eut241
   Hohnloser SH, 2012, CIRCULATION, V125, P669, DOI 10.1161/CIRCULATIONAHA.111.055970
   Janssen Pharmaceuticals Inc, 2013, XAR RIV PRESCR INF
   Jorgensen HS, 1996, STROKE, V27, P1765
   Lamassa M, 2001, STROKE, V32, P392
   Lehr T, 2011, J CLIN PHARMACOL, V52, P1373
   Lindhoff-Last E, 2010, THER DRUG MONIT, V32, P673, DOI 10.1097/FTD.0b013e3181f2f264
   Lip GYH, 2012, J AM COLL CARDIOL, V60, P738, DOI 10.1016/j.jacc.2012.03.019
   Lip GYH, 2011, EUROPACE, V13, P723, DOI 10.1093/europace/eur126
   Lip GYH, 2010, EUR HEART J, V31, P1311, DOI 10.1093/eurheartj/ehq117
   Lopes RD, 2010, AM HEART J, V159, P331, DOI 10.1016/j.ahj.2009.07.035
   Mahaffey KW, 2012, P EUR STROK C MAY 22
   Marlu R, 2012, THROMB HAEMOSTASIS, V108, P217, DOI 10.1160/TH12-03-0179
   Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277
   Miller CS, 2012, AM J CARDIOL, V110, P453, DOI 10.1016/j.amjcard.2012.03.049
   Mueck W, 2011, CLIN PHARMACOKINET, V50, P675, DOI 10.2165/11595320-000000000-00000
   Naccarelli GV, 2009, AM J CARDIOL, V104, P1534, DOI 10.1016/j.amjcard.2009.07.022
   Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546
   Nematullah A, 2009, J CAN DENT ASSOC, V75, P41
   Oldgren J, 2011, EUR HEART J, V32, P2781, DOI 10.1093/eurheartj/ehr113
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Peacock WF, 2012, CLIN CARDIOL, V35, P730, DOI 10.1002/clc.22037
   Bayer Pharma AG, 2013, XARELTO RIVAROXABAN
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Rasmussen LH, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7097
   Reynolds MW, 2004, CHEST, V126, P1938, DOI 10.1378/chest.126.6.1938
   ROCKET AF Study Investigators, 2010, AM HEART J, V159, P340
   Saini SD, 2009, AM J MANAG CARE, V15, pE22
   Samama MM, 2010, THROMB HAEMOSTASIS, V103, P815, DOI 10.1160/TH09-03-0176
   Schneeweiss S, 2012, CIRC-CARDIOVASC QUAL, V5, P480, DOI 10.1161/CIRCOUTCOMES.112.965988
   Skanes AC, 2012, CAN J CARDIOL, V28, P125, DOI 10.1016/j.cjca.2012.01.021
   Stangier J, 2007, BRIT J CLIN PHARMACO, V64, P292, DOI 10.1111/j.1365-2125.2007.02899.x
   Uchino K, 2012, ARCH INTERN MED, V172, P397, DOI 10.1001/archinternmed.2011.1666
   van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758
   Wallentin L, 2010, LANCET, V376, P975, DOI 10.1016/S0140-6736(10)61194-4
   Wann LS, 2011, CIRCULATION, V123, P1144, DOI 10.1161/CIR.0b013e31820f14c0
   Watanabe M, 2012, NEUROCRIT CARE, V16, P203, DOI 10.1007/s12028-011-9591-y
   Wilcox Ryan, 2011, Hosp Pract (1995), V39, P23, DOI 10.3810/hp.2011.08.576
   WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561
   WOLF PA, 1991, STROKE, V22, P983
   You JJ, 2012, CHEST S, V141, pe531S, DOI DOI 10.1378/CHEST.11-2304
NR 88
TC 36
Z9 37
U1 2
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
EI 1932-8737
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD JAN
PY 2014
VL 37
IS 1
BP 32
EP 47
DI 10.1002/clc.22204
PG 16
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 287LX
UT WOS:000329544400003
PM 24254991
ER


PT J
AU Tsirogiannis, IL
   Katsoulas, N
   Savvas, D
   Karras, G
   Kittas, C
AF Tsirogiannis, I. L.
   Katsoulas, N.
   Savvas, D.
   Karras, G.
   Kittas, C.
TI Relationships between Reflectance and Water Status in a Greenhouse
   Rocket (Eruca sativa Mill.) Cultivation
SO EUROPEAN JOURNAL OF HORTICULTURAL SCIENCE
LA English
DT Article
DE crop coefficient; crop water stress; evapotranspiration index; spectral
   index
ID STRESS DETECTION; INDEX; TEMPERATURE; LEAVES; PLANTS; LIGHT
AB Crop water status is an important parameter for plant growth and yield performance in greenhouses, and thus early detection of water stress is essential for efficient crop management. Therefore, the aim of this work was to study the relationship between crop reflectance and common soil and crop water status indicators. Two different irrigation regimes, namely 50 and 100 % of the crop potential evapotranspiration were imposed to rocket plants (Eruca sativa Mill.) grown in pots filled with soil inside a greenhouse. Leaf area index and mid-season crop coefficient, which are essential for irrigation schedulling were estimated. Crop reflectance indices were calculated using the radiation reflected by the crop in 8 narrow wavelength bands (10 nm in width), centred at 460, 510, 560, 610, 660, 710, 760 and 810 nm. Canopy reflection measurements were carried out during July and August 2010 in a greenhouse located in Arta, Greece. The results showed that crop reflectance to radiation ranging from 510 to 710, and at 810 rim, is strongly related to water stress in rocket plants. Crop reflectance has not been extensively studied under greenhouse conditions and seems to be a promising, easy-to-use, non-contact and non-destructive tool for crop water status assessment.
C1 [Tsirogiannis, I. L.; Karras, G.] Technol Educ Inst Epirus, Fac Agr Technol, Dept Floriculture & Landscape Architecture, GR-47100 Arta, Greece.
   [Katsoulas, N.; Kittas, C.] Univ Thessaly, Sch Agr Sci, Dept Agr Crop Prod & Rural Environm, GR-38446 Magnisia, Greece.
   [Savvas, D.] Agr Univ Athens, Dept Crop Sci, GR-11855 Athens, Greece.
RP Tsirogiannis, IL (reprint author), Technol Educ Inst Epirus, Fac Agr Technol, Dept Floriculture & Landscape Architecture, TEIEP Kostakioi Campus, GR-47100 Arta, Greece.
EM itsirog@teiep.gr
OI Savvas, Dimitrios/0000-0002-0064-7985
CR Akoumianakis KA, 2008, J FOOD AGRIC ENVIRON, V6, P206
   Allen R. G., 1998, FAO Irrigation and Drainage Paper
   Baille A, 2001, AGR FOREST METEOROL, V107, P293, DOI 10.1016/S0168-1923(01)00216-7
   Barton CVM, 2001, REMOTE SENS ENVIRON, V78, P264, DOI 10.1016/S0034-4257(01)00224-3
   Ceccato P, 2002, REMOTE SENS ENVIRON, V82, P188, DOI 10.1016/S0034-4257(02)00037-8
   Chaves MM, 2002, ANN BOT-LONDON, V89, P907, DOI 10.1093/aob/mcf105
   CURE WW, 1989, REMOTE SENS ENVIRON, V29, P273, DOI 10.1016/0034-4257(89)90006-0
   Dane J. H., 2002, SOIL SCI SOC AM BOOK, V5
   Decagon Devices, 2011, SPECTR REFL SENS SRS
   Erdem Y, 2010, AGR WATER MANAGE, V98, P148, DOI 10.1016/j.agwat.2010.08.013
   Fernandez MD, 2010, IRRIGATION SCI, V28, P497, DOI 10.1007/s00271-010-0210-z
   Grant OM, 2006, PHYSIOL PLANTARUM, V127, P507, DOI 10.1111/j.1399-3054.2006.00686.x
   JACKSON RD, 1981, WATER RESOUR RES, V17, P1133, DOI 10.1029/WR017i004p01133
   Jacquemoud S, 2009, REMOTE SENS ENVIRON, V113, pS56, DOI 10.1016/j.rse.2008.01.026
   Jones H. G., 2008, General and Applied Plant Physiology, V34, P19
   Kacira Murat, 2005, Journal of Agricultural Meteorology, V61, P15, DOI 10.2480/agrmet.61.15
   Katsoulas N, 2009, SCI HORTIC-AMSTERDAM, V123, P90, DOI 10.1016/j.scienta.2009.08.004
   KNIPLING E B, 1970, Remote Sensing of Environment, V1, P155, DOI 10.1016/S0034-4257(70)80021-9
   Koksal ES, 2011, IRRIG DRAIN, V60, P187, DOI 10.1002/ird.558
   Nicola S, 2003, ACTA HORTIC, P685
   Norikane JH, 2001, T ASAE, V44, P1915
   Omirou M., 2009, THESIS AGR U ATHENS
   Padulosi S., 1995, 1 M 13 15 NOV 1994 L
   Padulosi S., 1996, WORKSH 13 14 DEC 199
   PENUELAS J, 1994, REMOTE SENS ENVIRON, V48, P135, DOI 10.1016/0034-4257(94)90136-8
   PISIMANIS D, 1987, SOL ENERGY, V39, P159, DOI 10.1016/S0038-092X(87)80024-5
   Sarlikioti V, 2010, ANN APPL BIOL, V157, P81, DOI 10.1111/j.1744-7348.2010.00411.x
   Schlemmer MR, 2005, AGRON J, V97, P106
   Suarez L, 2009, REMOTE SENS ENVIRON, V113, P730, DOI 10.1016/j.rse.2008.12.001
   Wheeler R.M., 2006, POTATO RES, V49, P67, DOI DOI 10.1007/S11540-006-9003-4
   Zakaluk R., 2008, CAN BIOS ENG, V50, P71
   Zakaluk R., 2007, POTATO RES, V49, P255, DOI 10.1007/s11540-007-9021-x
NR 32
TC 2
Z9 3
U1 0
U2 4
PU INT SOC HORTICULTURAL SCIENCE-ISHS
PI LEUVEN
PA PO BOX 500, LEUVEN, 3001, BELGIUM
SN 1611-4426
EI 1611-4434
J9 EUR J HORTIC SCI
JI Eur. J. Hortic. Sci.
PD DEC
PY 2013
VL 78
IS 6
BP 275
EP 282
PG 8
WC Horticulture
SC Agriculture
GA 300ZV
UT WOS:000330503400005
ER


PT J
AU Piccini, JP
   Garg, J
   Patel, MR
   Lokhnygina, Y
   Goodman, SG
   Becker, RC
   Berkowitz, SD
   Breithardt, G
   Hacke, W
   Halperin, JL
   Hankey, GI
   Nessel, CC
   Mahaffey, KW
   Singer, DE
   Califf, RM
   Fox, KA
AF Piccini, Jonathan P.
   Garg, Jyotsna
   Patel, Manesh R.
   Lokhnygina, Yuliya
   Goodman, Shaun G.
   Becker, Richard C.
   Berkowitz, Scott D.
   Breithardt, Gunter
   Hacke, Werner
   Halperin, Jonathan L.
   Hankey, Graeme I.
   Nessel, Christopher C.
   Mahaffey, Kenneth W.
   Singer, Daniel E.
   Califf, Robert M.
   Fox, Keith A.
TI Management of Major Bleeding Events in Patients Treated With Rivaroxaban
   Versus Warfarin: Results From the ROCKET AF Trial
SO CIRCULATION
LA English
DT Meeting Abstract
CT Scientific Sessions and Resuscitation Science Symposium of the
   American-Heart-Association
CY NOV 16-17, 2013
CL Dallas, TX
SP Amer Heart Assoc
DE Atrial fibrillation; Stroke; Risk factors
C1 [Piccini, Jonathan P.; Patel, Manesh R.; Becker, Richard C.; Mahaffey, Kenneth W.] Duke Clin Rsch Inst, Dept Med, Div Cardiol, Durham, NC USA.
   [Garg, Jyotsna] Duke Clin Rsch Inst, Stat Grp, Durham, NC USA.
   [Lokhnygina, Yuliya] Duke Clin Rsch Inst, Dept Biostat & Bioinformat, Durham, NC USA.
   [Goodman, Shaun G.] Univ Toronto, St Michaels Hosp, Canadian Heart Rsch Cntr, Toronto, ON, Canada.
   [Goodman, Shaun G.] Terrence Donnelly Heart Cntr, Toronto, ON, Canada.
   [Berkowitz, Scott D.] Bayer HealthCare Pharmaceut, Global Therapeut Rsch, Cardiovasc Pharmacol, Montville, NJ USA.
   [Breithardt, Gunter] Hosp Univ Munster, Dept Cardiol & Angiol, Munster, Germany.
   [Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany.
   [Halperin, Jonathan L.] Mt Sinai, Icahn Sch Med, Mt Sinai Med Cntr, Cardiovasc Inst, New York, NY USA.
   [Hankey, Graeme I.] Univ Western Australia, Sch Med & Pharmacol, Dept Neurol, Perth, WA 6009, Australia.
   [Hankey, Graeme I.] Royal Perth Hosp, Stroke Unit, Perth, WA 6001, Australia.
   [Nessel, Christopher C.] Janssen Rsch & Dev, Clin Rsch, Raritan, NJ USA.
   [Singer, Daniel E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
   [Califf, Robert M.] Duke Translat Med Inst, Dept Med, Div Cardiol, Durham, NC USA.
   [Fox, Keith A.] Univ Edinburgh, Cntr Cardiovasc Sci, Edinburgh, Midlothian, Scotland.
   [Fox, Keith A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
RI Hankey, Graeme /H-4968-2014
OI Hankey, Graeme /0000-0002-6044-7328
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
EI 1524-4539
J9 CIRCULATION
JI Circulation
PD NOV 26
PY 2013
VL 128
IS 22
SU S
MA 15879
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AC0CR
UT WOS:000332162905238
ER


PT J
AU DeLuca, LT
   Bernelli, F
   Maggi, F
   Tadini, P
   Pardini, C
   Anselmo, L
   Grassi, M
   Pavarin, D
   Francesconi, A
   Branz, F
   Chiesa, S
   Viola, N
   Bonnal, C
   Trushlyakov, V
   Belokonov, I
AF DeLuca, L. T.
   Bernelli, F.
   Maggi, F.
   Tadini, P.
   Pardini, C.
   Anselmo, L.
   Grassi, M.
   Pavarin, D.
   Francesconi, A.
   Branz, F.
   Chiesa, S.
   Viola, N.
   Bonnal, C.
   Trushlyakov, V.
   Belokonov, I.
TI Active space debris removal by a hybrid propulsion module
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Active debris removal; Debris rendezvous; Adhesive debris capture;
   De-orbiting strategy; De-orbiting; Hybrid propulsion module
ID ELECTRODYNAMIC TETHERS; EARTH-ORBIT; IN-ORBIT; SURVIVABILITY; EVOLUTION
AB During the last 40 years, the mass of the artificial objects in orbit increased quite steadily at the rate of about 145 metric tons annually, leading to a total tally of approximately 7000 metric tons. Now, most of the cross-sectional area and mass (97% in LEO) is concentrated in about 4600 intact objects, i.e. abandoned spacecraft and rocket bodies, plus a further 1000 operational spacecraft Simulations and parametric analyses have shown that the most efficient and effective way to prevent the outbreak of a long-term exponential growth of the catalogued debris population would be to remove enough cross-sectional area and mass from densely populated orbits. In practice, according to the most recent NASA results, the active yearly removal of approximately 0.1% of the abandoned intact objects would be sufficient to stabilize the catalogued debris in low Earth orbit, together with the worldwide adoption of mitigation measures. The candidate targets for removal would have typical masses between 500 and 1000 kg, in the case of spacecraft, and of more than 1000 kg, in the case of rocket upper stages. Current data suggest that optimal active debris removal missions should be carried out in a few critical altitude-inclination bands. This paper deals with the feasibility study of a mission in which the debris is removed by using a hybrid propulsion module as propulsion unit Specifically, the engine is transferred from a servicing platform to the debris target by a robotic arm so to perform a controlled disposal. Hybrid rocket technology for de-orbiting applications is considered a valuable option due to high specific impulse, intrinsic safety, thrust throttle ability, low environmental impact and reduced operating costs. Typically, in hybrid rockets a gaseous or liquid oxidizer is injected into the combustion chamber along the axial direction to burn a solid fuel. However, the use of tangential injection on a solid grain Pancake Geometry allows for more compact design of the propulsion unit Only explorative tests were performed in the past on this rocket configuration, which appears to be suitable as de-orbiting system of new satellites as well as for direct application on large debris in the framework of a mission for debris removal. The paper describes some critical aspects of the mission with particular concern to the target selection, the hybrid propulsion module, the operations as well as the systems needed to rendezvous and dock with the target, and the disposal strategy. (C) 2013 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [DeLuca, L. T.; Bernelli, F.; Maggi, F.; Tadini, P.] Politecn Milan, I-20156 Milan, Italy.
   [Pardini, C.; Anselmo, L.] ISTI CNR, I-56124 Pisa, Italy.
   [Grassi, M.] Univ Naples Federico II, I-80125 Naples, Italy.
   [Pavarin, D.; Francesconi, A.; Branz, F.] CISAS G Colombo, I-35131 Padua, Italy.
   [Chiesa, S.; Viola, N.] Politecn Torino, I-10129 Turin, Italy.
   [Bonnal, C.] Ctr Natl Etud Spatiales, F-75039 Paris, France.
   [Trushlyakov, V.] Omsk State Tech Univ, Omsk 644050, Russia.
   [Belokonov, I.] Samara State Aerosp Univ, Samara 443086, Russia.
RP DeLuca, LT (reprint author), Politecn Milan, Via La Masa 34, I-20156 Milan, Italy.
EM luigi.deluca@polimi.it; franco.bernelli@polimi.it;
   filippo.maggi@polimi.it; pietro.tadini@polimi.it;
   carmen.pardini@isti.cnr.it; luciano.anselmo@isti.cnr.it;
   michele.grassi@unina.it; daniele.pavarin@unipd.it;
   alessandro.francesconi@unipd.it; francesco.branz@unipd.it;
   sergio.chiesa@polito.it; nicole.viola@polito.it;
   christophe.bonnal@cnes.fr; trushlyakov@omgtu.ru; acad@ssau.ru
RI Grassi, Michele/I-2379-2012; Bernelli Zazzera, Franco/E-8941-2012;
   Maggi, Filippo/C-7094-2008; DeLuca, Luigi/C-6532-2008; Trushlyakov,
   Valeriy/D-7270-2015; Pardini, Carmen/C-7170-2015; Belokonov,
   Igor/A-4905-2016; Anselmo, Luciano/C-4384-2012; 
OI Francesconi, Alessandro/0000-0001-7987-6117; Maggi,
   Filippo/0000-0001-9657-8955; Tadini, Pietro/0000-0002-7597-6265; Grassi,
   Michele/0000-0001-8480-4353; Bernelli Zazzera,
   Franco/0000-0002-9982-4661; Maggi, Filippo/0000-0003-1548-9542; Pardini,
   Carmen/0000-0001-6060-2335; Belokonov, Igor/0000-0002-5486-8820;
   Anselmo, Luciano/0000-0001-5875-2975; Branz,
   Francesco/0000-0002-3677-1726; Trushlyakov, Valeriy/0000-0002-8444-6880
CR AIAA Technical Committee on Space Systems, 1981, SPAC DEBR AIAA POS P
   Alby F., 2010, P 1 EUR WORKSH ACT D
   Alby F., 2012, P 2 EUR WORKSH ACT D
   Alferez R, 1999, IEEE T PATTERN ANAL, V21, P505, DOI 10.1109/34.771318
   [Anonymous], 2002, AIAA ED SERIES
   Anselmo L, 2005, ACTA ASTRONAUT, V56, P391, DOI 10.1016/j.actaastro.2004.05.067
   Anselmo L, 2001, SCI TECH, V103, P137
   Arianespace, 2006, VEGA USER MANUAL
   Bodin P, 2009, J SPACECRAFT ROCKETS, V46, P615, DOI 10.2514/1.40161
   Bombardelli C., 2010, SPAC DEBR MIT WORKSH
   Bonnal C, 2005, ESA SP PUBL, V587, P361
   Burkhardt H., 2002, 4208 AIAA
   Chiaverini M.J., 2007, AIAA PROGR ASTRONAUT, V218
   Czysz PA, 2006, S-P B ASTRONAUT ENG, P1, DOI 10.1007/3-540-37641-0
   DeLuca L.T., 2012, P 2 EUR WORKSH ACT D
   DeLuca L.T., 2012, ACTIVE SPACE DEBRIS
   European Space Debris Safety and Mitigation Standard Working Group, 2004, EUR COD COND SPAC DE
   [Anonymous], 2006, POS PAP SPAC DEBR MI
   [European Space Agency ESA Space Debris Working Group], 1988, ESA
   Fasano G., 2009, STEREO VISION BASED
   Forward R.L., 1998, CP1998206900 NASA, VNASA CP-1998-206900, P109
   Gibbon D.M., 2001, SPBB2628701 SURR SAT
   Gonzales R. C., 2008, DIGITAL IMAGE PROCES
   [International Academy of Astronautics (IAA) IAA Space Debris Subcommittee], 2001, POS PAP ORB DEBR
   [Inter-Agency Space Debris Coordination Committee (IADC) IADC Steering Group & Working Group 4], 2007, SPAC DEBR MIT GUID
   [Inter-Agency Space Debris Coordination Committee (IADC) IADC Steering Group & Working Group 4], 2002, SPAC DEBR MIT GUID
   Iess L, 2002, ACTA ASTRONAUT, V50, P399, DOI 10.1016/S0094-5765(01)00180-1
   [JSOC (JSpOC) Space-track.org], JSOC JSPOC SPAC TRAC
   Kawamoto S., 2012, 30 IADC PLEN M MONTR
   KESSLER DJ, 1978, J GEOPHYS RES-SPACE, V83, P2637, DOI 10.1029/JA083iA06p02637
   Klinkrad H., 2009, ESA, VESA SP-672
   Klinkrad H., 2011, TECHNICAL REPORT
   Liou JC, 2011, ADV SPACE RES, V47, P1865, DOI 10.1016/j.asr.2011.02.003
   Liou JC, 2009, ACTA ASTRONAUT, V64, P236, DOI 10.1016/j.actaastro.2008.07.009
   Liou JC, 2006, SCIENCE, V311, P340, DOI 10.1126/science1121337
   Liou J.C., 2010, ACTA ASTRONAUT, V66, P236
   Melamed N., 2008, 59 INT ASTR C GLASG, VPaper IAC-08-D4.1.8
   [NASA DARPA], 2006, P INT C ORB DEBR REM
   Nishida S.I., 2003, P 2003 IEEE ASME INT
   Nishida S.I., 2008, ACTA ASTRONAUT, V68, P113
   Ohkawa Y., 2012, 2 EUR WORKSH ACT DEB
   Oki T., 2007, P 2007 IEEE RSJ INT
   Pardini C, 2005, ESA SP PUBL, V587, P353
   Pardini C, 2011, ADV SPACE RES, V48, P557, DOI 10.1016/j.asr.2011.04.006
   Pardini C, 2009, ADV SPACE RES, V44, P545, DOI 10.1016/j.asr.2009.04.014
   Pardini C., 2006, IADC0608
   Pardini C., 2009, ACTA ASTRONAUT, V64, P511
   Pinson R. M., 2008, AIAA GUID NAV CONTR
   Quinlan J.R., 2011, AIAA SPAC 2011 C EXP
   ROSSI A, 1994, J GEOPHYS RES-PLANET, V99, P23195, DOI 10.1029/94JE02320
   Rossi A., 2009, AN MIT MEAS BAS SEM
   Rossi A., 2009, ESA
   Sako H., 1994, P 12 IAPR INT C COMP, V2
   Schonenborg R., 2009, ESA, VESA SP-672
   Tadini P., 2012, 8 INT SCI TECHN C DY
   Diaz Tellez J.P., 2011, P 2001 IEEE INT C RO
   Trushlyakov V., 2010, BEIJ ORB DEBR MIT WO
   [United Nations Committee on the Peaceful Uses of Outer Space (UNCOPUOS) UNCOPUOS Scientific and Technical Sub-committee], 1999, AAC105720 UNCOPUOS
   Uphoff C, 1998, SPACE TECHNOL PROC, V1, P347
   Ventura M., 2007, HIST DISCUSSION HAZA
   Bastida Virgili B., 2009, ESA
   Yoshida K., 2006, P 2006 IEEE RSJ INT
NR 62
TC 16
Z9 16
U1 4
U2 63
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD OCT-NOV
PY 2013
VL 91
BP 20
EP 33
DI 10.1016/j.actaastro.2013.04.025
PG 14
WC Engineering, Aerospace
SC Engineering
GA 207GB
UT WOS:000323585800003
ER


PT J
AU Aslanov, V
   Yudintsev, V
AF Aslanov, Vladimir
   Yudintsev, Vadim
TI Dynamics of large space debris removal using tethered space tug
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Space debris; Attitude motion; Space tug; Tether; Thruster; De-orbit
ID SYSTEM; ORBIT
AB At present, thousands of space debris are located in Earth's orbits. It has a different size ranging from a few millimeters to tens of meters. Tethered systems are promising technology to de-orbit the space debris. The tethers have been proposed for reduction of space debris either through momentum transfer or use of electrodynamic effects. Another possible way to remove the large space debris from the critical areas of near-Earth orbit is using a tethered space tug attached to the space debris. Large space debris can strongly affect the motion of the space tug and the tether during the transportation process, which can lead to the loss of control of the tethered system. The problem of removal of a large space debris from the orbit to the Earth's surface is studied. The space transportation system is composed of two bodies connected by the tether. The first body is a space debris (upper rocket stage or a large nonfunctional satellite) and the second body is a space tug. The spatial motion of the system is studied in the gravity field of the Earth under the action of the space tug thruster, aerodynamic drag and the gravitational torque. Osculating elements of the orbit are used to describe the motion of the center of mass of the system. Particular attention is given to investigate the spatial motion of the space debris relative to the tether and to the space tug. The influence of the initial conditions and the properties of the system on the motion of the system are studied. (C) 2013 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [Aslanov, Vladimir; Yudintsev, Vadim] Samara State Aerosp Univ, Samara, Russia.
RP Aslanov, V (reprint author), Samara State Aerosp Univ, Samara, Russia.
EM aslanov_vs@mail.ru
RI Yudintsev, Vadim/N-1367-2014; Aslanov, Vladimir/G-1367-2013
OI Yudintsev, Vadim/0000-0002-3244-017X; 
FU Russian Foundation for Basic Research [12-01-00317-a]
FX This research was supported by Russian Foundation for Basic Research
   (12-01-00317-a).
CR Bastida B., 2009, 5 EUR C SPAC DEBR GE
   Bischof B, 2004, SCI TECH, V109, P183
   Braun V., ADV SPACE RES, DOI DOI 10.1016/J.ASR.2012.12.003)
   Cougnet C., 2012, 63 INT ASTR C 1 5 OC
   DeLuca L.T., 2012, 63 INT ASTR C 1 5 OC
   Elyasberg P.E., 1965, VVEDENIE TEORIYU POL, P303
   Hoyt R.P., 2009, AIAA SPAC 2009 C, P6733
   Jasper L., 2012, AAS AIAA ASTR SPEC C
   Kaiser C., 2012, 63 INT ASTR C 1 5 OC
   Liou J.C., 2008, ACTA ASTRONAUT, V64, P236
   Mankala KK, 2004, MULTIBODY SYST DYN, V11, P235, DOI 10.1023/B:MUBO.0000029393.25494.64
   Nishida SI, 2011, ACTA ASTRONAUT, V68, P113, DOI 10.1016/j.actaastro.2010.06.045
   Nishida SI, 2009, ACTA ASTRONAUT, V65, P95, DOI 10.1016/j.actaastro.2009.01.041
   Schaub H., AIAA417
   Williams P, 2012, RECENT PATENTS SPACE, V2, P22, DOI [10.2174/1877611611202010022, DOI 10.2174/1877611611202010022]
   Wittenburg J., 2008, DYNAMICS MULTIBODY S
   Yamaigiwa Y, 2005, AEROSP SCI TECHNOL, V9, P366, DOI 10.1016/j.ast.2004.09.005
NR 17
TC 18
Z9 20
U1 2
U2 47
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD OCT-NOV
PY 2013
VL 91
BP 149
EP 156
DI 10.1016/j.actaastro.2013.05.020
PG 8
WC Engineering, Aerospace
SC Engineering
GA 207GB
UT WOS:000323585800017
ER


PT J
AU Williams, RJ
   Fries, CA
   Midwinter, M
   Lambert, AW
AF Williams, R. J.
   Fries, C. A.
   Midwinter, M.
   Lambert, A. W.
TI Battlefield scrotal trauma: How should it be managed in a deployed
   military hospital?
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Penetrating; Injuries; Scrotum; Genitourinary
ID OPERATION-IRAQI-FREEDOM; UROGENITAL INJURIES; WAR INJURIES; EXPERIENCE
AB Aim: There is little documented advice on the management of scrotal trauma sustained in combat. This paper reviews this injury, its present surgical management and makes recommendations for the future.
   Method: All UK forces sustaining scrotal injuries between 2003 and 2009, in Iraq and Afghanistan, initially treated at a Role 2 (enhanced) or Role 3 deployed military surgical facility were identified from the Joint Theatre Trauma Registry. The cause and extent of the injury, in addition to the surgical management, are reported.
   Results: Twenty-seven patients sustained trauma to their scrotum; improvised explosive device (IED) (n = 21), mine (n = 3), rocket propeller grenade (RPG) (n = 2), mortar round (n = 1). Of those injured by an IED, eleven had traumatic orchidectomies, of which 4 were bilateral, one received fragmentation wounds to the scrotum with a testicular injury that was salvaged and there were six scrotal fragmentation wounds not associated with a testicular injury. Scrotal exploration was performed with testicular salvage in all cases involving mortar, RPG or mines. For all aetiologies the scrotum was debrided with primary closure over a drain (n = 7), debridement and subsequent delayed primary closure (DPC) (n = 4) or healing by secondary intension (n = 6). Skin grafts were applied in two cases of traumatic bilateral orchidectomy. To date there have been two cases of delayed orchidectomy; chronic pain and delayed presentation of a disrupted testis. All reported patients survived.
   Conclusion: The established principles of debridement should be the mainstay of treatment. Testicular ischaemia, a consequence of cord transaction, necessitates orchidectomy. Salvage of the disrupted testis, with debridement and closure of the tunica rather than orchidectomy, should be performed whenever possible, particularly when there is significant bilateral testicular injury. Scrotal wounds can be treated by closure over a drain, DPC or healing by secondary intention. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Williams, R. J.; Fries, C. A.] Inst Naval Med, Gosport PO12 2DL, Hants, England.
RP Williams, RJ (reprint author), Inst Naval Med, Gosport PO12 2DL, Hants, England.
EM Richard.williams8@nhs.net
RI Midwinter, Mark/P-6264-2015
OI Midwinter, Mark/0000-0003-1836-7137
CR Heidarpour A, 1999, MIL MED, V164, P138
   Hodgetts T, 2007, J R Army Med Corps, V153, P252
   Hodgetts T J, 2007, J R Army Med Corps, V153, P299
   Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1
   Hudak SJ, 2005, UROLOGY, V65, P1041, DOI 10.1016/j.urology.2004.11.031
   Hudolin T, 2003, J UROLOGY, V169, P1357, DOI 10.1097/01.ju.0000051220.77880.64
   Jansen JO, 2012, INJURY, V43, P976, DOI 10.1016/j.injury.2011.08.027
   Kelly JF, 2008, J TRAUMA, V64, pS21, DOI 10.1097/TA.0b013e318160b9fb
   National Audit Office, 2010, TREAT INJ ILLN AR MI
   Paquette EL, 2007, J UROLOGY, V177, P2196, DOI 10.1016/j.juro.2007.01.132
   SALVATIERRA O, 1969, J UROLOGY, V101, P615
   Schreiber MA, 2004, CRIT CARE CLIN, V20, P101, DOI 10.1016/S0749-0704(03)00095-2
   Smith Jason, 2007, J R Army Med Corps, V153, P239
   Thompson IM, 1998, J AM COLL SURGEONS, V187, P139, DOI 10.1016/S1072-7515(98)00120-3
   TUCAK A, 1995, J UROLOGY, V153, P121, DOI 10.1097/00005392-199501000-00043
   VUCKOVIC I, 1995, J TRAUMA, V39, P733, DOI 10.1097/00005373-199510000-00023
   Waxman S, 2009, INT J IMPOT RES, V21, P145, DOI 10.1038/ijir.2008.59
NR 17
TC 2
Z9 2
U1 1
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
J9 INJURY
JI Injury-Int. J. Care Inj.
PD SEP
PY 2013
VL 44
IS 9
BP 1246
EP 1249
DI 10.1016/j.injury.2013.02.023
PG 4
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 211VX
UT WOS:000323940600020
PM 23587211
ER


PT J
AU Kaneko, M
   Tanigawa, T
   Hashizume, K
   Kajikawa, M
   Tajiri, M
   Mueck, W
AF Kaneko, Masato
   Tanigawa, Takahiko
   Hashizume, Kensei
   Kajikawa, Mariko
   Tajiri, Masahiro
   Mueck, Wolfgang
TI Confirmation of Model-based Dose Selection for a Japanese Phase III
   Study of Rivaroxaban in Non-valvular Atrial Fibrillation Patients
SO DRUG METABOLISM AND PHARMACOKINETICS
LA English
DT Article
DE PK-PD model; rivaroxaban; Japanese phase III; population PK;
   anticoagulants
ID FACTOR-XA INHIBITOR; POPULATION PHARMACOKINETICS; ANTITHROMBOTIC
   THERAPY; HEALTHY-SUBJECTS; PHARMACODYNAMICS; WARFARIN; STROKE; SAFETY;
   BAY-59-7939; ANTICOAGULATION
AB This study was designed to confirm the appropriateness of the dose setting for a Japanese phase III study of rivaroxaban in patients with non-valvular atrial fibrillation (NVAF), which had been based on model simulation employing phase II study data. The previously developed mixed-effects pharmacokinetic/pharmacodynamic (PK-PD) model, which consisted of an oral one-compartment model parameterized in terms of clearance, volume and a first-order absorption rate, was rebuilt and optimized using the data for 597 subjects from the Japanese phase III study, J-ROCKET AF. A mixed-effects modeling technique in NONMEM was used to quantify both unexplained inter-individual variability and inter-occasion variability, which are random effect parameters. The final PK and PK-PD models were evaluated to identify influential covariates. The empirical Bayes estimates of AUC and C-max from the final PK model were consistent with the simulated results from the Japanese phase II study. There was no clear relationship between individual estimated exposures and safety-related events, and the estimated exposure levels were consistent with the global phase III data. Therefore, it was concluded that the dose selected for the phase III study with Japanese NVAF patients by means of model simulation employing phase II study data had been appropriate from the PK-PD perspective.
C1 [Kaneko, Masato; Tanigawa, Takahiko; Hashizume, Kensei] Bayer Yakuhin Ltd, Clin Pharmacol Asia, Osaka 5300001, Japan.
   [Tanigawa, Takahiko; Mueck, Wolfgang] Bayer HealthCare, Clin Sci, Berlin, Germany.
   [Kajikawa, Mariko; Tajiri, Masahiro] Bayer Yakuhin Ltd, Clin Dev Gen Med, Osaka 5300001, Japan.
RP Kaneko, M (reprint author), Bayer Yakuhin Ltd, Kita Ku, 2-4-9 Umeda, Osaka 5300001, Japan.
EM masato.kaneko@bayer.com
CR Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670
   Atarashi H, 2011, CIRC J, V75, P1328, DOI 10.1253/circj.CJ-10-1119
   Beal S, 2008, NONMEM USERS GUIDES
   BEAL SL, 1982, CRIT REV BIOMED ENG, V8, P195
   Becker R, 2010, AM HEART J, V159, P340
   Camm AJ, 2010, EUR HEART J, V31, P2369, DOI 10.1093/eurheartj/ehq278
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Du Bois D, 1916, ARCH INTERN MED, V17, P863
   Fuster V, 2011, CIRCULATION, V123, pE269, DOI 10.1161/CIR.0b013e318214876d
   Gisleskog PO, 2002, J PHARMACOKINET PHAR, V29, P473, DOI 10.1023/A:1022972420004
   HALLYNCK TH, 1981, BRIT J CLIN PHARMACO, V11, P523
   Hart RG, 2007, NEUROLOGY, V69, P546
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Hylek EM, 2009, J CARDIOVASC MED, V10, P605, DOI 10.2459/JCM.0b013e32832e4954
   Japanese Circulation Society Joint Working Group, 2011, NIHON RINSHO S9, V69, P567
   Kubitza D, 2005, CLIN PHARMACOL THER, V78, P412, DOI 10.1016/j.clpt.2005.06.011
   Kubitza D, 2005, EUR J CLIN PHARMACOL, V61, P873, DOI 10.1007/s00228-005-0043-5
   Kubitza D, 2008, CURR MED RES OPIN, V24, P2757, DOI 10.1185/03007990802361499 
   Kubitza D, 2007, J CLIN PHARMACOL, V47, P218, DOI 10.1177/0091270006296058
   Lopes RD, 2010, AM HEART J, V159, P331, DOI 10.1016/j.ahj.2009.07.035
   Mueck W, 2007, INT J CLIN PHARM TH, V45, P335
   Mueck W, 2008, THROMB HAEMOSTASIS, V100, P453, DOI 10.1160/07-12-0714
   Mueck W, 2008, CLIN PHARMACOKINET, V47, P203
   Mueck W, 2011, CLIN PHARMACOKINET, V50, P675, DOI 10.2165/11595320-000000000-00000
   Ogawa S, 2010, CIRC J, V74, P2479, DOI 10.1253/circj.CJ-88-0001
   Ohsawa M, 2005, J EPIDEMIOL, V15, P194, DOI 10.2188/jea.15.194
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Rohde G, 2008, J CHROMATOGR B, V872, P43, DOI 10.1016/j.jchromb.2008.07.015
   Ruff CT, 2010, AM HEART J, V160, P635, DOI 10.1016/j.ahj.2010.06.042
   Samama MM, 2010, THROMB HAEMOSTASIS, V103, P815, DOI 10.1160/TH09-03-0176
   Singer DE, 2008, CHEST, V133, p546S, DOI 10.1378/chest.08-0678
   Tanigawa T., 2012, DRUG METAB PHARMACOK, V28, P59
   Tanizaki Y, 2000, STROKE, V31, P2616
   Zhao X, 2009, BRIT J CLIN PHARMACO, V68, P77, DOI 10.1111/j.1365-2125.2009.03390.x
NR 38
TC 7
Z9 7
U1 0
U2 5
PU JAPANESE SOC STUDY XENOBIOTICS
PI TOKYO
PA INT MED INF CENTER SHINANOMACHI RENGAKAN, 35 SHINANO-MACHI SHINJUKU-KU,
   TOKYO, 160-0016, JAPAN
SN 1347-4367
J9 DRUG METAB PHARMACOK
JI Drug Metab. Pharmacokinet.
PD AUG 25
PY 2013
VL 28
IS 4
BP 321
EP 331
DI 10.2133/dmpk.DMPK-12-RG-109
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 198MX
UT WOS:000322928100006
PM 23337693
ER


PT J
AU Hankey, GJ
   Eikelboom, JW
AF Hankey, Graeme J.
   Eikelboom, John W.
TI Novel Oral Anticoagulants for Atrial Fibrillation
SO CURRENT ATHEROSCLEROSIS REPORTS
LA English
DT Article
DE Atrial fibrillation; Novel oral anticoagulants; Stroke prevention
ID TRANSIENT ISCHEMIC ATTACK; RE-LY TRIAL; VITAMIN-K ANTAGONISM; FACTOR XA
   INHIBITOR; STROKE PREVENTION; COST-EFFECTIVENESS; DABIGATRAN ETEXILATE;
   SYSTEMIC EMBOLISM; ROCKET-AF; RANDOMIZED EVALUATION
AB Three novel oral anticoagulants (NOACS)-dabigatran etexilate, rivaroxaban, and apixaban-have been approved in many countries for stroke prevention in atrial fibrillation, because they are associated with the same or lower rates of stroke, bleeding (particularly intracranially) and death compared with warfarin; and unlike warfarin, they can be given in fixed doses without routine coagulation monitoring. The effects of NOACs compared with warfarin are consistent in almost all populations and patient subgroups studied. Pharmacoeconomic analyses indicate that the NOACs are also cost-effective in Europe and North America. The lack of an antidote to the NOACs in patients who experience major bleeding has not been associated with a worse outcome among patients treated with NOACs compared with warfarin in secondary analyses. Multiple guidelines for the management of AF now recommend the NOACs for stroke prevention among atrial fibrillation (AF) patients at risk for stroke.
C1 [Hankey, Graeme J.] Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA, Australia.
   [Eikelboom, John W.] McMaster Univ, Dept Med, Populat Hlth Res Inst, Hamilton, ON, Canada.
   [Eikelboom, John W.] McMaster Univ, Dept Med, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada.
   [Hankey, Graeme J.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia.
RP Hankey, GJ (reprint author), Royal Perth Hosp, Dept Neurol, Stroke Unit, 197 Wellington St, Perth, WA, Australia.
EM graeme.hankey@uwa.edu.au; eikelbj@mcmaster.ca
RI Hankey, Graeme /H-4968-2014
OI Hankey, Graeme /0000-0002-6044-7328
CR Adam SS, 2012, ANN INTERN MED, V157, P796, DOI 10.7326/0003-4819-157-10-201211200-00532
   Adcock AK, 2012, NEUROLOGIST, V18, P102, DOI 10.1097/NRL.0b013e318247bcb6
   Anderson JL, 2013, CIRCULATION
   Baker WL, 2012, CIRC-CARDIOVASC QUAL, V5, P711, DOI 10.1161/CIRCOUTCOMES.112.966572
   Banerjee A, 2012, THROMB HAEMOSTASIS, V107, P584, DOI 10.1160/TH11-11-0784
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Capodanno D, 2012, INT J CARDIOL
   Connolly SJ, 7 NOV 2012 AM HEART
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Dale B, 2013, J THROMB THROMBOLYS, V35, P295, DOI 10.1007/s11239-012-0857-9
   Dans AL, 2012, CIRCULATION
   Deitelzweig Steve, 2012, J Med Econ, V15, P776, DOI 10.3111/13696998.2012.680555
   Dentali F, 2012, CIRCULATION, V126, P2381, DOI 10.1161/CIRCULATIONAHA.112.115410
   Diener HC, 2012, LANCET NEUROL, V11, P225, DOI 10.1016/S1474-4422(12)70017-0
   Easton JD, 2012, LANCET NEUROL, V11, P503, DOI 10.1016/S1474-4422(12)70092-3
   Eikelboom JW, 2012, J STROKE CEREBROVASC, V21, P429, DOI 10.1016/j.jstrokecerebrovasdis.2012.05.007
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Flaker GC, 2012, STROKE, V43, P3291, DOI 10.1161/STROKEAHA.112.664144
   FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6
   Furie KL, 2012, STROKE, V43, P3442, DOI 10.1161/STR.0b013e318266722a
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Haas S, 2009, EUR J HAEMATOL, V82, P339, DOI 10.1111/j.1600-0609.2009.01230.x
   Hankey GJ, 2012, LANCET NEUROL, V11, P315, DOI 10.1016/S1474-4422(12)70042-X
   Harenberg J, 2012, INT ANGIOL, V31, P330
   Hart RG, 2012, STROKE, V43, P1511, DOI 10.1161/STROKEAHA.112.650614
   Healey JS, 2012, CIRCULATION, V126, P343, DOI 10.1161/CIRCULATIONAHA.111.090464
   Hohnloser SH, 2012, CIRCULATION, V125, P669, DOI 10.1161/CIRCULATIONAHA.111.055970
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Hori M, 2011, CIRC J, V75, P800, DOI 10.1253/circj.CJ-11-0191
   Kamel H, 2012, NEUROLOGY, V79, P1428, DOI 10.1212/WNL.0b013e31826d5fe8
   Kamel H, 2012, STROKE, V43, P881, DOI 10.1161/STROKEAHA.111.641027
   Kansal AR, 2012, THROMB HAEMOSTASIS, V108, P672, DOI 10.1160/TH12-06-0388
   Kansal AR, 2012, HEART, V98, P573, DOI 10.1136/heartjnl-2011-300646
   Kirchhof P, 2013, EUR HEART J
   Langkilde Lars K, 2012, J Med Econ, V15, P695, DOI 10.3111/13696998.2012.673525
   Lee S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047473
   Lee S, 2012, AM J CARDIOL, V110, P845, DOI 10.1016/j.amjcard.2012.05.011
   Lip GYH, 2012, J AM COLL CARDIOL, V60, P738, DOI 10.1016/j.jacc.2012.03.019
   Lopes RD, 2012, LANCET, V380, P1749, DOI 10.1016/S0140-6736(12)60986-6
   Mackman N, 2009, ANESTH ANALG, V108, P1447, DOI 10.1213/ane.0b013e31819bceb1
   Mantha S, 2012, THROMB HAEMOSTASIS, V108, P476, DOI 10.1160/TH12-02-0093
   McKeage K, 2012, PHARMACOECONOMICS, V30, P841, DOI 10.2165/11209130-000000000-00000
   Miller CS, 2012, AM J CARDIOL, V110, P453, DOI 10.1016/j.amjcard.2012.03.049
   O'Dell KM, 2012, CLIN THER, V34, P894, DOI 10.1016/j.clinthera.2012.01.019
   Ogawa S, 2011, CIRC J, V75, P1852, DOI 10.1253/circj.CJ-10-1183
   O'Neil WM, 2013, THROMB HAEMOST, V109
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2013, CIRCULATION, V127, P224, DOI 10.1161/CIRCULATIONAHA.112.107128
   Pisters R, 2012, THROMB HAEMOST, V109
   Rasmussen LH, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7097
   Schneeweiss S, 2012, CIRC-CARDIOVASC QUAL, V5, P480, DOI 10.1161/CIRCOUTCOMES.112.965988
   Schulman S, 2013, NEW ENGL J MED, V368, P709, DOI 10.1056/NEJMoa1113697
   Singer DE, 2013, J AM HEART ASS, V2, DOI 10.1161/JAHA.112.000067
   Skanes AC, 2012, CAN J CARDIOL, V28, P125, DOI 10.1016/j.cjca.2012.01.021
   Ross Southworth M, 2013, N ENGL J MED
   Testa L, 2012, QJM-INT J MED, V105, P949, DOI 10.1093/qjmed/hcs114
   Uchino K, 2012, ARCH INTERN MED, V172, P397, DOI 10.1001/archinternmed.2011.1666
   Van de Werf F, 2012, AM HEART J, V163, P931, DOI 10.1016/j.ahj.2012.03.011
   Weitz JI, 2012, AM J HEMATOL, V87, pS133, DOI 10.1002/ajh.23139
   You JHS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039640
   [Anonymous], 2012, STROKE, V43, pe181
NR 64
TC 8
Z9 8
U1 1
U2 15
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1523-3804
J9 CURR ATHEROSCLER REP
JI Curr. Atheroscleros. Rep.
PD AUG
PY 2013
VL 15
IS 8
AR 344
DI 10.1007/s11883-013-0344-6
PG 11
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 194ZI
UT WOS:000322670800004
PM 23761015
ER


PT J
AU Tse, HF
   Wang, YJ
   Ai-Abdullah, MA
   Pizarro-Borromeo, AB
   Chiang, CE
   Krittayaphong, R
   Singh, B
   Vora, A
   Wang, CX
   Zubaid, M
   Clemens, A
   Lim, P
   Hu, DY
AF Tse, Hung-Fat
   Wang, Yong-Jun
   Ai-Abdullah, Moheeb Ahmed
   Pizarro-Borromeo, Annette B.
   Chiang, Chern-En
   Krittayaphong, Rungroj
   Singh, Balbir
   Vora, Amit
   Wang, Chun-Xue
   Zubaid, Mohammad
   Clemens, Andreas
   Lim, Paul
   Hu, Dayi
TI Stroke prevention in atrial fibrillation-An Asian stroke perspective
SO HEART RHYTHM
LA English
DT Review
DE Atrial fibrillation; Asia; Stroke prevention
ID FACTOR XA INHIBITOR; INTERNATIONAL NORMALIZED RATIO; ACUTE
   ISCHEMIC-STROKE; RE-LY TRIAL; J-ROCKET AF; JAPANESE PATIENTS;
   RISK-FACTORS; WARFARIN THERAPY; RACIAL/ETHNIC DIFFERENCES; DABIGATRAN
   ETEXILATE
AB Despite relatively lower prevalence of atrial fibrillation (AF) in Asians (similar to 1%) than in Caucasians (similar to 2%), Asia has a much higher overall disease burden because of its proportionally larger aged population. For example, on the basis of reported age-adjusted prevalence rates and projected population figures in China, there will be an estimated 5.2 million men and 3.1 million women with AF older than 60 years by year 2050. Stroke is a disabling complication of AF that is of increasing cause for concern in Asians patients. Implementing consensus expert recommendations for managing stroke risk in patients with AF can considerably reduce stroke rates. However, caution is necessary when aligning management of Asian patients with AF to that of their Caucasian counterparts. Current international guidelines and risk stratification tools for AF management are based on findings in predominantly Caucasian populations and may therefore have limited relevance, in certain respects, to Asian patients. Oral anticoagulants play an important role in preventing AF-related stroke. The vitamin K antagonist warfarin is recommended for reducing the risk of stroke and thromboembolism in high-risk patients with nonvalvular AF; however, warfarin interacts with many drugs and food ingredients, which may pose significant challenges in administration and monitoring among Asian patients. Further research is needed to inform specific guidance on the implications of different stroke and bleeding profiles in Asians vs Caucasians. Moreover, there is scope to improve physician perceptions and patient knowledge, as well as considering alternative new oral anticoagulants, for example, direct thrombin inhibitors or factor Xa inhibitors.
C1 [Tse, Hung-Fat] Univ Hong Kong, Dept Med, Div Cardiol, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Yong-Jun; Wang, Chun-Xue] Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Ai-Abdullah, Moheeb Ahmed] Prince Sultan Cardiac Ctr, Riyadh, Saudi Arabia.
   [Pizarro-Borromeo, Annette B.] Philippine Heart Ctr, Quezon City, Philippines.
   [Chiang, Chern-En] Taipei Vet Gen Hosp, Gen Clin Res Ctr, Taipei, Taiwan.
   [Chiang, Chern-En] Natl Yang Ming Univ, Taipei 112, Taiwan.
   [Krittayaphong, Rungroj] Mahidol Univ, Siriraj Hosp, Bangkok 10700, Thailand.
   [Singh, Balbir] Medanta Heart Inst, Gurgaon, Haryana, India.
   [Vora, Amit] Arrhythmia Associates, Bombay, Maharashtra, India.
   [Zubaid, Mohammad] Kuwait Univ, Fac Med, Dept Med, Kuwait, Kuwait.
   [Clemens, Andreas] Boehringer Ingelheim Pharma GmbH & Co KG, Global Clin Dev & Med Affairs, Biberach, Germany.
   [Lim, Paul] Boehringer Ingelheim Singapore Pte Ltd, Singapore, Singapore.
   [Hu, Dayi] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China.
RP Tse, HF (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Div Cardiol, 102 Pokfulam Rd,Room 1928,Block K, Hong Kong, Hong Kong, Peoples R China.
EM hftse@hkucc.hku.hk
FU Boehringer Ingelheim
FX Dr David Neil of UBM Medica Asia Pte Ltd provided writing and editorial
   support, which was funded by Boehringer Ingelheim.
CR Alonso A, 2011, CIRCULATION, V123, P2946, DOI 10.1161/CIRCULATIONAHA.111.020982
   Bateman BT, 2006, STROKE, V37, P440, DOI 10.1161/01.STR.0000199851.24668.f1
   Benjamin EJ, 1998, CIRCULATION, V98, P946
   Camm AJ, 2012, EUR HEART J, V31, P2719
   Chan HT, 2011, J CARDIOVASC PHARM, V58, P87, DOI 10.1097/FJC.0b013e31821cd888
   Chien KL, 2010, INT J CARDIOL, V139, P173, DOI 10.1016/j.ijcard.2008.10.045
   Chung N, 2011, THROMB HAEMOSTASIS, V105, P535, DOI 10.1160/TH10-07-0451
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292
   Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Pisters R, 2012, INT J CARDIOL, DOI [10.1016/j.ijcard.2012.09.187, DOI 10.1016/J.IJCARD.2012.09.187.[]
   Guo Y, 2012, INT J CARDIOL, DOI [10.1016/j.ijcard.2012.10.052, DOI 10.1016/J.IJCARD.2012.10.052.[]
   Holmes DR, 2009, LANCET, V374, P534, DOI 10.1016/S0140-6736(09)61343-X
   Hori M, 2012, CEREBROVASC DIS, V34, pS6
   Hori M, 2013, CIRC J, V77, P632, DOI 10.1253/circj.CJ-12-0899
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Hori M, 2011, CIRC J, V75, P800, DOI 10.1253/circj.CJ-11-0191
   Hu DY, 2008, J AM COLL CARDIOL, V52, P865, DOI 10.1016/j.jacc.2008.05.042
   Iguchi Y, 2010, AM J CARDIOL, V106, P1129, DOI 10.1016/j.amjcard.2010.06.030
   Inoue H, 2004, CIRC J, V68, P417, DOI 10.1253/circj.68.417
   Jiang J, 2010, THROMB HAEMOSTASIS, V103, P234, DOI 10.1160/TH09-03-0196
   Liesenfeld KH, 2011, J THROMB HAEMOST, V9, P2168, DOI 10.1111/j.1538-7836.2011.04498.x
   Lin LJ, 2008, CLIN THER, V30, P1726, DOI 10.1016/j.clinthera.2008.09.010
   Lip GYH, 2011, J THROMB HAEMOST, V9, P344, DOI 10.1111/j.1538-7836.2011.04302.x
   Lip GYH, 2002, STROKE, V33, P238, DOI 10.1161/hs0102.101817
   Long MJ, 2011, INT J CARDIOL, V148, P48, DOI 10.1016/j.ijcard.2009.10.022
   Maeda K, 2004, INTERNAL MED, V43, P553, DOI 10.2169/internalmedicine.43.553
   National Collaborating Centre for Chronic Conditions, 2006, ATR FIBR MAN ATR FIB, pCG36
   Ogawa S, 2011, CIRC J, V75, P1852, DOI 10.1253/circj.CJ-10-1183
   Ohsawa M, 2007, CIRC J, V71, P814, DOI 10.1253/circj.71.814
   Olesen JB, 2011, THROMB HAEMOSTASIS, V106, P739, DOI 10.1160/TH11-05-0364
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Pink J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6333
   Sato H, 2006, STROKE, V37, P447, DOI 10.1161/01.STR.0000198839.61112.ee
   Schnabel RB, 2009, LANCET, V373, P739, DOI 10.1016/S0140-6736(09)60443-8
   Shen AYJ, 2007, J AM COLL CARDIOL, V50, P309, DOI 10.1016/j.jacc.2007.01.098
   Shen AYJ, 2010, J NATL MED ASSOC, V102, P906
   Shen Q, 2011, AUSTRALAS J AGEING, V30, P143, DOI 10.1111/j.1741-6612.2010.00477.x
   Tanizaki Y, 2000, STROKE, V31, P2616
   United Nation Department of economic and social affairs Population division, 2011, WORLD POP PROSP 2010
   Veenstra DL, 2005, PHARMACOGENET GENOM, V15, P687, DOI 10.1097/01.fpc.0000174789.77614.68
   Vora A, 2006, CURR OPIN CARDIOL, V21, P47, DOI 10.1097/01.hco.0000198985.78508.55
   Wallentin L, 2010, LANCET, V376, P975, DOI 10.1016/S0140-6736(10)61194-4
   Wang DR, 2011, CLIN NEUROL NEUROSUR, V113, P442, DOI 10.1016/j.clineuro.2011.01.005
   World Health Organization, 2011, GLOB ATL CARD DIS PR
   WOLF PA, 1991, STROKE, V22, P983
   Yamashita T, 2012, CIRC J, V76, P1840, DOI 10.1253/circj.CJ-11-1140
   Yap KB, 2008, J ELECTROCARDIOL, V41, P94, DOI 10.1016/j.electrocard.2007.03.012
   Yasaka M, 2001, INTERNAL MED, V40, P1183, DOI 10.2169/internalmedicine.40.1183
   Zhou ZQ, 2008, J EPIDEMIOL, V18, P209, DOI 10.2188/jea.JE2008021
NR 51
TC 35
Z9 36
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
J9 HEART RHYTHM
JI Heart Rhythm
PD JUL
PY 2013
VL 10
IS 7
BP 1082
EP 1088
DI 10.1016/j.hrthm.2013.03.017
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 179DA
UT WOS:000321497500027
PM 23501173
ER


PT J
AU Harris, K
   Mant, J
AF Harris, K.
   Mant, J.
TI Potential impact of new oral anticoagulants on the management of atrial
   fibrillation-related stroke in primary care
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Review
ID RANDOMIZED-CONTROLLED-TRIALS; CLOPIDOGREL PLUS ASPIRIN; EVENTS ACTIVE-W;
   COST-EFFECTIVENESS; DABIGATRAN ETEXILATE; ANTITHROMBOTIC THERAPY;
   PREDICTING STROKE; RISK STRATIFICATION; SYSTEMIC EMBOLISM;
   GENERAL-PRACTICE
AB Aim Anticoagulant prophylaxis with vitamin K antagonists (such as warfarin) is effective in reducing the risk of stroke in patients with atrial fibrillation (AF). New oral anticoagulants have emerged as potential alternatives to traditional oral agents. The purpose of this review was to summarise the effectiveness and safety of rivaroxaban, dabigatran and apixaban in stroke prevention in patients with AF in phase III trials, evaluate their cost-effectiveness and consider the implications for primary care. Methodology A literature search was performed between 2007 and 2012, selecting all phase III trials (ROCKET AF, RE-LY and ARISTOTLE) of new oral anticoagulants and relevant cost-benefit studies. Results Evidence shows that all three agents are at least as effective as warfarin in the prevention of stroke and systemic emboli, with similar safety profiles. Cost-benefit studies of rivaroxaban and dabigatran further confirm their potential use as alternatives to warfarin in clinical practice. These observations may allow stratification of the general practice AF population, to help prioritise which patients may benefit from receiving a new oral anticoagulant. Conclusion The clinical and economic benefits of the new oral anticoagulants, along with appropriate risk stratification, may enable a higher number of patients with AF to receive effective and convenient prophylaxis for stroke prevention.
C1 [Harris, K.; Mant, J.] Univ Cambridge, Strangeways Res Lab, Primary Care Unit, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England.
RP Mant, J (reprint author), Univ Cambridge, Strangeways Res Lab, Primary Care Unit, Dept Publ Hlth & Primary Care, Worts Causeway, Cambridge CB1 8RN, England.
EM jm677@medschl.cam.ac.uk
FU Bayer HealthCare Pharmaceuticals; Janssen Scientific Affairs, LLC.
FX The authors would like to acknowledge Kelly Farrell, who provided
   editorial support with funding from Bayer HealthCare Pharmaceuticals and
   Janssen Scientific Affairs, LLC.
CR Aguilar M, 2007, COCHRANE DATABASE SY, V3
   Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
   Ali A, 2012, AGE AGEING, V41, P681, DOI 10.1093/ageing/afs017
   Andersson P, 2012, J INTERN MED, V272, P170, DOI 10.1111/j.1365-2796.2012.02519.x
   Ansell J, 2008, CHEST, V133, p160S, DOI 10.1378/chest.08-0670
   Birman-Deych E, 2006, STROKE, V37, P1070, DOI 10.1161/01.STR.0000208294.46968.a4
   Burton C, 2006, BRIT J GEN PRACT, V56, P697
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Carroll K, 2001, BRIT J GEN PRACT, V51, P884
   Connolly S, 2006, LANCET, V367, P1903
   Connolly SJ, 2009, NEW ENGL J MED, V360, P2066, DOI 10.1056/NEJMoa0901301
   Connolly SJ, 2008, CIRCULATION, V118, P2029, DOI 10.1161/CIRCULATIONAHA.107.750000
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Cowan C, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d1153
   Davidson T, 2013, EUR HEART J, V34, P177, DOI 10.1093/eurheartj/ehs157
   Department of Health, 2010, NHS REF COSTS 2008 2
   European Medicines Agency, 2012, EUR PUBL ASS REP ROS
   Fang MC, 2010, CIRC-CARDIOVASC QUAL, V3, P624, DOI 10.1161/CIRCOUTCOMES.110.937680
   Freeman JV, 2011, ANN INTERN MED, V154, P1, DOI 10.7326/0003-4819-154-1-201101040-00289
   GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839
   Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864
   Go AS, 1999, ANN INTERN MED, V131, P927
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Gross CP, 2003, CLIN THER, V25, P1750, DOI 10.1016/S0149-2918(03)80167-4
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Healey JS, 2008, STROKE, V39, P1482, DOI 10.1161/STROKEAHA.107.500199
   Healthcare Improvement Scotland, 2012, PREV STROK SYST EMB
   The Health and Social Care Information Centre. Technical Steering Committee, 2011, GEN PRACT TRENDS UK
   Holt Tim A, 2012, Br J Gen Pract, V62, pe710, DOI 10.3399/bjgp12X656856
   Jones M, 2005, HEART, V91, P472, DOI 10.1136/hrt.2004.042465
   Jowett S, 2011, STROKE, V42, P1717, DOI 10.1161/STROKEAHA.110.600767
   Kannel WB, 1998, AM J CARDIOL, V82, p2N, DOI 10.1016/S0002-9149(98)00583-9
   Kansal AR, 2012, HEART, V98, P573, DOI 10.1136/heartjnl-2011-300646
   Langkilde Lars K, 2012, J Med Econ, V15, P695, DOI 10.3111/13696998.2012.673525
   LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449
   Lee S, 2012, AM J CARDIOL, V110, P845, DOI 10.1016/j.amjcard.2012.05.011
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Mant J, 2004, HLTH CARE NEEDS ASSE, P141
   Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1
   Mega JL, 2011, NEW ENGL J MED, V365, P1052, DOI 10.1056/NEJMe1109748
   National Collaborating Centre for Chronic Conditions, 2006, ATR FIBR NAT CLIN GU
   National Health Service, 2009, GUID RISK ASS STROK
   National Health Service, 2009, HEART STROK IMPR COM
   National Institute for Health and Clinical Excellence, 2012, DAB ET PREV STROK SY
   National Institute for Health and Clinical Excellence, 2006, NICE CLIN GUID 36
   National Institute for Health and Clinical Excellence, 2011, FIN APPR DET DAB ET
   National Institute for Health and Clinical Excellence, 2012, RIV PREV STROK SYST
   National Institute for Health and Clinical Excellence, 2006, ATR FIBR MAN ATR FIB
   Olesen JB, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d124
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Pink J, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6333
   Ruigomez A, 2002, J CLIN EPIDEMIOL, V55, P358, DOI 10.1016/S0895-4356(01)00478-4
   Shah SV, 2011, CIRCULATION, V123, P2562, DOI 10.1161/CIRCULATIONAHA.110.985655
   Sorensen SV, 2011, THROMB HAEMOSTASIS, V105, P908, DOI 10.1160/TH11-02-0089
   Spackman E, 2011, DABIGATRAN ETEXILATE
   Stewart S, 2001, HEART, V86, P516, DOI 10.1136/heart.86.5.516
   Thomson R, 2000, LANCET, V355, P956, DOI 10.1016/S0140-6736(00)90012-6
   Uchino K, 2012, ARCH INTERN MED, V172, P397, DOI 10.1001/archinternmed.2011.1666
   van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441
   Weitz JI, 2010, THROMB HAEMOSTASIS, V104, P633, DOI 10.1160/TH10-01-0066
   WOLF PA, 1991, STROKE, V22, P983
NR 63
TC 2
Z9 3
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD JUL
PY 2013
VL 67
IS 7
BP 647
EP 655
DI 10.1111/ijcp.12177
PG 9
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA 164GM
UT WOS:000320397200009
PM 23621153
ER


PT J
AU Dean, D
AF Dean, D.
TI Creating a space debris catalogue for an orbital band with suitable
   candidates for active removal
SO AERONAUTICAL JOURNAL
LA English
DT Article
AB There are over 16,000 pieces of debris that are larger than 10cm in diameter being tracked which could cause a catastrophic destruction of a satellite if they were to collide. To reduce the likelihood of this happening, debris production is being reduced through debris mitigation techniques; however the debris already in space will need to be removed as well. To design an effective debris removal mission, the first logical step would be to gather as much detail as possible on debris that is known to exist within the orbital band of interest. This report presents a catalogue of debris, created entirely from open source data, for an orbital band within the 900-1,000km altitude range and 82-83 degrees inclination, and offers a possible candidate for deorbit - the Cosmos 3M final-stage rocket body, of which there are 142, each with a mass of 1,435kg, length of 6.5m and diameter of 2.4m.
C1 DSTL, Sensors & Countermeasures Dept, Salisbury, Wilts, England.
RP Dean, D (reprint author), DSTL, Sensors & Countermeasures Dept, Salisbury, Wilts, England.
EM daviddean_24@hotmail.com
CR BWGS, ONL DAT SAT FLASH PE
   CelesTrak, 2012, SAT CAT
   GRIFFITHS M, 2010, POSTNOTE SPACE DEBRI
   Mehrholz D., 2002, ESA B, V109
   N2YO, SAT TRACK
   Orbital Debris, 2008, NASAIM2008214779 ORB
   [Anonymous], COSM 3M DET
NR 7
TC 0
Z9 0
U1 1
U2 9
PU ROYAL AERONAUTICAL SOC
PI LONDON
PA 4 HAMILTON PL, LONDON W1J 7BQ, ENGLAND
SN 0001-9240
J9 AERONAUT J
JI Aeronaut. J.
PD JUN
PY 2013
VL 117
IS 1192
BP 617
EP 628
PG 12
WC Engineering, Aerospace
SC Engineering
GA 180LT
UT WOS:000321597400004
ER


PT J
AU Chen, T
   Li, JW
   Jin, P
   Cai, GB
AF Chen, Tao
   Li, Jiawen
   Jin, Ping
   Cai, Guobiao
TI Reusable rocket engine preventive maintenance scheduling using genetic
   algorithm
SO RELIABILITY ENGINEERING & SYSTEM SAFETY
LA English
DT Article
DE Reusable rocket engine; Preventive maintenance; Effective age;
   Reliability; Cost; Genetic algorithm
ID REPAIRABLE SYSTEMS; OPTIMIZATION; REDUCTION; INTENSITY; POLICIES; AGE
AB This paper deals with the preventive maintenance (PM) scheduling problem of reusable rocket engine (RRE), which is different from the ordinary repairable systems, by genetic algorithm. Three types of PM activities for RRE are considered and modeled by introducing the concept of effective age. The impacts of PM on all subsystems' aging processes are evaluated based on improvement factor model. Then the reliability of engine is formulated by considering the accumulated time effect. After that, optimization model subjected to reliability constraint is developed for RRE PM scheduling at fixed interval. The optimal PM combination is obtained by minimizing the total cost in the whole life cycle for a supposed engine. Numerical investigations indicate that the subsystem's intrinsic reliability characteristic and the improvement factor of maintain operations are the most important parameters in RRE's PM scheduling management. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Chen, Tao; Li, Jiawen; Jin, Ping; Cai, Guobiao] Beijing Univ Aeronaut & Astronaut, Sch Astronaut, Beijing 100191, Peoples R China.
RP Cai, GB (reprint author), Beijing Univ Aeronaut & Astronaut, Sch Astronaut, Beijing 100191, Peoples R China.
EM cgb@buaa.edu.cn
CR Amari SV, 2007, IEEE T SYST MAN CY A, V37, P406, DOI 10.1109/TSMCA.2007.893454
   Bartholomew-Biggs M, 2009, RELIAB ENG SYST SAFE, V94, P53, DOI 10.1016/j.ress.2008.03.002
   Chou JS, 2011, RELIAB ENG SYST SAFE, P96
   Coley David A, 2002, INTRO GENETIC ALGORI
   Dedopoulos IT, 1998, COMPUT IND ENG, V34, P643, DOI 10.1016/S0360-8352(97)00281-7
   Doyen L, 2004, RELIAB ENG SYST SAFE, V84, P45, DOI 10.1016/S0951-8320(03)00173-X
   KIJIMA M, 1989, J APPL PROBAB, V26, P89, DOI 10.2307/3214319
   Kuo W., 2007, COMPUTATIONAL INTELL, V39, P1, DOI 10.1007/978-3-540-37368-1_1
   Levitin G, 2000, RELIAB ENG SYST SAFE, V67, P193, DOI 10.1016/S0951-8320(99)00067-8
   Lewis EE, 1987, INTRO RELIABILITY EN, P250
   Marseguerra M, 2000, RELIAB ENG SYST SAFE, V68, P69, DOI 10.1016/S0951-8320(00)00007-7
   Mettas A, 2005, P ANN REL MAINT S VI
   Moghaddam KS, 2011, COMPUT IND ENG, V60, P654, DOI 10.1016/j.cie.2010.12.021
   Moghaddam KS, 2010, PREVENTIVE MAINTENAN
   NAKAGAWA T, 1988, IEEE T RELIAB, V37, P295, DOI 10.1109/24.3758
   Rasky D. J., 2006, REUSABLE LAUNCH VEHI
   Rausand M, 2010, SYSTEM RELIABILITY T, P164
   Shin I, 1996, RELIAB ENG SYST SAFE, V54, P1, DOI 10.1016/S0951-8320(96)00097-X
   Sutton G. P., 2001, ROCKET PROPULSION EL
   Tsai YT, 2004, RELIAB ENG SYST SAFE, V84, P261, DOI 10.1016/j.ress.2003.11.011
   Tsai Y-T, 2001, RELIAB ENG SYST SAFE, V74, P87
   Usher JS, 1998, IIE TRANS, V30, P1121, DOI 10.1023/A:1007524100829
   Wang GJ, 2011, APPL MATH COMPUT, V218, P3158, DOI 10.1016/j.amc.2011.08.050
   Yoshida M, 2009, P AIAA ASME SAE ASEE
   Zhou XJ, 2012, RELIAB ENG SYST SAFE, V101, P14, DOI 10.1016/j.ress.2012.01.005
NR 25
TC 4
Z9 4
U1 1
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0951-8320
J9 RELIAB ENG SYST SAFE
JI Reliab. Eng. Syst. Saf.
PD JUN
PY 2013
VL 114
BP 52
EP 60
DI 10.1016/j.ress.2012.12.020
PG 9
WC Engineering, Industrial; Operations Research & Management Science
SC Engineering; Operations Research & Management Science
GA 117AD
UT WOS:000316923600006
ER


PT J
AU Karimmojeni, H
   Pirbaloti, AG
   Kudsk, P
   Kanani, V
   Ghafori, A
AF Karimmojeni, Hassan
   Pirbaloti, Ahmad G.
   Kudsk, Per
   Kanani, Vahid
   Ghafori, Abbas
TI Influence of Postemergence Herbicides on Weed Management in Spring-Sown
   Linseed
SO AGRONOMY JOURNAL
LA English
DT Article
ID KOCHIA KOCHIA-SCOPARIA; FLAX; L.; SETHOXYDIM; EFFICACY; WHEAT
AB Linseed (Linum usitatissimum L.) is a very poor competitor with weeds, and to obtain acceptable linseed yields, weeds should be effectively controlled. Very little information is available on the tolerance of linseed to herbicide applications. In this study, the effects of nine herbicide treatments on the control of broadleaf weeds and yield response in spring-sown linseed were evaluated. The dominant weed species were garden rocket (Eruca sativa Mill.) and field bindweed (Convolvulus arvensis L.). A tank mixture of bromoxynil (337.5 ga.i. ha(-1).) plus a nonionic surfactant was more effective than bromoxynil applied alone at 450 ga.i. ha(-1) and led to greater yield increases. In contrast, addition of a nonionic surfactant to bentazon did not overcome a reduction in the bentazon dose from 960 to 720 ga.i. ha(-1), and the linseed yield was the same or lower than that of bentazon alone. Bromoxynil plus MCPA provided effective weed control but caused crop damage and resulted in lower yields than some of the other herbicides. Similarly, dichlorprop-P plus mecoprop-P plus MCPA caused severe crop phytotoxicity and reduced yield. The study confirmed that weeds can severely diminish linseed productivity and that many broadleaf weed herbicides can severely damage the linseed crop. We conclude that bentazon (1440 ga.i. ha(-1)), bromoxynil (337.5 g ha(-1) a.i.) plus a nonionic surfactant, and 2, 4-D plus MCPA are good options for chemical control of broadleaf weeds in linseed because they protected yield by providing satisfactory levels of weed control with acceptable levels of crop phytotoxicity.
C1 [Karimmojeni, Hassan; Pirbaloti, Ahmad G.; Kanani, Vahid; Ghafori, Abbas] Isfahan Univ Technol, Coll Agr, Dep Agron & Plant Breeding, Esfahan 8415683111, Iran.
   [Kudsk, Per] Aarhus Univ, Dep Agroecol, DK-4200 Slagelse, Denmark.
RP Karimmojeni, H (reprint author), Isfahan Univ Technol, Coll Agr, Dep Agron & Plant Breeding, Esfahan 8415683111, Iran.
EM kmojeni@cc.iut.ac.ir
FU Center of Excellence for Oilseed Crops at Isfahan University of
   Technology, Isfahan, Iran
FX This work was partially funded by the Center of Excellence for Oilseed
   Crops at Isfahan University of Technology, Isfahan, Iran.
CR Abouziena HFH, 2009, CROP PROT, V28, P1081, DOI 10.1016/j.cropro.2009.06.013
   ALESSI J, 1970, AGRON J, V62, P635
   AOCS, 1993, OFFICIAL METHODS REC
   Baghestani MA, 2007, CROP PROT, V26, P936, DOI 10.1016/j.cropro.2006.08.013
   BOWDEN BA, 1967, WEED RES, V7, P349, DOI 10.1111/j.1365-3180.1967.tb01389.x
   BOYDSTON RA, 1994, WEED TECHNOL, V8, P99
   Derksen DA, 1996, WEED TECHNOL, V10, P795
   Diepenbrock W, 1993, IND CROP PROD, V1, P165, DOI 10.1016/0926-6690(92)90015-N
   Dordas CA, 2010, IND CROP PROD, V31, P455, DOI 10.1016/j.indcrop.2010.01.008
   Froment MA, 1997, PROC BRIGHTON CROP, P839
   Harbour JD, 2003, WEED SCI, V51, P430, DOI 10.1614/0043-1745(2003)051[0430:SAHOKK]2.0.CO;2
   Kudsk P, 2007, CROP PROT, V26, P328, DOI 10.1016/j.cropro.2005.06.012
   Lutman PJW, 1997, PROC BRIGHTON CROP, P833
   MCMULLAN PM, 1993, CROP PROT, V12, P544, DOI 10.1016/0261-2194(93)90097-3
   Muir A. D., 2003, FLAX GENUS LINUM
   NALEWAJA JD, 1969, WEED SCI, V17, P385
   Vallduvi GES, 2011, J SUSTAIN AGR, V35, P914, DOI 10.1080/10440046.2011.611745
   Sanchez-Vallduvi G.E., 2007, BIOL AGR HORTIC, V25, P123, DOI [10.1080/01448765.2007.9755041, DOI 10.1080/01448765.2007.9755041]
   Soliman I.E., 2010, J PLANT PROT RES, V3, P372
   Stone AE, 2005, WEED TECHNOL, V19, P148, DOI 10.1614/WT-04-044R2
   Zand E., 2002, ANAL HERBICIDES IRAN
   Zand E, 2007, CROP PROT, V26, P1349, DOI 10.1016/j.cropro.2006.10.011
NR 22
TC 1
Z9 1
U1 0
U2 16
PU AMER SOC AGRONOMY
PI MADISON
PA 677 S SEGOE RD, MADISON, WI 53711 USA
SN 0002-1962
J9 AGRON J
JI Agron. J.
PD MAY-JUN
PY 2013
VL 105
IS 3
BP 821
EP 826
DI 10.2134/agronj2012.0238
PG 6
WC Agronomy
SC Agriculture
GA 138VE
UT WOS:000318537300032
ER


PT J
AU Braun, V
   Lupken, A
   Flegel, S
   Gelhaus, J
   Mockel, M
   Kebschull, C
   Wiedemann, C
   Vorsmann, P
AF Braun, Vitali
   Luepken, A.
   Flegel, S.
   Gelhaus, J.
   Moeckel, M.
   Kebschull, C.
   Wiedemann, C.
   Voersmann, P.
TI Active debris removal of multiple priority targets
SO ADVANCES IN SPACE RESEARCH
LA English
DT Article
DE Active debris removal; Space debris; De-orbit
AB Today's space debris environment shows major concentrations of objects within distinct orbital regions for nearly all size regimes. The most critical region is found at orbital altitudes near 800 km with high declinations. Within this region many satellites are operated in so called sun-synchronous orbits (SSO). Among those, there are Earth observation, communication and weather satellites. Due to the orbital geometry in SSO, head-on encounters with relative velocities of about 15 km/s are most probable and would thus result in highly energetic collisions, which are often referred to as catastrophic collisions, leading to the complete fragmentation of the participating objects. So called feedback collisions can then be triggered by the newly generated fragments, thus leading to a further population increase in the affected orbital region. This effect is known as the Kessler syndrome.
   Current studies show that catastrophic collisions are not a major problem today, but will become the main process for debris generation within the SSO region in the near future, even without any further launches. In order to avoid this effect, objects with a major impact on collisional cascading have to be actively removed from the critical region after their end of life. Not having the capability to perform an end-of-life maneuver in order to transfer to a graveyard orbit or to de-orbit, many satellites and rocket bodies would have to be de-orbited within a dedicated mission. In such a mission, a service satellite would perform a de-orbit maneuver, after having docked to a specific target.
   In this paper, chemical and electric propulsion systems were analysed with the main focus on removing multiple targets within one single mission. The targets were chosen from a previously defined priority list in order to enhance the mission efficiency. Total mission time, Delta V and system mass were identified as key parameters to allow for an evaluation of the different concepts. It was shown that it is possible to remove up to five high priority targets per year using a chemical propulsion system, however, missions may result in too high Delta V and/or mission duration depending on the orbital distribution of the targets. When using an electric propulsion system, the required fuel mass is significantly reduced when compared to the chemical propulsion system, but it was shown that mission duration strongly depends on the mass of the selected targets. More powerful engines as well as out-of-plane thrust are thus required to achieve the defined mission goals. 2012 COSPAR. Published by Elsevier Ltd. All rights reserved.
C1 [Braun, Vitali; Luepken, A.; Flegel, S.; Gelhaus, J.; Moeckel, M.; Kebschull, C.; Wiedemann, C.; Voersmann, P.] Tech Univ Carolo Wilhelmina Braunschweig, Inst Luft & Raumfahrtsyst, D-38108 Braunschweig, Germany.
RP Braun, V (reprint author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Luft & Raumfahrtsyst, Hermann Blenk Str 23, D-38108 Braunschweig, Germany.
EM v.braun@tu-braunschweig.de
CR Barbee BW, 2012, ADV ASTRONAUT SCI, V144, P93
   Bonnal C., 2010, INT ASTR C PRAG CZEC
   Braun V., 2011, DTSCH LUFT RAUMF DLR
   Castronuovo MM, 2011, ACTA ASTRONAUT, V69, P848, DOI 10.1016/j.actaastro.2011.04.017
   EADS Astrium website, 2012, RIT 10 THRUST CHAR
   Flegel S., 2011, MAINTENANCE ESA MAST
   Hokamoto S., 2011, 28 INT S SPAC TECHN
   Ishige Y, 2004, ACTA ASTRONAUT, V55, P917, DOI 10.1016/j.actaastro.2004.04.015
   KESSLER DJ, 1978, J GEOPHYS RES-SPACE, V83, P2637, DOI 10.1029/JA083iA06p02637
   Lewis H. G., 2011, INT ASTR C CAP TOWN
   Liou JC, 2008, ADV SPACE RES, V41, P1046, DOI 10.1016/j.asr.2007.04.081
   Liou JC, 2010, ACTA ASTRONAUT, V66, P648, DOI 10.1016/j.actaastro.2009.08.005
   Liou J. C., 2011, ORBITAL DEBRIS Q NEW, V47, P4
   LOFTUS JP, 1992, ACTA ASTRONAUT, V26, P477, DOI 10.1016/0094-5765(92)90118-3
   Martin T., 2011, 4 EUR C AER SCI EUCA
   Starke J., 2011, INT ASTR C CAP TOWN
   Wiedemann C., 2012, INT ASTR C NAPL IT
   [Anonymous], 2007, IADC SPACE DEBRIS MI
NR 18
TC 12
Z9 12
U1 0
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0273-1177
J9 ADV SPACE RES
JI Adv. Space Res.
PD MAY 1
PY 2013
VL 51
IS 9
BP 1638
EP 1648
DI 10.1016/j.asr.2012.12.003
PG 11
WC Astronomy & Astrophysics; Geosciences, Multidisciplinary; Meteorology &
   Atmospheric Sciences
SC Astronomy & Astrophysics; Geology; Meteorology & Atmospheric Sciences
GA 129YB
UT WOS:000317878800006
ER


PT J
AU Lyons, VJ
AF Lyons, Valerie J.
TI Power and Propulsion at NASA Glenn Research Center: Historic Perspective
   of Major Accomplishments
SO JOURNAL OF AEROSPACE ENGINEERING
LA English
DT Article
DE Power; Propulsion; Space power; NASA history; Lewis Research Center;
   Alternative energy; Solar power; Nuclear space power; Electric
   propulsion; Stirling convertors
ID SYSTEM
AB Propulsion and power have long been core competencies of the National Aeronautics and Space Administration (NASA) Glenn Research Center (GRC). At the dawn of the space era, the center brought key propulsion and power technology to support spacecraft development. This paper serves as an introduction to a series of papers describing the highlights of the GRC's power and propulsion research and development efforts. The power papers cover solar and nuclear power generation and energy conversion, energy storage (focusing on batteries, flywheels, and fuel cells), power systems, and power management and distribution. The propulsion papers cover chemical propulsion, cryogenic propellant systems, electric propulsion, and nuclear thermal rocket propulsion. Each paper addresses some history, current efforts, and future plans for each of the technology areas. DOI: 10.1061/(ASCE)AS.1943-5525.0000315. (C) 2013 American Society of Civil Engineers.
C1 NASA, Power & In Space Prop Div, Glenn Res Ctr, Cleveland, OH 44135 USA.
RP Lyons, VJ (reprint author), NASA, Power & In Space Prop Div, Glenn Res Ctr, 21000 Brookpk Rd, Cleveland, OH 44135 USA.
EM Valerie.J.Lyons@nasa.gov
CR Bailey S. G., 2011, ROLE NASA PHOTOVOLTA
   Beremand D. G., 1970, X52826 TM NASA
   Borowski SK, 2013, J AEROSPACE ENG, V26, P334, DOI 10.1061/(ASCE)AS.1943-5525.0000313
   Bulzan D., 2010, NASA GREEN AVIATION
   Burke K., 2012, 2012217421E18093 TM
   Chan J, 2007, AIP CONF PROC, V880, P615
   Dawson V., 2004, NASA
   Easton R.L., 1958, REV SCI INSTRUM, V30, P70
   Encyclopedia Astronautica, 1989, MIR 2
   Hendricks R. C., 2008, INT EN CONV ENG C EX
   Hoberecht M., 2011, 2011217107E17783 TM
   Kenny BH, 2005, IEEE T IND APPL, V41, P1029, DOI 10.1109/TIA.2005.851021
   Klann J. L., 1968, IEEE INT EN CONV ENG, V1, P407
   Klann J. L., 1968, D4600 TN NASA
   Linne DL, 2013, J AEROSPACE ENG, V26, P317, DOI 10.1061/(ASCE)AS.1943-5525.0000303
   Lyons V. J., 2008, TM2008215447 AM I AE
   Lyons V. J., 2009, 20094584 AM I AER AS
   Lyons V. J., 2012, AEROSPACE POWER TECH
   Mason LS, 2013, J AEROSPACE ENG, V26, P352, DOI 10.1061/(ASCE)AS.1943-5525.0000318
   Mason L. S., 1999, TM1999209380 NASA
   Meyer ML, 2013, J AEROSPACE ENG, V26, P343, DOI 10.1061/(ASCE)AS.1943-5525.0000297
   NASA, 1993, SOL DYN POW SYST DEV
   Patel M., 2005, SPACECRAFT POWER SYS
   Patterson MJ, 2013, J AEROSPACE ENG, V26, P300, DOI 10.1061/(ASCE)AS.1943-5525.0000304
   Peto M. A., 1994, LEWIS LEAD US RUSSIA
   Reid C. M., 2011, TM2011217209 NASA
   Reid CM, 2013, J AEROSPACE ENG, V26, P361, DOI 10.1061/(ASCE)AS.1943-5525.0000323
   Scheidegger B. T., 2012, INSTALLATION OHIOS 1
   Schulze N. R., 1991, FUSION TECHNOL, V19
   Scott J. H., 2008, 20085793 AM I AER AS
   Seng G. T., 2007, SMART EFFICIENT COMP
   Seng G. T., 2007, ZERO CO2 RES PROJECT
   Seng G. T., 2007, REVOLUTIONARY AEROPR
   Shaw R. J., 2003, TM2004212729 NASA
   Steffen CJ, 2009, NUCL TECHNOL, V166, P240
   Steffen C. J., 2005, GT200568619 ASME
   Veris J., 2001, AEROSP FRONTIERS, V3, P1
   Wilson K. K., 1995, LEWIS NEWS, V2, P1
   Witcofski R. D., 1979, TM80155 NASA
NR 39
TC 0
Z9 0
U1 5
U2 49
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 0893-1321
J9 J AEROSPACE ENG
JI J. Aerosp. Eng.
PD APR
PY 2013
VL 26
IS 2
SI SI
BP 288
EP 299
DI 10.1061/(ASCE)AS.1943-5525.0000315
PG 12
WC Engineering, Aerospace; Engineering, Civil
SC Engineering
GA 118YR
UT WOS:000317063900007
ER


PT J
AU Meyer, ML
   Chato, DJ
   Plachta, DW
   Zimmerli, GA
   Barsi, SJ
   Van Dresar, NT
   Moder, JP
AF Meyer, Michael L.
   Chato, David J.
   Plachta, David W.
   Zimmerli, Gregory A.
   Barsi, Stephen J.
   Van Dresar, Neil T.
   Moder, Jeffrey P.
TI Mastering Cryogenic Propellants
SO JOURNAL OF AEROSPACE ENGINEERING
LA English
DT Article
DE Space exploration; Spacecraft; Aerospace engineering; Research; Fluid
   dynamics; Thermodynamics; Tanks
AB The National Aeronautics and Space Administration (NASA) Glenn Research Center (GRC) began experimentation with cryogenic propellants in the early 1950s to understand the potential of these high-performance propellants for use in liquid propellant rocket engines. Supporting these tests required learning how to both design cryogenic systems and develop procedures to safely and reliably work with cryogenic fuels and oxidizers. This early work led to the development of a skill set that has been core to the center ever since. When NASA was formed and the exploration missions were defined, it became clear that the ability to use cryogenic propellants in the thermal and microgravity environment of space was critical to mission success, and the agency was tasked with enabling this capability. To support development of the Centaur upper stage and the Saturn S-IVB stage, GRC researchers and engineers initiated extensive technology development for the in-space application of cryogenic fluid management (CFM). These initial efforts addressed basic requirements of propellant slosh, settling, and short-term storage/pressure control. Over the ensuing years, the NASA GRC has advanced CFM technologies to enable more reliable and capable upper stages. Today, these CFM technologies are on the brink of enabling long-duration in-space cryogenic propulsion stages and cryogenic propellant depots. DOI: 10.1061/(ASCE)AS.1943-5525.0000297. (C) 2013 American Society of Civil Engineers.
C1 [Meyer, Michael L.] NASA, Power & In Space Prop Div, Glenn Res Ctr, Cleveland, OH 44135 USA.
   [Chato, David J.; Plachta, David W.; Zimmerli, Gregory A.; Barsi, Stephen J.; Van Dresar, Neil T.; Moder, Jeffrey P.] NASA, Glenn Res Ctr, Cleveland, OH 44135 USA.
RP Meyer, ML (reprint author), NASA, Power & In Space Prop Div, Glenn Res Ctr, 21000 Brookpk Rd, Cleveland, OH 44135 USA.
EM michael.l.meyer@nasa.gov; david.j.chato@nasa.gov;
   david.w.plachta@nasa.gov; greg.zimmerli@nasa.gov;
   stephen.j.barsi@nasa.gov; neil.t.vandresar@nasa.gov;
   jeffrey.p.moder@nasa.gov
RI Chato, David/B-2698-2013
OI Chato, David/0000-0003-2990-0646
CR Augustine N. R., 2009, REV US HUMAN SPACE F
   Aydelott J.C., 1985, TM87145 NASA
   Aydelott J. C., 1967, D4171 TN NASA
   Aydelott J.C., 1987, TM89873 NASA
   Aydelott J.C., 1983, TP2107 NASA
   Aydelott J.C., 1979, TP1487 NASA
   Barsi S, 2008, CRYOGENICS, V48, P122, DOI 10.1016/j.cryogenics.2008.01.003
   Bentz M. D., 1997, 972816 AM I AER ASTR
   Berns J. A., 1968, D4571 TN NASA
   Bradshaw R. D., 1976, CR135023 NASA
   Bush G. W., 2004, RENEWED SPIRIT DISCO
   Chato D.J., 1997, 972815 AM I AER ASTR
   Chato D. J., 1991, TM104444 NASA
   Chato DJ., 1990, TM103155 NASA
   Chato D. J., 2002, 20023983 AM I AER AS
   Chato D.J., 2004, THESIS CASE W RES U
   Chato D. J., 1998, 19983197 AM I AER AS
   Chen Y., 2011, 20111319 AM I AER AS
   Chrysler Corp, 1967, HSMR42167 NASA CHRYS
   Dawson V.P., 2004, SP20044230 NASA
   Defelice D.M., 1987, TM89921 NASA
   Dempsey P., 1995, TM106991 NASA
   Dodge F. T., 2008, CR2008215281 NASA
   Dye S., 2009, ADV CRYOG ENG T CRYO, V55, P946
   Feller J. R., 2008, P 16 INT CRYOC C, P601
   Flachbart R.H., 2007, ADV CRYOGEN ENG, V53, P1483
   Guzik M., 2011, TFAWS2011AT01 GLENN
   Hartwig J.W., 2012, P 50 ANN M AER SCI
   Hastings L.J., 2003, TM2003212926 NASA
   HOCHSTEIN JI, 1991, J PROPUL POWER, V7, P938, DOI 10.2514/3.23412
   Hochstein J. I., 1984, 841344 AM I AER ASTR
   Hotchkiss R. S., 1979, LA8163MS LOS AL SCI
   Jurns JM, 2012, CRYOGENICS, V52, P283, DOI 10.1016/j.cryogenics.2012.01.022
   Kartuzova O., 2011, 20116037 AM I AER AS
   Kassemi M., 2008, SCI REQUIREMENTS DEF
   Knoll R. H., 1962, X484 TM NASA
   Knoll R. H., 1987, 871557 AM I AER ASTR
   Knoll R.H., 1991, TM104493 NASA
   Kramer E., 1998, TP3523 NASA
   Kudlac M. T., 2006, 20065054 AM I AER AS
   Labus T.L., 1974, D7480 TN NASA
   Lacovic R., 1977, TM73749 NASA
   Lacovic R. F., 1975, X71821 TM NASA
   Lin C.S., 1994, 942079 AM I AER ASTR
   Marchetta J. G., 2007, 2007955 AM I AER AST
   Meyer M. L., 2012, TM2012217642 NASA GE
   Mitchell R.C., 1967, ADV CRYOGEN ENG, V12, P72
   Moran M.E., 1991, TM105273 NASA
   NASA, 2011, NASA GLENN RES FAC
   [Anonymous], 2005, TM2005214062 NASA
   National Research Council Steering Committee for NASA Technology Roadmaps, 2012, NASA SPAC TECHN ROAD
   Otto E.W., 1966, CHEM ENG PROGR S 60, V62, P158
   Petrash D. A., 1963, D1577 TN NASA
   Plachta DW, 2008, AIP CONF PROC, V985, P1457
   Plachta D. W., 2004, TM2004213390 NASA
   [Anonymous], SURF EV FLUID INT TO
   Sauter D.R., 2006, 2006984 AM I AER AST
   Stark J. A., 1974, CR134746 NASA
   Sumner I.E., 1978, TM78969 NASA
   Taylor W.J., 1991, TM104492 NASA
   Taylor W.J., 1992, TM106018 NASA
   Torrey M D, 1985, LA10612MS LOS AL NAT
   Van Dresar N. T., 2011, LIQUID OXYG IN PRESS
   Van Dresar N.T., 1992, TM105411 NASA
   VanOverbeke T.J., 2004, TM2004213193 NASA
   Vaughan D. A., 1991, 911842 AM I AER ASTR
   Warren R. P., 1967, ADV CRYOGEN ENG, V12, P63
   Zhang N., 2011, INT J AERO MECH ENG, V5, P203
   Zimmerli G. A., 2011, 20111320 AM I AER AS
NR 69
TC 3
Z9 3
U1 1
U2 19
PU ASCE-AMER SOC CIVIL ENGINEERS
PI RESTON
PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA
SN 0893-1321
J9 J AEROSPACE ENG
JI J. Aerosp. Eng.
PD APR
PY 2013
VL 26
IS 2
SI SI
BP 343
EP 351
DI 10.1061/(ASCE)AS.1943-5525.0000297
PG 9
WC Engineering, Aerospace; Engineering, Civil
SC Engineering
GA 118YR
UT WOS:000317063900011
ER


PT J
AU Rossi, R
   Amato, M
   Bitella, G
   Bochicchio, R
AF Rossi, R.
   Amato, M.
   Bitella, G.
   Bochicchio, R.
TI Electrical resistivity tomography to delineate greenhouse soil
   variability
SO INTERNATIONAL AGROPHYSICS
LA English
DT Article
DE electrical resistivity tomography; yield variability; greenhouse; soil
   spatial variability
ID STRUCTURAL HETEROGENEITY; TILLED LAYER; FIELD-SCALE; 2D; CONDUCTIVITY;
   BIOMASS; GROWTH; WATER; CLAY
AB Appropriate management of soil spatial variability is an important tool for optimizing farming inputs, with the result of yield increase and reduction of the environmental impact in field crops. Under greenhouses, several factors such as non-uniform irrigation and localized soil compaction can severely affect yield and quality. Additionally, if soil spatial variability is not taken into account, yield deficiencies are often compensated by extra-volumes of crop inputs; as a result, over-irrigation and over-fertilization in some parts of the field may occur. Technology for spatially sound management of greenhouse crops is therefore needed to increase yield and quality and to address sustainability. In this experiment, 2D-electrical resistivity tomography was used as an exploratory tool to characterize greenhouse soil variability and its relations to wild rocket yield. Soil resistivity well matched biomass variation (R-2 = 0.70), and was linked to differences in soil bulk density (R-2 = 0.90), and clay content (R-2 = 0.77). Electrical resistivity tomography shows a great potential in horticulture where there is a growing demand of sustainability coupled with the necessity of stabilizing yield and product quality.
C1 [Rossi, R.] CRA SCA, I-70125 Bari, Italy.
   [Amato, M.; Bitella, G.] Univ Basilicata, Sch Agr Forest Food & Environm Sci, I-85100 Potenza, Italy.
   [Bochicchio, R.] Univ Basilicata, Int Doctoral Sch Crop Syst Forest Food & Environm, I-85100 Potenza, Italy.
RP Amato, M (reprint author), Univ Basilicata, Sch Agr Forest Food & Environm Sci, Viale Ateneo Lucano, I-85100 Potenza, Italy.
EM marinria@gmail.com
FU EC-InterregIIIBWETMUST project
FX This work was partly funded by the EC-InterregIIIBWETMUST project,
   2010-2013.
CR Amato M, 2008, TREE PHYSIOL, V28, P1441
   Basso B, 2010, AGRON J, V102, P440, DOI 10.2134/agronj2009.0298
   Besson A, 2004, SOIL TILL RES, V79, P239, DOI 10.1016/j.still.2004.07.012
   Besson A, 2010, EUR J SOIL SCI, V61, P120, DOI 10.1111/j.1365-2389.2009.01211.x
   Corwin DL, 2005, COMPUT ELECTRON AGR, V46, P135, DOI 10.1016/j.compag.2004.11.003
   Dahlin T, 2004, GEOPHYS PROSPECT, V52, P379, DOI 10.1111/j.1365-2478.2004.00423.x
   de Groot CC, 2003, PLANT SOIL, V248, P257, DOI 10.1023/A:1022323215010
   de Tourdonnet S, 2001, AGRONOMIE, V21, P297, DOI 10.1051/agro:2001125
   Fukue M, 1999, ENG GEOL, V54, P43, DOI 10.1016/S0013-7952(99)00060-5
   Giao PH, 2003, J APPL GEOPHYS, V52, P157, DOI 10.1016/S0926-9851(03)00002-8
   Jin J, 2009, J AGR FOOD CHEM, V57, P5227, DOI 10.1021/jf9002973
   Kreij C, 2003, AGR WATER MANAGE, V60, P73
   Munoz P, 2008, AGRON SUSTAIN DEV, V28, P489, DOI 10.1051/agro:2008024
   Passioura JB, 2002, PLANT CELL ENVIRON, V25, P311, DOI 10.1046/j.0016-8025.2001.00802.x
   Rossi R, 2011, EUR J SOIL SCI, V62, P206, DOI 10.1111/j.1365-2389.2010.01329.x
   Samouelian A, 2005, SOIL TILL RES, V83, P173, DOI 10.1016/j.still.2004.10.004
   Samouelian A, 2003, SOIL SCI SOC AM J, V67, P1319
   Schwartz BF, 2008, J HYDROL, V362, P234, DOI 10.1016/j.jhydrol.2008.08.027
   Seger M, 2009, SOIL TILL RES, V103, P387, DOI 10.1016/j.still.2008.12.003
   Stirzaker RJ, 2003, IRRIGATION SCI, V22, P177, DOI 10.1007/s00271-003-0083-5
   Sudduth KA, 2005, COMPUT ELECTRON AGR, V46, P263, DOI 10.1016/j.compag.2004.11.010
NR 21
TC 1
Z9 1
U1 0
U2 5
PU POLISH ACAD SCIENCES
PI LUBLIN
PA INST AGROPHYSICS, DOSWIADCZALNA 4, LUBLIN, 20-290, POLAND
SN 0236-8722
J9 INT AGROPHYS
JI Int. Agrophys.
PD MAR
PY 2013
VL 27
IS 2
BP 211
EP 218
DI 10.2478/v10247-012-0087-6
PG 8
WC Agronomy
SC Agriculture
GA 140HA
UT WOS:000318643800012
ER


PT J
AU Hori, M
   Matsumoto, M
   Tanahashi, N
   Momomura, S
   Uchiyama, S
   Goto, S
   Izumi, T
   Koretsune, Y
   Kajikawa, M
   Kato, M
   Ueda, H
   Iwamoto, K
   Tajiri, M
AF Hori, Masatsugu
   Matsumoto, Masayasu
   Tanahashi, Norio
   Momomura, Shin-ichi
   Uchiyama, Shinichiro
   Goto, Shinya
   Izumi, Tohru
   Koretsune, Yukihiro
   Kajikawa, Mariko
   Kato, Masaharu
   Ueda, Hitoshi
   Iwamoto, Kazuya
   Tajiri, Masahiro
CA J-ROCKET AF Study Investigators
TI Safety and Efficacy of Adjusted Dose of Rivaroxaban in Japanese Patients
   With Non-Valvular Atrial Fibrillation - Subanalysis of J-ROCKET AF for
   Patients With Moderate Renal Impairment
SO CIRCULATION JOURNAL
LA English
DT Article
DE Atrial fibrillation; Renal impairment; Rivaroxaban; Stroke; Warfarin
ID FACTOR-XA INHIBITOR; ANTITHROMBOTIC THERAPY; STROKE PREVENTION;
   RISK-FACTORS; WARFARIN; PHARMACODYNAMICS; PHARMACOKINETICS;
   ANTICOAGULATION; BAY-59-7939; DABIGATRAN
AB Background: In the Japanese Rivaroxaban Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation (J-ROCKET AF) study, rivaroxaban 15 mg once daily was given to patients with creatinine clearance (CrCl) >= 50ml/min (preserved renal function), and was reduced to 10 mg once daily in patients with CrCl 30-49 ml/min (moderate renal impairment). The aim of this sub-analysis was to assess the safety and efficacy of the adjusted dose of rivaroxaban compared with warfarin in a cohort with moderate renal impairment.
   Methods and Results: Compared with patients with preserved renal function, those with moderate renal impairment (22.2% of all randomized patients) had higher rates of bleeding and stroke events irrespective of study treatment. Among those with moderate renal impairment, the principal safety endpoint occurred at 27.76%/year with rivaroxaban vs. 22.85%/year with warfarin (hazard ratio [HR], 1.22; 95% confidence interval [CI]: 0.78-1.91) and the rate of the primary efficacy endpoint was 2.77%/year vs. 3.34%/year (HR, 0.82; 95% Cl: 0.25-2.69), respectively. There were no significant interactions between renal function and study treatment in the principal safety and the primary efficacy endpoints (P=0.628, 0.279 for both interactions, respectively).
   Conclusions: The safety and efficacy of rivaroxaban vs. warfarin were consistent in patients with moderate renal impairment and preserved renal function. (Circ J 2013; 77: 632-638)
C1 [Hori, Masatsugu] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka 3578511, Japan.
   [Koretsune, Yukihiro] Osaka Natl Hosp, Inst Clin Res, Osaka, Japan.
   [Kajikawa, Mariko; Kato, Masaharu; Ueda, Hitoshi; Iwamoto, Kazuya; Tajiri, Masahiro] Bayer Yakuhin, Osaka, Japan.
   [Matsumoto, Masayasu] Hiroshima Univ, Dept Clin Neurosci & Therapeut, Hiroshima, Japan.
   [Tanahashi, Norio] Saitama Med Univ, Int Med Ctr, Dept Neurol, Saitama, Japan.
   [Momomura, Shin-ichi] Jichi Med Univ, Saitama Med Ctr, Div Cardiovasc Med, Saitama, Japan.
   [Uchiyama, Shinichiro] Tokyo Womens Med Univ, Dept Neurol, Tokyo, Japan.
   [Goto, Shinya] Tokai Univ, Sch Med, Dept Med Cardiol, Tokyo 151, Japan.
   [Izumi, Tohru] Kitasato Univ, Sch Med, Dept Cardioangiol, Sagamihara, Kanagawa 228, Japan.
RP Hori, M (reprint author), Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari Ku, 1-3-3 Nakamichi, Osaka 3578511, Japan.
EM hori-ma@mc.pref.osaka.jp
CR COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Ezekowitz MD, 2009, AM HEART J, V157, p810 el
   Ezekowitz MD, 2009, AM HEART J, V157, P805, DOI 10.1016/j.ahj.2009.02.005
   Fang MC, 2011, J AM COLL CARDIOL, V58, P395, DOI 10.1016/j.jacc.2011.03.031
   Fox KAA, 2011, EUR HEART J, V32, P2387, DOI 10.1093/eurheartj/ehr342
   Friberg L, 2012, EUR HEART J, V33, P1500, DOI 10.1093/eurheartj/ehr488
   Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292
   Go AS, 2009, CIRCULATION, V119, P1363, DOI 10.1161/CIRCULATIONAHA.108.816082
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Hori M, 2012, CIRC J, V76, P2104, DOI 10.1253/circj.CJ-12-0454
   Hori M, 2011, CIRC J, V75, P800, DOI 10.1253/circj.CJ-11-0191
   Kubitza D, 2005, CLIN PHARMACOL THER, V78, P412, DOI 10.1016/j.clpt.2005.06.011
   Kubitza D, 2005, EUR J CLIN PHARMACOL, V61, P873, DOI 10.1007/s00228-005-0043-5
   Kubitza D, 2008, CURR MED RES OPIN, V24, P2757, DOI 10.1185/03007990802361499 
   Kubitza D, 2010, BRIT J CLIN PHARMACO, V70, P703, DOI 10.1111/j.1365-2125.2010.03753.x
   Mueck W, 2011, CLIN PHARMACOKINET, V50, P675, DOI 10.2165/11595320-000000000-00000
   Ogawa S, 2011, CIRC J, V75, P2719, DOI 10.1253/circj.CJ-88-0026
   Ogawa S, 2011, CIRC J, V75, P1539, DOI 10.1253/circj.CJ-11-0304
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Schirmer SH, 2010, J AM COLL CARDIOL, V56, P2067, DOI 10.1016/j.jacc.2010.09.017
   Tanigawa T, 2012, DRUG METAB PHARMACOK
   Vazquez E, 2011, CHEST, P139, DOI DOI 10.1378/CHEST.10-2961
   Vazquez E, 2011, CHEST, V139, P1248, DOI 10.1378/chest.10-2961
   Whaley-Connell AT, 2008, AM J KIDNEY DIS, V51, pS13, DOI 10.1053/j.ajkd.2007.12.016
   Wolf P, 1991, STROKE, V2, P983
NR 28
TC 27
Z9 27
U1 3
U2 7
PU JAPANESE CIRCULATION SOC
PI KYOTO
PA KINKI INVENTION CENTER, 14 YOSHIDA KAWAHARACHO, SAKYO-KU, KYOTO,
   606-8305, JAPAN
SN 1346-9843
J9 CIRC J
JI Circ. J.
PD MAR
PY 2013
VL 77
IS 3
BP 632
EP 638
DI 10.1253/circj.CJ-12-0899
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 134IF
UT WOS:000318202900015
PM 23229461
ER


PT J
AU Tewari, A
AF Tewari, Ashish
TI Adaptive Vectored Thrust Deorbiting of Space Debris
SO JOURNAL OF SPACECRAFT AND ROCKETS
LA English
DT Article
ID SYSTEM; SATELLITE; REMOVAL
AB A novel but simple deorbiting control system is proposed for cleaning up space debris in a low Earth orbit. The method consists of employing a low-thrust spacecraft tug with a continuously varying thrust direction for collecting and decelerating debris items at a given orbital radius. A time-linear thrust-direction profile is the outcome of the nominal, two-point boundary-value problem for deceleration by a given velocity magnitude. Three simple model reference adaptive control strategies are proposed for driving the velocity error from nominal to zero in the presence of uncertain debris mass and rocket thrust variation. Although linear time-varying control with velocity feedback and a dead-zone is sufficient to minimize tracking error in most cases, it is improved significantly by a Lyapunov-based controller that guarantees asymptotic stability in the presence of a random but bounded acceleration disturbance. A nonlinear feedback adaptation law based upon the MIT rule achieves the fastest error decay rate error of the three techniques and is seen to have a logarithmic relationship between the steady-state value of controller parameter and adaptation gain.
C1 Indian Inst Technol, Dept Aerosp Engn, Kanpur 208016, Uttar Pradesh, India.
RP Tewari, A (reprint author), Indian Inst Technol, Dept Aerosp Engn, Kanpur 208016, Uttar Pradesh, India.
CR Astrom K. J., 1995, ADAPTIVE CONTROL, P185
   Battin R. H., 1999, AIAA ED SERIES, P524
   Bombardelli C, 2011, J GUID CONTROL DYNAM, V34, P916, DOI 10.2514/1.51832
   CLOHESSY WH, 1960, J AEROSP SCI, V27, P653
   Krstic M., 1995, NONLINEAR ADAPTIVE C
   Mendeck GF, 2005, ADV ASTRONAUT SCI, V120, P1923
   Nishida SI, 2009, ACTA ASTRONAUT, V65, P95, DOI 10.1016/j.actaastro.2009.01.041
   Patera RP, 2008, J SPACECRAFT ROCKETS, V45, P1031, DOI 10.2514/1.30173
   Phipps CR, 1997, P SOC PHOTO-OPT INS, V3092, P728, DOI 10.1117/12.270174
   Takeichi N, 2006, J SPACECRAFT ROCKETS, V43, P1283, DOI 10.2514/1.19635
   Tewari A., 2011, ADV CONTROL AIRCRAFT, P297
   Tewari A, 2009, J SPACECRAFT ROCKETS, V46, P299, DOI 10.2514/1.39651
NR 12
TC 2
Z9 2
U1 0
U2 13
PU AMER INST AERONAUTICS  ASTRONAUTICS
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 0022-4650
J9 J SPACECRAFT ROCKETS
JI J. Spacecr. Rockets
PD MAR-APR
PY 2013
VL 50
IS 2
BP 394
EP 401
DI 10.2514/1.A32421
PG 8
WC Engineering, Aerospace
SC Engineering
GA 121PY
UT WOS:000317257900015
ER


PT J
AU Johnson, L
   Meyer, M
   Palaszewski, B
   Coote, D
   Goebel, D
   White, H
AF Johnson, Les
   Meyer, Michael
   Palaszewski, Bryan
   Coote, David
   Goebel, Dan
   White, Harold
TI Development priorities for in-space propulsion technologies
SO ACTA ASTRONAUTICA
LA English
DT Article; Proceedings Paper
CT 7th IAA Symposium on Realistic Near-Term Advanced Scientific Space
   Missions - Missions to the Outer Solar System and Beyond
CY JUL 11-14, 2011
CL Aosta, ITALY
SP Int Acad Astronaut (IAA)
DE In-space propulsion; Chemical propulsion; Tether propulsion; Electric
   propulsion; Solar sail propulsion; Propulsion technology roadmap
AB During the summer of 2010, NASA's Office of Chief Technologist assembled 15 civil service teams to support the creation of a NASA integrated technology roadmap. The Aero-Space Technology Area Roadmap is an integrated set of technology area roadmaps recommending the overall technology investment strategy and prioritization for NASA's technology programs. The integrated set of roadmaps will provide technology paths needed to meet NASA's strategic goals. The roadmaps have been reviewed by senior NASA management and the National Research Council.
   With the exception of electric propulsion systems used for commercial communications satellite station-keeping and a handful of deep space science missions, almost all of the rocket engines in use today are chemical rockets; that is, they obtain the energy needed to generate thrust by combining reactive chemicals to create a hot gas that is expanded to produce thrust. A significant limitation of chemical propulsion is that it has a relatively low specific impulse. Numerous concepts for advanced propulsion technologies with significantly higher values of specific impulse have been developed over the past 50 years.
   Advanced in-space propulsion technologies will enable much more effective exploration of our solar system, near and far, and will permit mission designers to plan missions to "fly anytime, anywhere, and complete a host of science objectives at the destinations" with greater reliability and safety. With a wide range of possible missions and candidate propulsion technologies with very diverse characteristics, the question of which technologies are 'best' for future missions is a difficult one. A portfolio of technologies to allow optimum propulsion solutions for a diverse set of missions and destinations are described in the roadmap and herein. Published by Elsevier Ltd.
C1 [Johnson, Les] NASA, George C Marshall Space Flight Ctr, Huntsville, AL 35812 USA.
   [Meyer, Michael; Palaszewski, Bryan] NASA, Glenn Res Ctr, Cleveland, OH 44135 USA.
   [Coote, David] NASA, Stennis Space Ctr, MS 39529 USA.
   [Goebel, Dan] NASA, Jet Prop Lab, Pasadena, CA 91109 USA.
   [White, Harold] NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA.
RP Johnson, L (reprint author), NASA, George C Marshall Space Flight Ctr, Huntsville, AL 35812 USA.
EM c.les.johnson@nasa.gov
CR Beattie J. R., 1998, IND PHYS
   Carmain A., 2007, 2007 IEEE AER C BIG
   Dobrowolny M., NUOVO CIMENTO C, VC, P1
   Doty P., 1995, AIAA SPAC PROGR TECH
   Frisbee H. Robert, 2003, J PROPUL POWER, V19
   Fujii HA, 2009, ACTA ASTRONAUT, V64, P313, DOI 10.1016/j.actaastro.2008.07.006
   Grossi M., PLASMA MOTOR GENERAT
   Johnson L, 2002, NASACR2002212050
   Johnson L, 2011, ADV SPACE RES, V48, P1687, DOI 10.1016/j.asr.2010.12.011
   Jones P.A., 2011, IEEE AEROSP ELECT SY, V26
   Matloff G.L., 2007, LIVING LAND SPACE GR, P105
   Moore CL, 2010, ACTA ASTRONAUT, V67, P1170, DOI 10.1016/j.actaastro.2010.06.031
   Patterson M.J., 2005, P 43 AIAA ASME SAE A
   Summerer L, 2011, P I MECH ENG G-J AER, V225, P129, DOI 10.1243/09544100JAERO766
   Tsuda Y, 2011, ACTA ASTRONAUT, V69, P833, DOI 10.1016/j.actaastro.2011.06.005
   Witzberger K.E., NASATM2006214044
NR 16
TC 3
Z9 3
U1 4
U2 66
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD FEB
PY 2013
VL 82
IS 2
SI SI
BP 148
EP 152
DI 10.1016/j.actaastro.2012.05.006
PG 5
WC Engineering, Aerospace
SC Engineering
GA 073UZ
UT WOS:000313769900002
ER


PT J
AU Nechaeva, M
   Antipenko, A
   Bezrukovs, V
   Bezrukov, D
   Dementjev, A
   Dugin, N
   Konovalenko, A
   Kulishenko, V
   Liu, X
   Nabatov, A
   Nesteruk, V
   Pupillo, G
   Reznichenko, A
   Salerno, E
   Shmeld, I
   Shulga, O
   Sybiryakova, Y
   Tikhomirov, Y
   Tkachenko, A
   Volvach, A
   Yang, WJ
AF Nechaeva, M.
   Antipenko, A.
   Bezrukovs, V.
   Bezrukov, D.
   Dementjev, A.
   Dugin, N.
   Konovalenko, A.
   Kulishenko, V.
   Liu, X.
   Nabatov, A.
   Nesteruk, V.
   Pupillo, G.
   Reznichenko, A.
   Salerno, E.
   Shmeld, I.
   Shulga, O.
   Sybiryakova, Y.
   Tikhomirov, Yu.
   Tkachenko, A.
   Volvach, A.
   Yang, W. -J.
TI AN EXPERIMENT ON RADIO LOCATION OF OBJECTS IN THE NEAR-EARTH SPACE WITH
   VLBI IN 2012
SO BALTIC ASTRONOMY
LA English
DT Article; Proceedings Paper
CT Ventspils International Radio Astronomy Conference (VIRAC) on Advances
   in Radio Astronomy of Near-Earth Environment
CY AUG 13-15, 2012
CL Ventspils, LATVIA
SP Ventspils Univ Coll, Engn Res Inst Ventspils Int Radio Astronomy Ctr
DE instrumentation: interferometers, Very Long Baseline Interferometry;
   techniques: interferometric, radar astronomy; ephemeris
AB An experiment on radar location of space debris objects using of the method of VLBI was carried out in April, 2012. The radar VLBI experiment consisted in irradiation of some space debris objects (4 rocket stages and 5 inactive satellites) with a signal of the transmitter with RT-70 in Evpatoria, Ukraine. Reflected signals were received by a complex of radio telescopes in the VLBI mode. The following VLBI stations took part in the observations: Ventspils (RT-32), Urumqi (RT-25), Medicina (RT-32) and Simeiz (RT-22). The experiment included measurements of the Doppler frequency shift and the delay for orbit refining, and measurements of the rotation period and sizes of objects by the amplitudes of output interferometer signals. The cross-correlation of VLBI-data is performed at a correlator NIRFI-4 of Radiophysical Research Institute (Nizhny Novgorod). Preliminary data processing resulted in the series of Doppler frequency shifts, which comprised the information on radial velocities of the objects. Some results of the experiment are presented.
C1 [Nechaeva, M.; Bezrukovs, V.; Bezrukov, D.; Shmeld, I.] Ventspils Int Radio Astron Ctr, LV-3601 Ventspils, Latvia.
   [Antipenko, A.; Dementjev, A.; Dugin, N.; Tikhomirov, Yu.] Radiophys Res Inst, Nizhnii Novgorod 603950, Russia.
   [Konovalenko, A.; Kulishenko, V.; Nabatov, A.; Reznichenko, A.] Inst Radio Astron, UA-310002 Kharkov, Ukraine.
   [Yang, W. -J.] Chinese Acad Sci, Xinjiang Astron Observ, Urumqi 830011, Xinjiang, Peoples R China.
   [Nesteruk, V.] Natl Space Facil Control & Test Ctr, Saky Dist, Ar Crimea, Ukraine.
   [Pupillo, G.; Salerno, E.] INAF, Ist Radioastron, I-40129 Bologna, Italy.
   [Shulga, O.; Sybiryakova, Y.] Nikolaev Astron Observ, UA-54030 Nikolayev, Ukraine.
   [Tkachenko, A.] Air Force Univ, UA-61023 Kharkov 23, Ukraine.
   [Volvach, A.] Radio Astron Lab Crimean Astrophys Observ, UA-98688 Katsiveli, Crimea, Ukraine.
RP Nechaeva, M (reprint author), Ventspils Int Radio Astron Ctr, Inzenieru Str 101, LV-3601 Ventspils, Latvia.
EM m.nechaeva@gmail.com; vladislavsb@venta.lv; dugin@nirfi.sci-nnov.ru;
   akonov@ri.kharkov.ua; kulish@rikharkov.ua; liux@xao.ac.cn;
   nesteruk2007@rambler.ru; g.pupillo@isac.cnr.it; ram@ic.kharkov.ua;
   esalerno@ira.inafit; ivarss@venta.lv; avshulga@mail.ru;
   evg_sibir@mail.ru; aatkacenko@ukr.net; volvach@crao.crimea.ua;
   yangwj@xao.ac.cn
RI Nechaeva, Maria/E-7255-2014; 
OI Pupillo, Giuseppe/0000-0003-2172-1336
CR Alekseev V. A., 2000, Radiophysics and Quantum Electronics, V43, DOI 10.1023/A:1004850317777
   Alekseev V. A., 1989, KOSM ISSLED, V27, P765
   Alekseev V. A., 1989, KOSM ISSLED, V27, P447
   Jones DL, 2011, ASTRON J, V141, DOI 10.1088/0004-6256/141/2/29
   Kara I. V., 2011, Bulletin of the Crimean Astrophysical Observatory, V107, P98, DOI 10.3103/S0190271711010086
   Lanyi G, 2007, P IEEE, V95, P2193, DOI 10.1109/JPROC.2007.905183
   Lebreton JP, 2005, NATURE, V438, P758, DOI 10.1038/nature04347
   Molotov I, 2004, ADV SPACE RES, V34, P884, DOI 10.1016/j.asr.2003.09.053
   Molotov I., 2008, MEASURING FUTURE, P30
   Nechaeva MB, 2007, RADIOPHYS QUANT EL+, V50, P527, DOI 10.1007/s11141-007-0047-3
   Shulga Y., 2008, IAU S, V248, P128
NR 11
TC 3
Z9 4
U1 2
U2 12
PU INST THEORETICAL PHYSICS ASTRONOMY
PI MOLETAI
PA MOLETAI LT-4150, LITHUANIA
SN 1392-0049
J9 BALT ASTRON
JI Balt. Astron.
PY 2013
VL 22
IS 1
BP 35
EP 41
PG 7
WC Astronomy & Astrophysics
SC Astronomy & Astrophysics
GA 101CL
UT WOS:000315752700005
ER


PT J
AU Yap, KC
   Macias, J
   Kaouk, M
   Gafka, TL
   Kerr, JH
AF Yap, Keng C.
   Macias, Jesus
   Kaouk, Mohamed
   Gafka, Tammy L.
   Kerr, Justin H.
TI Structural Health Monitoring and Risk Management of a Reusable Launch
   Vehicle
SO JOURNAL OF SPACECRAFT AND ROCKETS
LA English
DT Article; Proceedings Paper
CT 19th AIAA/ASME/AHS Adaptive Structures Conference
CY APR 04-07, 2011
CL Denver, CO
SP AIAA, ASME, AHS
ID RANK PERTURBATION-THEORY
AB A structural-health-monitoring system can contribute to the risk management of a structure operating under hazardous conditions. An example is the wing leading-edge impact-detection system that monitors the debris hazards to the Space Shuttle Orbiter's reinforced carbon carbon panels. Since return to flight after the Columbia accident, the system was developed and subsequently deployed on board the orbiter to detect ascent and on-orbit debris impacts, so as to support the assessment of wing leading edge structural integrity before orbiter reentry. As structural health monitoring is inherently an inverse problem, the analyses involved, including those performed for this system, tend to be associated with significant uncertainty. The use of probabilistic approaches to handle the uncertainty has resulted in the successful implementation of many development and application milestones.
C1 [Yap, Keng C.] Boeing Space Explorat, Loads & Dynam, Boeing Def Space & Secur, Houston, TX 77059 USA.
   [Macias, Jesus] United Space Alliance, Vehicle & Syst Anal, USA Orbiter Element, Houston, TX 77058 USA.
   [Kaouk, Mohamed] NASA, Struct & Dynam ES6, NASA JSC, Houston, TX 77058 USA.
   [Kerr, Justin H.] NASA, Space Shuttle Orbiter Project Off MV6, NASA JSC, Houston, TX 77058 USA.
RP Yap, KC (reprint author), Boeing Space Explorat, Loads & Dynam, Boeing Def Space & Secur, Houston, TX 77059 USA.
EM Keng.C.Yap@Boeing.com; Jesus.Macias@USA-SpaceOps.com;
   Mohamed.Kaouk@NASA.com; Tammy.L.Gafka@NASA.com; Justin.H.Kerr@NASA.gov
CR Baeker J., 2005, 20056226 AIAA
   BAEKER JB, 1977, J SPACECRAFT ROCKETS, V14, P733, DOI 10.2514/3.27993
   Bohr J., 2009, SEM WINT TEST MEAS C
   Sumners J, 2007, IEEE POW ENG SOC GEN, P1
   COLLINS JD, 1988, RELIAB ENG SYST SAFE, V20, P87, DOI 10.1016/0951-8320(88)90091-9
   Doebling S. W., 1998, SHOCK VIBRATION DIGE, V30, P91, DOI DOI 10.1177/058310249803000201
   Grygier M, 2009, 26 INT MOD AN C IMAC
   Lyle K., 2004, 8 INT LS DYNA US C
   Gehman H, 2003, COLUMBIA ACCIDENT IN, V1, P53
   Anderson M., 2005, 46 STRUCT STRUCT DYN
   Yap K. C., 2005, 23 IMAC
   Hyde J. L., 2008, 59 INT ASTR C
   Iverson D.L, 2009, IEEE AER C, P1
   Castle J. P., 2009, AIAA INF AER C
   KAOUK M, 1994, AIAA J, V32, P836, DOI 10.2514/3.12061
   Kaul U. K., 2007, SAE AEROTECH C EXH
   Keller W, 2005, RELIAB ENG SYST SAFE, V89, P271, DOI 10.1016/j.ress.2004.08.022
   Eichler P., 1996, TM104825 NASA
   Du H. H., 2010, P SOC PHOTO-OPT INS, V7677
   Lear D., 2009, 50 SDM C, P3182
   Lin ML, 2003, J SAFETY RES, V34, P1, DOI 10.1016/S0022-4375(02)00089-0
   Madaras E. I., 2005, 20053630 AIAA
   NASA, 2003, NASAS IMPL PLAN INT
   Pate-Cornell E, 2001, RELIAB ENG SYST SAFE, V74, P345, DOI 10.1016/S0951-8320(01)00081-3
   Philipson LL, 1996, TOXICOLOGY, V111, P239, DOI 10.1016/0300-483X(96)03380-X
   Prosser W. H., 2004, 2 AUSTR WORKSH STRUC
   Stam M., 2002, Public Key Cryptography - PKC 2003. 6th International Workshop on Practice and Theory in Public Key Cryptography. Proceedings (Lecture Notes in Computer Science Vol.2567)
   Stamatelatos M. G., 2002, RISK ANAL AEROSPACE
   Studor G, 2006, CANEUS WORKSH
   Studor G, 2007, NASA CANEUS WORKSH
   Yap K. C., 2003, 44 SDM C NORF VA
   Walker J. D., 2003, TECHNOLOGY TODAY FAL, P2
   Carbon S. L., 1997, ARMY
   Yap K., 2003, 21 INT MOD AN C IMAC
   Yap K. C., 2002, International Journal of COMADEM, V5
   Yap KC, 1999, P SOC PHOTO-OPT INS, V3727, P1366
   Hodge J. C., 2010, JANNAF 4 SPAC VEH PR
   Hasselman T. K., 2002, 7 INT LS DYNA US C
   Yap K. C., 2011, 4 CANEUS FLY BY WIR
   Zimmerman DC, 1996, J VIB ACOUST, V118, P543, DOI 10.1115/1.2888333
NR 40
TC 1
Z9 1
U1 1
U2 9
PU AMER INST AERONAUT ASTRONAUT
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 0022-4650
J9 J SPACECRAFT ROCKETS
JI J. Spacecr. Rockets
PD NOV-DEC
PY 2012
VL 49
IS 6
BP 1099
EP 1108
DI 10.2514/1.A32156
PG 10
WC Engineering, Aerospace
SC Engineering
GA 064NS
UT WOS:000313082900014
ER


PT J
AU Zhou, R
   Vergalla, M
   Chintalapati, S
   Kirk, D
   Gutierrez, H
AF Zhou, Ran
   Vergalla, Michael
   Chintalapati, Sunil
   Kirk, Daniel
   Gutierrez, Hector
TI Experimental and Numerical Investigation of Liquid Slosh Behavior Using
   Ground-Based Platforms
SO JOURNAL OF SPACECRAFT AND ROCKETS
LA English
DT Article
AB Liquid-propellant slosh events occurring during orbital maneuvers of a rocket's upper stage may adversely affect vehicle performance. Mission planners require accurate and validated simulation tools to understand and predict the effects of slosh on the intended trajectory of the vehicle, as well as for propellant and tank thermal management. A coupled rigid-body and fluid-dynamics numerkal tool is presented which can be used to predict the effect of internal fluid slosh on a tank's trajectory. To benchmark the numerical tool, a novel experimental framework is presented which examines the influence of liquid slosh on the trajectory of moving tanks with multiple degrees of freedom. The motion history of the tank is measured along with synchronized camera images of the liquid distribution within the tank. The acquired experimental data are used to assess the accuracy of the numerical tool. The predictions from the numerical tool are in excellent agreement with the experimentally measured data over a wide range of tank motion profiles.
C1 [Zhou, Ran; Vergalla, Michael; Chintalapati, Sunil; Kirk, Daniel; Gutierrez, Hector] Florida Inst Technol, Melbourne, FL 32901 USA.
RP Zhou, R (reprint author), Florida Inst Technol, 150 W Univ Blvd, Melbourne, FL 32901 USA.
CR Barshan B, 2000, MEAS SCI TECHNOL, V11, P833, DOI 10.1088/0957-0233/11/6/330
   Berglund MD, 2007, ACTA ASTRONAUT, V61, P416, DOI 10.1016/j.actaastro.2007.01.048
   Bridges T. J., 1981, 3 INT C NUM SHIP HYD, P269
   Celebi MS, 2002, OCEAN ENG, V29, P1527, DOI 10.1016/S0029-8018(01)00085-3
   Dodge F. T., 2000, NEW DYNAMIC BEHAV LI
   Goldstein H., 2001, CLASSICAL MECH
   Jones E. M., APOLLO 11 LUNAR SURF
   Baysal O., 1990, RECENT ADV APPL COMP, V103, P15
   Prins J. J. M., 2000, INT ASTR C RIO JAN B
   Sicilian J. M., 1989, AM SOC MECH ENG COMP, V176
   Strikwerda TE, 2001, ADV ASTRONAUT SCI, V107, P597
   Zappa B, 2001, J DYN SYST-T ASME, V123, P552, DOI 10.1115/1.1386649
NR 12
TC 3
Z9 4
U1 0
U2 9
PU AMER INST AERONAUT ASTRONAUT
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 0022-4650
J9 J SPACECRAFT ROCKETS
JI J. Spacecr. Rockets
PD NOV-DEC
PY 2012
VL 49
IS 6
BP 1194
EP 1204
DI 10.2514/1.A32052
PG 11
WC Engineering, Aerospace
SC Engineering
GA 064NS
UT WOS:000313082900024
ER


PT J
AU Klein, E
   Katan, J
   Gamliel, A
AF Klein, Eyal
   Katan, Jaacov
   Gamliel, Abraham
TI Soil suppressiveness to Meloidogyne javanica as induced by organic
   amendments and solarization in greenhouse crops
SO CROP PROTECTION
LA English
DT Article
DE Artemisia dracunculus; Biological control; Diplotaxis tenuifolia;
   Fusarium; Herb residues; Mentha piperita; Organic amendment; Pest
   management; Salvia officinalis; Soil solarization
ID ROOT-KNOT NEMATODES; HETERODERA-SCHACHTII; SOILBORNE PATHOGENS;
   BIOLOGICAL-CONTROL; PLANT-PATHOGENS; METHYL-BROMIDE; RESISTANCE;
   MANAGEMENT; TEMPERATURE; INCOGNITA
AB We assessed soil suppressiveness against root-knot caused by Meloidogyne javanica, following the incorporation of crop residues (organic amendments [OA]) and soil solarization, under agricultural conditions. Two field experiments were established in tomato greenhouses and a third in a nethouse for growing Antirrhinums, all infested with M. javanica. Dried residues of wild rocket (WR) were incorporated into the soil and then it was solarized to moderate temperatures to partially effect the pathogen population. Root galling on the roots of the successive tomato crop was significantly reduced to different levels by WR, solarization or their combination, in two experiments. Solarization, alone or combined with WR amendment, significantly reduced root knot incidence in the roots of snapdragon, but suppression of root galling in the roots of snapdragon in the following crop was not evident. We further assessed the potential of various herb residues, incorporated in small plots, and solarization to induce soil suppressiveness against root-knot caused by M. javanica. Amending soil with residues of WR, tarragon, peppermint or sage induced soil suppressiveness to root knot even when M. javanica was introduced into the soil after the termination of the treatment, and reduced the galling index in subsequently grown tomato plants, compared with non-amended soil. Our findings further validate the potential role of OA and solarization in inducing soil suppressiveness, which contributes to sustainable management of soilborne pathogens. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Klein, Eyal; Gamliel, Abraham] ARO, Volcani Ctr, Inst Agr Engn, Lab Pest Management Res, IL-50250 Bet Dagan, Israel.
   [Klein, Eyal; Katan, Jaacov] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, Dept Plant Pathol & Microbiol, IL-76100 Rehovot, Israel.
RP Gamliel, A (reprint author), ARO, Volcani Ctr, Inst Agr Engn, Lab Pest Management Res, IL-50250 Bet Dagan, Israel.
EM agamliel@agri.gov.il
FU Ministry of Agricultural and Rural Development; Agriculture Research
   Organization
FX We thank I. Dori, H. Yehezkel and the staff of the Besor Experimental
   Farm for their cooperation; the staff of the Laboratory for Pest
   Management Research for their technical assistance; Prof. D. Orion for
   consultation, and H. Voet for advice in the statistical analysis. This
   research was partially supported by grants from the Chief Scientist of
   the Ministry of Agricultural and Rural Development; the "Ogenia and
   Prof. G. Mintz Grant" from the Agriculture Research Organization;
   contribution no. 731/11 series from the Agricultural Research
   Organization, The Volcani Center, Bet Dagan, Israel,
CR Abawi GS, 2000, APPL SOIL ECOL, V15, P37, DOI 10.1016/S0929-1393(00)00070-6
   Akhtar M, 2000, BIORESOURCE TECHNOL, V74, P35, DOI 10.1016/S0960-8524(99)00154-6
   Chitwood DJ, 2002, ANNU REV PHYTOPATHOL, V40, P221, DOI 10.1146/annurev.phyto.40.032602.130045
   DAVIS JR, 1986, PHYTOPATHOLOGY, V76, P1021, DOI 10.1094/Phyto-76-1021
   Duniway JM, 2002, PHYTOPATHOLOGY, V92, P1337, DOI 10.1094/PHYTO.2002.92.12.1337
   Gamliel A, 1998, PHYTOPARASITICA, V26, P53, DOI 10.1007/BF02981266
   GAMLIEL A, 1993, PLANT DIS, V77, P886
   Gamliel A, 2009, PLANT PATH 21ST, V1, P311, DOI 10.1007/978-1-4020-8804-9_22
   GREENBERGER A, 1987, PHYTOPATHOLOGY, V77, P1663, DOI 10.1094/Phyto-77-1663
   Klein E, 2007, PHYTOPATHOLOGY, V97, P1476, DOI 10.1094/PHYTO-97-11-1476
   Klein E, 2011, PLANT DIS, V95, P1116, DOI 10.1094/PDIS-01-11-0065
   Klein E, 2011, CROP PROT, V30, P368, DOI 10.1016/j.cropro.2010.12.005
   LACKEY BA, 1994, PHYTOPATHOLOGY, V84, P415, DOI 10.1094/Phyto-84-415
   Leader AJ, 2010, ACTA HORTIC, V883, P67
   MADULU JD, 1994, NEMATOLOGICA, V40, P230
   Martin FN, 2003, ANNU REV PHYTOPATHOL, V41, P325, DOI 10.1146/annurev.phyto.41.052002.095514
   McSorley R, 2008, APPL SOIL ECOL, V39, P291, DOI 10.1016/j.apsoil.2008.01.002
   MCSORLEY R, 1994, J NEMATOL, V26, P773
   Melakeberhan H, 2006, NEMATOLOGY, V8, P793, DOI 10.1163/156854106778877884
   Monfort WS, 2007, CROP PROT, V26, P1359, DOI 10.1016/j.cropro.2006.11.008
   Netscher C., 1990, P237
   Ogbuji R. O., 1981, GEOJOURNAL, V5, P79
   Oka Y, 2010, APPL SOIL ECOL, V44, P101, DOI 10.1016/j.apsoil.2009.11.003
   Oka Y, 2007, CROP PROT, V26, P1556, DOI 10.1016/j.cropro.2007.01.003
   Olatinwo R, 2006, PHYTOPATHOLOGY, V96, P111, DOI 10.1094/PHYTO-96-0111
   OMWEGA CO, 1990, J NEMATOL, V22, P446
   Orion D, 2001, J NEMATOL, V33, P203
   Ozores-Hampton M, 2004, ACTA HORTIC, P177
   Pandey R, 2005, PHYTOPARASITICA, V33, P304, DOI 10.1007/BF02979868
   Soprano E., 2006, 17 ACORBAT INT M BAN, P268
   Pegard A, 2005, PHYTOPATHOLOGY, V95, P158, DOI 10.1094/PHYTO-95-0158
   Pizano M., 2010, UN ENV PROGRAMME UNE
   Ploeg AT, 2001, NEMATOLOGY, V3, P855, DOI 10.1163/156854101753625353
   Pyrowolakis A, 2002, APPL SOIL ECOL, V19, P51, DOI 10.1016/S0929-1393(01)00170-6
   RODRIGUEZKABANA R, 1987, PLANT SOIL, V100, P237, DOI 10.1007/BF02370944
   SASSER JN, 1980, PLANT DIS, V64, P36
   Stapleton JJ, 2010, PHYTOPARASITICA, V38, P61, DOI 10.1007/s12600-009-0070-3
   STAPLETON JJ, 1983, PHYTOPATHOLOGY, V73, P1429, DOI 10.1094/Phyto-73-1429
   Stevens C, 2003, PLANT SOIL, V253, P493, DOI 10.1023/A:1024895131775
   Walker JT, 1996, J NEMATOL, V28, P629
   Weller DM, 2002, ANNU REV PHYTOPATHOL, V40, P309, DOI 10.1146/annurev.phyto.40.030402.110010
   Westphal A, 2001, SOIL BIOL BIOCHEM, V33, P9, DOI 10.1016/S0038-0717(00)00108-5
   Westphal A, 2011, PHYTOPATHOLOGY, V101, P878, DOI 10.1094/PHYTO-09-10-0245
   Whestphal A, 2005, J NEMATOL, V37, P121
   Zasada I.A., 2003, PMN, DOI [10.1094/PHP-2003-1120-01-RS, DOI 10.1094/PHP-2003-1120-01-RS]
   Zhou XG, 2007, PLANT DIS, V91, P92, DOI 10.1094/PD-91-0092
NR 46
TC 18
Z9 18
U1 0
U2 48
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0261-2194
J9 CROP PROT
JI Crop Prot.
PD SEP
PY 2012
VL 39
BP 26
EP 32
DI 10.1016/j.cropro.2012.02.013
PG 7
WC Agronomy
SC Agriculture
GA 980DI
UT WOS:000306873400004
ER


PT J
AU Praly, N
   Hillion, M
   Bonnal, C
   Laurent-Varin, J
   Petit, N
AF Praly, N.
   Hillion, M.
   Bonnal, C.
   Laurent-Varin, J.
   Petit, N.
TI Study on the eddy current damping of the spin dynamics of space debris
   from the Ariane launcher upper stages
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Space debris; Eddy currents; Damping of spin motion
AB This paper addresses the topic of damping of the spin dynamics of a spatial debris orbiting around the Earth. Such debris, which can consist of parts of heavy launchers such as the Ariane rocket under consideration in this article, are impacted by torques generated by eddy currents as their conducting non-ferromagnetic body orbits through the Earth magnetosphere. Several previous works have focused on describing this induction phenomenon and have proposed analysis of empirical observations of this particular and important effect which has attracted much attention since the number of spatial debris has emerged as a problem for the future of space programs, especially in low orbits. In this paper, we present a relatively comprehensive modeling of the induction phenomenon, by means of Maxwell's equations inside the conducting and non-ferromagnetic body. Through the generalized Ohm's law, we show how one can obtain a partial differential equation with Neumann's boundary conditions problem that, once solved, e.g. through a finite elements method, yields the values of induced currents and braking torques. The case of a depleted upper stage of a heavy launcher, having a cylindrical shape and thin walls is particularly studied. We show a methodology to estimate the decay-rate of the spinning velocity, which is proven to satisfy a first-order asymptotically stable linear dynamics. Special cases consisting of typical orbit of space debris are treated. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Praly, N.; Hillion, M.] SYSNAV, F-27200 Vernon, France.
   [Bonnal, C.] DLA, CNES, F-75612 Paris, France.
   [Laurent-Varin, J.] DCT SI GS, CNES, F-31401 Toulouse 4, France.
   [Petit, N.] CAS, MINES ParisTech, F-75272 Paris 06, France.
RP Praly, N (reprint author), SYSNAV, 57 Rue Montigny, F-27200 Vernon, France.
EM nicolas.praly@sysnav.fr; mathieu.hillion@sysnav.fr;
   christophe.bonnal@cnes.fr; julien.laurent-varin@cnes.fr;
   nicolas.petit@mines-paristech.fr
OI PETIT, Nicolas/0000-0003-3581-3856
FU CNES
FX The authors wish to thank CNES for financial support, and David Vissiere
   and Pierre-Jean Bristeau from SYSNAV for their technical support.
CR [Anonymous], 1987, ASNT1133 AER
   [Anonymous], 1994, A4DF1300000D AER ESP
   BOEHNHARDT H, 1989, ASTROPHYS SPACE SCI, V162, P297, DOI 10.1007/BF00640745
   Dautray R., 1990, MATH ANAL NUMERICAL, V1-3
   Hertz H., 1896, INDUCTION ROTATING S
   Ishige Y, 2004, ACTA ASTRONAUT, V55, P917, DOI 10.1016/j.actaastro.2004.04.015
   Kawamoto S., 2004, INT C ORB DEBR REM W
   Kelso T.S., 2009, AIAA AAS ASTR SPEC C
   KESSLER DJ, 1978, J GEOPHYS RES-SPACE, V83, P2637, DOI 10.1029/JA083iA06p02637
   Lappas V., 2010, CUBESAIL LOW COST SM
   Lebedev NIN, 1979, WORKED PROBLEMS APPL
   Liou JC, 2010, ACTA ASTRONAUT, V66, P648, DOI 10.1016/j.actaastro.2009.08.005
   Desjean M. C., 2010, 1 EUR WORKSH ACT DEB
   Smith G.L., 1962, TRR129 NASA
   Smythe W.R., 1950, STATIC DYNAMIC ELECT, P417
   Starke J., 2010, 38 COSPAR SCI ASS BR
   Wertz J.R., 1980, SPACECRAFT ATTITUDE, P501
   Wilson Jr R.H., 1977, ASTRON J, V13, P1
   [Anonymous], 2011, AMATEUR OBSERVATIONS
   [Anonymous], 2011, PDE SOLVER VERSION 3
NR 20
TC 11
Z9 11
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD JUL-AUG
PY 2012
VL 76
BP 145
EP 153
DI 10.1016/j.actaastro.2012.03.004
PG 9
WC Engineering, Aerospace
SC Engineering
GA 939EC
UT WOS:000303789200015
ER


PT J
AU Yarymovych, MI
AF Yarymovych, Michael I.
TI Santini memorial lecture: Space Challenges and Opportunities for Human
   Benefit
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Space systems; Space structures
AB Since the beginning of the Space Age the public was fascinated by the great challenges that needed to be overcome, but also inspired by the potential benefits that might arise from the utilization of space systems. This lecture examines the major technological breakthroughs that were necessary for many of the key space programs to succeed, and postulates the immediate and future benefits to humanity that became evident as a result of these advances. A dozen programs ranging from Sputnik and Apollo to the Global Navigation Satellite System are reviewed in view of the technical challenges in elements such as propulsion, power, structures, computing, guidance and control, spectrum management and payloads. Challenges in the cost of space launch, large structures, debris mitigation, humans in space and commercial promise are discussed and opportunities for improvements in the future are postulated. (c) 2012 Elsevier Ltd. All rights reserved.
C1 Sarasota Space Associates, Osprey, FL 34229 USA.
RP Yarymovych, MI (reprint author), Sarasota Space Associates, 3621 N Point Rd, Osprey, FL 34229 USA.
EM myarymovych@sarspace.com
RI CORTE TOPETE, MARTHA BEATRIZ/D-9298-2012
CR Santini P, 2009, ACTA ASTRONAUT, V64, P1224, DOI 10.1016/j.actaastro.2009.01.033
NR 1
TC 0
Z9 0
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD JUN-JUL
PY 2012
VL 75
BP 63
EP 70
DI 10.1016/j.actaastro.2012.01.009
PG 8
WC Engineering, Aerospace
SC Engineering
GA 928LS
UT WOS:000302984900006
ER


PT J
AU Subrahamanyam, DB
   Ramachandran, R
   Rani, SI
   Sijikumar, S
   Anurose, TJ
   Ghosh, AK
AF Subrahamanyam, D. Bala
   Ramachandran, Radhika
   Rani, S. Indira
   Sijikumar, S.
   Anurose, T. J.
   Ghosh, Asish Kumar
TI Location-specific weather predictions for Sriharikota (13.72A degrees N,
   80.22A degrees E) through numerical atmospheric models during satellite
   launch campaigns
SO NATURAL HAZARDS
LA English
DT Article
DE Advanced regional prediction system (ARPS); Chandrayaan; High-resolution
   regional model (HRM); Numerical weather prediction (NWP); Launch commit
   criteria (LCC); Nowcasting; Thunderstorms
ID MESOSCALE MODEL; SYSTEM ARPS; CUMULUS CONVECTION; PARAMETERIZATION;
   SIMULATION; FORECAST; CYCLONE; SUPPORT; SCHEME; LAYER
AB Accurate knowledge of different meteorological parameters over a launch site is very crucial for efficient management of satellite launch operations. Local weather over the Indian satellite launch site located at Sriharikota High Altitude Range (SHAR: 13.72A degrees N, 80.22A degrees E) is very much dependent on the atmospheric circulation prevailing over the Bay of Bengal oceanic region and topography-induced convective activities. With a view to providing severe weather threat prediction in terms of launch commit criteria (LCC), two numerical atmospheric models namely high-resolution regional model (HRM) and advanced regional prediction system (ARPS) are made operational over SHAR in a synoptic and mesoscale domain, respectively. In the present research article, two launch campaigns through Polar Satellite Launch Vehicle (PSLV-C11 and PSLV-C12) when contrasting weather conditions prevailed over the launch site are chosen for demonstration of potential of two models in providing location-specific short-to-medium-range weather predictions meeting the needs of LCC. In the case of PSLV-C11 campaign, when the launch site underwent frequent thundershower-associated rainfall, ARPS model-derived meteorological fields were effectively used in prediction of probability of the wet spells. On the other hand, Bay of Bengal underwent severe cyclonic storm during PSLV-C12 campaign, and its formation was reasonable captured through HRM simulations. It is concluded that a combination of HRM and ARPS provide reliable short-to-medium-range weather prediction over SHAR, which has got profound importance in launch-related activities.
C1 [Subrahamanyam, D. Bala; Sijikumar, S.; Anurose, T. J.] Indian Space Res Org, Space Phys Lab, Vikram Sarabhai Space Ctr, Dept Space,Govt India, Thiruvananthapuram 695022, Kerala, India.
   [Ramachandran, Radhika] Embassy India, ISRO Tech Liaison Unit, Paris, France.
   [Rani, S. Indira] Govt India, Natl Ctr Medium Range Weather Forecasting, Minist Earth Sci, Noida 201307, Uttar Pradesh, India.
   [Ghosh, Asish Kumar] SHAR, Meterol Facil, Satish Dhawan Space Ctr, Sriharikota 524124, Andhra Pradesh, India.
RP Subrahamanyam, DB (reprint author), Indian Space Res Org, Space Phys Lab, Vikram Sarabhai Space Ctr, Dept Space,Govt India, Thiruvananthapuram 695022, Kerala, India.
EM subrahamanyam@gmail.com
RI Sijikumar, S/A-5768-2010; D, Bala Subrahamanyam/A-1959-2011
OI Sijikumar, S/0000-0001-7582-8513; D, Bala
   Subrahamanyam/0000-0003-1970-8458
FU National Science Foundation (NSF); ISRO
FX We greatly acknowledge the support and inspiring guidance rendered by
   Dr. K. Krishna Moorthy, Director, SPL and Prof. R. Sridharan, Former
   Director, SPL. Special words of thanks go to Mr. Thomas C. Babu of AERO
   Parallel Computing Facility, VSSC for his help in maintenance of LINUX
   Cluster System at SPL, where the HRM and ARPS model simulations were
   carried out. We wish to thank Dr. Detlev Majewski, Deutscher
   Wetterdienst, Germany and his colleagues for providing continuous
   support to us in smooth functioning of HRM. The NCEP-FNL reanalysis data
   for this study are from the Research Data Archive (RDA) which is
   maintained by the Computational and Information Systems Laboratory
   (CISL) at the National Center for Atmospheric Research (NCAR). NCAR is
   sponsored by the National Science Foundation (NSF). The original data
   are available from the RDA (http://dss.ucar.edu) in data set number
   ds083.2. KALPANA Satellite images over the Indian subcontinent are
   downloaded from the Indian Meteorological Department
   (http://www.imd.gov.in/) and we duly acknowledge their services.
   Automatic Weather Station data for SHAR are made available to us through
   ISRO's PRWONAM Project (http://www.mosdac.gov.in/), and we acknowledge
   all the members of the project for their cooperation. One of the authors
   TJA would like to thank ISRO Research Fellowship for her PhD work.
CR ANTHES RA, 1978, MON WEATHER REV, V106, P1045, DOI 10.1175/1520-0493(1978)106<1045:DOHMSF>2.0.CO;2
   BANNON PR, 1995, J ATMOS SCI, V52, P1743, DOI 10.1175/1520-0469(1995)052<1743:HALP>2.0.CO;2
   BUSINGER JA, 1971, J ATMOS SCI, V28, P181, DOI 10.1175/1520-0469(1971)028<0181:FPRITA>2.0.CO;2
   Case JL, 2002, WEATHER FORECAST, V17, P3, DOI 10.1175/1520-0434(2002)017<0003:LDIOEC>2.0.CO;2
   Cox R, 1998, B AM METEOROL SOC, V79, P265, DOI 10.1175/1520-0477(1998)079<0265:AMMI>2.0.CO;2
   Das S, 2002, WEATHER FORECAST, V17, P1194, DOI 10.1175/1520-0434(2002)017<1194:SOMRFO>2.0.CO;2
   DUDHIA J, 1993, MON WEATHER REV, V121, P1493, DOI 10.1175/1520-0493(1993)121<1493:ANVOTP>2.0.CO;2
   Heise E, 2002, RES ACTIVITIES ATMOS, V32, P411
   Kain JS, 1993, METEOROL MONOGR, V46, P165
   KUO HL, 1965, J ATMOS SCI, V22, P40, DOI 10.1175/1520-0469(1965)022<0040:OFAIOT>2.0.CO;2
   KUO HL, 1974, J ATMOS SCI, V31, P1232, DOI 10.1175/1520-0469(1974)031<1232:FSOTPO>2.0.CO;2
   LOUIS JF, 1979, BOUND-LAY METEOROL, V17, P187, DOI 10.1007/BF00117978
   Majewski D, 2009, HRM USERS GUIDE DTSC, P124
   Manikiam B, 2008, TECHNOLOGY DEV ATMOS, P9
   Manobianco J, 1996, B AM METEOROL SOC, V77, P653, DOI 10.1175/1520-0477(1996)077<0653:WBRTMM>2.0.CO;2
   MELLOR GL, 1974, J ATMOS SCI, V31, P1791, DOI 10.1175/1520-0469(1974)031<1791:AHOTCM>2.0.CO;2
   NOILHAN J, 1989, MON WEATHER REV, V117, P536, DOI 10.1175/1520-0493(1989)117<0536:ASPOLS>2.0.CO;2
   Pielke R. A., 1984, MESOSCALE METEOROLOG, P612
   PLEIM JE, 1995, J APPL METEOROL, V34, P16, DOI 10.1175/1520-0450-34.1.16
   Radhika R, 2008, TECHNOLOGY DEV ATMOS, P463
   Rakesh V, 2007, PURE APPL GEOPHYS, V164, P1617, DOI 10.1007/s00024-007-0245-0
   Ramachandran R, 2006, CURR SCI INDIA, V91, P285
   RITTER B, 1992, MON WEATHER REV, V120, P303, DOI 10.1175/1520-0493(1992)120<0303:ACRSFN>2.0.CO;2
   Satyanarayana S, 2008, TECHNOLOGY DEV ATMOS, P142
   Singh R, 2005, J EARTH SYST SCI, V114, P427, DOI 10.1007/BF02702143
   Snook JS, 1998, WEATHER FORECAST, V13, P138, DOI 10.1175/1520-0434(1998)013<0138:LDMAAF>2.0.CO;2
   Subrahamanyam DB, 2006, P SOC PHOTO-OPT INS, V6404, pK4040, DOI 10.1117/12.694106
   Subrahamanyam D. Bala, 2008, Ocean Science Journal, V43, P165
   TIEDTKE M, 1989, MON WEATHER REV, V117, P1779, DOI 10.1175/1520-0493(1989)117<1779:ACMFSF>2.0.CO;2
   Xue M, 2003, METEOROL ATMOS PHYS, V82, P139, DOI 10.1007/s00703-001-0595-6
   Xue M, 2001, METEOROL ATMOS PHYS, V76, P143, DOI 10.1007/s007030170027
   Xue M, 2000, METEOROL ATMOS PHYS, V75, P161, DOI 10.1007/s007030070003
   Xue M., 1995, ARPS VERSION 4 0 USE, P380
NR 33
TC 3
Z9 3
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0921-030X
EI 1573-0840
J9 NAT HAZARDS
JI Nat. Hazards
PD APR
PY 2012
VL 61
IS 3
BP 893
EP 910
DI 10.1007/s11069-011-9942-1
PG 18
WC Geosciences, Multidisciplinary; Meteorology & Atmospheric Sciences;
   Water Resources
SC Geology; Meteorology & Atmospheric Sciences; Water Resources
GA 917BO
UT WOS:000302147200002
ER


PT J
AU Skanes, AC
   Healey, JS
   Cairns, JA
   Dorian, P
   Gillis, AM
   McMurtry, MS
   Mitchell, LB
   Verma, A
   Nattel, S
AF Skanes, Allan C.
   Healey, Jeff S.
   Cairns, John A.
   Dorian, Paul
   Gillis, Anne M.
   McMurtry, M. Sean
   Mitchell, L. Brent
   Verma, Atul
   Nattel, Stanley
CA Canadian Cardiovasc Soc Atrial Fib
TI Focused 2012 Update of the Canadian Cardiovascular Society Atrial
   Fibrillation Guidelines: Recommendations for Stroke Prevention and
   Rate/Rhythm Control
SO CANADIAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ACUTE CORONARY SYNDROME; RISK STRATIFICATION SCHEMES;
   GLOMERULAR-FILTRATION-RATE; PHASE-II TRIAL; HEMODIALYSIS-PATIENTS;
   ANTITHROMBOTIC THERAPY; ANTIPLATELET THERAPY; ANTICOAGULANT-THERAPY;
   RANDOMIZED EVALUATION; PREDICTING STROKE
AB The Canadian Cardiovascular Society (CCS) published the complete set of 2010 Atrial Fibrillation (AF) Guidelines in the January, 2011 issue of the Canadian Journal of Cardiology. During its deliberations, the CCS Guidelines Committee engaged to a timely review of future evidence, with periodic composition of focused updates to address clinically important advances. In 2011, results were published from 3 pivotal AF trials: the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonist for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF), the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study, and the Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy (PALLAS), comparing dronedarone with placebo in patients with permanent AF and additional cardiovascular disease risk-factor burden. Each of these large randomized trials provided clear results with major implications for AF management. Other important evidence that has emerged since the 2010 Guidelines includes findings about prediction instruments for AF-associated stroke and bleeding risk, stroke risk in paroxysmal-AF patients, risk-benefit considerations related to oral anticoagulation in patients with chronic kidney disease, and risk/benefit considerations in the use of antiplatelet agents, alone and in combination with each other or with oral anticoagulants, in AF patients. The Guidelines Committee judged that this extensive and important new evidence required focused updating of the 2010 Guidelines with respect to stroke prevention and rate/rhythm control. This report presents the details of the new recommendations, along with the background and rationale.
C1 [Skanes, Allan C.] Univ Western Ontario, Univ Hosp, Arrhythmia Serv, London, ON N6A 5A5, Canada.
   [Healey, Jeff S.] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada.
   [Cairns, John A.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
   [Dorian, Paul] Univ Toronto, St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
   [Gillis, Anne M.; Mitchell, L. Brent] Univ Calgary, Libin Cardiovasc Inst Alberta, Calgary, AB, Canada.
   [McMurtry, M. Sean] Univ Alberta, Edmonton, AB, Canada.
   [Verma, Atul] Southlake Reg Hlth Ctr, Newmarket, ON, Canada.
   [Nattel, Stanley] Univ Montreal, Montreal Heart Inst, Montreal, PQ, Canada.
RP Skanes, AC (reprint author), Univ Western Ontario, Univ Hosp, Arrhythmia Serv, 339 Windermere Rd, London, ON N6A 5A5, Canada.
EM askanes@uwo.ca
RI 刘, 李陆/H-8469-2015
CR Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819
   Alexander JH, 2009, CIRCULATION, V119, P2877, DOI 10.1161/CIRCULATIONAHA.108.832139
   Baber U, 2011, CIRC-ARRHYTHMIA ELEC, V4, P26, DOI 10.1161/CIRCEP.110.957100
   Becker RC, 2008, CHEST, V133, p776S, DOI 10.1378/chest.08-0685
   Boriani G, 2003, DRUGS, V63, P1489, DOI 10.2165/00003495-200363140-00005
   Cairns JA, 2011, CAN J CARDIOL, V27, P74, DOI 10.1016/j.cjca.2010.11.007
   Camm AJ, 2011, EUR HEART J, V32, P1172, DOI 10.1093/eurheartj/ehq512
   Camm AJ, 2010, EUR HEART J, V31, P2369, DOI 10.1093/eurheartj/ehq278
   Chan KE, 2009, J AM SOC NEPHROL, V20, P2223, DOI 10.1681/ASN.2009030319
   Chan KE, 2009, J AM SOC NEPHROL, V20, P872, DOI 10.1681/ASN.2008080824
   Connolly SJ, 2011, NEW ENGL J MED, V365, P2268, DOI 10.1056/NEJMoa1109867
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Connolly SJ, 2009, CIRCULATION, V120, P1174, DOI 10.1161/CIRCULATIONAHA.109.875252
   Dorian P, 2005, CAN J CARDIOL, V21, p26B
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Fang MC, 2011, J AM COLL CARDIOL, V58, P395, DOI 10.1016/j.jacc.2011.03.031
   Fuster V, 2006, CIRCULATION, V114, pe257
   Gage BF, 2004, CIRCULATION, V110, P2287, DOI 10.1161/01.CIR.0000145172.55640.93
   Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864
   Genovesi S, 2008, AM J KIDNEY DIS, V51, P255, DOI 10.1053/j.ajkd.2007.10.034
   Gillis AM, 2011, CAN J CARDIOL, V27, P47, DOI 10.1016/j.cjca.2010.11.001
   Gillis AM, 2011, CAN J CARDIOL, V27, P27, DOI 10.1016/j.cjca.2010.11.003
   Glotzer TV, 2009, CIRC-ARRHYTHMIA ELEC, V2, P474, DOI 10.1161/CIRCEP.109.849638
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Groenveld HF, 2011, J AM COLL CARDIOL, V58, P1795, DOI 10.1016/j.jacc.2011.06.055
   Harder S, 2011, J CLIN PHARM
   Hart RG, 2008, STROKE, V39, P1901, DOI 10.1161/STROKEAHA.107.501825
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Hart RG, 2011, CLIN J AM SOC NEPHRO, V6, P2599, DOI 10.2215/CJN.02400311
   Healey JS, 2012, NEW ENGL J MED, V366, P120, DOI 10.1056/NEJMoa1105575
   Herzog CA, 2011, KIDNEY INT, V80, P572, DOI 10.1038/ki.2011.223
   Hohnloser SH, 2012, CIRCULATION, V125, P669, DOI 10.1161/CIRCULATIONAHA.111.055970
   Hohnloser SH, 2009, NEW ENGL J MED, V360, P668, DOI 10.1056/NEJMoa0803778
   Iguchi Y, 2008, AM J CARDIOL, V102, P1056, DOI 10.1016/j.amjcard.2008.06.018
   Joghetaei N, 2011, CIRC-ARRHYTHMIA ELEC, V4, P592, DOI 10.1161/CIRCEP.111.963447
   Jonsson KM, 2011, THROMB RES, V128, P341, DOI 10.1016/j.thromres.2011.04.022
   Kober L, 2008, NEW ENGL J MED, V358, P2678, DOI 10.1056/NEJMoa0800456
   Lai Hoang M, 2009, Int J Nephrol Renovasc Dis, V2, P33
   Lane DA, 2009, THROMB HAEMOSTASIS, V101, P802, DOI 10.1160/TH09-02-0106
   Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Lip GYH, 2010, THROMB HAEMOSTASIS, V103, P13, DOI 10.1160/TH09-08-0580
   Mega JL, 2009, LANCET, V374, P29, DOI 10.1016/S0140-6736(09)60738-8
   Mega JL, 2012, NEW ENGL J MED, V366, P9, DOI 10.1056/NEJMoa1112277
   Nakagawa K, 2011, AM J CARDIOL, V107, P912, DOI 10.1016/j.amjcard.2010.10.074
   Nieuwlaat R, 2011, EUR HEART J, V32, P618
   Oldgren J, 2011, EUR HEART J, V32, P2781, DOI 10.1093/eurheartj/ehr113
   Olesen JB, 2011, J THROMB HAEMOST, V9, P1460, DOI 10.1111/j.1538-7836.2011.04378.x
   Olesen JB, 2011, BMJ-BRIT MED J, V342, P124
   Paikin JS, 2010, NAT REV CARDIOL, V7, P498, DOI 10.1038/nrcardio.2010.101
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Rabi D. M., 2011, CAN J CARDIOL, V27, P415, DOI [10.1016/j.cjca.2011.03.015, DOI 10.1016/J.CJCA.2011.03.015]
   Rietbrock S, 2008, AM HEART J, V156, P57, DOI 10.1016/j.ahj.2008.03.010
   Singer DE, 2008, CHEST, V133, p546S, DOI 10.1378/chest.08-0678
   To AC, 2007, NEPHROLOGY, V12, P441, DOI 10.1111/j.1440-1797.2007.00835.x
   Uchino K., 2012, ARCH INTERN MED
   van Staa TP, 2011, J THROMB HAEMOST, V9, P39, DOI 10.1111/j.1538-7836.2010.04085.x
   Wizemann V, 2010, KIDNEY INT, V77, P1098, DOI 10.1038/ki.2009.477
NR 60
TC 267
Z9 277
U1 2
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0828-282X
J9 CAN J CARDIOL
JI Can. J. Cardiol.
PD MAR-APR
PY 2012
VL 28
IS 2
BP 125
EP 136
DI 10.1016/j.cjca.2012.01.021
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 921ME
UT WOS:000302480900002
PM 22433576
ER


PT J
AU Tani, N
   Yamanishi, N
   Tsujimoto, Y
AF Tani, Naoki
   Yamanishi, Nobuhiro
   Tsujimoto, Yoshinobu
TI Influence of Flow Coefficient and Flow Structure on Rotational
   Cavitation in Inducer
SO JOURNAL OF FLUIDS ENGINEERING-TRANSACTIONS OF THE ASME
LA English
DT Article
ID VORTEX STRUCTURE; BACKFLOW; INLET
AB Cavitation instability is a major vibration source in turbopump inducers, and its prevention is a critical design problem in rocket-engine development. As reported by Kang et al., (2009, "Cause of Cavitation Instabilities in Three Dimensional Inducer," Int. J. Fluid Mach. Syst., 2(3), pp. 206-214), the flow coefficient plays an important role in the onset of cavitation instabilities such as rotating and asymmetric cavitation. At high flow rates, various cavitation instabilities occur; on the other hand, as the flow coefficient is reduced, these cavitation instabilities either become absent or may change in character. The purpose of the present study is to investigate the relationship between rotating cavitation and flow coefficient through numerical simulations using the Combustion Research Unstructured Navier-stokes solver with CHemistry (CRUNCH) computational fluid dynamics (CFD) code (Ahuja et al., 2001, " Simulations of Cavitating Flows Using Hybrid Unstructured Meshes," J. Fluids Eng. Trans ASME, 123(2), pp. 331-340), and to investigate the internal flow. As a first step, the interaction between the tip vortex and inducer blade was investigated through steady-state simulations. The tip vortex was identified by a vortex detection variable, i.e., the Q-function, a second invariant of the velocity tensor, and the distance between the blade and Q-function peak was measured. For a better understanding of cavitation instabilities, unsteady simulations were also performed for two different flow coefficients. The internal flow was carefully investigated, and the relation between cavity collapse/growth and the change in angle of attack was evaluated. The tip-vortex interaction is not a primary cause of unsteady cavitation, but the negative flow divergence caused by cavity collapse has a great influence on the flow angle. Moreover, changes in flow angle also introduce backflow from the tip clearance; these two factors are primary causes of cavitation instability. When the flow coefficient is large, the backflow is weak, and the interaction with the cavity collapse is strong. In contrast, as the flow coefficient decreases, stronger backflow occurs, and the interaction between backflow, cavity collapse, and flow angle weakens. [DOI: 10.1115/1.4005903]
C1 [Tani, Naoki; Yamanishi, Nobuhiro] Japan Aerosp Explorat Agcy, JAXAs Engn Digital Innovat Ctr, Tsukuba, Ibaraki 3058505, Japan.
   [Tsujimoto, Yoshinobu] Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan.
RP Tani, N (reprint author), Japan Aerosp Explorat Agcy, JAXAs Engn Digital Innovat Ctr, 2-1-1 Sengen, Tsukuba, Ibaraki 3058505, Japan.
EM tani.naoki@jaxa.jp; yamanishi.nobuhiro@jaxa.jp;
   tujimoto@me.es.osaka-u.ac.jp
CR Ahuja V, 2001, J FLUID ENG-T ASME, V123, P331, DOI 10.1115/1.1362671
   An B. J., 2009, P 7 INT S CAV ANN AR
   Combustion Research and Flow Technology Inc., 2011, CRUNCH CFD MULT V2 1, P47
   Hosangadi A., 2007, P 43 AIAA ASME SAE A
   Hosangadi A., 2005, P 41 AIAA ASME SAE A
   Iga Y, 2004, J FLUID ENG-T ASME, V126, P419, DOI 10.1115/1.1760539
   Johnson M. W., 1978, ASME, V100, P553
   Kamijo K, 2001, T JPN SOC AERONAUT S, V44, P155, DOI 10.2322/tjsass.44.155
   Kamijo K., 1992, P 28 AIAA ASME SAE A
   Kang D., 2009, INT J FLUID MACH SYS, V2, P206
   Kimura T., 2008, T ASME J FLUIDS ENG, V130, P31
   Kolar V, 2009, AIAA J, V47, P473, DOI 10.2514/1.40131
   Pouffary B., 2005, FEDSM200577357 ASME
   Semenov YA, 2004, J FLUID ENG-T ASME, V126, P87, DOI 10.1115/1.1637926
   Shamsborhan H., 2008, P WIMRC CAV FOR WARW, P217
   Subbaraman M., 2003, P INT CAV S OS JAP
   Tsujimoto Y, 1997, J FLUID ENG-T ASME, V119, P775, DOI 10.1115/1.2819497
   Yamanishi N, 2007, J FLUID ENG-T ASME, V129, P587, DOI 10.1115/1.2717613
   Yokota K, 1999, JSME INT J B-FLUID T, V42, P451
   Yoshida Y., 2009, P ASME FLUIDS ENG DI
   Yoshida Y., 2008, P 12 INT S TRANSP PH
NR 21
TC 4
Z9 4
U1 3
U2 16
PU ASME-AMER SOC MECHANICAL ENG
PI NEW YORK
PA THREE PARK AVE, NEW YORK, NY 10016-5990 USA
SN 0098-2202
J9 J FLUID ENG-T ASME
JI J. Fluids Eng.-Trans. ASME
PD FEB
PY 2012
VL 134
IS 2
AR 021302
DI 10.1115/1.4005903
PG 13
WC Engineering, Mechanical
SC Engineering
GA 923DI
UT WOS:000302599000009
ER


PT J
AU Iverson, DL
   Martin, R
   Schwabacher, M
   Spirkovska, L
   Taylor, W
   Mackey, R
   Castle, JP
   Baskaran, V
AF Iverson, David L.
   Martin, Rodney
   Schwabacher, Mark
   Spirkovska, Lilly
   Taylor, William
   Mackey, Ryan
   Castle, J. Patrick
   Baskaran, Vijayakumar
TI General Purpose Data-Driven System Monitoring for Space Operations
SO JOURNAL OF AEROSPACE COMPUTING INFORMATION AND COMMUNICATION
LA English
DT Article
AB Modern space propulsion and exploration system designs are becoming increasingly sophisticated and complex. Determining the health state of these systems using traditional methods is becoming more difficult as the number of sensors and component interactions grows. Data-driven monitoring techniques have been developed to address these issues by analyzing system operations data to automatically characterize normal system behavior. The Inductive Monitoring System is a data-driven system health monitoring software tool that has been successfully applied to several aerospace applications. Inductive Monitoring System uses a data mining technique called clustering to analyze archived system data and characterize normal interactions between parameters. This characterization, or model, of nominal operation is stored in a knowledge base that can be used for real-time system monitoring or for analysis of archived events. Ongoing and developing Inductive Monitoring System space operations applications include International Space Station flight control, spacecraft vehicle system health management, launch vehicle ground operations, and fleet supportability. As a common thread of discussion this paper will employ the evolution of the Inductive Monitoring System data-driven technique as related to several Integrated Systems Health Management elements. Thematically, the projects listed will be used as case studies. The maturation of Inductive Monitoring System via projects where it has been deployed or is currently being integrated to aid in fault detection will be described. The paper will also explain how Inductive Monitoring System can be used to complement a suite of other Integrated System Health Management tools, providing initial fault detection support for diagnosis and recovery.
C1 [Iverson, David L.; Martin, Rodney; Schwabacher, Mark; Spirkovska, Lilly; Taylor, William] NASA, Ames Res Ctr, Intelligent Syst Div, Moffett Field, CA 94035 USA.
   [Mackey, Ryan] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA.
   [Castle, J. Patrick; Baskaran, Vijayakumar] NASA, Stinger Ghaffarian Technol, Ames Res Ctr, Intelligent Syst Div, Moffett Field, CA 94035 USA.
RP Iverson, DL (reprint author), NASA, Ames Res Ctr, Intelligent Syst Div, Mail Stop 269-4, Moffett Field, CA 94035 USA.
EM David.L.Iverson@nasa.gov
CR BARRETT A, 2005, P INT JOINT C ART IN
   Bay Stephen D., 2003, P 9 ACM SIGKDD INT C
   Bolt K., 2004, 21109 NASA ISS TCS T
   Colgren R., 2000, P 19 DIG AV SYST C
   IVERSON D, 2004, P 2004 INT C ART INT
   Iverson D. L., 2008, P SPACEOPS 2008 C
   Iverson D. L., 2005, P 4 JANNAF MOD SIM S
   Kurien J., 2000, P NAT C ART INT
   Mackey R., 2006, TM2006213482 NASA
   Mackey R, 2010, IEEE INTELL SYST, V25, P27, DOI 10.1109/MIS.2010.124
   Martin R. A., 2010, P INT C PROGN HLTH M
   Martin R. A., 2007, P JANNAF PROP M
   Martin RA, 2010, AEROSPACE TECHNOLOGIES ADVANCEMENTS, P141
   Narasimham S., 2007, P 18 INT WORKSH PRIN, p162 
   Narasimhan S., 2004, P 15 INT WORKSH PRIN
   PARK H, 2002, P IEEE AER C IEEE NE, V6
   Quinlan J. R., 1993, C4 5 PROGRAMS MACHIN
   Schwabacher M., 2008, AIAA INF AER C
   Schwabacher M., 2009, P IEEE AER C
   Schwabacher M., 2008, P IEEE AER C
   Schwabacher M., 2007, P AIAA INF AER C
   Tax DMJ, 1999, PATTERN RECOGN LETT, V20, P1191, DOI 10.1016/S0167-8655(99)00087-2
   Williams BC, 2003, AI MAG, V24, P61
   Williams B. C., 1996, P NAT C ART INT
NR 24
TC 4
Z9 5
U1 0
U2 15
PU AMER INST AERONAUTICS  ASTRONAUTICS
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 1940-3151
EI 2327-3097
J9 J AEROS COMP INF COM
JI J. Aerosp. Comput. Inf. Commun.
PY 2012
VL 9
IS 2
BP 26
EP 44
DI 10.2514/1.54964
PG 19
WC Engineering, Aerospace
SC Engineering
GA 083KE
UT WOS:000314461500001
ER


PT J
AU Schumacher, B
   Langbein, A
AF Schumacher, B.
   Langbein, A.
TI Antithrombotic management in patients with atrial fibrillation
SO NERVENHEILKUNDE
LA German
DT Article
DE Atrial fibrillation; stroke; warfarin; dabigatran; apixaban; watchman
   device
ID STROKE PREVENTION; WARFARIN; TRIAL; RISK; DABIGATRAN; THERAPY; ASPIRIN
AB In this review article, the current recommendations for prevention of thromboembolic complications in patients with atrial fibrillation are summarized and discussed. Preventive strategies of thromboembolic complications depend, on the individual risk of the patient, e. g. stratified with the CHA(2)DS(2)-VASc score and the HAS-BLED score. If oral anticoagulation is adequate, vitamin K antagonists are the backbone of therapy. Vitamin K antagonists result in a relative risk reduction of 65 to 70% for ischemic strokes. However, the annual risk for major bleeding events exceeds 1% in most studies. In this context, novel oral direct thrombin or factor Xa antagonists (e. g. dabigatran, rivaroxaban, apixaban, edoxaban) are highly anticipated since the risk/benefit ratio presumably is superior to that of vitamin K antagonists. Recent data support this (RELY trial, Rocket-AF trial, ARISTOTLE trial). In the ARISTOTLE trial, apixaban compared to warfarin resulted in a relative risk reduction of 21% for the composite end-point (ischemic strokes, hemorrhagic strokes, systemic embolic events), a relative risk reduction of 31% for major bleeding events, and a relative risk reduction of almost 50% for hemorrhagic strokes. In patients not eligible for oral anticoagulation due to an excessive bleeding risk, transvenous left atrial appendage occlusion is an alternative treatment option. ASS has no proven effect in patients with atrial fibrillation and is not recommended anymore.
C1 [Schumacher, B.; Langbein, A.] Westpfalz Klinikum GmbH, Med Klin 2, D-67655 Kaiserslautern, Germany.
RP Schumacher, B (reprint author), Westpfalz Klinikum GmbH, Med Klin 2, Hellmut Hartert Str 1, D-67655 Kaiserslautern, Germany.
EM bschumacher@westpfalz-klinikum.de
CR Camm AJ, 2010, EUR HEART J, V31, P2369, DOI 10.1093/eurheartj/ehq278
   Connolly SJ, 2006, LANCET, V367, P190
   Connolly SJ, 2011, NEW ENGL J MED, V364, P806, DOI 10.1056/NEJMoa1007432
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370
   Granger CB, 2011, N ENGL J MED, V28
   Hart RG, 2007, ANN INTERN MED, V146, P857
   Holmes DR, 2009, LANCET, V374, P534, DOI 10.1016/S0140-6736(09)61343-X
   Kirchhof P, 2007, EUR HEART J, V28, P2803, DOI 10.1093/eurheartj/ehm358
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1
   Patel MR, 2011, N ENGL J MED, V10
   Pisters R, 2010, CHEST           0318
   Sato H, 2006, STROKE, V37, P447, DOI 10.1161/01.STR.0000198839.61112.ee
   Stangier J, 2010, CLIN PHARMACOKINET, V49, P259, DOI 10.2165/11318170-000000000-00000
   Zipes DP, 2011, HEART RHYTHM, V8, P1, DOI 10.1016/j.hrthm.2010.12.001
NR 17
TC 0
Z9 0
U1 0
U2 0
PU SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN
PI STUTTGART
PA HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY
SN 0722-1541
J9 NERVENHEILKUNDE
JI Nervenheilkunde
PY 2012
VL 31
IS 4
BP 250
EP 255
PG 6
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 932EE
UT WOS:000303272400009
ER


PT J
AU O'Brien, BJ
AF O'Brien, Brian J.
TI Review of measurements of dust movements on the Moon during Apollo
SO PLANETARY AND SPACE SCIENCE
LA English
DT Article; Proceedings Paper
CT 1st Workshop on Lunar Dust, Plasma and Atmosphere - The Next Steps
   (LDAP)
CY JAN 27-29, 2010
CL Boulder, CO
SP NASA Lunar Sci Inst (NLSI), Colorado Ctr Lunar Dust & Atmospher Studies (CCLDAS)
DE Moon; Apollo; Dust; Measurements; LEAM; Astronaut aura
AB This is the first review of 3 Apollo experiments, which made the only direct measurements of dust on the lunar surface: (i) minimalist matchbox-sized 270 g Dust Detector Experiments (DDEs) of Apollo 11, 12, 14 and 15, produced 30 million Lunar Day measurements 21 July 1969-30 September, 1977; (ii) Thermal Degradation Samples (TDS) of Apollo 14, sprinkled with dust, photographed, taken back to Earth into quarantine and lost; and (iii) the 7.5 kg Lunar Ejecta and Meteoroids (LEAM) experiment of Apollo 17, whose original tapes and plots are lost. LEAM, designed to measure rare impacts of cosmic dust, registered scores of events each lunation most frequently around sunrise and sunset. LEAM data are accepted as caused by heavily-charged particles of lunar dust at speeds of < 100 m/s, stimulating theoretical models of transporting lunar dust and adding significant motivation for returning to the Moon. New analyses here show some raw data are sporadic bursts of 1, 2, 3 or more events within time bubbles smaller than 0.6 s, not predicted by theoretical dust models but consistent with noise bits caused by electromagnetic interference (EMI) from switching of large currents in the Apollo 17 Lunar Surface Experiment Package (ALSEP), as occurred in pre-flight LEAM-acceptance tests. On the Moon switching is most common around sunrise and sunset in a dozen heavy-duty heaters essential for operational survival during 350 h of lunar night temperatures of minus 170 degrees C. Another four otherwise unexplained features of LEAM data are consistent with the "noise bits" hypothesis. Discoveries with DDE and TDS reported in 1970 and 1971, though overlooked, and extensive DDE discoveries in 2009 revealed strengths of adhesive and cohesive forces of lunar dust. Rocket exhaust gases during Lunar Module (LM) ascent caused dust and debris to (i) contaminate instruments 17 m distant (Apollo 11) as expected, and (ii) unexpectedly cleanse Apollo hardware 130 m (Apollo 12) and 180 m (Apollo 14) from LM. TDS photos uniquely document in situ cohesion of dust particles and their adhesion to 12 different test surfaces. This review finds the entire TDS experiment was contaminated, being inside the aura of outgassing from astronaut Alan Shepard's spacesuit, and applies an unprecedented caveat to all TDS discoveries. Published and further analyses of Apollo DDE, TDS and LEAM measurements can provide evidence-based guidance to theoretical analyses and to management and mitigation of major problems from sticky dust, and thus help optimise future lunar and asteroid missions, manned and robotic. (C) 2011 Elsevier Ltd. All rights reserved.
C1 Univ Western Australia, Sch Phys, Crawley, WA 6009, Australia.
RP O'Brien, BJ (reprint author), Univ Western Australia, Sch Phys, Crawley, WA 6009, Australia.
EM brianjobrien@ozemail.com.au
CR BAILEY CL, 1977, NAS523557 NASA CONC
   BATES JR, 1979, NASA REFERENCE PUBLI, V1036
   BATES JR, 2001, SOLAR ENERGY MAT SOL, V68
   BATES J.R., 1969, NASA
   BEAN A, 1970, NASA, P33
   *BEND, 1972, N7274302 BEND
   *BEND, 1972, N7272591 BEND
   Berg O.E., 1973, NASA, V330, P16
   Berg O. E., 1976, INTERPLANETARY DUST, P233
   BERG OE, 1969, D5267 NASA TN
   COLLIER MR, 2010, NLSI NEXT STEPS WORK
   COLWELL J.E., 2007, REV GEOPHYS, V45
   Farrell WM, 2010, J GEOPHYS RES-PLANET, V115, DOI 10.1029/2009JE003464
   FREEMAN JW, 1973, J GEOPHYS RES, V78, P4560, DOI 10.1029/JA078i022p04560
   FREEMAN JW, 1974, EARTH MOON PLANETS, V14, P103, DOI DOI 10.1007/BFOO562976
   GAIER J, 2009, 2 LUN SCI FOR JUL 21
   Gaier J. R., 2005, NASATM2005213610 GLE
   Gold T., 1973, PHOTON PARTICLE INTE, P557
   GOLD T., 1971, NASA
   Harris Jr R., 1972, D6738 NASA TN
   JACOBS S, 1971, P AIAA 6 THERM C TUL
   JAMES JT, 2009, P 39 INT C ENV SYST
   Johnson F.E., 1970, SP235 NASA SCIENC RE, P93
   JONES JT, 2009, 2009012379 SAE INT
   Lane J. E., 2010, P EARTH SPAC 2010 12
   Metzger PT, 2010, ADV ENG, P551
   Metzger P. T., 2010, P EARTH SPAC 2010 12
   MITCHELL JK, 1974, U CALIFORNIA SPACE S, V15
   *NASA, 1969, NASA AP MISS REP
   O'Brien B, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL037116
   OBRIEN BJ, 1970, J APPL PHYS, V41, P4538, DOI 10.1063/1.1658493
   OBRIEN BJ, 2009, GAIER ANN LEAG C NOV
   O'BRIEN B.J., 1971, NASA, P193
   OBRIEN BJ, 1962, SPACE SCI REV, V1, P415
   PERKINS D, 1976, 4233 BSR BEND AER SY
   Schmitt Harrison, 2005, BIOL EFF LUN DUST WO, P29
   SINGER SF, 1962, ICARUS, V1, P112, DOI 10.1016/0019-1035(62)90011-8
   SPACE SCIENCE BOARD, 1969, LUN EXPL STRAT RES 1
   Stubbs TJ, 2010, PLANET SPACE SCI, V58, P830, DOI 10.1016/j.pss.2010.01.002
   Stubbs TJ, 2006, ADV SPACE RES, V37, P59, DOI 10.1016/j.asr.2005.04.048
   STUBBS T.J., 2007, ESA
   Sullivan T. A., 1994, NASA REFERENCE PUBLI, V1317
   WOLF H, 1977, 7713 AMA
NR 43
TC 15
Z9 16
U1 1
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0032-0633
J9 PLANET SPACE SCI
JI Planet Space Sci.
PD NOV
PY 2011
VL 59
IS 14
SI SI
BP 1708
EP 1726
DI 10.1016/j.pss.2011.04.016
PG 19
WC Astronomy & Astrophysics
SC Astronomy & Astrophysics
GA 837GQ
UT WOS:000296179500005
ER


PT J
AU Castronuovo, MM
AF Castronuovo, Marco M.
TI Active space debris removal-A preliminary mission analysis and design
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Space debris; Removal; Capture; Low Earth orbit (LEO)
AB The active removal of five to ten large objects per year from the low Earth orbit (LEO) region is the only way to prevent the debris collisions from cascading. Among the three orbital regions near the Earth where most catastrophic collisions are predicted to occur, the one corresponding to a sun-synchronous condition is considered the most relevant. Forty-one large rocket bodies orbiting in this belt have been identified as the priority targets for removal. As part of a more comprehensive system engineering solution, a space mission dedicated to the de-orbiting of five rocket bodies per year from this orbital regime has been designed. The selected concept of operations envisages the launch of a satellite carrying a number of de-orbiting devices, such as solid propellant kits. The satellite performs a rendezvous with an identified object and mates with it by means of a robotic arm. A de-orbiting device is attached to the object by means of a second robotic arm, the object is released and the device is activated. The spacecraft travels then to the next target. The present paper shows that an active debris removal mission capable of de-orbiting 35 large objects in 7 years is technically feasible, and the resulting propellant mass budget is compatible with many existing platforms. (C) 2011 Elsevier Ltd. All rights reserved.
C1 ASI, I-00198 Rome, Italy.
RP Castronuovo, MM (reprint author), ASI, Viale Liegi 26, I-00198 Rome, Italy.
EM marco.castronuovo@asi.it
FU Deutsches Zentrum fur Luft- und Raumfahrt (DLR)
FX The present paper is based on the work carried out by the author for the
   Central Case Project (CCP) of the 12th SpaceTech post-graduate master
   program on Space Systems Engineering of the Delft University of
   Technology. The SpaceTech CCP has been partly sponsored by the Deutsches
   Zentrum fur Luft- und Raumfahrt (DLR) and developed during the 2009/2010
   academic year by the following 12 participants: Marco M. Castronuovo
   (Agenzia Spaziale Italiana), Fabio Covello (Agenzia Spaziale Italiana),
   Frank J. de Bruin (European Space Agency), James Geary (European Space
   Agency), Simon Hyde (Advanced Operations and Engineering Services),
   Wolfgang Jung (Deutsches Zentrum fur Luft- und Raumfahrt), Martin Loesch
   (Astrium Satellites GmbH), Francesco Longo (Agenzia Spaziale Italiana),
   Monica Martinez Fernandez (Serco Group Plc), Shawn Mason (COM DEV
   Limited), Kristina Springborn (The Boeing Company), Susanne Wagenbach
   (Deutsches Zentrum fur Luft- und Raumfahrt).
CR *AN GRAPH, SAT TOOL KIT
   BASTIDA B, 2009, ESA SP, V672
   DePontieu B, 1997, ADV SPACE RES-SERIES, V19, P229, DOI 10.1016/S0273-1177(97)00005-7
   ENGLISH C, 2005, P ISAIRAS MUN GERM
   Fehse W, 2003, CAMBRIDGE AEROSPACE, V16
   FLOHRER T, 2009, ESA SP, V672
   Liou JC, 2008, ADV SPACE RES, V41, P1046, DOI 10.1016/j.asr.2007.04.081
   Liou J.C., 2008, ACTA ASTRONAUT, V64, P236
   Sellmaier F., 2010, SPACEOPS 2010 C HUNT
   Weismuller T., 2006, 29 ANN AAS GUID CONT
   WILLIAMS V, 1978, PLANET SPACE SCI, V26, P721, DOI 10.1016/0032-0633(78)90003-X
   2010, SPACETECH12 SYSTEM E
NR 12
TC 19
Z9 19
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD NOV-DEC
PY 2011
VL 69
IS 9-10
BP 848
EP 859
DI 10.1016/j.actaastro.2011.04.017
PG 12
WC Engineering, Aerospace
SC Engineering
GA 822SJ
UT WOS:000295069600010
ER


PT J
AU Anfinan, N
   Sait, K
   Ghatage, P
   Nation, J
   Chu, P
AF Anfinan, Nisrin
   Sait, Khalid
   Ghatage, Prafull
   Nation, Jill
   Chu, Pam
TI Ten years experience in the management of borderline ovarian tumors at
   Tom Baker Cancer Centre
SO ARCHIVES OF GYNECOLOGY AND OBSTETRICS
LA English
DT Article
DE Borderline ovarian tumor; Recurrence; Survival
ID TERM FOLLOW-UP; CONSERVATIVE TREATMENT; PERITONEAL IMPLANTS; FERTILITY;
   MICROINVASION; MALIGNANCY; SURGERY; WOMEN
AB The aim of this study was to review the clinical outcomes of patients with borderline ovarian tumors (BOTs) at Tom Baker Cancer Centre (TBCC) and to assess the value of surgical staging.
   This retrospective study included 138 patients treated for BOTs at TBCC between January 1994 and December 2005. Patients were divided into two groups: group I with complete surgical staging (n = 89) and group II with incomplete surgical staging (n = 49). This population-based study identified patients using the Alberta Cancer Registry. Charts were reviewed by a single person. Data extracted included demographic information and prognostic factors such as age, histological type, laterality of the cyst, presence of microinvasion, and the type of surgical procedure. Data were extracted and entered into a study database for analysis. Overall survival and overall recurrence-free survival of both groups were calculated using the Kaplan-Meier method. Risk factors for recurrence were analyzed using Cox regression analysis.
   A total of 138 patients were enrolled, with a mean age of 46 years. The median follow-up time was 37 months. The most common histological type of BOT was the serous type found in 70 (50.7%) patients. Microinvasion was identified in four (2.9%) patients. Twelve patients were found to have implants as result of the staging procedure; two of them were invasive implants and both required chemotherapy. Forty-three (31%) patients had conservative surgery and 95 (68.8%) patients had non-conservative surgery. Nine (6.5%) patients experienced recurrence: five (5.6%) patients in group I versus four (8.2%) patients in group II. The presence of microinvasion is the risk factor for recurrence (P = 0.013).
   The indications for restaging surgery remain controversial, as there was no difference in recurrence rates observed between the study groups. However, surgical staging is important for identifying invasive extraovarian implants that need to be treated with chemotherapy. For patients who have conservative surgery, close- and long-term follow-up is required.
C1 [Anfinan, Nisrin; Ghatage, Prafull; Nation, Jill; Chu, Pam] Tom Baker Canc Clin, Dept Gynecol Oncol, Calgary, AB T2N 4N1, Canada.
   [Sait, Khalid] King Abdulaziz Univ Hosp, Dept Obstet & Gynecol, Jeddah, Saudi Arabia.
RP Anfinan, N (reprint author), Tom Baker Canc Clin, Dept Gynecol Oncol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM Dr_nisreen2001@yahoo.com
CR Ayhan A, 2003, EUR J GYNAECOL ONCOL, V24, P223
   BELL DA, 1990, HUM PATHOL, V21, P397, DOI 10.1016/0046-8177(90)90201-F
   Boran N, 2005, GYNECOL ONCOL, V97, P845, DOI 10.1016/j.gygno.2005.03.010
   Buttin BM, 2002, OBSTET GYNECOL, V99, P11, DOI 10.1016/S0029-7844(01)01675-1
   Camatte S, 2004, EUR J CANCER, V40, P1842, DOI 10.1016/j.ejca.2004.04.017
   CASEY AC, 1993, GYNECOL ONCOL, V50, P316, DOI 10.1006/gyno.1993.1218
   Fauvet R, 2004, CANCER, V100, P1145, DOI 10.1002/cncr.20098
   Gershenson DM, 1998, CANCER, V83, P2157, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D
   Gershenson DM, 2002, BEST PRACT RES CL OB, V16, P513, DOI 10.1053/beog.2002.0308
   Gershenson DM, 1998, CANCER, V82, P1096, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1096::AID-CNCR13>3.0.CO;2-1
   Gotlieb WH, 1998, CANCER, V82, P141, DOI 10.1002/(SICI)1097-0142(19980101)82:1<141::AID-CNCR17>3.0.CO;2-2
   [Anonymous], 1987, AM J OBSTET GYNECOL, V156, P263
   Kennedy AW, 1996, CANCER, V78, P278, DOI 10.1002/(SICI)1097-0142(19960715)78:2<278::AID-CNCR14>3.0.CO;2-T
   LEAKE JF, 1992, GYNECOL ONCOL, V47, P150, DOI 10.1016/0090-8258(92)90099-5
   Morice P, 2001, FERTIL STERIL, V75, P92, DOI 10.1016/S0015-0282(00)01633-2
   SCULLY RE, 1982, B CANCER, V69, P228
   Seidman JD, 2000, HUM PATHOL, V31, P539, DOI 10.1053/hp.2000.8048
   TAZELAAR HD, 1985, OBSTET GYNECOL, V66, P417
   Trimble CL, 2002, GYNECOL ONCOL, V86, P34, DOI 10.1006/gyno.2002.6711
   Trope C, 1998, SEMIN ONCOL, V25, P372
   Winter WE, 2002, OBSTET GYNECOL, V100, P671, DOI 10.1016/S0029-7844(02)02171-3
NR 21
TC 17
Z9 18
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0932-0067
J9 ARCH GYNECOL OBSTET
JI Arch. Gynecol. Obstet.
PD SEP
PY 2011
VL 284
IS 3
BP 731
EP 735
DI 10.1007/s00404-010-1713-9
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 807TQ
UT WOS:000293923100035
PM 20963432
ER


PT J
AU Hu, CS
   Xu, CD
AF Hu, Chunsheng
   Xu, Chengdong
TI Template-Based Integrated Design Environment for Rocket Design
SO ADVANCED SCIENCE LETTERS
LA English
DT Article
DE Integrated Design Environment (IDE); Template-Based; Rocket Design;
   Architecture
AB Aiming at the complexity and high iteration of rocket design, a template-based Integrated Design Environment (TIDE) is proposed to provide a uniform design environment, reduce the interactions with program applications, decrease the communication obstacles and achieve rapid design. Some important methodologies such as Integrated Design Environment (IDE), Product Lifecycle Management (PLM) and Knowledge Management (KM) are employed in this environment to simplify the design activity. The architecture of this environment is presented first, and the main modules of this architecture and their functions are interpreted. And then a typical design process in rocket design is presented to illustrate the running mechanism of this environment. A prototype system of this architecture has been developed and through the running of this system on some cases, the results show that the environment is practicable.
C1 [Hu, Chunsheng; Xu, Chengdong] Beijing Inst Technol, Sch Aerosp Engn, Beijing 100081, Peoples R China.
RP Xu, CD (reprint author), Beijing Inst Technol, Sch Aerosp Engn, Beijing 100081, Peoples R China.
CR CHEN JX, 2006, J COMPUT INFORM SYST, V2, P2
   CHEN M, 2008, P 2008 IEEE INT C IN
   CHOI I, 2004, INT J INNOVAT LEARN, V4, P1
   Ciaramella A., 2009, P 11 INT C ENT INF S
   CURRAN R, 2007, INT J PROD ECON, V1, P109
   DESHMUKH A, 1998, P 36 AER SCI M EXH R
   Eriksson H., 2000, BUSINESS MODELING UM
   Fu Xiang, 2004, P 13 C WORLD WID WEB
   GRANT RM, 1996, ORGAN SCI, V4, P7
   JOHNS B, 2002, P 40 AER SCI M EXH R
   JUNG J, 2007, COMPUT IND, V1, P58
   LI WD, 2004, COMPUT IND, V1, P55
   LUBKE D, 2008, INT J BUS PROCESS IN, V2, P3
   MA YS, 2006, P 4 IEEE INT C IND I
   Nonaka I., 2008, MANAGING FLOW PROCES
   NUNES VT, 2009, INFORM SCI, V15, P179
   VANDERAALST WMP, 1998, J CIRCUIT SYST COMP, V1, P8
   van der Aalst W. M. P., 2003, P 1 INT C BUS PROC M
   WANG LH, 2001, P 6 INT C COMP SUPP
NR 19
TC 1
Z9 2
U1 1
U2 2
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1936-6612
J9 ADV SCI LETT
JI Adv. Sci. Lett.
PD AUG-OCT
PY 2011
VL 4
IS 8-10
BP 3187
EP 3192
DI 10.1166/asl.2011.1414
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 822OJ
UT WOS:000295057700113
ER


PT J
AU Iga, Y
   Yoshida, Y
AF Iga, Yuka
   Yoshida, Yoshiki
TI Numerical Analysis of Controlling Cavitation Instabilities in Tandem
   Cascades
SO TRANSACTIONS OF THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES
LA English
DT Article
DE Rotating Cavitation; Cavitation Surge; Tandem Cascade; Homogeneous
   Model; CFD
ID SHEET CAVITATION; PUMP
AB Cavitation is an inevitable phenomenon that occurs when improvements such as performance enhancement and weight reduction are made to the turbopump in liquid-propellant rocket engines. Unsteady cavitation may cause oscillations (cavitation instabilities) in the turbopump. Accurate prediction and efficient suppression of cavitation instabilities are important for designing turbopumps. We performed a numerical simulation of the unsteady cavitation in tandem cascades and compared the results with those obtained for a single-stage cascade. The type of cavitation instability could be controlled by changing the front- and rear-blade chord lengths. When the clearance gap between the front and rear blades was located near the cascade throat entrance, rotating-stall conditions could be easily achieved, even at high flow rates. Cavitation surge and super-synchronous and sub-synchronous rotating cavitations were suppressed when the clearance gap was located at 40% of the total chord length. When the clearance gap was located inside the cascade throat, cavitation reached a steady state at the a value where the cavity length equaled the front-blade length; then, cavitation instabilities and unsteady cavitation were suppressed in the low-a region. When the clearance gap was located at 80% of the total chord length, cavitation surge was completely suppressed, although rotating cavitation occurred over a larger region.
C1 [Iga, Yuka] Tohoku Univ, Inst Fluid Sci, Sendai, Miyagi, Japan.
   [Yoshida, Yoshiki] Japan Aerosp Explorat Agcy JAXA, Kakuda Space Ctr, Kakuda, Miyagi, Japan.
RP Iga, Y (reprint author), Tohoku Univ, Inst Fluid Sci, Sendai, Miyagi, Japan.
CR Hashimoto T, 1997, J PROPUL POWER, V13, P488, DOI 10.2514/2.5210
   Iga Y, 2004, J FLUID ENG-T ASME, V126, P419, DOI 10.1115/1.1760539
   Iga Y, 2003, J FLUID ENG-T ASME, V125, P643, DOI 10.1115/1.1596239
   IGA Y, 2002, JSME T B, V68, P368
   IGA Y, 2009, P 2009 ASME FLUIDS E
   MORINO M, 1989, TURBOMACHINERY, V17, P516
   Pham TM, 1999, J FLUID ENG-T ASME, V121, P289, DOI 10.1115/1.2822206
   SHIMAGAKI M, 2005, J JPN SOC AERONAUT S, V53, P266, DOI 10.2322/jjsass.53.266
   Shimura T, 2002, JSME INT J B-FLUID T, V45, P41, DOI 10.1299/jsmeb.45.41
   Tsujimoto Y, 2001, J PROPUL POWER, V17, P636, DOI 10.2514/2.5790
   Tsujimoto Y, 1997, J FLUID ENG-T ASME, V119, P775, DOI 10.1115/1.2819497
   YAMAMOTO K, 1991, JSME INT J II-FLUID, V34, P9
   Yee H.C., 1987, 89464 NASATM
NR 13
TC 1
Z9 1
U1 2
U2 9
PU JAPAN SOC AERONAUT SPACE SCI
PI TOKYO
PA KOKUKAIKAN-BUNKAN 1-18-2 SHINBASHI MINATO-KU, TOKYO, JAPAN
SN 0549-3811
J9 T JPN SOC AERONAUT S
JI Trans. Jpn. Soc. Aeronaut. Space Sci.
PD AUG
PY 2011
VL 54
IS 184
BP 137
EP 143
PG 7
WC Engineering, Aerospace
SC Engineering
GA 810CD
UT WOS:000294102100008
ER


PT J
AU De Ridder, S
   Mooij, E
AF De Ridder, S.
   Mooij, E.
TI Optimal Longitudinal Trajectories for Reusable Space Vehicles in the
   Terminal Area
SO JOURNAL OF SPACECRAFT AND ROCKETS
LA English
DT Article
AB This paper concerns optimal longitudinal trajectories and guidance strategies of a reusable launch vehicle during the terminal-area energy-management phase. During this phase, it is important to know the limits of the vehicle capabilities and the best strategy for a flight in the vertical plane. This paper describes optimal trajectories using a genetic algorithm and guidance strategies for both maximum-range and maximum-dive flights. The optimal trajectories show an increased maximum range up to 6%, compared with the trajectories using an angle of attack for maximum lift-to-drag ratio. A turning flight has an influence on the optimal trajectories and optimal turns are flown at a lower velocity. Based on the calculation of optimal trajectories and an energy-state approximation analysis, a longitudinal guidance law is designed, using robust design to approximate the optimal trajectories. Offnominal conditions, in terms of a change in initial altitude and velocity, also have an influence on the optimal trajectories. Maximum-range trajectories for different initial states define the minimum-energy boundary in the energy space.
C1 [Mooij, E.] Delft Univ Technol, Fac Aerosp Engn, NL-2629 HS Delft, Netherlands.
RP De Ridder, S (reprint author), Royal Mil Acad, Dept Elect Engn, Brussels, Belgium.
EM sven.de.ridder@elec.rma.ac.be; e.mooij@tudelft.nl
CR BRANSCOME H, 1990, ACTA ASTRONAUT, V21, P243
   BRYSON AE, 1968, 68877 AIAA
   BUCHNER T, 2003, INT ASTR C
   Da Costa R.R., 2003, AIAA GUID NAV CONTR
   DARWIN CR, 1991, ACTA ASTRONAUT, V25, P165, DOI 10.1016/0094-5765(91)90144-T
   De Ridder S, 2011, ACTA ASTRONAUT, V68, P915, DOI 10.1016/j.actaastro.2010.08.032
   DERIDDER S, 2009, 20095769 AIAA
   FEUSTELBUECHL, 1991, ESA B, V66, P21
   HANSON J, 2003, AEROSPACE AM     MAR, P36
   HELMERSSON A, 1988, 6718858 TNESA
   Hull J.R., 2005, 20057114 AIAA
   Kluever CA, 2007, J GUID CONTROL DYNAM, V30, P162, DOI 10.2514/1.24864
   KLUEVER CA, 2005, AIAA GUID NAV CONTR
   Michalewicz Z., 1996, GENETIC ALGORITHMS D
   Mooij E., 1998, THESIS DELFT U TECHN
   MOOIJ E, 1995, M692 DELFT U TECHN F
   Moore T.E., 1991, TM104744 NASA
   Vinh N, 1981, OPTIMAL TRAJECTORIES
NR 18
TC 2
Z9 2
U1 0
U2 9
PU AMER INST AERONAUT ASTRONAUT
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 0022-4650
J9 J SPACECRAFT ROCKETS
JI J. Spacecr. Rockets
PD JUL-AUG
PY 2011
VL 48
IS 4
BP 642
EP 653
DI 10.2514/1.51083
PG 12
WC Engineering, Aerospace
SC Engineering
GA 804UM
UT WOS:000293679500011
ER


PT J
AU Torre, L
   Pasini, A
   Cervone, A
   Pace, G
   Miloro, P
   d'Agostino, L
AF Torre, L.
   Pasini, A.
   Cervone, A.
   Pace, G.
   Miloro, P.
   d'Agostino, L.
TI Effect of Tip Clearance on the Performance of a Three-Bladed Axial
   Inducer
SO JOURNAL OF PROPULSION AND POWER
LA English
DT Article
ID ROTATING CAVITATION; CLOUD CAVITATION
AB This paper illustrates the results of an experimental campaign conducted in the Cavitating Pump Rotordynamic Test Facility. Tests have been carried out at two values of the blade tip clearance on the three-bladed DAPAMITO3 inducer, designed by means of a reduced-order model, with geometry and noncavitating performance representative of typical space rocket inducers. Different cavitating behaviors have been observed at different values of the blade tip clearance, particularly near breakdown conditions. The intensity of pressure oscillations tends to decrease as the tip blade clearance increases, and cavitation-induced azimuthal flow instabilities appear to be more sensitive to changes of the blade tip clearance than axial flow instabilities. Finally, the presence of backflow seems to have a stabilizing effect on rotating cavitation instabilities.
C1 [Torre, L.; Pasini, A.; Cervone, A.] ALTA SpA, I-56121 Pisa, Italy.
   [Pace, G.; Miloro, P.; d'Agostino, L.] Univ Pisa, Dept Aerosp Engn, I-56126 Pisa, Italy.
RP Torre, L (reprint author), ALTA SpA, Via Gherardesca 5, I-56121 Pisa, Italy.
EM l.torre@alta-space.com; a.pasini@alta-space.com;
   a.cervone@alta-space.com; giov.pace@gmail.com; duncanidaho@hotmail.it;
   luca.dagostino@ing.unipi.it
FU ESA [20081/06/NL/IA]
FX The present work has been supported by the ESA under contract no.
   20081/06/NL/IA. The authors would like to express their gratitude to
   Johan Steelant of ESA-European Space Research and Technology Centre and
   Mariano Andrenucci and Fabrizio Paganucci of the Aerospace Department,
   University of Pisa, for their constant and friendly encouragement. A
   special thank goes to our friend and colleague K. Shinkatsu from
   GMYS-Space.
CR Acosta A. J., 1958, P 2 S NAV HYDR, P533
   Brennen C. E., 1994, HYDRODYNAMICS PUMPS, P169
   CALLENAERE M, 1998, P 3 INT S CAV GREN, V1, P209
   CERVONE A, 2009, 7 INT S CAV CAV2009
   Cervone A., 2005, 41 AIAA ASME SAE ASE
   d'Agostino L, 2008, J FLUID ENG-T ASME, V130, DOI 10.1115/1.2979007
   DAGOSTINO L, 2008, 44 AIAA ASME SAE ASE
   FRANC JP, 2001, CAV2001 INT S CAV CA
   GOIRAND B, 1992, J MECH ENG SCI C, V453, P263
   Hashimoto T, 1997, J PROPUL POWER, V13, P488, DOI 10.2514/2.5210
   HIGASHI S, 2001, CAV2001 INT S CAV CA
   Horiguchi H, 2006, J FLUID ENG-T ASME, V128, P430, DOI 10.1115/1.2173291
   Horiguchi H, 2000, J FLUID ENG-T ASME, V122, P412, DOI 10.1115/1.483271
   IMAMURA H, 2003, CAV 2003 5 INT S CAV
   JANIGRO A, 1973, LECT SERIES VONKARMA, V61, pA1
   KAMIJO K, 1993, J PROPUL POWER, V9, P819, DOI 10.2514/3.23695
   Kawanami Y, 1997, J FLUID ENG-T ASME, V119, P788, DOI 10.1115/1.2819499
   KJELDSEN M, 1998, P US JAP SEM ABN FLO
   KUBOTA A, 1989, J FLUID ENG-T ASME, V111, P204
   Rapposelli E., 2002, 38 AIAA ASME SAE ASE
   RYAN RS, 1994, 30 AIAA ASME SAE ASE
   SAKODA M, 2001, INT S CAV PAS CA
   SHIMURA T, 2003, CAV 2003 5 INT S CAV
   SUBBARAMAN M, 2006, CAV2006 6 INT S CAV
   Tomaru H., 2007, 43 AIAA ASME SAE ASE
   Torre L, 2009, 45 AIAA ASME SAE ASE
   TSUJIMOTO Y, 1993, J FLUID ENG-T ASME, V115, P135, DOI 10.1115/1.2910095
   Tsujimoto Y, 1997, J FLUID ENG-T ASME, V119, P775, DOI 10.1115/1.2819497
   TSUJIMOTO Y, 2005, ASME FLUID ENG DIV S
   Tsujimoto Y., 2002, SPAC LAUNCH LIQ PROP
   TSUJIMOTO Y, 1998, P US JAP SEM ABN FLO
   TSUJIMOTO Y, 2001, CAV2001 INT S CAV CA
   UCHIUMI M, 2008, P ISROMAC 12
   Yoshida Y, 2001, J FLUID ENG-T ASME, V123, P762, DOI 10.1115/1.1411969
   Zoladz T., 2000, 36 AIAA ASME SAE ASE
NR 35
TC 11
Z9 11
U1 1
U2 9
PU AMER INST AERONAUT ASTRONAUT
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 0748-4658
J9 J PROPUL POWER
JI J. Propul. Power
PD JUL-AUG
PY 2011
VL 27
IS 4
BP 890
EP 898
DI 10.2514/1.B34067
PG 9
WC Engineering, Aerospace
SC Engineering
GA 797SF
UT WOS:000293149700017
ER


PT J
AU Lamprecht, SC
   Tewoldemedhin, YT
   Calitz, FJ
   Mazzola, M
AF Lamprecht, Sandra C.
   Tewoldemedhin, Yared T.
   Calitz, Frikkie J.
   Mazzola, Mark
TI Evaluation of strategies for the control of canola and lupin seedling
   diseases caused by Rhizoctonia anastomosis groups
SO EUROPEAN JOURNAL OF PLANT PATHOLOGY
LA English
DT Article
DE Binucleate; Multinucleate; Protective effect; Resistance; Seed treatment
ID PREEMERGENCE DAMPING-OFF; ROOT-ROT; BINUCLEATE RHIZOCTONIA; SOLANI AG-4;
   BIOLOGICAL-CONTROL; 1ST REPORT; PATHOGENICITY; RAPESEED; GROWTH;
   VARIANCE
AB Several methods with potential for the management of Rhizoctonia diseases of canola and lupin including plant resistance, fungicide seed treatment and biological control using binucleate Rhizoctonia anastomosis groups (AGs) were evaluated under glasshouse conditions. Screening included the examination of resistance of eight canola and eight lupin cultivars/selections to damping-off and hypocotyl/root rot caused by the multinucleate Rhizoctonia solani AG-2-1, 2-2, 4 and 11. All canola cultivars were highly susceptible to AG-2-1, but Rocket, Spectrum and 44C11 were more resistant than the other cultivars. Spectrum and 44C73 were also more resistant to AG-4 than the other canola cultivars. On lupin, R. solani AG-2-2 and 4 were most virulent, and the cultivar Cedara 6150 and selection E16 were most resistant to AG-2-2; Cedara 6150, E16, Mandelup and Quilinock were more resistant to AG-4 than the other cultivars/selections. The Lupinus luteus selections, E80.1.1.2 and E82.1.1 were most susceptible to AG-2-2, 4 and 11. Seed treatment with the fungicides Cruiser OSR (a.i. difenconazole, fludioxonil, metalaxyl-M, thiamethoxam) and SA-combination (a. i. iprodione, metalaxyl, thiram) significantly increased survival of canola and lupin seedlings, decreased hypocotyl/root rot and improved the percentage of healthy seedlings, with the SA-combination being significantly more effective than Cruiser OSR. Application of the binucleate Rhizoctonia AGs (A, Bo, K and I) significantly increased the survival of lupin seedlings inoculated with R. solani AG-2-2 and 4, and AG-I and K significantly improved survival of canola in the presence of AG-4. This is the first report of the potential of binucleate AGs to protect canola and lupin seedlings against infection by multinucleate AGs.
C1 [Lamprecht, Sandra C.; Tewoldemedhin, Yared T.] Agr Res Council, Plant Protect Res Inst, ZA-7599 Stellenbosch, South Africa.
   [Calitz, Frikkie J.] Agr Res Council, Biometry Unit, ZA-0001 Pretoria, South Africa.
   [Mazzola, Mark] USDA ARS, Tree Fruit Res Lab, Wenatchee, WA 98801 USA.
RP Lamprecht, SC (reprint author), Agr Res Council, Plant Protect Res Inst, Private Bag X5017, ZA-7599 Stellenbosch, South Africa.
EM lamprechts@arc.agric.za
FU Protein Research Trust (PRT); Agricultural Research Council-Plant
   Protection Research Institute (ARC-PPRI); Agricultural Research Service
   of the United States Department of Agriculture (USDA-ARS)
FX This research was financially supported by the Protein Research Trust
   (PRT), the Agricultural Research Council-Plant Protection Research
   Institute (ARC-PPRI) and the Agricultural Research Service of the United
   States Department of Agriculture (USDA-ARS). Seeds were supplied by Piet
   Lombaard of the Western Cape Department of Agriculture, Elsenburg,
   Stellenbosch. We also thank Alta Schoeman, Almarie Van den Heever,
   Sheryldene Williams, Gregory Anthony, John Deysel and Lizzie Hugo for
   technical assistance.
CR AGENBAG H, 2008, LUPIN PRODUCTION W S
   Baird RE, 1996, PLANT DIS, V80, P104
   BELL DK, 1984, PHYTOPATHOLOGY, V74, P625
   BURPEE LL, 1984, PLANT DIS, V71, P167
   Chang KF, 2005, PLANT DIS, V89, P685, DOI 10.1094/PD-89-0685C
   De Villiers R. J., 2006, South African Journal of Plant and Soil, V23, P287
   DEVILLIERS RJ, 2004, THESIS U STELLENBOSC
   DOYLE P, 2002, P INT S SEED TREATM
   GLASS GV, 1972, REV EDUC RES, V42, P237, DOI 10.3102/00346543042003237
   GUGEL RK, 1987, CAN J PLANT PATHOL, V9, P119
   HERR LJ, 1995, CROP PROT, V14, P179, DOI 10.1016/0261-2194(95)00017-G
   HUBER DM, 1992, PLANT DIS, V76, P1251
   Hwang J, 2002, PLANT DIS, V86, P47, DOI 10.1094/PDIS.2002.86.1.47
   HWANG SF, 1986, PLANT DIS, V70, P681, DOI 10.1094/PD-70-681
   KAMINSKI DA, 1985, CAN J PLANT PATHOL, V7, P256
   KATARIA HR, 1990, CAN J PLANT PATHOL, V12, P409
   KATARIA HR, 1993, ANN APPL BIOL, V123, P233, DOI 10.1111/j.1744-7348.1993.tb04088.x
   KATATRIA HR, 1991, PHYTOPATHOLOGY, V133, P121
   Khangura RK, 1999, PLANT DIS, V83, P714, DOI 10.1094/PDIS.1999.83.8.714
   Klein-Gebbinck HW, 2002, PLANT DIS, V86, P1005, DOI 10.1094/PDIS.2002.86.9.1005
   LAMPRECHT S C, 1986, Phytophylactica, V18, P111
   LEACH SS, 1992, PLANT DIS, V76, P417
   Levene H, 1960, CONTRIBUTIONS PROBAB, P278
   MASUHARA G, 1994, MYCOL RES, V98, P83
   Nel A, 2003, GUIDE CONTROL PLANT
   Paulitz TC, 2006, PLANT DIS, V90, P829, DOI 10.1094/PD-90-0829B
   Paulsrud B.E., 2001, OREGON PESTICIDE APP
   Ross RE, 1998, CROP PROT, V17, P99, DOI 10.1016/S0261-2194(97)00109-9
   SCHISLER DA, 1993, MYCOLOGICAL RES, V98, P77
   SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.2307/2333709
   SWEETINGHAM MW, 1989, AUST J AGR RES, V40, P781, DOI 10.1071/AR9890781
   Tewoldemedhin YT, 2006, PLANT DIS, V90, P1399, DOI 10.1094/PD-90-1399
   Verma PR, 1996, PHYTOPROTECTION, V77, P99
   YANG J, 1992, CROP PROT, V11, P443, DOI 10.1016/0261-2194(92)90028-4
   YANG J, 1989, THESIS U SASKATCHEWA
   YITBAREK SM, 1987, CAN J PLANT PATHOL, V9, P6
   You MP, 2008, PLANT SOIL, V302, P203, DOI 10.1007/s11104-007-9469-0
NR 37
TC 4
Z9 5
U1 1
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0929-1873
J9 EUR J PLANT PATHOL
JI Eur. J. Plant Pathol.
PD JUL
PY 2011
VL 130
IS 3
BP 427
EP 439
DI 10.1007/s10658-011-9764-8
PG 13
WC Agronomy; Plant Sciences; Horticulture
SC Agriculture; Plant Sciences
GA 794WI
UT WOS:000292931600013
ER


PT J
AU Meghoo, C
   Dennis, JW
   Tuman, C
   Fang, R
AF Meghoo, Colin
   Dennis, James W.
   Tuman, Caroline
   Fang, Raymond
TI Characterization and Management of Cervical Vascular Injuries Resulting
   from Improvised Explosive Devices (IEDs) and Rocket Propelled Grenades
   (RPGs)
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 16-18, 2011
CL Chicago, IL
SP Soc Vasc Surg
C1 [Meghoo, Colin; Tuman, Caroline; Fang, Raymond] Landstuhl Reg Med Ctr, Landstuhl, Germany.
   [Dennis, James W.] Univ Florida, Coll Med, Jacksonville, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2011
VL 53
SU S
BP 9S
EP 10S
PG 2
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA 774TY
UT WOS:000291410700015
ER


PT J
AU Alcantara, C
   Pujadas, A
   Saavedra, M
AF Alcantara, C.
   Pujadas, A.
   Saavedra, M.
TI Management of cruciferous cover crops by mowing for soil and water
   conservation in southern Spain
SO AGRICULTURAL WATER MANAGEMENT
LA English
DT Article
DE Regrowth ability; Crucifers; Erosion control; Herbicide use reduction;
   Soil moisture
ID GREEN MANURE; VERTICILLIUM WILT; GROWTH-STAGES; RAPESEED; POTATO; WEEDS;
   SUPPRESSION; GERMINATION
AB In recent years, the use of cover crops in Mediterranean olive orchards has increased due to serious soil erosion problems and surface water contamination by herbicides. In these areas, the annual precipitation regime is strongly seasonal, with dry summers that require killing the cover crop before it competes with the trees for water. Cruciferous species are being introduced as cover crops in southern Spain, and their management by mowing could reduce the use of herbicides. However, the use of mowing as a management system requires an understanding of the phenology of these species to identify the most suitable mowing date to derive the greatest possible soil water content. The aims of this study were the following: (1) to assess the susceptibility of cruciferous species to mowing, their regrowth ability and the persistence of their residues on the soil surface after mowing, and (2) to identify the best mowing date for the cover crops in relation to the soil moisture content in the environmental conditions of southern Spain. For these purposes, the emergence, ground cover, biomass and regrowth after two mowing dates of common mustard (Sinapis alba L subsp. mairei), rocket (Eruca vesicaria), radish (Raphanus sativus) and Ethiopian mustard (Brassica carinata) were evaluated in field trials during 2001/2002. In addition, during 2002/2003 and 2003/2004, the moisture content of soil sowed with common mustard and rocket cover crops was assessed at different mowing dates and compared with a bare soil control. Common mustard was the most favourable species for management by mowing due to its lack of regrowth after mowing. Early mowing (March 10th) reduced soil moisture due to the regrowth of the cover crop, fast decomposition of cover residues and weed proliferation. Late mowing (April 24th) led to little or no regrowth of the cover crops, large biomass and high persistence of cover residues, which provided effective soil ground cover, avoided the emergence of spring-summer weeds and helped retain soil moisture, reaching a similar water content to bare soil. These results suggest that cruciferous cover crops killed by mowing in late April can be used to replace no-tillage bare soil management systems to reduce the use of herbicides and preserve soil and water quality. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Alcantara, C.; Saavedra, M.] CAP Junta de Andalucia, IFAPA Ctr Alameda del Obispo, Area Protecc Cultivos, Cordoba 14080, Spain.
   [Pujadas, A.] Univ Cordoba, Dept Ciencias & Recursos Agr & Forestales, E-14071 Cordoba, Spain.
RP Alcantara, C (reprint author), CAP Junta de Andalucia, IFAPA Ctr Alameda del Obispo, Area Protecc Cultivos, Avda Menendez Pidal S-N,Apdo 3092, Cordoba 14080, Spain.
EM mariac.alcantara@juntadeandalucia.es
RI Pujadas, Antonio/K-4285-2014; Alcantara, Cristina/M-5133-2015; Saavedra,
   Milagros/C-4619-2016
OI Pujadas, Antonio/0000-0003-4146-5886; Alcantara,
   Cristina/0000-0003-0519-5479; Saavedra, Milagros/0000-0002-4980-4136
FU FEDER-INIA [TRT2006-0007-C4-3]; CICE-Junta de Andalucia [RMN-03205]
FX This research was made possible with funding provided by FEDER-INIA and
   CICE-Junta de Andalucia through projects TRT2006-0007-C4-3 and
   RMN-03205, respectively. The authors would like to thank Dr. J.A. Gomez
   for critical reading of the manuscript and A. Moreno, E. Espejo, T.
   Gutierrez, F. Pedregoso and A. Gutierrez for technical assistance.
CR Alcantara C, 2009, J SUSTAIN AGR, V33, P619, DOI 10.1080/10440040903073693
   AlKhatib K, 1997, WEED SCI, V45, P439
   Andreasen C, 2002, WEED TECHNOL, V16, P873, DOI 10.1614/0890-037X(2002)016[0873:ROWSAC]2.0.CO;2
   Bowman G., 2000, MANAGING COVER CROPS, P9
   Boydston RA, 1995, WEED TECHNOL, V9, P669
   Brandsaeter LO, 1999, CROP SCI, V39, P1369
   Brown PD, 1996, PLANT SOIL, V181, P307, DOI 10.1007/BF00012065
   Castro G, 2006, AGR WATER MANAGE, V86, P249, DOI 10.1016/j.agwat.2006.05.011
   CASTRO G, 2004, THESIS U CORDOBA
   CASTRO J, 1993, THESIS U CORDOBA
   CIVANTOS L, 1981, ITEA, V44, P38
   Davis JR, 1996, PHYTOPATHOLOGY, V86, P444, DOI 10.1094/Phyto-86-444
   DOUGLAS LK, 1993, SUSTAINABLE AGR SYST, P47
   Gomez JA, 2009, SOIL TILL RES, V106, P137, DOI 10.1016/j.still.2009.04.008
   Gomez JA, 2009, SOIL TILL RES, V102, P5, DOI 10.1016/j.still.2008.05.005
   Hartwig NL, 2002, WEED SCI, V50, P688, DOI 10.1614/0043-1745(2002)050[0688:AIACCA]2.0.CO;2
   Hess M, 1997, WEED RES, V37, P433, DOI 10.1046/j.1365-3180.1997.d01-70.x
   HUMANES MD, 1995, ACT C 1995 SOC ESP M, P235
   LAFLEN JM, 1981, J SOIL WATER CONSERV, V36, P341
   LANCASHIRE PD, 1991, ANN APPL BIOL, V119, P561, DOI 10.1111/j.1744-7348.1991.tb04895.x
   MOJTAHEDI H, 1993, PLANT DIS, V77, P42
   MOJTAHEDI H, 1991, J NEMATOL, V23, P170
   PASTOR M, 1989, P 4 EWRS MED S VAL S, P17
   PASTOR M, 1991, ESTUDIO DIVERSOS MET
   PURVIS CE, 1985, WEED RES, V25, P415, DOI 10.1111/j.1365-3180.1985.tb00664.x
   Saavedra M., 2002, SISTEMAS CULTIVO OLI
   Saavedra M, 1995, ACT C 1995 SOC ESP M, P175
   SARRANTONIO M, 2000, MANAGING COVER CROPS, P16
   SHANKS LW, 1995, COVER CROPPING VINEY, P80
   Shetty KG, 2000, PHYTOPATHOLOGY, V90, P305, DOI 10.1094/PHYTO.2000.90.3.305
   Smolinska U, 1999, J PHYTOPATHOL, V147, P119, DOI 10.1046/j.1439-0434.1999.147002119.x
   Vaughn Steven F., 1993, American Potato Journal, V70, P852
   WOLFE D, 2000, MANAGING COVER CROPS, P84
NR 33
TC 13
Z9 13
U1 7
U2 42
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-3774
J9 AGR WATER MANAGE
JI Agric. Water Manage.
PD APR
PY 2011
VL 98
IS 6
BP 1071
EP 1080
DI 10.1016/j.agwat.2011.01.016
PG 10
WC Agronomy; Water Resources
SC Agriculture; Water Resources
GA 760WD
UT WOS:000290354000018
ER


PT J
AU Russell, MJ
   Lecakes, GD
   Mandayam, S
   Jensen, S
AF Russell, Michael J.
   Lecakes, George D., Jr.
   Mandayam, Shreekanth
   Jensen, Scott
TI The "Intelligent" Valve: A Diagnostic Framework for Integrated
   System-Health Management of a Rocket-Engine Test Stand
SO IEEE TRANSACTIONS ON INSTRUMENTATION AND MEASUREMENT
LA English
DT Article
DE Automated test and diagnostic systems; human-computer interface; virtual
   measurement systems
ID SENSOR VALIDATION
AB Valves play a critical role in rocket-engine test stands because they are essential for the cryogen transport mechanisms that are vital to test operations. Sensors that are placed on valves monitor the pressure, temperature, flow rate, valve position, and any other features that are required for diagnosing their functionality. Integrated system-health management (ISHM) algorithms have been used to identify and evaluate anomalous operating conditions of systems and subsystems (e. g., valves and valve components) on complex structures, such as rocket test stands. In order for such algorithms to be useful, there is a need to develop realistic models for the most common and problem-prone elements. Furthermore, the user needs to be provided with efficient tools to explore the nature of the anomaly and its possible effects on the element, as well as its relationship to the overall system state. This paper presents the development of an intelligent-valve framework that is capable of tracking and visualizing events of the large linear actuator valve (LLAV) in order to detect anomalous conditions. The framework employs a combination of technologies, including a dynamic data exchange data-transfer protocol, autoassociative neural networks, empirical and physical models, and virtual-reality environments. The diagnostic procedure that is developed has the ability to be integrated into existing ISHM systems and can be used for assessing the integrity of rocket-engine test-stand components.
C1 [Russell, Michael J.; Lecakes, George D., Jr.; Mandayam, Shreekanth] Rowan Univ, Elect & Comp Engn Dept, Glassboro, NJ 08028 USA.
   [Jensen, Scott] Natl Aeronaut & Space Adm, Stennis Space Ctr, MS 39529 USA.
RP Russell, MJ (reprint author), Rowan Univ, Elect & Comp Engn Dept, Glassboro, NJ 08028 USA.
EM shreek@rowan.edu
FU National Aeronautics and Space Administration (NASA) Stennis Space
   Center [NNX08BA19A]; NASA [NNX08AV98H, NNX07AO92H]
FX Manuscript received May 27, 2010; revised August 13, 2010; accepted
   October 5, 2010. Date of publication January 17, 2011; date of current
   version March 8, 2011. This work was supported in part by the National
   Aeronautics and Space Administration (NASA) Stennis Space Center under
   Grant/Cooperative Agreement-NNX08BA19A and in part by the NASA Graduate
   Student Researchers Program under Grants/Cooperative
   Agreements-NNX08AV98H and NNX07AO92H. The Associate Editor coordinating
   the review process for this paper was Dr. John Sheppard.
CR Aarabi P, 2004, IEEE T SYST MAN CY B, V34, P1007, DOI 10.1109/TSMCB.2003.818555
   Baglio S, 2006, IEEE T INSTRUM MEAS, V55, P761, DOI 10.1109/TIM.2006.873806
   Baybutt M, 2009, IEEE T INSTRUM MEAS, V58, P255, DOI 10.1109/TIM.2008.2005966
   Choi K, 2009, IEEE T INSTRUM MEAS, V58, P602, DOI 10.1109/TIM.2008.2004340
   Daigle Matthew, 2009, P ANN C PROGN HLTH M
   HASELMAIER H, 2006, 14 INCH LOX VALVE DA
   Ibarguengoytia PH, 2001, IEEE T POWER SYST, V16, P770, DOI 10.1109/59.962425
   JENSEN S, 2006, P SPIE SENSORS PROPU
   KRAMER MA, 1991, AICHE J, V37, P233, DOI 10.1002/aic.690370209
   Lecakes GD, 2009, IEEE T INSTRUM MEAS, V58, P3050, DOI 10.1109/TIM.2009.2016823
   Lienhard IV J. H., 2008, HEAT TRANSFER TXB
   Liu J, 2010, IEEE T INSTRUM MEAS, V59, P309, DOI 10.1109/TIM.2009.2023814
   Ljung L., 2007, SYSTEM IDENTIFICATIO
   MATTERN DL, 1998, P 34 JOINT PROP C CL
   Napolitano MR, 1998, IEEE T CONTR SYST T, V6, P596, DOI 10.1109/87.709495
   Puig V, 2008, IEEE T CONTR SYST T, V16, P1083, DOI 10.1109/TCST.2007.906339
   Reichard K., 2007, P REL MAINT S ORL FL, P107
   Rizzo A, 2002, IEEE T CONTR SYST T, V10, P421, DOI 10.1109/87.998031
   [Anonymous], 2009, P IEEE SENS C CHRIST
   Schmalzel J, 2005, IEEE T INSTRUM MEAS, V54, P1612, DOI 10.1109/TIM.2005.851477
   Scott AR, 2009, IEEE T INSTRUM MEAS, V58, P297, DOI 10.1109/TIM.2008.2005961
   Shapiro L. G., 2001, COMPUTER VISION
   Vachtsevanos G., 2006, INTELLIGENT FAULT DI
NR 23
TC 4
Z9 4
U1 1
U2 8
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9456
EI 1557-9662
J9 IEEE T INSTRUM MEAS
JI IEEE Trans. Instrum. Meas.
PD APR
PY 2011
VL 60
IS 4
BP 1489
EP 1497
DI 10.1109/TIM.2010.2101350
PG 9
WC Engineering, Electrical & Electronic; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA 746AJ
UT WOS:000289212900040
ER


PT J
AU Lee, BS
   Hwang, Y
   Kim, HY
   Kim, J
AF Lee, Byoung-Sun
   Hwang, Yoola
   Kim, Hae-Yeon
   Kim, Jaehoon
TI Design and implementation of the flight dynamics system for COMS
   satellite mission operations
SO ACTA ASTRONAUTICA
LA English
DT Article; Proceedings Paper
CT 60th International Astronautical Congress
CY OCT 12-16, 2009
CL Daejeon, SOUTH KOREA
DE Satellite operation; Orbit determination; Station-keeping maneuver;
   Geostationary orbit; Flight dynamics
AB The first Korean multi-mission geostationary Earth orbit satellite, Communications, Ocean, and Meteorological Satellite (COMS) was launched by an Ariane 5 launch vehicle in June 26, 2010. The COMS satellite has three payloads including Ka-band communications, Geostationary Ocean Color Imager, and Meteorological Imager. Although the COMS spacecraft bus is based on the Astrium Eurostar 3000 series, it has only one solar array to the south panel because all of the imaging sensors are located on the north panel. In order to maintain the spacecraft attitude with 5 wheels and 7 thrusters, COMS should perform twice a day wheel off-loading thruster firing operations, which affect on the satellite orbit. COMS flight dynamics system provides the general on-station functions such as orbit determination, orbit prediction, event prediction, station-keeping maneuver planning, station-relocation maneuver planning, and fuel accounting. All orbit related functions in flight dynamics system consider the orbital perturbations due to wheel off-loading operations. There are some specific flight dynamics functions to operate the spacecraft bus such as wheel off-loading management, oscillator updating management, and on-station attitude reacquisition management. In this paper, the design and implementation of the COMS flight dynamics system is presented. An object oriented analysis and design methodology is applied to the flight dynamics system design. Programming language C# within Microsoft .NET framework is used for the implementation of COMS flight dynamics system on Windows based personal computer. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Lee, Byoung-Sun; Hwang, Yoola; Kim, Hae-Yeon; Kim, Jaehoon] ETRI, Taejon 305700, South Korea.
RP Lee, BS (reprint author), ETRI, 138 Gajeongno, Taejon 305700, South Korea.
EM lbs@etri.re.kr; ylhwang@etri.re.kr; specialk@etri.re.kr;
   jhkim@etri.re.kr
OI Lee, Byoung-Sun/0000-0003-1798-7684
CR DICHMANN D, 1998, STK VALIDATION VERIF, V2
   DICHMANN D, 1998, STK VALIDATION VERIF, V1
   HWANG Y, 2006, P AIAA AAS ASTR SPEC
   HWANG Y, 2006, P 24 AIAA INT COMM S
   Hwang Y, 2008, ETRI J, V30, P774, DOI 10.4218/etrij.08.0108.0152
   KIM HY, 2007, P 25 AIAA INT COMM S
   KIM HY, 2006, P 24 AIAA INT COMM S
   KIM HY, 2007, J KOREA SOC SPACE TE, V2, P16
   Lee BS, 2003, ETRI J, V25, P387, DOI 10.4218/etrij.03.0102.0518
   LEE BS, 2008, P AAS AIAA SPAC FLIG
   LEE BS, 2003, P KSAS FALL ANN M KS, P194
   LEE BS, 2007, P 3 INT C REC ADV SP, P595
   LEE BS, 1995, J ASTRONOMY SPACE SC, V12, P102
   LEE BS, 1998, P KSAS FALL M, P559
   LEE BS, 2006, J KOREA SOC SPACE TE, V1, P16
   LEE BS, 2008, P 26 AIAA INT COMM S
   LEE BS, 2007, P 25 AIAA INT COMM S
   LEE BS, 2008, P 2008 KSAS SPRING C, P980
   Pooley R., 1999, USING UML SOFTWARE E
NR 19
TC 5
Z9 5
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD APR-MAY
PY 2011
VL 68
IS 7-8
BP 1292
EP 1306
DI 10.1016/j.actaastro.2010.09.002
PG 15
WC Engineering, Aerospace
SC Engineering
GA 727SL
UT WOS:000287821600062
ER


PT J
AU Avdeev, AV
   Bashkin, AS
   Katorgin, BI
   Parfen'ev, MV
AF Avdeev, A. V.
   Bashkin, A. S.
   Katorgin, B. I.
   Parfen'ev, M. V.
TI About possibilities of clearing near-Earth space from dangerous debris
   by a spaceborne laser system with an autonomous cw chemical HF laser
SO QUANTUM ELECTRONICS
LA English
DT Article
DE spaceborne laser station; autonomous cw chemical laser; space debris;
   ablation regime; repetitively pulsed lasing
AB The possibility of clearing hazardous near-Earth space debris using a spaceborne laser station with a large autonomous cw chemical HF laser is substantiated and the requirements to its characteristics (i.e., power and divergence of laser radiation, pulse duration in the repetitively pulsed regime, repetition rate and total time of laser action on space debris, necessary to remove them from the orbits of the protected spacecrafts) are determined. The possibility of launching the proposed spaceborne laser station to the orbit with the help of a 'Proton-M' carrier rocket is considered.
C1 [Avdeev, A. V.; Bashkin, A. S.] State Univ Aerosp Technol, Moscow Aviat Inst, Moscow 125871, Russia.
   [Katorgin, B. I.; Parfen'ev, M. V.] NPO Energomash, Chimki 141400, Moscow Region, Russia.
RP Avdeev, AV (reprint author), State Univ Aerosp Technol, Moscow Aviat Inst, Volokolamskoe Sh 4, Moscow 125871, Russia.
EM alex021894@mail.ru
FU Federal Agency for Science and Innovations of Russia [02.740.11.0227]
FX The authors express their gratitude to E.M. Zemskov for useful
   discussions. The work was supported by the Federal Agency for Science
   and Innovations of Russia (State Contract No. 02.740.11.0227 dated 7
   July 2009).
CR AGAPOV V, 2008, PYATAYA EZHEGODNAYA, P2
   ALEKSANDROV BP, 2010, T NPO EN MOSC, V27, P396
   BASOV NG, 1988, P SPIE INT SOC OPT E, V3574, P437
   Bulgakov AV, 1999, QUANTUM ELECTRON+, V29, P433, DOI 10.1070/QE1999v029n05ABEH001503
   CAMPBELL IW, 1996, 108522 NASA
   GUSCHIN VN, 2003, OSNOVY USTROISTVA KO
   KATORGIN BI, 2004, PUT RAKETNOY TEKHNIK, P165
   KHUTOROVSKY ZN, 1995, SCI T, P19
   KOZLOV DI, 2003, KONSTRUIROVANIE AVTO
   Kuprenyuk VI, 2007, QUANTUM ELECTRON+, V37, P248, DOI 10.1070/QE2007v037n03ABEH013359
   Kuznetsov LI, 1998, QUANTUM ELECTRON+, V28, P361, DOI 10.1070/QE1998v028n04ABEH001222
   PHIPPS C, 1994, P C PHYS NUCL IND PL
   Phipps CR, 2004, P SOC PHOTO-OPT INS, V5448, P1201, DOI 10.1117/12.568419
   POZDNYAKOV ZG, 1977, SPRAVOCHNIK PROMYSHL
   RYKHLOVA LV, 1993, ZEMLYA VSELENNAYA, P30
   SCHALL WO, 1998, P SPIE INT SOC OPT E, V3574, P428
   SEMENOV SN, 2008, T NPO EN MOSC, V26, P260
   TAGANOVA AA, 2005, GERMETICHNYE KHIMICH
NR 18
TC 2
Z9 2
U1 1
U2 10
PU TURPION LTD
PI BRISTOL
PA C/O TURPION LTD, IOP PUBLISHING, TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1
   6HG, ENGLAND
SN 1063-7818
EI 1468-4799
J9 QUANTUM ELECTRON+
JI Quantum Electron.
PY 2011
VL 41
IS 7
BP 669
EP 674
DI 10.1070/QE2011v041n07ABEH014534
PG 6
WC Engineering, Electrical & Electronic; Physics, Applied
SC Engineering; Physics
GA 802LD
UT WOS:000293511500018
ER


PT J
AU Castoldi, N
   Bechini, L
   Ferrante, A
AF Castoldi, Nicola
   Bechini, Luca
   Ferrante, Antonio
TI Fossil energy usage for the production of baby leaves
SO ENERGY
LA English
DT Article
DE Agro-ecological indicators; Energy efficiency; Floating system; Fossil
   energy; Greenhouse
ID TOMATO PRODUCTION; VEGETABLE PRODUCTION; ECONOMIC-ANALYSIS; ANTALYA
   REGION; GREENHOUSE; TURKEY; QUALITY; SYSTEMS
AB The cultivation of fresh-cut crops is shifting from traditional systems in open fields to soilless cropping systems in greenhouses. As a result, the energy requirements of crop cultivation are increasing rapidly. In this study, we analysed the economic and energetic performance of four baby leaf species (lettuce, rocket, spinach, and lamb's lettuce) cultivated in a greenhouse under floating system. Four indicators were calculated, namely fossil energy input per unit area (Enla: sum of the direct and indirect energy input per m(2) per cycle), fossil energy input per unit product (Enlp: ratio of Enla to fresh product mass per m(2) per cycle), economic efficiency (EE: ratio of the gross income per m(2) per cycle to the Enla), and gross margin (GM: the difference between the gross income and the variable costs per m(2) per cycle). In general, the Enlas obtained in this study were high (10.2-31.6 MJ m(-2) cycle(-1)). Lettuce provided the lowest Enlp (3.0 MJ kg(-1)), and the highest EEs were attained under low nutrient conditions (0.81 and 0.48 (sic) MJ(-1) for lamb's lettuce and lettuce, respectively). The GM of lettuce (on average 1.85 (sic) m(-2)) and Iamb's lettuce (1.67 (sic) m(-2)) were high. However, the consumption of fossil energy by baby leaves cultivated under soilless conditions in a greenhouse can be reduced by adopting precise nutrient management practices. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Castoldi, Nicola; Bechini, Luca; Ferrante, Antonio] Univ Milan, Dept Plant Prod, I-20133 Milan, Italy.
RP Castoldi, N (reprint author), Univ Milan, Dept Plant Prod, Via Celoria 2, I-20133 Milan, Italy.
EM nicola.castoldi@unimi.it
RI Bechini, Luca/A-4241-2009; Ferrante, Antonio/B-1927-2008; 
OI Ferrante, Antonio/0000-0001-7781-9784; Bechini, Luca/0000-0002-8152-6121
FU University of Milano
FX This work was conducted under project PUR 2008, which was funded by the
   University of Milano.
CR ALBERICI A, 2008, ISHS ACTA HORTICULTU, V801, P1167
   ALCORN A, 1998, COEFFICIENTS, V2
   Baird G, 1997, IPENZ T, V24
   BALDI L, 2008, SOC AGRARIA LOMBARDI
   Bechini L, 2009, ECOL INDIC, V9, P1096, DOI 10.1016/j.ecolind.2008.12.008
   Bhat M.G., 1994, ORNLSUB90997322
   Bianco V.V., 1990, HORTICULTURE
   BIERMANN S, 1999, EFMA PUBLICATION
   Canakci M., 2006, Energy (Oxford), V31, P1243, DOI 10.1016/j.energy.2005.05.021
   Canakci M, 2005, ENERG CONVERS MANAGE, V46, P655, DOI 10.1016/j.enconman.2004.04.008
   Cetin B, 2008, RENEW ENERG, V33, P428, DOI 10.1016/j.renene.2007.03.008
   Cocetta G., 2007, Agricoltura Mediterranea, V137, P79
   DINASSO NNO, ENERGY INTE IN PRESS
   Djevic M, 2009, ENERGY, V34, P1325, DOI 10.1016/j.energy.2009.03.008
   Esengun K, 2007, RENEW ENERG, V32, P1873, DOI 10.1016/j.renene.2006.07.005
   Ferrante A., 2000, Advances in Horticultural Science, V14, P99
   Gericke W F, 1937, Science, V85, P177, DOI 10.1126/science.85.2198.177
   Gericke W. F., 1929, AM J BOT, V16, P862
   Gruda N, 2005, CRIT REV PLANT SCI, V24, P227, DOI 10.1080/07352680591008628
   Hatirli SA, 2006, RENEW ENERG, V31, P427, DOI 10.1016/j.renene.2005.04.007
   Hoagland D. R., 1950, 347 U CAL CAL AGR EX
   Jarach M, 1985, RIV INGEGNERIA AGRAR, V2, P102
   Koga N, 2008, AGR ECOSYST ENVIRON, V125, P101, DOI 10.1016/j.agee.2007.12.002
   Kongshaug G., 1998, INT FERT IND ASS TEC
   Monti A, 2009, EUR J AGRON, V31, P77, DOI 10.1016/j.eja.2009.04.001
   Nicola S, 2007, ACTA HORTIC, P585
   Ozkan B, 2004, BIOMASS BIOENERG, V26, P89, DOI 10.1016/S0961-9534(03)00080-1
   Ozkan B, 2007, ENERGY, V32, P1500, DOI 10.1016/j.energy.2006.09.010
   Pardossi A., 2005, CROPS QUALITY GROWTH, P360
   Patzek TW, 2004, CRIT REV PLANT SCI, V23, P519, DOI 10.1080/07352680490886905
   Pimentel David, 2003, NATURAL RESOURCES RE, V12, P127, DOI DOI 10.1023/A:1024214812527
   Rico D, 2007, TRENDS FOOD SCI TECH, V18, P373, DOI 10.1016/j.tifs.2007.03.011
   Shapouri H., 2002, 814 USDA EC RES SERV
   VOLPI R, 1992, ENERGY BALANCES AGR
   WIJNANDS J, 2003, ISHS ACTA HORTICULTU, V611, P79
   Zekki H, 1996, J AM SOC HORTIC SCI, V121, P1082
   [Anonymous], 2009, R LANGUAGE ENV STAT
NR 37
TC 5
Z9 5
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0360-5442
J9 ENERGY
JI Energy
PD JAN
PY 2011
VL 36
IS 1
BP 86
EP 93
DI 10.1016/j.energy.2010.11.004
PG 8
WC Thermodynamics; Energy & Fuels
SC Thermodynamics; Energy & Fuels
GA 714BL
UT WOS:000286781800009
ER


PT J
AU Shen-Gunther, J
   Ellison, R
   Kuhens, C
   Roach, CJ
   Jarrard, S
AF Shen-Gunther, Jane
   Ellison, Richard
   Kuhens, Charles
   Roach, Christopher J.
   Jarrard, Steve
TI Operation Enduring Freedom: Trends in Combat Casualty Care by Forward
   Surgical Teams Deployed to Afghanistan
SO MILITARY MEDICINE
LA English
DT Article
ID SCORE; ARMY
AB This study examined the clinical experience of a U.S. Army Forward Surgical Team (FST) deployed to Afghanistan in 2005 and compared the findings with those of 3 previously deployed FSTs. Medical records of all patients evaluated by the FST were abstracted for analysis. Demographically, the cohort (n = 614) was predominantly male (94%), with a median age of 24, and distributed according to the following: disease (8.6%), nonbattle injury (42%), and battle injury (49%). Combat casualties were mostly Afghan National Army or Police (56%) and U.S. military (21%). Predominant wounding instruments were small arms (34%), improvised explosive devices (33%), and rocket-propelled grenades (15%). Anatomical sites of battle injury were extremities (38%), external soft tissue (35%), and head/neck/torso (28%). Operative procedures for combat injury (n = 227) were primarily orthopedic (45%) or thoracic/abdominal (36%). Combat casualty statistics provide insight to trauma epidemiology, patterns, and trends vital for surgical management. Workload statistics guides the structuring, training, and employment of FSTs.
C1 [Shen-Gunther, Jane] Brooke Army Med Ctr, Dept Clin Invest, ATTN MCHE CI, Ft Sam Houston, TX 78234 USA.
   [Ellison, Richard] Off Corps Surg, Hlth Affairs, Airborne Corps 18, Ft Bragg, NC 28310 USA.
   [Kuhens, Charles] Walter Reed Army Med Ctr, Dept Nursing, Washington, DC 20307 USA.
   [Roach, Christopher J.] McDonald Army Hlth Ctr, Orthoped Clin, Ft Eustis, VA 23604 USA.
   [Jarrard, Steve] Winn Army Community Hosp, Dept Surg, Ft Stewart, GA 31314 USA.
RP Shen-Gunther, J (reprint author), Brooke Army Med Ctr, Dept Clin Invest, ATTN MCHE CI, 3400 Rawley E Chambers Ave,Suite A, Ft Sam Houston, TX 78234 USA.
CR ABC News, 2006, ABC NEWS
   BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001
   Beekley AC, 2004, AM J SURG, V187, P652, DOI 10.1016/j.amjsurg.2004.02.001
   Burris DG, 2004, EMERGENCY WAR SURG 3
   *DEP ARM, 2003, FIELD MAN 4 02 25 EM
   FRANKEL HL, 1998, TRAUMA MANUAL, P401
   FREUDIGMAN PT, 1998, TRAUMA MANUAL, P293
   *JOINT IMPR EXPL D, ANN REP FY 2008
   Kauvar DS, 2006, J TRAUMA, V61, P181, DOI 10.1097/01.ta.0000222671.84335.64
   Moore L, 2006, J TRAUMA, V61, P718, DOI 10.1097/01.ta.0000197906.28846.87
   MOREAU R, 2006, NEWSWEEK        1002, P25
   Peoples GE, 2005, MIL MED, V170, P462
   Place Ronald J, 2003, Curr Surg, V60, P418, DOI 10.1016/S0149-7944(02)00718-3
   Stinger H, 2006, MIL MED, V171, P269
   Zouris JM, 2006, MIL MED, V171, P246
   1997, TABULAR ICD 9 CM, V1, P1
   [Anonymous], 2007, BBC NEWS
   2002, CURRENT PROCEDURAL T, P47
   [Anonymous], 2006, BBC NEWS
NR 19
TC 17
Z9 18
U1 0
U2 3
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
J9 MIL MED
JI Milit. Med.
PD JAN
PY 2011
VL 176
IS 1
BP 67
EP 78
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 703XS
UT WOS:000286015800013
PM 21305963
ER


PT J
AU Berend, N
   Olive, X
AF Berend, Nicolas
   Olive, Xavier
TI Bi-objective optimization of a multiple-target active debris removal
   mission
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Active debris removal; Branch and Bound; Space debris; Orbit transfer
AB The increasing number of space debris in Low-Earth Orbit (LEO) raises the question of future Active Debris Removal (ADR) operations. Typical ADR scenarios rely on an Orbital Transfer Vehicle (OTV) using one of the two following disposal strategies: the first one consists in attaching a deorbiting kit, such as a solid rocket booster, to the debris after rendezvous; with the second one, the OTV captures the debris and moves it to a low perigee disposal orbit. For multiple-target ADR scenarios, the design of such a mission is very complex, as it involves two optimization levels: one for the space debris sequence, and a second one for the "elementary" orbit transfer strategy from a released debris to the next one in the sequence. This problem can be seen as a Time-Dependant Traveling Salesman Problem (TDTSP) with two objective functions to minimize: the total mission duration and the total propellant consumption.
   In order to efficiently solve this problem, ONERA has designed, under CNES contract, TOPAS (Tool for Optimal Planning of ADR Sequence), a tool that implements a Branch & Bound method developed in previous work together with a dedicated algorithm for optimizing the "elementary" orbit transfer. A single run of this tool yields an estimation of the Pareto front of the problem, which exhibits the trade-off between mission duration and propellant consumption. We first detail our solution to cope with the combinatorial explosion of complex ADR scenarios with 10 debris. The key point of this approach is to define the orbit transfer strategy through a small set of parameters, allowing an acceptable compromise between the quality of the optimum solution and the calculation cost. Then we present optimization results obtained for various 10 debris removal scenarios involving a 15-ton OTV, using either the deorbiting kit or the disposal orbit strategy.
   We show that the advantage of one strategy upon the other depends on the propellant margin, the maximum duration allowed for the mission and the orbit inclination domain. For high inclination orbits near 98 deg, the disposal orbit strategy is more appropriate for short duration missions, while the deorbiting kit strategy ensures a better propellant margin. Conversely, for lower inclination orbits near 65 deg, the deorbiting kit strategy appears to be the only possible with a 10 debris set. We eventually explain the consistency of these results with regards to astrodynamics. (C) 2016 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [Berend, Nicolas; Olive, Xavier] Off Natl Etud & Rech Aerosp, BP 80100,Chemin Huniere, F-91123 Palaiseau, France.
RP Berend, N (reprint author), Off Natl Etud & Rech Aerosp, BP 80100,Chemin Huniere, F-91123 Palaiseau, France.
EM nicolas.berend@onera.fr; xavier.olive@onera.fr
RI Berend, Nicolas/B-4387-2013
OI Olive, Xavier/0000-0002-2335-5774; Berend, Nicolas/0000-0002-7521-9758
FU French Space Agency CNES
FX The work presented in this paper has been funded by the French Space
   Agency CNES.
CR Barbee B.W., 2011, AER C IEEE, P1
   Bonnal C, 2005, ESA SP PUBL, V587, P361
   Bonnal C, 2013, ACTA ASTRONAUT, V85, P51, DOI 10.1016/j.actaastro.2012.11.009
   Cerf M, 2013, J OPTIMIZ THEORY APP, V156, P761, DOI 10.1007/s10957-012-0130-6
   Labourdette P., 2012, P 5 INT C ASTR TOOLS
   Liou JC, 2010, ACTA ASTRONAUT, V66, P648, DOI 10.1016/j.actaastro.2009.08.005
   Madakat D, 2013, ACTA ASTRONAUT, V84, P182, DOI 10.1016/j.actaastro.2012.10.038
   Missel J, 2013, ADV SPACE RES, V52, P1339, DOI 10.1016/j.asr.2013.07.008
   Murakami J., 2010, 61 INT ASTR C PRAG C
   Stodgell TR, 2008, ADV ASTRONAUT SCI, V129, P2069
   Wadsley BJ, 2008, ADV ASTRONAUT SCI, V129, P2705
   Zuiani F., 2012, J AEROSPACE ENG, V2012, DOI DOI 10.1155/2012/836250
NR 12
TC 0
Z9 0
U1 7
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
EI 1879-2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD MAY-JUN
PY 2016
VL 122
BP 324
EP 335
DI 10.1016/j.actaastro.2016.02.005
PG 12
WC Engineering, Aerospace
SC Engineering
GA DJ3AE
UT WOS:000374076000027
ER


PT J
AU Jankovic, M
   Paul, J
   Kirchner, F
AF Jankovic, Marko
   Paul, Jan
   Kirchner, Frank
TI GNC architecture for autonomous robotic capture of a non-cooperative
   target: Preliminary concept design
SO ADVANCES IN SPACE RESEARCH
LA English
DT Article
DE GNC; Active debris removal; Space debris; Proximity operations; Space
   robotics
ID SPACE DEBRIS REMOVAL; DYNAMICS; ORBIT; LEO
AB Recent studies of the space debris population in low Earth orbit (LEO) have concluded that certain regions have already reached a critical density of objects. This will eventually lead to a cascading process called the Kessler syndrome. The time may have come to seriously consider active debris removal (ADR) missions as the only viable way of preserving the space environment for future generations. Among all objects in the current environment, the SL-8 (Kosmos 3M second stages) rocket bodies (R/Bs) are some of the most suitable targets for future robotic ADR missions. However, to date, an autonomous relative navigation to and capture of an non-cooperative target has never been performed. Therefore, there is a need for more advanced, autonomous and modular systems that can cope with uncontrolled, tumbling objects. The guidance, navigation and control (GNC) system is one of the most critical ones. The main objective of this paper is to present a preliminary concept of a modular GNC architecture that should enable a safe and fuel-efficient capture of a known but uncooperative target, such as Kosmos 3M R/B. In particular, the concept was developed having in mind the most critical part of an ADR mission, i.e. close range proximity operations, and state of the art algorithms in the field of autonomous rendezvous and docking. In the end, a brief description of the hardware in the loop (HIL) testing facility is made, foreseen for the practical evaluation of the developed architecture. (C) 2015 COSPAR. Published by Elsevier Ltd. All rights reserved.
C1 [Jankovic, Marko] German Res Ctr Artificial Intelligence DFKI, Robert Hooke Str 1, D-28359 Bremen, Germany.
   Univ Bremen, D-28359 Bremen, Germany.
RP Jankovic, M (reprint author), German Res Ctr Artificial Intelligence DFKI, Robert Hooke Str 1, D-28359 Bremen, Germany.
EM marko.jankovic@dfki.de
RI Kirchner, Frank/P-6503-2016
OI Kirchner, Frank/0000-0002-1713-9784
FU Research Executive Agency (REA) by European Commission within Marie
   Curie Initial Training Network Stardust [317185]; REA; European
   Commission
FX The work of this research was supported by the Research Executive Agency
   (REA), acting, under powers delegated by the European Commission, within
   the Marie Curie Initial Training Network Stardust, FP7-PEOPLE-2012-ITN,
   [Grant agreement No. 317185] of the Seventh Framework Program of the
   European Commission. Thus, the authors would like to thank the REA and
   the European Commission for their support and funding. Moreover, we
   would like to thank our reviewers for their invaluable advises and
   suggestions.
CR Aghili F, 2011, IEEE SENS J, V11, P176, DOI 10.1109/JSEN.2010.2056365
   Airbus Defence & Space, 2012, ASTR WINS DEOS CONTR
   Arantes G, 2014, MATH PROBL ENG, DOI 10.1155/2014/508516
   Barbee B. W., 2010, BORN S NASA GODD SPA, P1
   Bonnal C., 2013, ACTA ASTRON, P51
   Breger L, 2008, J GUID CONTROL DYNAM, V31, P1478, DOI 10.2514/1.29590
   Castronuovo MM, 2011, ACTA ASTRONAUT, V69, P848, DOI 10.1016/j.actaastro.2011.04.017
   Cimen T, 2010, ANNU REV CONTROL, V34, P32, DOI 10.1016/j.arcontrol.2010.03.001
   Committee on the Peaceful Uses of Outer Space, 2014, AAC1052014CRP13 UN O
   Crassidis J. L., 2007, J GUIDANCE CONTROL D, V30, P12
   Davis T., 2003, 17 ANN AIAA USU C SM, P1
   DeLuca LT, 2013, ACTA ASTRONAUT, V91, P20, DOI 10.1016/j.actaastro.2013.04.025
   Di Mauro G., 2013, THESIS POLITECNICO M
   Ellery A, 2004, P I MECH ENG G-J AER, V218, P79, DOI 10.1243/0954410041321998
   EoPortal, 2007, XSS EXP SPAC SYST XS
   Fehse W., 2003, CAMBRIDGE AEROSPACE
   Flores-Abad A, 2014, PROG AEROSP SCI, V68, P1, DOI 10.1016/j.paerosci.2014.03.002
   Hablani HB, 2002, J GUID CONTROL DYNAM, V25, P553, DOI 10.2514/2.4916
   Haugen Finn, 2010, DISCRETIZATION SIMUL
   Hawkes EW, 2013, IEEE INT C INT ROBOT, P5487, DOI 10.1109/IROS.2013.6697151
   Hillenbrand U., 2005, ESA PUBLICATIONS DIV, P1
   Hirzinger G., 2009, NEW TECHNOLOGIES ROB, P642
   Karr CL, 1997, ENG APPL ARTIF INTEL, V10, P293, DOI 10.1016/S0952-1976(97)00008-0
   Kennedy F., 2008, ORBITAL EXPRESS
   Kervendal E., 2013, ADV AEROSPACE GUIDAN, P761
   KESSLER DJ, 1978, J GEOPHYS RES-SPACE, V83, P2637, DOI 10.1029/JA083iA06p02637
   Lampariello R, 2013, IEEE INT C INT ROBOT, P5652, DOI 10.1109/IROS.2013.6697175
   LaViola JJ, 2003, P AMER CONTR CONF, P2435
   Lee D., 2010, INT J AERONAUT SPACE, V11, P206, DOI DOI 10.5139/IJASS.2010.11.3.206
   Liou JC, 2008, ADV SPACE RES, V41, P1046, DOI 10.1016/j.asr.2007.04.081
   Liou JC, 2011, ADV SPACE RES, V47, P1865, DOI 10.1016/j.asr.2011.02.003
   Liou JC, 2010, ACTA ASTRONAUT, V66, P648, DOI 10.1016/j.actaastro.2009.08.005
   Liou JC, 2009, ACTA ASTRONAUT, V64, P236, DOI 10.1016/j.actaastro.2008.07.009
   Liou J.C., 2011, ORBITAL DEBRIS Q NEW, V15, P4
   Luo YZ, 2014, CHINESE J AERONAUT, V27, P1, DOI 10.1016/j.cja.2013.07.042
   Luo YZ, 2005, AEROSP SCI TECHNOL, V9, P732, DOI 10.1016/j.ast.2005.07.010
   Ma Z., 2012, J ASTRONAUT SCI, V55, P407
   Matsumoto S., 2002, IEEE INT C ROB AUT 2, V3, P2309
   Matsumoto S., 2003, P 7 INT S ART INT RO, P1
   Naasz B., 2010, AIAA GUID NAV CONTR, P1
   Nolet S., 2007, THESIS MIT CAMBRIDGE
   Orbital Debris Program Office N., 2012, ORB DEBR FREQ ASK QU
   Paul J., 2014, P INT S ART INT ROB
   Pavone M., 2014, LECT NOTES IN PRESS
   Personne G., 2006, 6 INT ESA C GUID NAV, P1
   Praly N, 2012, ACTA ASTRONAUT, V76, P145, DOI 10.1016/j.actaastro.2012.03.004
   Rupp Th, 2009, 21 INT S SPAC FLIGHT
   Sellmaier F., 2010, SPACEOPS 2010 C HUNT, P1
   Sommer J., 2013, P 5 INT C SPAC FORM, P1
   Space Debris Office E., 2013, AB SPAC DEBR
   Stengel R. F., 1986, OPTIMAL CONTROL ESTI
   Tellez J. P. D., 2011, 2011 IEEE International Conference on Robotics and Biomimetics (ROBIO), P1867, DOI 10.1109/ROBIO.2011.6181562
   Truszkowski W, 2009, NASA MONOGR SYST SOF, P1
   Tzschichholz T, 2011, ACTA ASTRONAUT, V68, P1156, DOI 10.1016/j.actaastro.2010.10.003
   Wan E. A., 2002, WILEY SERIES ADAPTIV, P221
   Woffinden DC, 2007, J SPACECRAFT ROCKETS, V44, P898, DOI 10.2514/1.30734
   Wormnes K., 2013, 6 EUR C SPAC DEBR ES, P1
   Wright M., 2011, ORBITAL EXPRESS OVER
   Yoshida K, 2008, SPRINGER HDB ROBOTIC, P1031, DOI 10.1007/978-3-540-30301-5_46
   Yoshida Kazuya, 2009, ROBOTICS AUTOMATION, V16, P20, DOI DOI 10.1109/MRA.2009.934818
   Yoshida K, 2006, 2006 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS, VOLS 1-12, P4127, DOI 10.1109/IROS.2006.281900
   Youmans EA, 1998, J GUID CONTROL DYNAM, V21, P116, DOI 10.2514/2.4206
   [Anonymous], 2007, DEFENSE IND DAIL APR
NR 63
TC 1
Z9 1
U1 5
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0273-1177
EI 1879-1948
J9 ADV SPACE RES
JI Adv. Space Res.
PD APR 15
PY 2016
VL 57
IS 8
BP 1715
EP 1736
DI 10.1016/j.asr.2015.05.018
PG 22
WC Astronomy & Astrophysics; Geosciences, Multidisciplinary; Meteorology &
   Atmospheric Sciences
SC Astronomy & Astrophysics; Geology; Meteorology & Atmospheric Sciences
GA DJ7CH
UT WOS:000374369000009
ER


PT J
AU Lin, HY
   Zhao, CY
   Zhang, MJ
AF Lin, Hou-Yuan
   Zhao, Chang-Yin
   Zhang, Ming-Jiang
TI Frequency analysis of the non-principal-axis rotation of uniaxial space
   debris in circular orbit subjected to gravity-gradient torque
SO ADVANCES IN SPACE RESEARCH
LA English
DT Article
DE Active debris removal; Rotational motion of space debris; Frequency
   analysis; State estimation
ID CYLINDRICAL EARTH SATELLITE; ARTIFICIAL SATELLITE; VISUAL OBSERVATIONS;
   SOLAR-SYSTEM; MOTION; EVOLUTION; LOCATION; DYNAMICS; BODY; LEO
AB The non-principal-axis rotational motion of uniaxial space debris can be decomposed into periodic motions associated with two frequencies: the polhode frequency of the space debris rotating around the symmetry axis, and the tumbling frequency of the symmetry axis rotating around the angular momentum. To determine from optical measurements the rotational motion of upper rocket stages in circular orbits subjected to gravity-gradient torque, the evolutions of these two frequencies need to be analyzed. Taking into account only the long-term changes in the long-period variables, the differential equations of the non-principal axis rotational motion of the uniaxial space debris are averaged and reduced, from which the evolutions of the polhode and tumbling frequencies are then obtained analytically. The theoretical results are verified by numerical simulations of the diffuse reflection model. The frequencies in the variation of the reflected light intensity in the simulation are analyzed using the frequency map analysis (FMA) method. Errors of these results are found to be less than 1%. Based on the theoretical expressions, the rotational state of the uniaxial space debris can be estimated in the simulation without any prior information except the orbital parameters. A series of state variables are estimated, including the ratio of the moments of inertia about the transverse axis and the symmetry axis, the instantaneous rotation velocity, the orientation of the angular momentum, and the precession cone of the symmetry axis. (C) 2015 COSPAR. Published by Elsevier Ltd. All rights reserved.
C1 [Lin, Hou-Yuan; Zhao, Chang-Yin; Zhang, Ming-Jiang] Chinese Acad Sci, Purple Mt Observ, Nanjing 210008, Jiangsu, Peoples R China.
   [Lin, Hou-Yuan; Zhao, Chang-Yin; Zhang, Ming-Jiang] Chinese Acad Sci, Purple Mt Observ, Key Lab Space Object & Debris Observat, Nanjing 210008, Jiangsu, Peoples R China.
   [Lin, Hou-Yuan; Zhang, Ming-Jiang] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Zhao, CY (reprint author), Chinese Acad Sci, Purple Mt Observ, Nanjing 210008, Jiangsu, Peoples R China.
EM linhouyuan@pmo.ac.cn; cyzhao@pmo.ac.cn; mjzhang@pmo.ac.cn
FU Key Program of the National Natural Science Foundation of China
   [11533010]; National Science Fund for Distinguished Young Scientists of
   China [11125315]
FX This research was supported by the Key Program of the National Natural
   Science Foundation of China (Grant No. 11533010) and the National
   Science Fund for Distinguished Young Scientists of China (Grant No.
   11125315). We wish to thank the anonymous reviewers for their valuable
   comments.
CR Cochran J. E., 1972, Celestial Mechanics, V6, P127, DOI 10.1007/BF01227777
   CRENSHAW JW, 1968, AIAA J, V6, P2140
   Giese R, 1963, SAO SPECIAL REPORT, P1
   Hitzl D. L., 1971, Celestial Mechanics, V3, DOI 10.1007/BF01231806
   HOLLAND RL, 1969, ASTRON J, V74, P490, DOI 10.1086/110826
   LASKAR J, 1990, ICARUS, V88, P266, DOI 10.1016/0019-1035(90)90084-M
   LASKAR J, 1993, PHYSICA D, V67, P257, DOI 10.1016/0167-2789(93)90210-R
   LASKAR J, 1988, ASTRON ASTROPHYS, V198, P341
   Laskar J, 1995, P 3 DHAM 95 NATO ADV, V5333, P134
   Lin HY, 2015, ASTROPHYS SPACE SCI, V357, DOI 10.1007/s10509-015-2396-2
   Liou JC, 2011, ADV SPACE RES, V47, P1865, DOI 10.1016/j.asr.2011.02.003
   Liou JC, 2009, ACTA ASTRONAUT, V64, P236, DOI 10.1016/j.actaastro.2008.07.009
   LIU JJF, 1975, CELESTIAL MECH, V12, P463, DOI 10.1007/BF01595391
   Markeyev A. P., 2006, THEORETICAL MECH
   Ojakangas G.W., 2012, 13 ANN ADV MAUI OPT
   Praly N, 2012, ACTA ASTRONAUT, V76, P145, DOI 10.1016/j.actaastro.2012.03.004
   Santoni F, 2013, J SPACECRAFT ROCKETS, V50, P701, DOI 10.2514/1.A32372
   WILLIAMS V, 1979, PLANET SPACE SCI, V27, P885, DOI 10.1016/0032-0633(79)90014-X
   WILLIAMS V, 1978, PLANET SPACE SCI, V26, P721, DOI 10.1016/0032-0633(78)90003-X
   WILLIAMS V, 1979, PLANET SPACE SCI, V27, P891, DOI 10.1016/0032-0633(79)90015-1
   Wilson R. H.  Jr., 1977, Irish Astronomical Journal, V13, P1
   Yanagisawa T, 2012, ADV SPACE RES, V50, P136, DOI 10.1016/j.asr.2012.03.021
NR 22
TC 0
Z9 0
U1 3
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0273-1177
EI 1879-1948
J9 ADV SPACE RES
JI Adv. Space Res.
PD MAR 1
PY 2016
VL 57
IS 5
BP 1189
EP 1196
DI 10.1016/j.asr.2015.12.036
PG 8
WC Astronomy & Astrophysics; Geosciences, Multidisciplinary; Meteorology &
   Atmospheric Sciences
SC Astronomy & Astrophysics; Geology; Meteorology & Atmospheric Sciences
GA DF1LE
UT WOS:000371100400005
ER


PT J
AU Liang, ZX
   Li, QD
   Ren, Z
AF Liang, Zixuan
   Li, Qingdong
   Ren, Zhang
TI Onboard planning of constrained longitudinal trajectory for reusable
   launch vehicles in terminal area
SO ADVANCES IN SPACE RESEARCH
LA English
DT Article
DE Reusable launch vehicle; Terminal area energy management; Onboard
   planning; Trajectory optimization; Flight constraint
ID ENERGY MANAGEMENT; ENTRY GUIDANCE
AB A rapid planning algorithm is developed to generate a constrained longitudinal trajectory onboard for reusable launch vehicles (RLVs) in the terminal area energy management (TAEM) phase. The longitudinal trajectory is planned in the flight-path angle vs. altitude space. This flight-path angle profile is designed with required altitude, flight-path angle and range-to-go, and then optimized as a one-parameter search problem to meet the velocity constraint. Considering the dynamic pressure constraint, a dynamic pressure protection (DPP) method is designed. With the DPP, the highly constrained longitudinal trajectory is generated by tracking the planned flight path angle profile. Finally, the TAEM trajectory planning algorithm is tested on the X-33 vehicle model in different cases. The algorithm is shown to be effective and robust to generate longitudinal flight trajectories with all constraints satisfied in high precision. In each case, the constrained trajectory is planned within 1 s on a PC, which indicates that the algorithm is feasible to be employed onboard. (C) 2015 COSPAR. Published by Elsevier Ltd. All rights reserved.
C1 [Liang, Zixuan; Li, Qingdong; Ren, Zhang] Beihang Univ, Sci & Technol Aircraft Control Lab, Beijing 100191, Peoples R China.
RP Li, QD (reprint author), Beihang Univ, Sci & Technol Aircraft Control Lab, Beijing 100191, Peoples R China.
EM aliang@buaa.edu.cn; buaa.gnc@gmail.com; renzhang@buaa.edu.cn
OI Liang, Zixuan/0000-0002-0764-2538
FU National Natural Science Foundation of China [61121003, 61333011,
   91116002, 91216304]
FX The authors would like to thank the reviewers for their helpful comments
   and suggestions. This work is supported by the National Natural Science
   Foundation of China (Nos. 61121003, 61333011, 91116002, and 91216304).
CR Barton G.H., 2002, P 2002 COR TECHN SPA
   Barton G. H., 1999, AIAA ATM FLIGHT MECH
   BOLLINO K, 2006, AIAA GUID NAV CONTR
   Burchett BT, 2004, J SPACECRAFT ROCKETS, V41, P444, DOI 10.2514/1.10938
   Chen G, 2011, THESIS HARBIN I TECH
   Corraro F., 2011, AIAA GUID NAV CONTR
   Da Costa R.R., 2003, AIAA GUID NAV CONTR
   Freeman DC, 1997, ACTA ASTRONAUT, V41, P777, DOI 10.1016/S0094-5765(97)00197-5
   Girerd A.R., 2001, THESIS MIT
   Hanson JM, 2004, J GUID CONTROL DYNAM, V27, P960, DOI 10.2514/1.10886
   HARPOLD JC, 1979, J ASTRONAUT SCI, V27, P239
   Helers H., 1977, AUTOMATICA, V13, P11, DOI 10.1016/0005-1098(77)90005-X
   Horneman K.R., 2004, AIAA ATM FLIGHT MECH
   ISO (International Organization for Standardization), 1975, 2533 ISO
   Kluever CA, 2007, J GUID CONTROL DYNAM, V30, P162, DOI 10.2514/1.24864
   Kluever CA, 2004, J GUID CONTROL DYNAM, V27, P967, DOI 10.2514/1.7877
   Kluever C.A., 2015, J GUID CONTROL DYNAM, P38
   Liang ZX, 2014, 2014 IEEE CHINESE GUIDANCE, NAVIGATION AND CONTROL CONFERENCE (CGNCC), P850, DOI 10.1109/CGNCC.2014.7007320
   Lu P, 1997, J GUID CONTROL DYNAM, V20, P143, DOI 10.2514/2.4008
   Lu P., 2014, J GUID CONTROL DYNAM, P713
   Mayanna A., 2006, AIAA GUID NAV CONTR
   Moore T.E., 1991, TM104744 NASA
   Morani G, 2011, P I MECH ENG G-J AER, V225, P631, DOI 10.1177/2041302510393001
   Morio V, 2010, IET CONTROL THEORY A, V4, P472, DOI 10.1049/iet-cta.2008.0463
   Morio V., 2007, P 17 IFAC S AUT CONT
   Peng YB, 1996, IEEE CONTR SYST MAG, V16, P48, DOI 10.1109/37.526915
   Rasky D.J., 2006, SPACE 2006
   Ridder S., 2011, J SPACECRAFT ROCKETS, V48, P642
   Ridder S.D., 2011, ACTA ASTRONAUT, V68, P915
   Vinh N. X., 1980, HYPERSONIC PLANETARY
NR 30
TC 0
Z9 0
U1 2
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0273-1177
EI 1879-1948
J9 ADV SPACE RES
JI Adv. Space Res.
PD FEB 1
PY 2016
VL 57
IS 3
BP 742
EP 753
DI 10.1016/j.asr.2015.11.027
PG 12
WC Astronomy & Astrophysics; Geosciences, Multidisciplinary; Meteorology &
   Atmospheric Sciences
SC Astronomy & Astrophysics; Geology; Meteorology & Atmospheric Sciences
GA DC8FX
UT WOS:000369456400002
ER


PT J
AU Zhou, M
   Zhou, J
   Guo, JG
AF Zhou, Min
   Zhou, Jun
   Guo, Jianguo
TI Terminal area guidance for reusable launch vehicles
SO PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART G-JOURNAL OF
   AEROSPACE ENGINEERING
LA English
DT Article
DE Terminal area energy management; guidance; ranging capability; tracking
   law
ID ENERGY MANAGEMENT; ENTRY; CONSTRAINTS; DESIGN
AB In this paper, a ranging-capability-estimation approach and an adaptive guidance law are developed for reusable launch vehicle during the terminal area energy management. The reference trajectory is planned within the neighborhood of the center of ranging capability. To estimate the ranging capability, a group of algebraic formulas are derived to compute its upper boundary, and an iteration logic is investigated to compute the lower boundary. This approach is simple and potential to be used on-board. A more precise range prediction and the consideration of bank angle and normal acceleration constraints improve the feasibility of the planned Shuttle-based ground track. In the longitudinal guidance, a new dynamic-pressure tracking scheme is designed to combine with the tracking of a reference altitude profile. This combination strategy guarantees the controlling of altitude, velocity, and flight-path angle. Finally, an automatic gain-tuning method, based on the feedback linearization technique, is developed for the proportional and derivative gains in the trajectory-tracking law. Numerical simulations of the X-33 demonstrate that the proposed ranging-capability-estimation approach has high precision, and its computation time is short; the new guidance law can automatically deliver the reusable launch vehicle to the desired approach and landing interface state even when there are initial-state dispersion and flying disturbances.
C1 [Zhou, Min; Zhou, Jun; Guo, Jianguo] Northwestern Polytech Univ, Inst Precis Guidance & Control, POB 234, Xian 710072, Peoples R China.
RP Zhou, M (reprint author), Northwestern Polytech Univ, Inst Precis Guidance & Control, POB 234, Xian 710072, Peoples R China.
EM zhoumin_npu@139.com
CR Barton GH, 2002, 2002 COR TECHN SPAC, V22
   Bharadwaj S, 1998, J GUID CONTROL DYNAM, V21, P726, DOI 10.2514/2.4318
   Burchett BT, 2004, J SPACECRAFT ROCKETS, V41, P444, DOI 10.2514/1.10938
   Chartres J, 2005, 56 INT ASTR C 2005 F, P3191
   Chen G, 2012, HARBIN GONGYE DAXUE, V44, P20
   Da Costa R.R., 2003, AIAA GUID NAV CONTR
   De Ridder S, 2011, ACTA ASTRONAUT, V68, P915, DOI 10.1016/j.actaastro.2010.08.032
   Hanson J. M., 2002, AIAA GUID NAV CONTR
   HULL JR, 2005, INFOTECH AEROSPACE
   Kluever CA, 2007, J GUID CONTROL DYNAM, V30, P162, DOI 10.2514/1.24864
   Kluever CA, 2005, AIAA PAPER
   Kluever C A, 2009, AIAA GUID NAV CONTR
   Lu P, 2014, J GUID CONTROL DYNAM, V37, P713, DOI 10.2514/1.62605
   Mayanna A., 2006, AIAA GUID NAV CONTR
   Moore TE, 1991, 104744 NASA LB JOHNS
   Morani G, 2011, P I MECH ENG G-J AER, V225, P631, DOI 10.1177/2041302510393001
   Ridder S., 2011, J SPACECRAFT ROCKETS, V48, P642
   Saraf A, 2004, J SPACECRAFT ROCKETS, V41, P986, DOI 10.2514/1.11015
   Zhang S.-G, 2008, P 17 WORLD C INT FE, P13022, DOI 10.1117/12.819613
   [周敏 Zhou Min], 2015, [宇航学报, Journal of Astronautics], V36, P151
   Zhou M, 2014, APPL MECH MATER, V446-447, P611, DOI 10.4028/www.scientific.net/AMM.446-447.611
NR 21
TC 0
Z9 0
U1 5
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0954-4100
EI 2041-3025
J9 P I MECH ENG G-J AER
JI Proc. Inst. Mech. Eng. Part G-J. Aerosp. Eng.
PD FEB
PY 2016
VL 230
IS 2
BP 333
EP 349
DI 10.1177/0954410015591615
PG 17
WC Engineering, Aerospace; Engineering, Mechanical
SC Engineering
GA DC0TT
UT WOS:000368931400009
ER


PT J
AU Schumack, M
AF Schumack, Mark
TI A computational model for a rocket mass heater
SO APPLIED THERMAL ENGINEERING
LA English
DT Article
DE Rocket mass heater; Masonry heater; Rocket stove; Biomass stove; Thermal
   modeling
ID BIOMASS COOKSTOVES; STOVES
AB A simple one dimensional pseudo-steady computational model of a rocket mass heater is presented. A rocket mass heater is a space heating device that utilizes an insulated "J-tube" to promote complete combustion of burning wood, a steel barrel to act as a heat radiator, and a thermal mass usually shaped into a bench that stores heat from the exhaust before the combustion gases are released to the atmosphere. The gas model is based on fundamental relationships for steady compressible flow through one-dimensional geometry and is coupled to an unsteady finite difference model for two dimensional heat conduction in the thermal mass, which is modeled as a hollow cylinder. The model accounts for detailed heat transfer effects and fluid frictional losses, and is able to predict efficiency, flow rate, and spatial variations in temperature and pressure as functions of key parameters such as burn rate, thermal mass volume and length, duct routing details, and chimney height. Key results demonstrate how insufficient chimney height and narrow barrel clearances can threaten heater performance, how a system damper and increasing duct length can improve heater efficiency, and that axial temperature variation in the mass is small compared to radial gradients. (C) 2015 Published by Elsevier Ltd.
C1 [Schumack, Mark] Univ Detroit Mercy, Dept Mech Engn, Detroit, MI 48221 USA.
RP Schumack, M (reprint author), Univ Detroit Mercy, Dept Mech Engn, 4001 W McNichols, Detroit, MI 48221 USA.
EM schumamr@udmercy.edu
CR Agenbroad J, 2011, ENERGY SUSTAIN DEV, V15, P160, DOI 10.1016/j.esd.2011.04.004
   Bergman T. L., 2011, INTRO HEAT TRANSFER
   Bryden M., 2005, DESIGNING IMPROVED W
   Bryden M., 2005, EPA402K05004 OFF AIR
   Evans I., 2014, ROCKET MASS HEATERS
   Felaco E., 2013, J MATH IND, V3, P3
   Howell R. H., 2013, PRINCIPLES HEATING V
   Kumar M, 2013, RENEW SUST ENERG REV, V26, P265, DOI 10.1016/j.rser.2013.05.010
   Lyle D., 1984, BOOK MASONRY STOVES
   MacCarty N., 2013, P ASME 2013 INT DES
   MacCarty N., 2013, THESIS
   MacCarty NA, 2015, ENERGY SUSTAIN DEV, V26, P1, DOI 10.1016/j.esd.2015.02.001
   Menghini D, 2008, EXP THERM FLUID SCI, V32, P1371, DOI 10.1016/j.expthermflusci.2007.11.018
   Munson B. R., 2013, FUNDAMENTAL FLUID ME
   Pritchard P. J., 2011, FOX MCDONALDS INTRO
   Saastamoinen J, 2005, APPL THERM ENG, V25, P2878, DOI 10.1016/j.applthermaleng.2005.02.009
   Spearpoint MJ, 2000, COMBUST FLAME, V123, P308, DOI 10.1016/S0010-2180(00)00162-0
   Sutar KB, 2015, RENEW SUST ENERG REV, V41, P1128, DOI 10.1016/j.rser.2014.09.003
NR 18
TC 0
Z9 0
U1 4
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-4311
J9 APPL THERM ENG
JI Appl. Therm. Eng.
PD JAN 25
PY 2016
VL 93
BP 763
EP 778
DI 10.1016/j.applthermaleng.2015.10.035
PG 16
WC Thermodynamics; Energy & Fuels; Engineering, Mechanical; Mechanics
SC Thermodynamics; Energy & Fuels; Engineering; Mechanics
GA DA4NN
UT WOS:000367776700081
ER


PT J
AU Chen, SY
   Xia, QL
AF Chen, Si-Yuan
   Xia, Qun-Li
TI A Multiconstrained Ascent Guidance Method for Solid Rocket-Powered
   Launch Vehicles
SO International Journal of Aerospace Engineering
LA English
DT Article
ID TRAJECTORY OPTIMIZATION; NAVIGATION
AB This study proposes amulticonstrained ascent guidance method for a solid rocket-powered launch vehicle, which uses a hypersonic glide vehicle (HGV) as payload and shuts off by fuel exhaustion. First, pseudospectral method is used to analyze the two-stage launch vehicle ascent trajectory with different rocket ignitionmodes. Then, constraints, such as terminal height, velocity, flight path angle, and angle of attack, are converted into the constraints within height-time profile according to the second-stage rocket flight characteristics. The closed-loop guidance method is inferred by different spline curves given the different terminal constraints. Afterwards, a thrust bias energy management strategy is proposed to waste the excess energy of the solid rocket. Finally, the proposed method is verified through nominal and dispersion simulations. The simulation results show excellent applicability and robustness of this method, which can provide a valuable reference for the ascent guidance of solid rocket-powered launch vehicles.
C1 [Chen, Si-Yuan; Xia, Qun-Li] Beijing Inst Technol, Sch Aerosp Engn, Beijing 100081, Peoples R China.
RP Chen, SY (reprint author), Beijing Inst Technol, Sch Aerosp Engn, Beijing 100081, Peoples R China.
EM 0035@bit.edu.cn
CR Abrahamson M. J., 2007, BOOST REENTRY TRAJEC
   Avanzini G, 2008, J GUID CONTROL DYNAM, V31, P1587, DOI 10.2514/1.36426
   Battin R. H., 1983, J GUIDANCE CONTROL D, V1, P662
   Benson D A, 2005, GAUSS PSEUDOSPECTRAL
   Benson DA, 2006, J GUID CONTROL DYNAM, V29, P1435, DOI 10.2514/1.20478
   Betts JT, 1998, J GUID CONTROL DYNAM, V21, P193, DOI 10.2514/2.4231
   Brauer G., 1977, CAPABILITIES APPL PR
   BROWN KR, 1967, IEEE T AUTOMAT CONTR, VAC12, P501, DOI 10.1109/TAC.1967.1098718
   Dukeman G., 2003, 20035638 AIAA
   Dukeman G. A., 2005, CLOSED LOOP NOMINAL
   Dukeman G. A., 2002, P AIAA GUID NAV CONT, V4559, P5
   Huntington G. T., 2007, P AIAA GUID NAV CONT, V6405, P840
   Lu P, 1996, J GUID CONTROL DYNAM, V19, P99, DOI 10.2514/3.21585
   Lu P, 2003, J GUID CONTROL DYNAM, V26, P283, DOI 10.2514/2.5045
   Lu P., 2013, 20134648 AIAA
   Lu P, 2010, J GUID CONTROL DYNAM, V33, P404, DOI 10.2514/1.45632
   MARTIN DT, 1967, J SPACECRAFT ROCKETS, V4, P891, DOI 10.2514/3.28984
   MCHENRY RL, 1979, J ASTRONAUT SCI, V27, P1
   NELSON SL, 1992, J GUID CONTROL DYNAM, V15, P1003, DOI 10.2514/3.20935
   Paris S., 1996, OTIS 3 0 MANUAL, V24
   Patha J. T., 1976, P AIAA GUID CONTR C, P1
   Phillips T. H., 2003, COMMON AEROVEHICLE C, V27
   Rao A. V., 2011, USERS MANUAL GPOPS V
   SEYWALD H, 1994, J GUID CONTROL DYNAM, V17, P1154, DOI 10.2514/3.21327
   Tewari A, 2011, AEROSPACE SERIES, P1, DOI 10.1002/9781119971191
   Walker S. H., 2008, 20082539 AIAA
   Xu H., 2011, POLYM B, P1
   Zarchan P, 2012, TACTICAL STRATEGIC M
   Zipfel P. H., 2014, J MODELING SIMULATIO, V2, P31
NR 29
TC 0
Z9 0
U1 10
U2 10
PU HINDAWI PUBLISHING CORP
PI NEW YORK
PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA
SN 1687-5966
EI 1687-5974
J9 INT J AEROSPACE ENG
JI Int. J. Aerosp. Eng.
PY 2016
AR 6346742
DI 10.1155/2016/6346742
PG 11
WC Engineering, Aerospace
SC Engineering
GA DS3PS
UT WOS:000380695800001
ER


PT J
AU Thompson, AS
   Heister, SD
AF Thompson, Andrew S.
   Heister, Stephen D.
TI CHARACTERISTICS OF FLASHING FLOWS WITHIN A HIGH ASPECT RATIO INJECTOR
SO ATOMIZATION AND SPRAYS
LA English
DT Article
DE flash boiling; cavitation; slot injector; super heat
ID CAVITATION; ATOMIZATION
AB Thermal management issues necessitate the use of fuel as a heat sink for gas turbine and liquid rocket engines. As interest in heated fuels increases, it is important to understand what occurs in the flow path of an injector under flashing conditions. This article describes a flow visualization study to characterize the flow of flashing methanol through two high aspect ratio slot orifice injectors of differing sizes. Flashing conditions inside the injector flow path were induced via a combination of heating and back pressure adjustments. Volume flow rate, pressure measurements, and temperature measurements were made that allowed the discharge characteristics, the level of super heat, and other parameters to be calculated and compared. To give a basis for comparison, the flashing results are compared to the flow through the injector under cavitating conditions. Cavitation and flashing are observed to follow similar trends. As such, they appear to be related phenomena, and this relationship is shown. Bubble formation under cavitating or flashing conditions is observed to attenuate the injector's discharge characteristics. High-speed videos of the flow field were also collected. Several flow regimes and flow structures, unique to these regimes, were observed. The results suggest a possible way to predict an injector's performance under flashing conditions without running heated fuel through the injector. These results may be applicable to real world injector design and testing.
C1 [Thompson, Andrew S.; Heister, Stephen D.] Purdue Univ, Maurice J Zucrow Labs, Dept Aeronaut & Astronaut, W Lafayette, IN 47906 USA.
RP Thompson, AS (reprint author), Purdue Univ, Maurice J Zucrow Labs, Dept Aeronaut & Astronaut, W Lafayette, IN 47906 USA.
EM thomps79@purdue.edu
FU Rolls Royce under University Technology Center in High Mach Propulsion
   at Purdue University
FX We thank Rolls Royce for the support that made this project possible
   under the University Technology Center in High Mach Propulsion at Purdue
   University.
CR Ballester J., 1994, ATOMIZATION SPRAY, V4, P315
   Brennen C. E., 1995, CAVITATION BUBBLE DY
   Chaves H., 1995, EXPT STUDY CAVITATIO
   Crockett H., 2010, J PRESSURE VESSEL TE, V132, P1
   Dunn P., 2010, PHYS FLUIDS, V22, P1
   Franc J., 2006, 8107 LML ENSAM UMR C, V8, P1
   Gavaises M., 2009, PHYS FLUIDS, V21, P1
   Habchi C., 2013, ILASS EUR 2013 25 EU
   He L, 1995, ATOMIZATION SPRAY, V5, P569
   Lee J, 2009, P COMBUST INST, V32, P3215, DOI 10.1016/j.proci.2008.06.153
   Martynov S, 2006, P 13 INT HEAT TRANSF
   Martynov S., 2005, THESIS U BRIGHTON
   Michel J., 2001, EN010 RTO VONK I LAB
   Munson B.R., 1940, FUNDAMENTALS FLUID M
   NURICK WH, 1976, J FLUID ENG-T ASME, V98, P681
   Polanco G, 2010, J HAZARD MATER, V173, P2, DOI 10.1016/j.jhazmat.2009.08.138
   Schmidt D.P., 1997, THESIS U WISCONSIN M
   Sou A, 2007, INT J HEAT MASS TRAN, V50, P3575, DOI 10.1016/j.ijheatmasstransfer.2006.12.033
   Thompson A. S., 2014, THESIS PURDUE U
   Vieira MM, 2007, J FLUID MECH, V572, P121, DOI 10.1017/S0022112006003430
   Wiest H., 2013, 49 AIAA ASME SAE ASE
   Wirth K., 2006, ASME JOINT US EUR FL, P1
   Witlox H. W. M., 2002, FLASHING LIQUID JETS
NR 23
TC 0
Z9 0
U1 4
U2 4
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1044-5110
EI 1936-2684
J9 ATOMIZATION SPRAY
JI Atom. Sprays
PY 2016
VL 26
IS 7
BP 633
EP 658
DI 10.1615/AtomizSpr.2015011677
PG 26
WC Engineering, Multidisciplinary; Engineering, Chemical; Engineering,
   Mechanical; Materials Science, Multidisciplinary; Physics, Applied
SC Engineering; Materials Science; Physics
GA DL6KV
UT WOS:000375749000001
ER


PT J
AU Austin, JL
   Temple, WJ
   Puloski, S
   Schachar, NS
   Paolucci, EO
   Kurien, E
   Sarkhosh, K
   Mack, LA
AF Austin, Janice L.
   Temple, Walley J.
   Puloski, Shannon
   Schachar, Norman S.
   Paolucci, Elizabeth Oddone
   Kurien, Elizabeth
   Sarkhosh, Kourosh
   Mack, Lloyd A.
TI Outcomes of surgical treatment alone in patients with superficial soft
   tissue sarcoma regardless of size or grade
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE sarcoma; neoplasm recurrence; local; neoplasms; subcutaneous tissue;
   retrospective studies; fascia
ID PROGNOSTIC-FACTORS; ADJUVANT CHEMOTHERAPY; LOCAL RECURRENCE; EXTREMITY;
   BRACHYTHERAPY; EXPERIENCE; MANAGEMENT; RADIATION; VARIABLES; SURGERY
AB Background and ObjectivesCurrently, standard treatment of soft tissue sarcoma (STS) is wide local excision and adjuvant radiation, but radiation may be unnecessary in superficial STS. The primary objective is to assess local recurrence rates in patients treated with surgical management alone for superficial STS.
   MethodsA retrospective cancer registry review of patients treated with surgery alone for superficial STS at the Tom Baker Cancer Center (TBCC) was performed. Patient and tumor characteristics as well as recurrence data were collected.
   ResultsSixty-one patients met study criteria. Local and overall recurrence rates were 7/61 (11.5%) and 12/61 (19.7%), respectively. The proportion with a T2 tumor was 38.8% versus 33.3% (P=0.69), with Grade 2 or 3 tumors was 59.2% versus 83.3% (P=0.14), and with resection margins <1cm was 28.6% versus 75.0% (P=0.008) for patients without and with recurrence, respectively. Median time to recurrence was 1.7 (0.4-5.2) years.
   ConclusionsSurgical resection alone appears to be a viable option for superficial STS that can save patients from potential side effects of radiation. The association between recurrence and inadequate margins (<1cm) requires additional treatment be offered to this subset of patients. J. Surg. Oncol. 2016;113:108-113. (c) 2015 Wiley Periodicals, Inc.
C1 [Austin, Janice L.] Univ Calgary, Foothills Med Ctr, Div Gen Surg, Calgary, AB T2N 4N2, Canada.
   [Temple, Walley J.; Mack, Lloyd A.] Univ Calgary, Tom Baker Canc Ctr, Div Surg Oncol, 1331 29th St NW, Calgary, AB T2N 4N2, Canada.
   [Puloski, Shannon; Schachar, Norman S.] Univ Calgary, Div Orthoped Surg, Calgary, AB T2N 4N2, Canada.
   [Paolucci, Elizabeth Oddone] Univ Calgary, Cumming Sch Med, Dept Surg, Calgary, AB T2N 4N2, Canada.
   [Paolucci, Elizabeth Oddone] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB T2N 4N2, Canada.
   [Kurien, Elizabeth] Univ Calgary, Div Radiat Oncol, Calgary, AB T2N 4N2, Canada.
   [Sarkhosh, Kourosh] Kaiser Permanente, Dept Surg, Fresno, CA USA.
RP Mack, LA (reprint author), Univ Calgary, Tom Baker Canc Ctr, Div Surg Oncol, 1331 29th St NW, Calgary, AB T2N 4N2, Canada.
EM Lloyd.Mack@albertahealthservices.ca
CR ALHO A, 1989, ACTA ORTHOP SCAND, V60, P687, DOI 10.3109/17453678909149605
   Arai E, 2010, CLIN ORTHOP RELAT R, V468, P3028, DOI 10.1007/s11999-010-1392-7
   Biau DJ, 2012, CANCER-AM CANCER SOC, V118, P5867, DOI 10.1002/cncr.27639
   Borden EC, 2003, CLIN CANCER RES, V9, P1941
   Brooks AD, 1998, ANN SURG ONCOL, V5, P41, DOI 10.1007/BF02303763
   Cany L, 1999, J SURG ONCOL, V71, P4, DOI 10.1002/(SICI)1096-9098(199905)71:1<4::AID-JSO2>3.0.CO;2-W
   Casali PG, 2010, ANN ONCOL, V21, pv198, DOI 10.1093/annonc/mdq209
   Coindre JM, 1996, J CLIN ONCOL, V14, P869
   COLLIN C, 1987, ANN SURG, V205, P331, DOI 10.1097/00000658-198704000-00001
   ELIAS AD, 1993, CLIN ORTHOP RELAT R, P94
   Fabrizio PL, 2000, INT J RADIAT ONCOL, V48, P227, DOI 10.1016/S0360-3016(00)00601-5
   Lachenmayer A, 2009, WORLD J SURG, V33, P1641, DOI 10.1007/s00268-009-0051-1
   Mack LA, 2005, ANN SURG ONCOL, V12, P646, DOI 10.1245/ASO.2005.03.064
   Mierzwa ML, 2007, BRACHYTHERAPY, V6, P298, DOI 10.1016/j.brachy.2007.08.004
   Pisters PWT, 2007, ANN SURG, V246, P675, DOI 10.1097/SLA.0b013e318155a9ae
   [Anonymous], 2007, ANN SURG
   Pisters PWT, 1996, J CLIN ONCOL, V14, P859
   RAVAUD A, 1992, BRIT J CANCER, V66, P961, DOI 10.1038/bjc.1992.393
   Riouallon G, 2013, ORTHOP TRAUMATOL-SUR, V99, P473, DOI 10.1016/j.otsr.2012.11.020
   Salas S, 2009, EUR J CANCER, V45, P2091, DOI 10.1016/j.ejca.2009.03.006
   Swallow CJ, 2007, SEMIN ONCOL, V34, P256, DOI 10.1053/j.seminoncol.2007.03.008
   TIERNEY JF, 1995, BRIT J CANCER, V72, P469, DOI 10.1038/bjc.1995.357
   TROJANI M, 1984, INT J CANCER, V33, P37, DOI 10.1002/ijc.2910330108
   Yang JC, 1998, J CLIN ONCOL, V16, P197
NR 24
TC 0
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD JAN 1
PY 2016
VL 113
IS 1
BP 108
EP 113
DI 10.1002/jso.24091
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA DB9OM
UT WOS:000368845800017
PM 26661586
ER


PT J
AU Lan, XJ
   Liu, L
   Wang, YJ
AF Lan, Xue-Jing
   Liu, Lei
   Wang, Yong-Ji
TI Online trajectory planning and guidance for reusable launch vehicles in
   the terminal area
SO ACTA ASTRONAUTICA
LA English
DT Article
DE RLV; TAEM; Online planning; Guidance
ID ENERGY MANAGEMENT
AB A guidance scheme has been proposed based on a new online trajectory planning algorithm for an unpowered reusable launch vehicle (RLV) in the terminal area energy management (TAEM) phase. The trajectory planning algorithm is able to rapidly generate a feasible path from the current state to a desired state at approach and landing interface (ALI) based on the dynamic pressure profile and new ground track geometry. Simple guidance laws are used to keep the RLV flying along the reference path which can be adjusted online by five related parameters. Then, the effectiveness and adaptability of the proposed TAEM guidance scheme is demonstrated by numerical trials with variations in the initial energy, position and aerodynamic performance. (C) 2015 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [Lan, Xue-Jing; Liu, Lei; Wang, Yong-Ji] Natl Key Lab Sci & Technol Multispectral Informat, Wuhan, Peoples R China.
   [Lan, Xue-Jing; Liu, Lei; Wang, Yong-Ji] Huazhong Univ Sci & Technol, Sch Automat, Wuhan 430074, Peoples R China.
RP Liu, L (reprint author), Huazhong Univ Sci & Technol, Sch Automat, Wuhan 430074, Peoples R China.
EM lanxuejing906@hust.edu.cn; Lei.Liu.chn@gmail.com; wangyjch@hust.edu.cn
OI Liu, Lei/0000-0003-3606-122X
FU National Natural Science Foundation of China [61473124, 61203081,
   61174079]; Doctoral Fund of Ministry of Education of China
   [20120142120091]; Precision Manufacturing Technology and Equipment for
   Metal Parts [2012DFG70640]
FX This work was supported by National Natural Science Foundation of China
   (Grant nos. 61473124, 61203081, and 61174079), Doctoral Fund of Ministry
   of Education of China (Grant no. 20120142120091), and Precision
   Manufacturing Technology and Equipment for Metal Parts (Grant no.
   2012DFG70640).
CR Burchett BT, 2004, J SPACECRAFT ROCKETS, V41, P444, DOI 10.2514/1.10938
   DARWIN CR, 1991, ACTA ASTRONAUT, V25, P165, DOI 10.1016/0094-5765(91)90144-T
   Feustel-Bech D., 1991, ESA B, V66, P21
   Grantham K., 2003, 2003305 AIAA
   Grubler A.C., 2001, THESIS
   Hall CE, 2006, J GUID CONTROL DYNAM, V29, P1315, DOI 10.2514/1.20151
   Hanson JM, 2004, J GUID CONTROL DYNAM, V27, P960, DOI 10.2514/1.10886
   Hanson J.M., 2002, 20024557 AIAA
   Horneman K.R., 2004, 20045183 AIAA
   Hull J.R., 2005, 20057114 AIAA
   Jiang W., 2014, MATH PROBL ENG, V2014
   Kluever CA, 2007, J GUID CONTROL DYNAM, V30, P162, DOI 10.2514/1.24864
   Kluever C.A., 2004, 20044770 AIAA
   Kluever C.A., 2009, 20095766 AIAA
   Kluever C.A., 2005, 20056058 AIAA
   Mayanna A., 2006, 20066037 AIAA
   Moore T.E., 1991, 104744 NASA
   Morio V, 2010, IET CONTROL THEORY A, V4, P472, DOI 10.1049/iet-cta.2008.0463
   Ridder S., 2011, J SPACECRAFT ROCKETS, V48, P642
   Ridder S.D., 2011, ACTA ASTRONAUT, V68, P915
   Sun C S, 2008, THESIS
   [唐鹏 TANG Peng], 2009, [宇航学报, Journal of Chinese Society of Astronautics], V30, P1340
   Zhang J., 2010, J APPL SCI, V28, P77
   [周敏 Zhou Min], 2015, [宇航学报, Journal of Astronautics], V36, P151
NR 24
TC 0
Z9 0
U1 3
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
EI 1879-2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD JAN-FEB
PY 2016
VL 118
BP 237
EP 245
DI 10.1016/j.actaastro.2015.10.019
PG 9
WC Engineering, Aerospace
SC Engineering
GA CZ1NQ
UT WOS:000366873000021
ER


PT J
AU Tomasi, N
   Pinton, R
   Costa, LD
   Cortella, G
   Terzano, R
   Mimmo, T
   Scampicchio, M
   Cesco, S
AF Tomasi, Nicola
   Pinton, Roberto
   Costa, Luisa Dalla
   Cortella, Giovanni
   Terzano, Roberto
   Mimmo, Tanja
   Scampicchio, Matteo
   Cesco, Stefano
TI New 'solutions' for floating cultivation system of ready-to-eat salad: A
   review
SO TRENDS IN FOOD SCIENCE & TECHNOLOGY
LA English
DT Review
DE Biofortification; Biostimulants; Hydroponics; Nutrient solution; Nitrate
ID DIFFERENT NITROGEN-SOURCES; SOILLESS CULTURE-SYSTEMS; SPINACIA-OLERACEA
   L.; ROCKET ERUCA-SATIVA; NATURAL FE COMPLEXES; LOW NITRATE CONTENT;
   HUMIC SUBSTANCES; PLANT-GROWTH; NUTRIENT SOLUTION; LEAFY VEGETABLES
AB Soilless cultivation systems represent an alternative to traditional agriculture, as they offer the possibility to reduce water use and to design nutrient formulations of the hydroponic solutions in order to maximize yield and quality of the products. Reduction in accumulation of undesired compounds, like e.g. nitrate, and enhanced nutritional value for human consumption, like e.g. Se-rich compounds, could be reasonably achieved. These aspects, together with the extension of the shelf life, would increase the market value of ready-to-cut vegetables. This review discusses how recent advances in understanding the role of plant nutrients and their interactions and the management of nutrient solution composition, including the addition of non-essential elements, micronutrients' biofortification, biostimulants, together with the control of some crucial environmental conditions, like temperature, can help accomplishing this task. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Tomasi, Nicola; Pinton, Roberto; Costa, Luisa Dalla] Univ Udine, Dipartimento Sci Agr & Ambientali, I-33100 Udine, Italy.
   [Cortella, Giovanni] Univ Udine, Dipartimento Ingn Elettr Gestionale & Meccan, I-33100 Udine, Italy.
   [Terzano, Roberto] Univ Bari Aldo Moro, Dipartimento Sci Suolo Pianta & Alimenti, I-70126 Bari, Italy.
   [Mimmo, Tanja; Scampicchio, Matteo; Cesco, Stefano] Free Univ Bolzano, Fac Sci & Technol, I-39100 Bolzano, Italy.
RP Tomasi, N (reprint author), Univ Udine, Dipartimento Sci Agr & Ambientali, Via Sci 208, I-33100 Udine, Italy.
EM nicola.tomasi@uniud.it
RI Pinton, Roberto/H-7931-2016; Tomasi, Nicola/A-7505-2012; Cesco,
   Stefano/F-3088-2011; 
OI Pinton, Roberto/0000-0003-3134-3842; Tomasi, Nicola/0000-0002-2136-7720;
   Cesco, Stefano/0000-0001-5191-0520; CORTELLA,
   Giovanni/0000-0003-2737-4304
FU "Ager-Agroalimentare e Ricerca" Foundation [2010 2370]
FX This research was supported by a grant from "Ager-Agroalimentare e
   Ricerca" Foundation, project "Novel strategies meeting the needs of the
   fresh-cut vegetable sector-STAYFRESH; no. 2010 2370."
CR Ali H, 2013, CHEMOSPHERE, V91, P869, DOI 10.1016/j.chemosphere.2013.01.075
   Balanza V, 2012, ACTA HORTIC, V952, P679
   Zandonadi DB, 2007, PLANTA, V225, P1583, DOI 10.1007/s00425-006-0454-2
   Blasco B, 2008, ANN APPL BIOL, V152, P289, DOI 10.1111/j.1744-7348.2008.00217.x
   Borgognone D, 2014, J SCI FOOD AGR, V94, P1231, DOI 10.1002/jsfa.6403
   Bottex B., 2008, TRENDS FOOD SCI TECH, V19, P113
   Brecht J. K., 2004, Horticultural Reviews, V30, P185
   Britto DT, 2001, NEW PHYTOL, V150, P37, DOI 10.1046/j.1469-8137.2001.00080.x
   Brown P. H., 2007, HDB PLANT NUTR, P395
   Bruccoleri AG, 2001, ROY SOC CH, P193, DOI 10.1039/9781847551085-00193
   Carvalho SMP, 2013, FOOD RES INT, V54, P961, DOI 10.1016/j.foodres.2012.12.021
   CHAILLOU S, 1991, J EXP BOT, V42, P189, DOI 10.1093/jxb/42.2.189
   Chen BM, 2004, PLANT SCI, V167, P635, DOI 10.1016/j.plantsci.2004.05.015
   CLARKSON DT, 1988, SYM SOC EXP BIOL, V42, P281
   Colla G, 2013, J SCI FOOD AGR, V93, P1119, DOI 10.1002/jsfa.5861
   Coronel G., 2009, ACTA HORTIC, V483, P137
   Cortella G., 2014, APPL THERM ENG, V73, P1053
   Coruzzi G, 2001, PLANT PHYSIOL, V125, P61, DOI 10.1104/pp.125.1.61
   Coruzzi GM, 2001, CURR OPIN PLANT BIOL, V4, P247, DOI 10.1016/S1369-5266(00)00168-0
   CRAMER MD, 1993, ANN BOT-LONDON, V72, P359, DOI 10.1006/anbo.1993.1119
   Dakhara Sanjay L, 2012, Pharmacogn Rev, V6, P16, DOI 10.4103/0973-7847.95853
   Dalla Costa L, 2011, HORTSCIENCE, V46, P1619
   Datnoff LE, 1997, CROP PROT, V16, P525, DOI 10.1016/S0261-2194(97)00033-1
   de Benoist B, 2008, FOOD NUTR BULL, V29, P195
   Di Gioacchino M, 2014, ANN MED, V46, P31, DOI 10.3109/07853890.2013.861158
   Dillard CJ, 2000, J SCI FOOD AGR, V80, P1744, DOI 10.1002/1097-0010(20000915)80:12<1744::AID-JSFA725>3.0.CO;2-W
   Diwadkar-Navsariwala V, 2006, P NATL ACAD SCI USA, V103, P8179, DOI 10.1073/pnas.0508218103
   Domingues DS, 2012, COMPUT ELECTRON AGR, V84, P53, DOI 10.1016/j.compag.2012.02.006
   Economakis CD, 2002, ACTA HORTIC, P411
   Egea-Gilabert C., 2010, SCI HORTICOLTURAE, V121, P260
   Epstein E, 1999, ANNU REV PLANT PHYS, V50, P641, DOI 10.1146/annurev.arplant.50.1.641
   Fallovo C, 2009, J SCI FOOD AGR, V89, P1682, DOI 10.1002/jsfa.3641
   Fan RQ, 2012, SCI HORTIC-AMSTERDAM, V144, P48, DOI 10.1016/j.scienta.2012.06.037
   Feng RW, 2013, ENVIRON EXP BOT, V87, P58, DOI 10.1016/j.envexpbot.2012.09.002
   Fontana E, 2004, ACTA HORTIC, P763
   Gavito ME, 2001, J EXP BOT, V52, P1913, DOI 10.1093/jexbot/52.362.1913
   Gonnella M, 2004, ACTA HORTIC, P61
   Goto F, 2000, THEOR APPL GENET, V100, P658, DOI 10.1007/s001220051336
   Gottardi S, 2012, PLANT PHYSIOL BIOCH, V56, P14, DOI 10.1016/j.plaphy.2012.04.002
   Gruda N, 2005, CRIT REV PLANT SCI, V24, P227, DOI 10.1080/07352680591008628
   Gruda N, 2009, J APPL BOT FOOD QUAL, V82, P141
   Guerinot ML, 2001, PLANT PHYSIOL, V125, P164, DOI 10.1104/pp.125.1.164
   Gustafsson J. P., 2006, VISUAL MINTEQ VER 2
   Hansch R, 2009, CURR OPIN PLANT BIOL, V12, P259, DOI 10.1016/j.pbi.2009.05.006
   Halpern M., 2015, Advances in Agronomy, V130, P141
   Harborne JB, 1999, BIOCHEM SYST ECOL, V27, P335, DOI 10.1016/S0305-1978(98)00095-7
   Hartikainen H, 2000, PLANT SOIL, V225, P193, DOI 10.1023/A:1026512921026
   Heber D, 2004, J NUTR, V134, p3175S
   Hernandez-Apaolaza L, 2014, PLANTA, V240, P447, DOI 10.1007/s00425-014-2119-x
   Hosseini H, 2013, SCI HORTIC-AMSTERDAM, V164, P178, DOI 10.1016/j.scienta.2013.09.030
   Iacuzzo F, 2011, J SCI FOOD AGR, V91, P344, DOI 10.1002/jsfa.4192
   Inoue K, 2000, J HORTIC SCI BIOTECH, V75, P209
   Jensen M. H., 1985, Horticultural Reviews, V7, P483
   Jensen M. H., 1999, ACTA HORTIC, V481, P719
   Kader AA, 2008, J SCI FOOD AGR, V88, P1863, DOI 10.1002/jsfa.3293
   Kanjanamaneesathian M., 2014, New Zealand Plant Protection, V67, P213
   Kawashima LM, 2003, J FOOD COMPOS ANAL, V16, P605, DOI 10.1016/S0889-1575(03)00057-7
   Khan NK, 1999, SOIL SCI PLANT NUTR, V45, P569
   Khan NK, 2000, SOIL SCI PLANT NUTR, V46, P199
   Khoshgoftarmanesh AH, 2012, J PLANT NUTR SOIL SC, V175, P474, DOI 10.1002/jpln.201100241
   Khoshgoftarmanesh AH, 2011, SCI HORTIC-AMSTERDAM, V130, P381, DOI 10.1016/j.scienta.2011.07.009
   Kim HJ, 2013, COMPUT ELECTRON AGR, V93, P46, DOI 10.1016/j.compag.2013.01.011
   Korndorfer G. K., 2001, SILICON AGR, P133
   Li Z, 2010, J AGR FOOD CHEM, V58, P6503, DOI 10.1021/jf1006962
   Liang YC, 2007, ENVIRON POLLUT, V147, P422, DOI 10.1016/j.envpol.2006.06.008
   LINDSAY W L, 1991, P89
   Lucena JJ, 2003, J PLANT NUTR, V26, P1969, DOI 10.1081/PLN-120024257
   Lyons GH, 2009, PLANT SOIL, V318, P73, DOI 10.1007/s11104-008-9818-7
   Ma JF, 2004, SOIL SCI PLANT NUTR, V50, P11
   Ma JF, 2002, SOIL FERTILIZER PLAN
   Ma JF, 2006, TRENDS PLANT SCI, V11, P392, DOI 10.1016/j.tplants.2006.06.007
   MacCarthy P, 2001, ROY SOC CH, P19, DOI 10.1039/9781847551085-00019
   Mangmang J., 2015, ORGANIC AGR, P1
   Manzocco L, 2011, J SCI FOOD AGR, V91, P1373, DOI 10.1002/jsfa.4313
   Marschner P, 2012, MARSCHNER'S MINERAL NUTRITION OF HIGHER PLANTS, 3RD EDITION, P1
   Marschner H., 1995, MINERAL NUTR HIGHER
   Massantini F., 1976, P 4 INT C SOILL CULT, P91
   Meskin M. S., 2004, PHYTOCHEMICALS MECH
   MOORBY H, 1984, PLANT SOIL, V78, P283, DOI 10.1007/BF02450362
   Nardi S, 2002, SOIL BIOL BIOCHEM, V34, P1527, DOI 10.1016/S0038-0717(02)00174-8
   Nicola S, 2006, ACTA HORTIC, P223
   Nicola S, 2005, ACTA HORTIC, P549
   Nicola S, 2004, ACTA HORTIC, P509
   Nicola S, 2003, ACTA HORTIC, P685
   Nielsen N. E., 1984, INT C SOIL CULT 6 LU, P421
   Nikolic M, 2007, FUNCT PLANT BIOL, V34, P402, DOI 10.1071/FP07022
   Olympios C. M., 2005, CAHIERS OPTIONS MEDI, V31, P307
   PACKTER A, 1974, J CRYST GROWTH, V21, P191, DOI 10.1016/0022-0248(74)90004-9
   Pardossi A, 2002, SCI HORTIC-AMSTERDAM, V92, P89, DOI 10.1016/S0304-4238(01)00292-8
   Park S, 2009, PLANT BIOTECHNOL J, V7, P106, DOI 10.1111/j.1467-7652.2008.00379.x
   Pasqualini S, 2001, PLANT CELL ENVIRON, V24, P439, DOI 10.1046/j.1365-3040.2001.00692.x
   Pavlovic J, 2013, NEW PHYTOL, V198, P1096, DOI 10.1111/nph.12213
   Piccolo A, 2001, SOIL SCI, V166, P810, DOI 10.1097/00010694-200111000-00007
   Pii Y, 2015, BIOL FERT SOILS, V51, P403, DOI 10.1007/s00374-015-0996-1
   Pilon-Smits EAH, 2010, PLANT CELL MONOGR, V17, P225, DOI 10.1007/978-3-642-10613-2_10
   Pinton R., 2009, BIOPHYSICOCHEMICAL P, P341, DOI 10.1002/9780470494950.ch9
   Pregitzer KS, 2000, NEW PHYTOL, V147, P105, DOI 10.1046/j.1469-8137.2000.00689.x
   Pregitzer KS, 2005, NUTR ACQUISITION PLA, P277, DOI 10.1007/3-540-27675-0_10
   Prosser IM, 2001, J EXP BOT, V52, P113, DOI 10.1093/jexbot/52.354.113
   Ramos SJ, 2011, PLANTA, V233, P649, DOI 10.1007/s00425-010-1323-6
   Rayman MP, 2002, P NUTR SOC, V61, P203, DOI 10.1079/PNS2002153
   REININK K, 1987, EUPHYTICA, V36, P11, DOI 10.1007/BF00730642
   Richmond KE, 2003, CURR OPIN PLANT BIOL, V6, P268, DOI 10.1016/S1369-5266(03)00041-4
   Rios JJ, 2008, SCI HORTIC-AMSTERDAM, V116, P248, DOI 10.1016/j.scienta.2008.01.008
   Rios JJ, 2010, J PLANT GROWTH REGUL, V29, P164, DOI 10.1007/s00344-009-9130-7
   ROLLE RS, 1987, J FOOD QUALITY, V10, P157, DOI 10.1111/j.1745-4557.1987.tb00856.x
   Rose MT, 2014, ADV AGRON, V124, P37, DOI 10.1016/B978-0-12-800138-7.00002-4
   ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588
   Salerno A, 2005, ACTA HORTIC, P87
   Sambo P., 2001, ITALUS HORTUS, V8, P64
   Santamaria P, 2006, J SCI FOOD AGR, V86, P10, DOI 10.1002/jsfa.2351
   Santamaria P, 1999, J SCI FOOD AGR, V79, P1882, DOI 10.1002/(SICI)1097-0010(199910)79:13<1882::AID-JSFA450>3.3.CO;2-4
   Santamaria P, 2001, ACTA HORTIC, P529
   Santamaria P, 1998, J PLANT NUTR, V21, P1791, DOI 10.1080/01904169809365524
   Santos J, 2014, FOOD CHEM, V151, P311, DOI 10.1016/j.foodchem.2013.11.083
   Savvas D, 2009, ENVIRON EXP BOT, V65, P11, DOI 10.1016/j.envexpbot.2008.07.004
   Schenkeveld WDC, 2007, PLANT SOIL, V290, P85, DOI 10.1007/s11104-006-9135-y
   Schmidt W, 2007, PLANT SOIL, V300, P259, DOI 10.1007/s11104-007-9411-5
   Scuderi D, 2011, POSTHARVEST BIOL TEC, V59, P132, DOI 10.1016/j.postharvbio.2010.08.016
   Selma MV, 2012, POSTHARVEST BIOL TEC, V63, P16, DOI 10.1016/j.postharvbio.2011.08.002
   Smolen S, 2014, SCI HORTIC-AMSTERDAM, V166, P9, DOI 10.1016/j.scienta.2013.11.011
   Sonneveld C., 1999, NUTR SOLUTIONS VEGET
   Takahashi H, 2000, PLANT J, V23, P171, DOI 10.1046/j.1365-313x.2000.00768.x
   Terry N, 2000, ANNU REV PLANT PHYS, V51, P401, DOI 10.1146/annurev.arplant.51.1.401
   Terzano R, 2014, PLANT SOIL, V386, P399
   THOMAS RB, 1991, PLANT PHYSIOL, V96, P627, DOI 10.1104/pp.96.2.627
   Tomasi N., 2015, CROP PASTURE SCI
   Tomasi N, 2014, BIOL FERT SOILS, V50, P973, DOI 10.1007/s00374-014-0919-6
   Tomasi N, 2009, PLANT SOIL, V325, P25, DOI 10.1007/s11104-009-0069-z
   Tonacchera M, 2013, J CLIN ENDOCR METAB, V98, P694
   Valenzano V, 2008, J HORTIC SCI BIOTECH, V83, P71
   Van Hoewyk D, 2005, PLANT PHYSIOL, V139, P1518, DOI 10.1104/pp.105.068684
   Van Hoewyk D, 2008, PHYSIOL PLANTARUM, V132, P236, DOI 10.1111/j.1399-3054.2007.01002.x
   Van Hoewyk D, 2013, ANN BOT-LONDON, V112, P965, DOI 10.1093/aob/mct163
   van Os E. A., 2001, ITALUS HORTUS, V8, P9
   Varanini Z, 2001, BOOK SOIL P, P141
   Verbruggen N, 2009, NEW PHYTOL, V181, P759, DOI 10.1111/j.1469-8137.2008.02748.x
   Vessey JK, 2003, PLANT SOIL, V255, P571, DOI 10.1023/A:1026037216893
   Wang LP, 2010, ACTA HORTIC, V856, P229
   Wang XF, 1997, J JPN SOC HORTIC SCI, V66, P313
   Wang ZH, 2004, J PLANT NUTR, V27, P539, DOI 10.1081/PLN-120028877
   White PJ, 2009, NEW PHYTOL, V182, P49, DOI 10.1111/j.1469-8137.2008.02738.x
   White PJ, 2005, TRENDS PLANT SCI, V10, P586, DOI 10.1016/j.tplants.2005.10.001
   White PJ, 2004, J EXP BOT, V55, P1927, DOI 10.1093/jxb/erh192
   Rius-Ruiz FX, 2014, FOOD CHEM, V147, P92, DOI 10.1016/j.foodchem.2013.09.114
   Yoshimoto N, 2002, PLANT J, V29, P465, DOI 10.1046/j.0960-7412.2001.01231.x
   Zanin G, 2009, ACTA HORTIC, V807, P433
   Zanin G, 2011, ACTA HORTIC, P821
   Zanin L, 2015, PHYSIOL PLANTARUM, V154, P82, DOI 10.1111/ppl.12296
   Zhang SR, 2007, FOREST SCI, V53, P453
   Zhao X, 2006, HORTTECHNOLOGY, V16, P449
   Zhu YG, 2004, PLANT SOIL, V261, P99, DOI 10.1023/B:PLSO.0000035539.58054.e1
   Zhu YG, 2009, TRENDS PLANT SCI, V14, P436, DOI 10.1016/j.tplants.2009.06.006
   Zimmermann MB, 2009, ENDOCR REV, V30, P376, DOI 10.1210/er.2009-0011
   Zuchi S, 2009, PLANTA, V230, P85, DOI 10.1007/s00425-009-0919-1
   Zuo XF, 2002, CHINESE SCI BULL, V47, P558, DOI 10.1360/02tb9128
NR 156
TC 6
Z9 6
U1 21
U2 55
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0924-2244
J9 TRENDS FOOD SCI TECH
JI Trends Food Sci. Technol.
PD DEC
PY 2015
VL 46
IS 2
BP 267
EP 276
DI 10.1016/j.tifs.2015.08.004
PN B
PG 10
WC Food Science & Technology
SC Food Science & Technology
GA DA4IV
UT WOS:000367764500002
ER


PT J
AU Spencer, RJ
   Amerena, JV
AF Spencer, Ryan J.
   Amerena, John V.
TI Rivaroxaban in the Prevention of Stroke and Systemic Embolism in
   Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of
   the ROCKET AF Trial and Its Subanalyses
SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
LA English
DT Review
ID FACTOR-XA INHIBITOR; ANTICOAGULATION MANAGEMENT; PERIOPERATIVE
   MANAGEMENT; ANTITHROMBOTIC THERAPY; VENOUS THROMBOEMBOLISM; RENAL
   IMPAIRMENT; ORAL RIVAROXABAN; RANDOMIZED-TRIAL; HEALTHY-SUBJECTS;
   WARFARIN
AB Atrial fibrillation (AF) is an increasingly common cause of stroke and systemic embolism. While warfarin has been the mainstay of stroke prevention in patients with AF, newer novel oral anticoagulant medications are now available. Rivaroxaban, a direct factor Xa inhibitor with a rapid onset and offset after oral administration, offers potential advantages over warfarin, predominantly due to its predictable pharmacokinetics across wide patient populations. It requires no coagulation monitoring, and only two different doses are needed (20 mg daily for patients with normal renal function and 15 mg daily in those with reduced renal function). A large randomized trial (ROCKET AF) has shown non-inferiority to warfarin for preventing stroke or systemic embolism in the per-protocol population and superiority to warfarin in the on-treatment safety population. Several subanalyses confirm that the treatment effect of rivaroxaban is consistent across different patient subgroups, including those with reduced renal function. The tolerability of rivaroxaban appears similar to that of warfarin, with comparable overall bleeding rates in clinical trials. In ROCKET AF, significantly lower rates of fatal and intracranial bleeding were seen with rivaroxaban, while lower rates of gastrointestinal bleeding were seen with warfarin. Important contraindications to rivaroxaban include valvular AF, the presence of a prosthetic valve (mechanical or bioprosthetic) or valve repair, the need for concurrent dual antiplatelet therapy, and creatinine clearance < 30 ml/min. Once-daily dosing and the lack of coagulation monitoring may increase utilization and adherence compared with warfarin, potentially decreasing the large burden of care associated with stroke secondary to AF. Overall, rivaroxaban offers a useful alternative to warfarin for stroke prevention in patients with AF.
C1 [Spencer, Ryan J.; Amerena, John V.] Deakin Univ, Geelong, Vic 3217, Australia.
RP Amerena, JV (reprint author), Deakin Univ, Geelong, Vic 3217, Australia.
EM johnamerena@gmail.com
CR Bang MC, 2004, ARCH INTERN MED, V164, P55
   Bauersachs R, 2010, NEW ENGL J MED, V363, P2499, DOI 10.1056/NEJMoa1007903
   Birnie DH, 2013, NEW ENGL J MED, V368, P2084, DOI 10.1056/NEJMoa1302946
   Buller HR, 2012, NEW ENGL J MED, V366, P1287, DOI 10.1056/NEJMoa1113572
   Di Biase L, 2014, CIRCULATION, V129, P2638, DOI 10.1161/CIRCULATIONAHA.113.006426
   Douketis JD, 2012, CHEST, V141, pE326S, DOI 10.1378/chest.11-2298
   Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
   Eikelboom JW, 2013, NEW ENGL J MED, V369, P1206, DOI 10.1056/NEJMoa1300615
   Eriksson BI, 2008, NEW ENGL J MED, V358, P2765, DOI 10.1056/NEJMoa0800374
   Falga C, 2007, THROMB HAEMOSTASIS, V98, P771, DOI 10.1160/TH07-02-0132
   Fox KAA, 2011, EUR HEART J, V32, P2387, DOI 10.1093/eurheartj/ehr342
   Furie KL, 2012, STROKE, V43, P3442, DOI 10.1161/STR.0b013e318266722a
   Glader EL, 2010, STROKE, V41, P397, DOI 10.1161/STROKEAHA.109.566950
   Gogarten W, 2010, EUR J ANAESTH, V27, P999, DOI 10.1097/EJA.0b013e32833f6f6f
   Goodman SG, 2014, J AM COLL CARDIOL, V63, P891, DOI 10.1016/j.jacc.2013.11.013
   Hankey GJ, 2012, LANCET NEUROL, V11, P315, DOI 10.1016/S1474-4422(12)70042-X
   Hylek EM, 2007, CIRCULATION, V115, P2689, DOI 10.1161/CIRCULATIONHA.106.653048
   Jones WS, 2014, EUR HEART J, V35, P242, DOI 10.1093/eurheartj/eht492
   Kubitza D, 2005, EUR J CLIN PHARMACOL, V61, P873, DOI 10.1007/s00228-005-0043-5
   Kubitza D, 2008, CURR MED RES OPIN, V24, P2757, DOI 10.1185/03007990802361499 
   Kubitza D, 2010, BRIT J CLIN PHARMACO, V70, P703, DOI 10.1111/j.1365-2125.2010.03753.x
   Laux V, 2007, SEMIN THROMB HEMOST, V33, P515, DOI 10.1055/s-2007-982083
   Loewen P, 2011, ANN HEMATOL, V90, P1191, DOI 10.1007/s00277-011-1267-3
   Mahaffey KW, 2013, ANN INTERN MED, V158, P861, DOI 10.7326/0003-4819-158-12-201306180-00003
   McGrath ER, 2013, NEUROLOGY, V81, P825, DOI 10.1212/WNL.0b013e3182a2cc15
   Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140
   Mueck W, 2013, BRIT J CLIN PHARMACO, V76, P455, DOI 10.1111/bcp.12075
   Mueck W, 2011, CLIN PHARMACOKINET, V50, P675, DOI 10.2165/11595320-000000000-00000
   Ortel TL, 2012, BLOOD, V120, P4699, DOI 10.1182/blood-2012-05-423228
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Reynolds MR, 2006, AM J CARDIOL, V97, P538, DOI 10.1016/j.amjcard.2005.09.086
   Samama MM, 2010, THROMB HAEMOSTASIS, V103, P815, DOI 10.1160/TH09-03-0176
   Saw J, 2014, JACC-CARDIOVASC INTE, V7, P1205, DOI 10.1016/j.jcin.2014.05.026
   Sherwood MW, 2014, CIRCULATION, V129, P1850, DOI 10.1161/CIRCULATIONAHA.113.005754
   Spyropoulos AC, 2006, J THROMB HAEMOST, V4, P1246, DOI 10.1111/j.1538-7836.2006.01908.x
   van Diepen S, 2013, CIRC-HEART FAIL, V6, P740, DOI 10.1161/CIRCHEARTFAILURE.113.000212
   WOLF PA, 1991, STROKE, V22, P983
   Wysokinski WE, 2008, MAYO CLIN PROC, V83, P639, DOI 10.4065/83.6.639
NR 40
TC 1
Z9 1
U1 1
U2 6
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-3277
EI 1179-187X
J9 AM J CARDIOVASC DRUG
JI Am. J. Cardiovasc. Drugs
PD DEC
PY 2015
VL 15
IS 6
BP 395
EP 401
DI 10.1007/s40256-015-0127-2
PG 7
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA CX7GB
UT WOS:000365869100003
PM 26062914
ER


PT J
AU Spangelo, S
   Landau, D
   Johnson, S
   Arora, N
   Randolph, T
AF Spangelo, Sara
   Landau, Damon
   Johnson, Shawn
   Arora, Nitin
   Randolph, Thomas
TI Defining the Optimal Requirements for the Liquid Indium Microelectric
   Propulsion System
SO JOURNAL OF SPACECRAFT AND ROCKETS
LA English
DT Article
ID SOLAR ELECTRIC PROPULSION; MISSIONS; CUBESATS
AB Recent technology advancements in microelectric propulsion will enable the next generation of small spacecraft to perform trajectory and attitude maneuvers with significant V requirements, provide thrust over long mission durations, and replace reaction wheels for attitude control. These advancements will open up the class of mission architectures achievable by small spacecraft to include formation flying, proximity operations, and precision pointing missions in both low Earth orbit and interplanetary destinations. The goal of this study is to establish the optimal performance parameters for future microelectric propulsion technology that are applicable to a broad range of flight demonstration platforms (for example, dedicated 3- to 12-unit CubeSats to evolved expendable launch vehicle secondary payload adaptor-class spacecraft) for a variety of applications, including low Earth orbit and Earth escape orbit transfers, travel to interplanetary destinations, hover and drag makeup missions, and performing reaction-wheel-free attitude control. An integrated systems-level model for propulsion, spacecraft (power, data, telecommunication, thermal management), and orbit and attitude maneuvers is developed to support solution space exploration. Microelectric propulsion system performance parameters are derived that maximize the performance capability subject to realistic system-level constraints in the context of upcoming mission opportunities where microelectric propulsion is enabling or advantageous relative to other technologies.
C1 [Spangelo, Sara; Landau, Damon; Johnson, Shawn; Arora, Nitin; Randolph, Thomas] CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA.
RP Spangelo, S (reprint author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.
CR Baker D. N., 2008, EOS T AM GEOPHYS UN, V89, P301, DOI [10.1029/2008EO330001, DOI 10.1029/2008EO330001]
   Blandino JJ, 2006, J SPACECRAFT ROCKETS, V43, P673, DOI 10.2514/1.15227
   Co TC, 2014, J SPACECRAFT ROCKETS, V51, P938, DOI 10.2514/1.A32405
   Cohe B., 2014, INT SMALL SAT C ISSC
   Griffiths W. T., 2012, TOR200885837560 AIR
   Johnson L, 2011, ACTA ASTRONAUT, V68, P571, DOI 10.1016/j.actaastro.2010.02.008
   Ketsdever A. D., 2000, MICROPROPULSION SMAL
   Moretto T., 2008, SPACE WEATHER J, V6
   Oh DY, 2007, J SPACECRAFT ROCKETS, V44, P399, DOI 10.2514/1.21613
   Oh DY, 2004, J SPACECRAFT ROCKETS, V41, P831, DOI 10.2514/1.13096
   Rayman MD, 2002, J SPACECRAFT ROCKETS, V39, P589, DOI 10.2514/2.3848
   SCHWAIGER LE, 1971, J SPACECRAFT ROCKETS, V8, P612, DOI 10.2514/3.59700
   Selva D, 2012, ACTA ASTRONAUT, V74, P50, DOI 10.1016/j.actaastro.2011.12.014
   Staehle R. L., 2013, J SMALL SATELLITES, V2, P161
   Swenson C., 2009, AM GEOPH UN AGU FALL
   Wang J, 2000, J SPACECRAFT ROCKETS, V37, P545, DOI 10.2514/2.3608
   Williams SN, 2000, J SPACECRAFT ROCKETS, V37, P71, DOI 10.2514/2.3528
   Woellert K, 2011, ADV SPACE RES, V47, P663, DOI 10.1016/j.asr.2010.10.009
NR 18
TC 1
Z9 1
U1 0
U2 1
PU AMER INST AERONAUTICS  ASTRONAUTICS
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 0022-4650
EI 1533-6794
J9 J SPACECRAFT ROCKETS
JI J. Spacecr. Rockets
PD NOV
PY 2015
VL 52
IS 6
BP 1651
EP 1664
DI 10.2514/1.A33242
PG 14
WC Engineering, Aerospace
SC Engineering
GA DA1YB
UT WOS:000367590800012
ER


PT J
AU Kluever, CA
   Neal, DA
AF Kluever, Craig A.
   Neal, David A.
TI Approach and Landing Range Guidance for an Unpowered Reusable Launch
   Vehicle
SO JOURNAL OF GUIDANCE CONTROL AND DYNAMICS
LA English
DT Article
ID SPACE-VEHICLES; FLIGHT-TEST
AB A new method has been developed for predicting and controlling the ground range of an unpowered reusable launch vehicle. The key feature is the use of the quasi-equilibrium glide condition to create a database of range-to-go versus energy for different values of the glide-efficiency factor. Downtrack range to runway touchdown is predicted by performing a two-dimensional table lookup of the range-to-go database. Unlike most predictor-corrector guidance methods, the proposed ground-range guidance scheme does not require onboard numerical integration of the governing equations of motion. Another key element is the coupling between the latter stages of the traditional terminal area energy management phase and the entire approach and landing phase, where the flare-to-touchdown maneuver is concisely parameterized by an exponential altitude profile. Numerical simulations demonstrate that this new method can accurately and reliably guide the vehicle to the desired touchdown conditions despite large errors in the initial states, large errors in the initial downtrack distance to the runway, and aerodynamic drag dispersions.
C1 [Kluever, Craig A.] Univ Missouri, Dept Mech & Aerosp Engn, Columbia, MO 65211 USA.
   [Neal, David A.] Barron Associates Inc, Charlottesville, VA 22911 USA.
RP Kluever, CA (reprint author), Univ Missouri, Dept Mech & Aerosp Engn, Columbia, MO 65211 USA.
EM KlueverC@missouri.edu; neal@barron-associates.com
FU United States Air Force/Air Force Materiel Command-Air Force Research
   Laboratory [FA8650-09-C-3904]
FX The work upon which this publication is based was performed pursuant to
   the United States Air Force/Air Force Materiel Command-Air Force
   Research Laboratory contract number FA8650-09-C-3904 under agreement to
   Barron Associates, Inc. The authors would like to thank Greg Moster of
   Air Force Research Laboratory for his role in overseeing this work. His
   support, feedback, and interest throughout the project are greatly
   appreciated.
CR Brauckmann GJ, 1999, J SPACECRAFT ROCKETS, V36, P229, DOI 10.2514/2.3453
   Brunner CW, 2008, J GUID CONTROL DYNAM, V31, P1210, DOI 10.2514/1.35055
   De Ridder S, 2011, J SPACECRAFT ROCKETS, V48, P642, DOI 10.2514/1.51083
   De Ridder S, 2011, ACTA ASTRONAUT, V68, P915, DOI 10.1016/j.actaastro.2010.08.032
   Girerd A. R., 2001, THESIS MIT CAMBRIDGE
   Hanson JM, 2004, J GUID CONTROL DYNAM, V27, P960, DOI 10.2514/1.10886
   Harl N, 2010, J GUID CONTROL DYNAM, V33, P186, DOI 10.2514/1.42654
   Jategaonkar R, 2006, J AIRCRAFT, V43, P1732, DOI 10.2514/1.19602
   Kluever CA, 2007, J GUID CONTROL DYNAM, V30, P882, DOI [10.5214/1.28081, 10.2514/1.28081]
   Kluever CA, 2004, J GUID CONTROL DYNAM, V27, P967, DOI 10.2514/1.7877
   Lu P, 2006, J GUID CONTROL DYNAM, V29, P662, DOI 10.2514/1.15789
   Moore T.E., 1991, TM104744 NASA
   Schierman JD, 2004, J GUID CONTROL DYNAM, V27, P975, DOI 10.2514/1.10344
   [Anonymous], 2000, RSS99D0001 BOEING CO
NR 14
TC 0
Z9 1
U1 3
U2 6
PU AMER INST AERONAUTICS  ASTRONAUTICS
PI RESTON
PA 1801 ALEXANDER BELL DRIVE, STE 500, RESTON, VA 22091-4344 USA
SN 0731-5090
EI 1533-3884
J9 J GUID CONTROL DYNAM
JI J. Guid. Control Dyn.
PD NOV
PY 2015
VL 38
IS 11
BP 2057
EP 2066
DI 10.2514/1.G000909
PG 10
WC Engineering, Aerospace; Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA CV5RM
UT WOS:000364328800001
ER


PT J
AU Saliba, W
AF Saliba, Walid
TI Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient
   Management in Atrial Fibrillation
SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
LA English
DT Review
ID FACTOR XA INHIBITOR; RE-LY TRIAL; ROCKET AF TRIAL; RISK STRATIFICATION
   SCHEMES; TRANSIENT ISCHEMIC ATTACK; DIRECT THROMBIN INHIBITOR; DRUG-DRUG
   INTERACTION; STROKE PREVENTION; RANDOMIZED EVALUATION; DABIGATRAN
   ETEXILATE
AB Atrial fibrillation (AF) is a significant problem for the aging population and remains a major factor underlying stroke risk. Warfarin anticoagulation has been proven effective for stroke prevention in AF, but can be difficult to manage and requires frequent monitoring. The non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to be as effective as warfarin for stroke prevention in nonvalvular AF (NVAF) and are associated with a reduced risk of bleeding compared with warfarin. Dabigatran, rivaroxaban, apixaban, and edoxaban have been approved in the USA for reducing the risk of stroke in patients with NVAF. In this article, AF risk assessment is discussed and NOAC phase III clinical trials for the prevention of stroke and systemic embolic events are reviewed. Further, differences in stroke and bleeding outcomes between NOACs are highlighted, the use of NOACs for cardioversion and special patient populations is discussed, and management considerations for patients with AF are reviewed.
C1 Cleveland Clin, Cleveland, OH 44195 USA.
RP Saliba, W (reprint author), Cleveland Clin, Main Campus,Mail Code J2-2,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM salibaw@ccf.org
FU Daiichi Sankyo, Inc.
FX The author would like to acknowledge writing assistance provided by
   Terri Schochet, PhD, of AlphaBioCom, LLC, which was funded by Daiichi
   Sankyo, Inc.
CR Ageno W, 2012, CHEST S, V141, DOI DOI 10.1378/CHEST.11-2292
   Alexander JH, 2014, EUR HEART J, V35, P224, DOI 10.1093/eurheartj/eht445
   Bakhru S, 2013, EUR HEART J, V34, P88
   Bassiouny M, 2013, CIRC-ARRHYTHMIA ELEC, V6, P460, DOI 10.1161/CIRCEP.113.000320
   Bathala MS, 2012, DRUG METAB DISPOS, V40, P2250, DOI 10.1124/dmd.112.046888
   [Anonymous], 2011, FEIBA NF ANT INH COA
   Blech S, 2008, DRUG METAB DISPOS, V36, P386, DOI 10.1124/dmd.107.019083
   [Anonymous], 2014, PRADAXA DEB ET MES F
   Brown K, 2014, J AM COLL CARDIOL, V63, pA2095
   Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Cappato R, 2014, EUR HEART J, V35, P3346, DOI 10.1093/eurheartj/ehu367
   Chang DN, 2013, AM J KIDNEY DIS, V61, P487, DOI 10.1053/j.ajkd.2012.08.047
   Chao TF, 2015, J AM COLL CARDIOL, V65, P635, DOI 10.1016/j.jacc.2014.11.046
   Colilla S, 2013, AM J CARDIOL, V112, P1142, DOI 10.1016/j.amjcard.2013.05.063
   Connolly SJ, 2010, NEW ENGL J MED, V363, P1875, DOI 10.1056/NEJMc1007378
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Crowther M, 2013, ARTERIOSCLER THROMB, V33
   [Anonymous], 2015, SAVAYSA ED TABL OR U
   Dans AL, 2013, CIRCULATION, V127, P634, DOI 10.1161/CIRCULATIONAHA.112.115386
   Deitelzweig Steven, 2013, Ochsner J, V13, P419
   Diener HC, 2010, LANCET NEUROL, V9, P1157, DOI 10.1016/S1474-4422(10)70274-X
   Dlott JS, 2014, CIRCULATION, V129, P1407, DOI 10.1161/CIRCULATIONAHA.113.002601
   Douketis JD, 2012, CHEST S, V141
   Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   European Medicines Agency, PRAD DAB ET SUMM PRO
   European H, 2010, EUR HEART J, V31, P2369, DOI DOI 10.1093/EURHEARTJ/EHQ278
   Fang MC, 2006, J AM GERIATR SOC, V54, P1231, DOI 10.1111/j.1532-5415.2006.00828.x
   Flaker G, 2014, J AM COLL CARDIOL, V63, P1082, DOI 10.1016/j.jacc.2013.09.062
   Fox KAA, 2011, EUR HEART J, V32, P2387, DOI 10.1093/eurheartj/ehr342
   Friberg L, 2015, J AM COLL CARDIOL, V65, P225, DOI 10.1016/j.jacc.2014.10.052
   Frost C, 2013, BRIT J CLIN PHARMACO, V75, P476, DOI 10.1111/j.1365-2125.2012.04369.x
   Fukuda T, 2012, THROMB HAEMOSTASIS, V107, P253, DOI 10.1160/TH11-09-0668
   Giugliano RP, 2014, STROKE, V45, P2372, DOI 10.1161/STROKEAHA.114.006025
   Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907
   Go AS, 2003, JAMA-J AM MED ASSOC, V290, P2685, DOI 10.1001/jama.290.20.2685
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Hartter S, 2012, BRIT J CLIN PHARMACO, V74, P490, DOI 10.1111/j.1365-2125.2012.04218.x
   Halim AB, 2014, THROMB RES, V134, P909, DOI 10.1016/j.thromres.2014.07.036
   Harrington AR, 2013, STROKE, V44, P1676, DOI 10.1161/STROKEAHA.111.000402
   Hart RG, 2005, STROKE, V36, P1588, DOI 10.1161/01.STR.0000170642.39876.f2
   Hart RG, 2012, STROKE, V43, P1511, DOI 10.1161/STROKEAHA.112.650614
   Heidbuchel H, 2013, EUROPACE, V15, P625, DOI 10.1093/europace/eut083
   Hernandez I, 2015, JAMA INTERN MED, V175, P18, DOI 10.1001/jamainternmed.2014.5398
   Hess PL, 2014, AM HEART J, V168, P239, DOI 10.1016/j.ahj.2014.04.007
   Hijazi Z, 2014, CIRCULATION, V129, P961, DOI 10.1161/CIRCULATIONAHA.113.003628
   Hirsh J, 2003, J AM COLL CARDIOL, V41, P1633, DOI 10.1016/S0735-1097(03)00416-9
   Hohnloser SH, 2013, EUR HEART J, V34, P2752, DOI 10.1093/eurheartj/eht292
   Hohnloser SH, 2012, EUR HEART J, V33, P2821, DOI 10.1093/eurheartj/ehs274
   Hughes M, 2008, THROMB HAEMOSTASIS, V99, P295, DOI 10.1160/TH07-08-0508
   Hylek EM, 2014, J AM COLL CARDIOL, V63, P2141, DOI 10.1016/j.jacc.2014.02.549
   [Anonymous], 2014, XARELTO RIV TABL FUL
   January CT, 2014, J AM COLL CARDIOL, V64, pE1, DOI 10.1016/j.jacc.2014.03.022
   Kasmeridis C, 2013, PHARMACOECONOMICS, V31, P971, DOI 10.1007/s40273-013-0090-1
   Kato ET, 2014, CIRCULATION, V130
   Kubitza D, 2010, BRIT J CLIN PHARMACO, V70, P703, DOI 10.1111/j.1365-2125.2010.03753.x
   Laulicht B, 2012, CIRCULATION, V126
   Lip GYH, 2014, CHEST, V146, P1337, DOI 10.1378/chest.14-0533
   Lip GYH, 2010, STROKE, V41, P2731, DOI 10.1161/STROKEAHA.110.590257
   Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584
   Magnani G, 2014, CIRCULATION, V130
   Mahaffey KW, 2014, EUR HEART J, V35, P233, DOI 10.1093/eurheartj/eht428
   Marini C, 2005, STROKE, V36, P1115, DOI 10.1161/01.STR.0000166053.83476.4a
   Marinigh R, 2010, J AM COLL CARDIOL, V56, P827, DOI 10.1016/j.jacc.2010.05.028
   Marlu R, 2012, THROMB HAEMOSTASIS, V108, P217, DOI 10.1160/TH12-03-0179
   McMurray JJV, 2013, CIRC-HEART FAIL, V6, P451, DOI 10.1161/CIRCHEARTFAILURE.112.000143
   Mendell J, 2014, J THROMB HAEMOST S, V12
   Mendell J, 2013, AM J CARDIOVASC DRUG, V13, P331, DOI 10.1007/s40256-013-0029-0
   Mendell J, 2011, J CLIN PHARMACOL, V51, P687, DOI 10.1177/0091270010370974
   Mikkaichi T, 2014, DRUG METAB DISPOS, V42, P520, DOI 10.1124/dmd.113.054866
   Mueck W, 2013, BRIT J CLIN PHARMACO, V76, P455, DOI 10.1111/bcp.12075
   Nagarakanti R, 2011, CIRCULATION, V123, P131, DOI 10.1161/CIRCULATIONAHA.110.977546
   NovoSeven RT Coagulation Factor VIIa (Recombinant), 2014, NOVOSEVEN RT COAG FA
   Ogata K, 2010, J CLIN PHARMACOL, V50, P743, DOI 10.1177/0091270009351883
   Ogilvie IM, 2010, AM J MED, V123, P638, DOI 10.1016/j.amjmed.2009.11.025
   Olesen JB, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d124
   Patel MR, 2013, J AM COLL CARDIOL, V61, P651, DOI 10.1016/j.jacc.2012.09.057
   Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638
   Piccini JP, 2013, J AM COLL CARDIOL, V61, P1998, DOI 10.1016/j.jacc.2013.02.025
   Pisters R, 2010, CHEST, V138, P1093, DOI 10.1378/chest.10-0134
   Potpara TS, 2012, CIRC-ARRHYTHMIA ELEC, V5, P319, DOI 10.1161/CIRCEP.111.966713
   [Anonymous], 2014, EL AP TABL OR US FUL
   Qureshi W, 2014, AM J CARDIOL, V113, P662, DOI 10.1016/j.amjcard.2013.10.044
   Roldan V, 2013, CHEST, V143, P179, DOI 10.1378/chest.12-0608
   Ruff CT, 2014, LANCET, V383, P955, DOI 10.1016/S0140-6736(13)62343-0
   Salazar DE, 2012, THROMB HAEMOSTASIS, V107, P925, DOI 10.1160/TH11-08-0566
   Sardar P, 2014, AM J CARDIOL, V113, P1173, DOI 10.1016/j.amjcard.2013.12.027
   Southworth MR, 2013, NEW ENGL J MED, V368, P1272, DOI 10.1056/NEJMp1302834
   Stangier J, 2007, BRIT J CLIN PHARMACO, V64, P292, DOI 10.1111/j.1365-2125.2007.02899.x
   Stangier J, 2010, CLIN PHARMACOKINET, V49, P259, DOI 10.2165/11318170-000000000-00000
   van Diepen S, 2013, CIRC-HEART FAIL, V6, P740, DOI 10.1161/CIRCHEARTFAILURE.113.000212
   van Walraven C, 2009, STROKE, V40, P1410, DOI 10.1161/STROKEAHA.108.526988
   Wang LF, 2010, DRUG METAB DISPOS, V38, P448, DOI 10.1124/dmd.109.029694
   Weinz C, 2009, DRUG METAB DISPOS, V37, P1056, DOI 10.1124/dmd.108.025569
   WOLF PA, 1991, STROKE, V22, P983
   Xu H, 2014, CIRCULATION, V130
   You JJ, 2012, CHEST, V141, pE531S, DOI 10.1378/chest.11-2304
   Zahir H, 2012, THROMB HAEMOSTASIS, V108, P166, DOI 10.1160/TH11-09-0676
   [Anonymous], 2010, MED NEWS TODAY
NR 100
TC 1
Z9 1
U1 1
U2 10
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-3277
EI 1179-187X
J9 AM J CARDIOVASC DRUG
JI Am. J. Cardiovasc. Drugs
PD OCT
PY 2015
VL 15
IS 5
BP 323
EP 335
DI 10.1007/s40256-015-0124-5
PG 13
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA CS3LF
UT WOS:000361975000004
PM 26055615
ER


PT J
AU Arunan, S
   Satish, R
AF Arunan, S.
   Satish, R.
TI Mars Orbiter Mission spacecraft and its challenges
SO CURRENT SCIENCE
LA English
DT Article
DE Challenges; interplanetary mission; Mars Orbiter; spacecraft
   configuration
AB Mars Orbiter Mission (MOM), India's first interplanetary mission, was launched on 5 November 2013 from the Satish Dhawan Space Centre (SDSC), Sriharikota, using PSLV XL C-25 rocket. MOM spacecraft was successfully inserted into the Martian orbit on 24 September 2014. One of the main objectives of the mission to Mars is to develop the technologies required for design, planning, management and operation of an interplanetary mission. Scientific objectives include exploration of surface features of Mars, morphology, topography, mineralogy and study of Martian atmosphere using indigenous scientific instruments. The spacecraft configuration is a balanced mix of design from flight-proven IRS/INSAT/Chandrayaan-1 bus. The configuration and subsequent design of the spacecraft had to take into consideration the many challenges it would face during its mission life. The spacecraft has been designed for interplanetary missions capable of operating in Earth burn, Mars transfer trajectory and Martian orbit environments. The major challenges of design are in thermal environment, radiation environment, power systems, communication systems, propulsion systems and on-board autonomy.
C1 [Arunan, S.; Satish, R.] Indian Space Res Org, Satellite Ctr, Bengaluru 560017, India.
RP Arunan, S (reprint author), Indian Space Res Org, Satellite Ctr, Bengaluru 560017, India.
EM arunan@isac.gov.in
NR 0
TC 1
Z9 1
U1 1
U2 18
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0011-3891
J9 CURR SCI INDIA
JI Curr. Sci.
PD SEP 25
PY 2015
VL 109
IS 6
BP 1061
EP 1069
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CS5GP
UT WOS:000362106000021
ER


PT J
AU Paiva, KV
   Mantelli, MBH
   Slongo, LK
AF Paiva, K. V.
   Mantelli, M. B. H.
   Slongo, L. K.
TI Experimental testing of mini heat pipes under microgravity conditions
   aboard a suborbital rocket
SO AEROSPACE SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Mini heat pipes; Sounding rocket; Microgravity tests
AB Heat pipe technologies have numerous applications under microgravity conditions in aerospace, from miniature devices in laptops used aboard the International Space Station (ISS) to heat transport systems in satellites. Advances in understanding the behavior of two-phase flow systems under microgravity conditions could lead to higher-efficiency devices and improved heat-exchanger designs. Under normal gravity conditions, heat pipes can function properly without any kind of capillary structure (thermosyphons, vertical position) or they can be aided by a wick material in the horizontal position, allowing the return of the condensate from the condenser to the evaporator. However, gravitational acceleration can significantly alter the flow regime, masking some effects that are not observed under microgravity conditions. This paper presents an experimental analysis of three miniature heat pipe technologies developed in Brazil for thermal management and heat dissipation of electronic devices under gravity and microgravity conditions. Different geometries of heat pipes charged with methanol were tested under microgravity conditions aboard a sounding rocket. Results demonstrated that the mini heat pipes present low thermal resistances for both gravity and microgravity conditions. (C) 2015 Elsevier Masson SAS. All rights reserved.
C1 [Paiva, K. V.; Mantelli, M. B. H.; Slongo, L. K.] Univ Fed Santa Catarina, Dept Mech Engn, Heat Pipe Lab, Florianopolis, SC, Brazil.
RP Paiva, KV (reprint author), Univ Fed Santa Catarina, Dept Mech Engn, Heat Pipe Lab, Florianopolis, SC, Brazil.
EM kpaiva@labtucal.ufsc.br
RI Paiva, Kleber/J-4377-2015
OI Paiva, Kleber/0000-0003-4126-8778
FU CNPq [20074518-2]
FX The authors are grateful to CNPq, for providing the scholarship under
   grant number 20074518-2, and Brazilian Space Agency - AEB, for providing
   the microgravity test conditions.
CR ABHAT A, 1983, SOL ENERGY, V30, P313, DOI 10.1016/0038-092X(83)90186-X
   Faghri A, 1995, HEAT PIPE SCI TECHNO
   Huang X., 2007, J POROUS MAT, V15, P635
   Innocentini MDM, 2001, J AM CERAM SOC, V84, P941
   Lin YJ, 2009, METALL MATER TRANS A, V40A, P2071, DOI 10.1007/s11661-009-9888-z
   Mongia R.K., 2007, 14 INT HEAT PIP C FL
   Mwaba MG, 2006, INT J ENERG RES, V30, P489, DOI 10.1002/er.1164
   Paiva K.V., 2007, 14 INT HEAT PIP C 14
   Paiva K.V., 2008, 9 INT HEAT PIP S BAN
   Paiva K.V., 2011, THESIS FEDERAL U SAN
   Peterson G. P., 1994, INTRO HEAT PIPES MOD
   Savino R, 2008, ACTA ASTRONAUT, V63, P24, DOI 10.1016/j.actaastro.2007.12.037
   Vasiliev L.L., 2006, APPL THERM ENG
NR 13
TC 1
Z9 1
U1 2
U2 12
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 1270-9638
EI 1626-3219
J9 AEROSP SCI TECHNOL
JI Aerosp. Sci. Technol.
PD SEP
PY 2015
VL 45
BP 367
EP 375
DI 10.1016/j.ast.2015.06.004
PG 9
WC Engineering, Aerospace
SC Engineering
GA CQ4TP
UT WOS:000360597800040
ER


PT J
AU Anselmo, L
   Pardini, C
AF Anselmo, Luciano
   Pardini, Carmen
TI Compliance of the Italian satellites in low Earth orbit with the
   end-of-life disposal guidelines for Space Debris Mitigation and ranking
   of their long-term criticality for the environment
SO ACTA ASTRONAUTICA
LA English
DT Article
DE Space Debris; Mitigation; Disposal guidelines compliance; Environmental
   criticality ranking; Active removal
ID COLLISIONS; REENTRY; BREAKUP
AB As of mid-2014, nearly 50 years since the launch of the first satellite, Italy had placed in low Earth orbit 29 objects: 27 payloads, 1 rocket body and 1 mission related object. 19 were yet in space: the IRIS rocket body and 18 payloads, 4 of which, belonging to the COSMO-SkyMed constellation, still operational and maneuverable. 16 objects had been deployed in space before the approval, in 2002, of the IADC Space Debris Mitigation Guidelines and 1 further payload had been launched before the ASI signature of the European Code of Conduct for Space Debris Mitigation, in 2005. While no object had been yet maneuvered to reduce its residual lifetime, due to the operational orbits chosen and area-to-mass ratios, 16 of them had decayed or were predicted to reenter in less than 25 years after mission completion, in agreement with current disposal recommendations. This corresponded to a compliance of 64% over 50 years, of 59% for the objects placed in orbit before the ASI signature of the European Code of Conduct, and of 75% for those launched afterwards, excluding the 4 maneuverable spacecraft still functional. Concerning the risk on the ground associated with uncontrolled reentries, just one satellite decayed in 2003 had a mass greater than 600 kg and a casualty expectancy in excess of 10(-4). For it, timely reentry predictions and alert time windows had been provided to the countries overflown. In order to evaluate the potential long-term detrimental effects on the environment of the abandoned or unmaneuverable objects, a new ranking index, also useful for active debris removal priority listing, was developed and applied. It is worth noting that all the 14 objects residing or descending below 1000 km exhibited an overall ranking index equivalent to just 8% of an average abandoned intact object in a 800 km sun-synchronous orbit. (C) 2015 IAA. Published by Elsevier Ltd. All rights reserved.
C1 [Anselmo, Luciano; Pardini, Carmen] CNR, ISTI, I-56100 Pisa, Italy.
RP Anselmo, L (reprint author), CNR, ISTI, I-56100 Pisa, Italy.
EM Luciano.Anselmo@isti.cnr.it; Carmen.Pardini@isti.cnr.it
RI Pardini, Carmen/C-7170-2015; 
OI Pardini, Carmen/0000-0001-6060-2335; Anselmo,
   Luciano/0000-0001-5875-2975
CR [Anonymous], 2014, SEM TOOL END LIF AN
   Committee on the Peaceful Uses of Outer Space (COPUOS), 2010, SPAC DEBR MIT GUID C
   DeLuca L. T., 2013, P 5 EUR C AER SPAC S
   European Space Debris Safety and Mitigation Standard Working Group, 2004, EUR COD COND SPAC DE
   IADC Steering Group & Working Group 4 (Mitigation), 2002, IADC0201
   [Anonymous], 2011, 20 ISOTC, VFirst
   Johnson NL, 2001, ADV SPACE RES, V28, P1377, DOI 10.1016/S0273-1177(01)00423-9
   Johnson N. L., 1987, ARTIFICIAL SPACE DEB
   Krisko P.H., 2011, ORBITAL DEBRIS Q NEW, V15-4, P4
   Liou JC, 2011, ADV SPACE RES, V47, P1865, DOI 10.1016/j.asr.2011.02.003
   Liou JC, 2009, ACTA ASTRONAUT, V64, P236, DOI 10.1016/j.actaastro.2008.07.009
   [Anonymous], 2010, ESASDDVD02 TU BRAUNS
   McKnight D. S., 1993, P NAT RES COUNC COMM
   Morand V., 2014, P 5 WORKSH SAT END L
   Opiela J. N., 2012, 64047 JSC NASA
   Pardini C, 2004, ADV SPACE RES, V34, P1038, DOI 10.1016/j.asr.2003.01.010
   Pardini C, 2011, ADV SPACE RES, V48, P557, DOI 10.1016/j.asr.2011.04.006
   Pardini C, 2009, ADV SPACE RES, V44, P545, DOI 10.1016/j.asr.2009.04.014
   Pardini C., 2014, P 3 EUR WORKSH SPAC
   Pardini C., 1994, C9417 CNUCE I CNR
   Pardini C, 2014, ACTA ASTRONAUT, V100, P30, DOI 10.1016/j.actaastro.2014.03.013
   Portelli C, 2004, ADV SPACE RES, V34, P1029, DOI 10.1016/j.asr.2003.11.011
   Rossi A., 2014, P 65 INT ASTR C INT
   Space Track Organization, 2014, SAT CAT DAT
   Stansbery E. G., 2014, NASATP2014217370
   Utzmann J., 2012, P 63 INT ASTR C INT
NR 26
TC 1
Z9 1
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0094-5765
EI 1879-2030
J9 ACTA ASTRONAUT
JI Acta Astronaut.
PD SEP-OCT
PY 2015
VL 114
BP 93
EP 100
DI 10.1016/j.actaastro.2015.04.024
PG 8
WC Engineering, Aerospace
SC Engineering
GA CM7VX
UT WOS:000357905700009
ER


PT J
AU Olmedo, MH
   Fernandez, CS
AF Hernandez Olmedo, Miguel
   Suarez Fernandez, Carmen
TI Progress of anticoagulation therapy in atrial fibrillation
SO MEDICINA CLINICA
LA Spanish
DT Review
DE New oral anticoagulants; Direct action anticoagulants; Atrial
   fibrillation; Stroke; Intracranial hemorrhage
ID J-ROCKET AF; STROKE PREVENTION; ORAL ANTICOAGULANTS; COST-EFFECTIVENESS;
   NATIONWIDE COHORT; PREDICTING STROKE; RANDOMIZED EVALUATION; RISK
   STRATIFICATION; JAPANESE PATIENTS; ARISTOTLE TRIAL
AB Atrial fibrillation is currently a very prevalent disease and it represents one of the most common causes of disabling stroke. Antithrombotic therapies have reduced the incidence of this complication although they pose many limitations and difficulties. As a result, a large number of high risk patients do not receive an appropriate treatment. In recent years, four new oral anticoagulants (NOAC) with relevant advantages in comparison to vitamin K antagonists have been released. Four large phase in clinical trials have demonstrated that NOAC are at least as safe and efficacious as warfarin in stroke prevention in non-valve atrial fibrillation patients with moderate-high thrombotic risk, being their main advantage the reduction in intracranial hemorrhage. The arrival of these drugs has caused great expectations in the management of these patients but also new doubts. Lacking data in some subgroups of frail patients, the absence of specific antidotes available and specially their high cost represent nowadays the main limitations for their generalization. (C) 2014 Elsevier Espana, S.L.U. All rights reserved.
C1 [Hernandez Olmedo, Miguel; Suarez Fernandez, Carmen] Hosp Univ La Princesa, Serv Med Interna, Madrid, Spain.
RP Fernandez, CS (reprint author), Hosp Univ La Princesa, Serv Med Interna, Madrid, Spain.
EM csuarezf@salud.madrid.org
CR Banerjee A, 2012, THROMB HAEMOSTASIS, V107, P584, DOI 10.1160/TH11-11-0784
   Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253
   Cea-Calvo L, 2007, REV ESP CARDIOL, V60, P616, DOI 10.1157/13107118
   Christensen LM, 2014, EUR J NEUROL, V21, P884, DOI 10.1111/ene.12400
   Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561
   Coyle D, 2013, VALUE HEALTH, V16, P498, DOI 10.1016/j.jval.2013.01.009
   Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747
   Eriksso